Cerebral O O
vasculitis O O
secondary O O
to O O
Crohn O O
's O O
disease O O
seems O O
to O O
be O O
a O O
very O O
rare O O
phenomenon O O
. O O

SELECTION O O
CRITERIA O O
: O O
Randomised O O
and O O
possibly O O
randomised O O
trials O O
using O O
acupuncture O O
to O O
treat O O
asthma O O
and O O
asthma O O
- O O
like O O
symptoms O O
. O O

SELECTION O O
CRITERIA O O
: O O
Randomised O O
trials O O
comparing O O
children O O
undergoing O O
systematic O O
therapy O O
focusing O O
on O O
the O O
family O O
in O O
conjunction O O
with O O
asthma O O
medication O O
, O O
with O O
children O O
taking O O
asthma O O
medication O O
only O O
. O O

To O O
test O O
the O O
hypothesis O O
that O O
progestin O O
- O O
mediated O O
increases O O
in O O
resting O O
core O O
temperature O O
and O O
the O O
core O O
temperature O O
threshold O O
for O O
sweating O O
onset O O
are O O
counteracted O O
by O O
estrogen O O
, O O
we O O
studied O O
eight O O
women O O
( O O
24 O O
+ O O
/- O O
2 O O
yr O O
) O O
at O O
27 O O
degrees O O
C O O
rest O O
, O O
during O O
20 O O
min O O
of O O
passive O O
heating O O
( O O
35 O O
degrees O O
C O O
) O O
, O O
and O O
during O O
40 O O
min O O
of O O
exercise O O
at O O
35 O O
degrees O O
C. O O

The O O
models O O
were O O
tested O O
by O O
studying O O
their O O
response O O
to O O
disturbances O O
of O O
the O O
afferent O O
signal O O
from O O
the O O
bladder O O
. O O

Our O O
data O O
show O O
also O O
that O O
phagocytic O O
killing O O
of O O
meningococci O O
is O O
probably O O
a O O
more O O
consistent O O
assay O O
than O O
antibody O O
titer O O
levels O O
for O O
antimeningococcal O O
immunity O O
, O O
especially O O
in O O
LCC O O
- O O
deficient O O
patients O O
. O O

These O O
studies O O
suggest O O
an O O
additional O O
component O O
or O O
cellular O O
environment O O
is O O
required O O
for O O
SPRK S-GENE O
activation O O
by O O
Cdc42 S-GENE O
. O O
M. O O

Jkappa B-GENE B-GENE
DNA I-GENE I-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
sites E-GENE E-GENE
were O O
not O O
required O O
for O O
this O O
activation O O
, O O
and O O
a O O
mutant S-GENE B-GENE
EBNA-3C B-GENE I-GENE
protein E-GENE E-GENE
unable O O
to O O
bind O O
Jkappa O S-GENE
activated O O
transcription O O
as O O
efficiently O O
as O O
wild B-GENE B-GENE
- I-GENE I-GENE
type I-GENE I-GENE
EBNA-3C E-GENE E-GENE
, O O
indicating O O
that O O
EBNA-3C O S-GENE
can O O
regulate O O
transcription O O
through O O
a O O
mechanism O O
that O O
is O O
independent O O
of O O
Jkappa O S-GENE
. O O
Thus O O
, O O
both O O
YY1 S-GENE O
and O O
CDP S-GENE S-GENE
appear O O
to O O
be O O
negative O O
regulators O O
of O O
the O O
differentiation O O
- O O
induced O O
HPV-6 B-GENE B-GENE
E1 I-GENE I-GENE
promoter E-GENE E-GENE
and O O
thereby O O
the O O
HPV O S-GENE
life O O
cycle O O
. O O
Sequential O O
cleavage O O
by O O
metallopeptidases S-GENE O
and O O
proteasomes O O
is O O
involved O O
in O O
processing O O
HIV-1 B-GENE B-GENE
ENV I-GENE I-GENE
epitope E-GENE E-GENE
for O O
endogenous O O
MHC B-GENE B-GENE
class I-GENE I-GENE
I I-GENE I-GENE
antigen E-GENE E-GENE
presentation O O
. O O
Cloning O O
and O O
characterization O O
of O O
human B-GENE O
Lnk E-GENE S-GENE
, O O
an O O
adaptor O O
protein O O
with O O
pleckstrin S-GENE O
homology O O
and O O
Src B-GENE B-GENE
homology I-GENE I-GENE
2 I-GENE I-GENE
domains E-GENE E-GENE
that O O
can O O
inhibit O O
T O O
cell O O
activation O O
. O O
Vancomycin O O
data O O
were O O
analyzed O O
according O O
to O O
a O O
one O O
- O O
compartment O O
open O O
model O O
with O O
use O O
of O O
NONMEM O O
population O O
pharmacokinetic O O
software O O
. O O

Finally O O
, O O
Cas S-GENE O
existed O O
mainly O O
in O O
cytosol O O
and O O
membrane O O
cytoskeleton O O
fractions O O
in O O
the O O
resting O O
state O O
, O O
and O O
remained O O
unchanged O O
during O O
platelet O B-GENE
aggregation O E-GENE
, O O
when O O
FAK S-GENE S-GENE
translocated O O
to O O
the O O
cytoskeletal O O
fraction O O
. O O
We O O
also O O
show O O
that O O
p65 S-GENE S-GENE
binds O O
to O O
these O O
targets O O
with O O
almost O O
equal O O
affinity O O
and O O
that O O
different O O
residues O O
have O O
variable O O
roles O O
in O O
binding O O
different O O
kappaB B-GENE O
targets E-GENE O
. O O
Transcriptional O O
regulation O O
of O O
the O O
yeast B-GENE O
PHO8 I-GENE B-GENE
promoter E-GENE E-GENE
in O O
comparison O O
to O O
the O O
coregulated O O
PHO5 B-GENE B-GENE
promoter E-GENE E-GENE
. O O
The O O
Siglecs S-GENE S-GENE
are O O
a O O
subfamily O O
of O O
I B-GENE B-GENE
- I-GENE I-GENE
type I-GENE I-GENE
lectins E-GENE E-GENE
( O O
immunoglobulin B-GENE B-GENE
superfamily I-GENE I-GENE
proteins E-GENE E-GENE
that O O
bind O O
sugars O O
) O O
that O O
specifically O O
recognize O O
sialic O O
acids O O
. O O
Our O O
data O O
provide O O
a O O
biochemical O O
explanation O O
for O O
the O O
similarity O O
in O O
phenotype O O
between O O
A O O
- O O
T O O
and O O
NBS O O
. O O

PATIENTS O O
OR O O
OTHER O O
PARTICIPANTS O O
: O O
Twenty O O
children O O
met O O
the O O
criteria O O
for O O
being O O
learning O O
disabled O O
. O O

Update O O
on O O
maternal O O
- O O
fetal O O
infections O O
by O O
hepatitis O O
C O O
, O O
HIV O O
and O O
cytomegalovirus O O

In O O
the O O
present O O
study O O
, O O
we O O
characterized O O
cis O O
- O O
elements O O
of O O
the O O
human B-GENE B-GENE
PCI I-GENE I-GENE
gene E-GENE E-GENE
required O O
for O O
expression O O
in O O
the O O
hepatoma O O
- O O
derived O O
cell O O
line O O
, O O
HepG2 O O
cells O O
, O O
and O O
also O O
evaluated O O
rat B-GENE B-GENE
PCI I-GENE I-GENE
mRNA E-GENE E-GENE
expression O O
, O O
particularly O O
on O O
the O O
effect O O
of O O
androgen O O
in O O
rat O O
reproductive O O
tissues O O
. O O
In O O
the O O
study O O
on O O
PCI B-GENE B-GENE
mRNA E-GENE E-GENE
expression O O
in O O
the O O
reproductive O O
organs O O
, O O
we O O
first O O
cloned O O
rat B-GENE B-GENE
PCI I-GENE I-GENE
cDNA E-GENE E-GENE
and O O
then O O
evaluated O O
the O O
effect O O
of O O
androgen O O
on O O
the O O
PCI O B-GENE
mRNA O E-GENE
expression O O
. O O
To O O
illustrate O O
its O O
performance O O
, O O
measurements O O
of O O
photoluminescence O O
in O O
GaAs O O
/ O O
AlGaAs O O
heterostructures O O
are O O
presented O O
. O O

The O O
stoichiometry O O
of O O
the O O
complexes O O
formed O O
with O O
the O O
dodeca O O
- O O
satellite O O
C O O
strand O O
suggests O O
that O O
, O O
in O O
DDP1 S-GENE S-GENE
, O O
the O O
15 O O
consecutive O O
KH O S-GENE
domains O O
are O O
organized O O
such O O
that O O
they O O
define O O
two O O
nucleic O O
acid O O
binding O O
surfaces O O
. O O
Mutational O O
analysis O O
of O O
mammalian B-GENE B-GENE
translation I-GENE I-GENE
initiation I-GENE I-GENE
factor I-GENE E-GENE
5 E-GENE O
( O O
eIF5 S-GENE S-GENE
) O O
: O O
role O O
of O O
interaction O O
between O O
the O O
beta O B-GENE
subunit O E-GENE
of O O
eIF2 S-GENE S-GENE
and O O
eIF5 O S-GENE
in O O
eIF5 O S-GENE
function O O
in O O
vitro O O
and O O
in O O
vivo O O
. O O
Much O O
evidence O O
indicates O O
that O O
p38 S-GENE S-GENE
is O O
an O O
activator O O
of O O
MyoD S-GENE S-GENE
: O O
( O O
i O O
) O O
p38 B-GENE B-GENE
kinase E-GENE E-GENE
activity O O
is O O
required O O
for O O
the O O
expression O O
of O O
MyoD O B-GENE
- O I-GENE
responsive O I-GENE
genes O E-GENE
, O O
( O O
ii O O
) O O
enforced O O
induction O O
of O O
p38 O S-GENE
stimulates O O
the O O
transcriptional O O
activity O O
of O O
a O O
Gal4-MyoD O B-GENE
fusion O I-GENE
protein O E-GENE
and O O
allows O O
efficient O O
activation O O
of O O
chromatin O O
- O O
integrated O O
reporters O O
by O O
MyoD O S-GENE
, O O
and O O
( O O
iii O O
) O O
MyoD O S-GENE
- O O
dependent O O
myogenic O O
conversion O O
is O O
reduced O O
in O O
mouse O O
embryonic O O
fibroblasts O O
derived O O
from O O
p38alpha(-/- B-GENE S-GENE
) E-GENE O
embryos O O
. O O
This O O
activity O O
is O O
stimulated O O
by O O
complex O O
formation O O
with O O
the O O
other O O
eIF2B B-GENE B-GENE
subunits E-GENE E-GENE
. O O
Our O O
analysis O O
of O O
nonsense O O
mutations O O
indicates O O
that O O
the O O
C O O
terminus O O
of O O
eIF2Bepsilon B-GENE S-GENE
( I-GENE O
residues I-GENE O
518 I-GENE O
to I-GENE O
712 I-GENE O
) E-GENE O
is O O
required O O
for O O
both O O
catalytic O O
activity O O
and O O
interaction O O
with O O
eIF2 O S-GENE
. O O
In O O
contrast O O
, O O
mutations O O
affecting O O
the O O
other O O
two O O
Nim1p B-GENE B-GENE
- I-GENE I-GENE
related I-GENE I-GENE
kinases E-GENE E-GENE
in O O
S. O O
cerevisiae O O
, O O
Hsl1p S-GENE S-GENE
and O O
Kcc4p S-GENE S-GENE
, O O
produce O O
no O O
detectable O O
effect O O
on O O
septin S-GENE O
organization O O
. O O
CONCLUSIONS O O
: O O
Physiologic O O
pacing O O
provides O O
little O O
benefit O O
over O O
ventricular O O
pacing O O
for O O
the O O
prevention O O
of O O
stroke O O
or O O
death O O
due O O
to O O
cardiovascular O O
causes O O
. O O

Among O O
non O O
- O O
cirrhotics O O
, O O
lack O O
of O O
portal O O
vein O O
visualisation O O
had O O
a O O
90% O O
sensitivity O O
, O O
88% O O
specificity O O
, O O
94% O O
negative O O
predictive O O
value O O
, O O
and O O
83% O O
positive O O
predictive O O
value O O
in O O
the O O
diagnosis O O
of O O
pre O O
- O O
sinusoidal O O
portal O O
hypertension O O
. O O

D5/D1(CT B-GENE O
) E-GENE O
or O O
D5/D1D(CT B-GENE O
) E-GENE O
tail O O
substitution O O
mutants O O
displayed O O
a O O
rank O O
order O O
of O O
potency O O
and O O
agonist O O
affinities O O
virtually O O
mimicking O O
wild B-GENE O
- I-GENE O
type I-GENE O
( I-GENE O
wt I-GENE O
) E-GENE O
D1 B-GENE B-GENE
receptors E-GENE E-GENE
, O O
as O O
indexed O O
by O O
both O O
ligand O O
binding O O
and O O
dopamine O O
- O O
stimulated O O
cAMP O O
accumulation O O
assays O O
, O O
and O O
, O O
similar O O
to O O
wt O O
D1 O B-GENE
receptors O E-GENE
, O O
did O O
not O O
exhibit O O
receptor O O
constitutive O O
activity O O
or O O
responsiveness O O
to O O
inverse O O
agonists O O
. O O
Modeling O O
also O O
revealed O O
a O O
very O O
hydrophobic O O
surface O O
due O O
to O O
the O O
absence O O
of O O
H12 O O
, O O
exposing O O
residues O O
from O O
H3 O O
, O O
loop O O
3 O O
- O O
4 O O
, O O
H4 O O
, O O
and O O
H11 O O
. O O

The O O
serine B-GENE B-GENE
- I-GENE I-GENE
threonine I-GENE I-GENE
kinase I-GENE I-GENE
gene E-GENE E-GENE
is O O
likely O O
functional O O
, O O
whereas O O
the O O
zinc O B-GENE
finger O I-GENE
motif O E-GENE
is O O
likely O O
nonfunctional O O
. O O
Stat S-GENE O
activation O O
in O O
response O O
to O O
GH S-GENE S-GENE
and O O
IL-6 S-GENE S-GENE
was O O
determined O O
by O O
reporter O O
gene O O
induction O O
. O O
HFA O O
134a O O
had O O
a O O
greater O O
tendency O O
to O O
take O O
up O O
moisture O O
from O O
the O O
environment O O
than O O
did O O
HFA O O
227 O O
. O O

RESULTS O O
: O O
Abnormal O O
color O O
perception O O
was O O
found O O
in O O
32% O O
of O O
the O O
epilepsy O O
patients O O
treated O O
with O O
vigabatrin O O
monotherapy O O
and O O
28% O O
of O O
the O O
epilepsy O O
patients O O
treated O O
with O O
carbamazepine O O
monotherapy O O
. O O

In O O
the O O
SPP2 O O
screening O O
test O O
, O O
a O O
few O O
plates O O
were O O
not O O
seen O O
in O O
both O O
groups O O
. O O

Mitogen B-GENE B-GENE
- I-GENE I-GENE
activated I-GENE I-GENE
protein I-GENE E-GENE
( I-GENE O
MAP I-GENE S-GENE
) I-GENE O
kinase I-GENE B-GENE
phosphatase-3 E-GENE E-GENE
( O O
MKP-3 S-GENE S-GENE
) O O
is O O
a O O
dual O O
specificity O O
phosphatase O S-GENE
that O O
inactivates O B-GENE
extracellular B-GENE I-GENE
signal I-GENE I-GENE
- I-GENE I-GENE
regulated I-GENE I-GENE
kinase E-GENE E-GENE
( O O
ERK S-GENE S-GENE
) O O
MAP B-GENE B-GENE
kinases E-GENE E-GENE
. O O
Consistent O O
with O O
this O O
, O O
we O O
show O O
that O O
peptides O O
representing O O
docking O O
sites O O
within O O
the O O
target O O
substrates O O
Elk-1 S-GENE S-GENE
and O O
p90(rsk O S-GENE
) O O
inhibit O O
ERK S-GENE S-GENE
- O O
dependent O O
activation O O
of O O
MKP-3 S-GENE S-GENE
. O O
HPLC O O
phosphopeptide O O
mapping O O
, O O
amino O O
acid O O
sequencing O O
, O O
and O O
site O O
- O O
directed O O
mutagenesis O O
determined O O
that O O
NCLK S-GENE B-GENE
phosphorylates O I-GENE
Ser(67 O E-GENE
) O O
of O O
I-1 S-GENE S-GENE
. O O
When O O
the O O
entire O O
diet O O
consisted O O
of O O
SBF O O
, O O
voluntary O O
feed O O
intake O O
was O O
reduced O O
, O O
indicating O O
that O O
SBF O O
should O O
not O O
be O O
fed O O
to O O
ponies O O
as O O
the O O
sole O O
dietary O O
ingredient O O
. O O

Hepatitis O O
C O O
virus O O
infection O O
and O O
lymphoproliferative O O
diseases O O
in O O
France O O
: O O
a O O
national O O
study O O
. O O

The O O
immune O O
system O O
is O O
closely O O
integrated O O
with O O
the O O
neuroendocrine O O
system O O
, O O
and O O
infection O O
- O O
induced O O
increases O O
in O O
cytokines O O
such O O
as O O
IL-1 S-GENE S-GENE
, O O
IL-6 S-GENE S-GENE
and O O
TNF S-GENE S-GENE
have O O
numerous O O
effects O O
on O O
the O O
central O O
nervous O O
system O O
. O O
Interestingly O O
, O O
a O O
decreased O O
transcription O O
from O O
the O O
endogenous O B-GENE
c B-GENE I-GENE
- I-GENE I-GENE
Myb I-GENE I-GENE
promoter E-GENE E-GENE
was O O
observed O O
in O O
several O O
HTLV O B-GENE
- O I-GENE
I O E-GENE
transformed O O
T O O
- O O
cell O O
lines O O
. O O
H19 S-GENE S-GENE
and O O
Igf2 S-GENE S-GENE
monoallelic O O
expression O O
is O O
regulated O O
in O O
two O O
distinct O O
ways O O
by O O
a O O
shared O O
cis O O
acting O O
regulatory O O
region O O
upstream O O
of O O
H19 O S-GENE
. O O
C. O O
elegans O O
KLP-11/OSM-3/KAP-1 O O
: O O
orthologs O O
of O O
the O O
sea B-GENE O
urchin E-GENE O
kinesin B-GENE O
- I-GENE O
II E-GENE O
, O O
and O O
mouse O O
KIF3A S-GENE O
/ O O
KIFB S-GENE O
/ O O
KAP3 S-GENE O
kinesin O O
complexes O O
. O O
Flavonoids O O
from O O
Brosimum O O
acutifolium O O
. O O

BACKGROUND O O
: O O
Hepatic O O
encephalopathy O O
is O O
a O O
neuropsychiatric O O
syndrome O O
associated O O
with O O
acute O O
liver O O
failure O O
, O O
chronic O O
parenchymal O O
liver O O
disease O O
or O O
portal O O
systemic O O
anastomosis O O
. O O

These O O
natural O O
antisense O B-GENE
S B-GENE I-GENE
transcripts E-GENE E-GENE
co O O
- O O
exist O O
with O O
several O O
less O O
abundant O O
sense O O
S O B-GENE
transcripts O E-GENE
. O O
Nor O O
is O O
such O O
adjustment O O
possible O O
unless O O
one O O
posits O O
a O O
model O O
that O O
relates O O
the O O
missing O O
observations O O
to O O
other O O
observed O O
information O O
for O O
each O O
subject O O
- O O
models O O
that O O
are O O
inherently O O
untestable O O
. O O

However O O
, O O
the O O
presence O O
of O O
effacement O O
seems O O
to O O
be O O
a O O
more O O
reliable O O
and O O
practical O O
parameter O O
that O O
will O O
be O O
preferred O O
in O O
that O O
prediction O O
. O O

The O O
data O O
are O O
compatible O O
with O O
the O O
idea O O
that O O
YLL031c S-GENE S-GENE
transfers O O
the O O
ethanolaminephosphate O O
to O O
the O O
inner O O
alpha1 O B-GENE
- O I-GENE
2-linked O I-GENE
mannose O E-GENE
, O O
i.e. O O
the O O
group O O
that O O
links O O
the O O
GPI O O
lipid O O
anchor O O
to O O
proteins O O
, O O
whereas O O
Mcd4p S-GENE S-GENE
and O O
Gpi7p S-GENE S-GENE
transfer O O
ethanolaminephosphate O O
onto O O
the O O
alpha1 O S-GENE
- O O
4- O O
and O O
alpha1 O B-GENE
- O I-GENE
6-linked O I-GENE
mannoses O E-GENE
of O O
the O O
GPI O S-GENE
anchor O O
, O O
respectively O O
. O O
The O O
C O O
terminus O O
of O O
TRBP S-GENE S-GENE
binds O O
to O O
CBP S-GENE B-GENE
/ O I-GENE
p300 S-GENE E-GENE
and O O
DRIP130 S-GENE S-GENE
, O O
a O O
component O O
of O O
the O O
DRIP O O
/ O O
TRAP S-GENE O
/ O O
ARC S-GENE O
complex O O
, O O
which O O
suggests O O
that O O
TRBP O S-GENE
may O O
activate O O
transcription O O
by O O
means O O
of O O
such O O
interactions O O
. O O
The O O
patients O O
who O O
presented O O
with O O
mucocutaneous O O
disease O O
also O O
had O O
low O O
CD4 B-GENE O
+ E-GENE O
T O O
lymphocyte O O
counts O O
, O O
and O O
most O O
of O O
them O O
had O O
AIDS O O
defining O O
illnesses O O
. O O
Increased O O
dietary O O
energy O O
decreased O O
PAB O O
and O O
the O O
use O O
of O O
added O O
dietary O O
CO O O
rather O O
than O O
PF O O
decreased O O
PSHL O O
in O O
broiler O O
breeders O O
between O O
26 O O
and O O
47 O O
wk O O
of O O
age O O
. O O

The O O
gene O O
amplification O O
model O O
of O O
Coquelle O O
et O O
al O O
. O O

Hierarchy O O
of O O
protein B-GENE B-GENE
tyrosine I-GENE I-GENE
kinases E-GENE E-GENE
in O O
interleukin-2 S-GENE S-GENE
( O O
IL-2 S-GENE S-GENE
) O O
signaling O O
: O O
activation O O
of O O
syk S-GENE S-GENE
depends O O
on O O
Jak3 S-GENE S-GENE
; O O
however O O
, O O
neither O O
Syk S-GENE S-GENE
nor O O
Lck S-GENE S-GENE
is O O
required O O
for O O
IL-2-mediated O B-GENE
STAT S-GENE I-GENE
activation O E-GENE
. O O
Immobilized O O
dimers O O
of O O
N B-GENE B-GENE
- I-GENE I-GENE
cadherin E-GENE I-GENE
- O I-GENE
Fc S-GENE I-GENE
chimera O I-GENE
mimic O I-GENE
cadherin O E-GENE
- O O
mediated O O
cell O O
contact O O
formation O O
: O O
contribution O O
of O O
both O O
outside O O
- O O
in O O
and O O
inside O O
- O O
out O O
signals O O
. O O
Although O O
the O O
OC B-GENE B-GENE
promoter E-GENE E-GENE
is O O
activated O O
in O O
a O O
C O O
terminus O O
dependent O O
manner O O
, O O
the O O
MDR S-GENE S-GENE
, O O
LTR O S-GENE
and O O
BSP B-GENE B-GENE
promoters E-GENE E-GENE
are O O
repressed O O
by O O
three O O
distinct O O
mechanisms O O
, O O
either O O
independent O O
of O O
or O O
involving O O
the O O
AML B-GENE B-GENE
C I-GENE I-GENE
terminus E-GENE E-GENE
, O O
or O O
requiring O O
only O O
the O O
conserved O O
C O O
- O O
terminal O O
pentapeptide O O
VWRPY O S-GENE
. O O
The O O
monoclonal O B-GENE
immunoglobulin S-GENE I-GENE
products O E-GENE
of O O
plasma O S-GENE
cell O O
neoplasm O O
can O O
give O O
rise O O
to O O
a O O
variety O O
of O O
manifestations O O
including O O
hyperviscosity O O
, O O
amyloidosis O O
, O O
cryoglobulinemia O O
, O O
neuropathy O O
, O O
and O O
renal O O
failure O O
. O O
Investigation O O
of O O
the O O
structural O O
basis O O
of O O
the O O
interaction O O
between O O
human B-GENE B-GENE
Igs E-GENE E-GENE
and O O
gp120 S-GENE O
shows O O
that O O
the O O
viral B-GENE B-GENE
gp120 I-GENE I-GENE
SAg E-GENE E-GENE
can O O
interact O O
only O O
with O O
a O O
subset O O
of O O
human B-GENE O
V(H)3 I-GENE O
+ I-GENE O
Igs E-GENE O
. O O
Double O O
- O O
blind O O
, O O
placebo O O
- O O
controlled O O
trial O O
. O O

Here O O
, O O
it O O
is O O
shown O O
that O O
TAFII250 S-GENE S-GENE
, O O
the O O
largest O O
subunit O O
of O O
TFIID S-GENE S-GENE
, O O
contains O O
two O O
tandem O O
bromodomain O O
modules O O
that O O
bind O O
selectively O O
to O O
multiply O O
acetylated O O
histone B-GENE B-GENE
H4 I-GENE I-GENE
peptides E-GENE E-GENE
. O O
Endostatin O S-GENE
treatment O O
for O O
10 O O
minutes O O
or O O
24 O O
hours O O
induced O O
tyrosine O O
phosphorylation O O
of O O
Shb S-GENE S-GENE
and O O
formation O O
of O O
multiprotein O O
complexes O O
. O O
Therefore O O
, O O
analogs O O
of O O
vitamin O O
D3 O O
have O O
been O O
investigated O O
in O O
a O O
number O O
of O O
trials O O
showing O O
improvement O O
of O O
psoriasis O O
. O O

The O O
transcript O O
was O O
initially O O
identified O O
as O O
a O O
partial O O
cDNA O O
sequence O O
in O O
the O O
course O O
of O O
constructing O O
a O O
transcript O O
map O O
of O O
the O O
region O O
between O O
markers O O
D11S1765 S-GENE S-GENE
and O O
uteroglobin S-GENE S-GENE
known O O
to O O
encompass O O
the O O
gene O O
causing O O
Best O O
disease O O
. O O
The O O
real O O
challenge O O
for O O
the O O
future O O
will O O
be O O
the O O
management O O
of O O
patients O O
who O O
do O O
not O O
respond O O
to O O
first O O
- O O
line O O
treatment O O
. O O

Iodine O O
deficiency O O
disorders O O
in O O
Bangladesh O O
. O O

The O O
network O O
evolution O O
was O O
interpreted O O
by O O
an O O
approach O O
based O O
on O O
the O O
Flory O O
model O O
. O O

RESULTS O O
: O O
Soluble O O
CD23 S-GENE S-GENE
levels O O
were O O
significantly O O
higher O O
in O O
women O O
with O O
endometriosis O O
before O O
treatment O O
than O O
in O O
ten O O
normal O O
controls O O
. O O
CONCLUSION O O
: O O
Our O O
findings O O
suggest O O
that O O
endometriosis O O
increases O O
soluble O O
CD23 S-GENE S-GENE
levels O O
, O O
which O O
can O O
be O O
suppressed O O
with O O
either O O
danazol O O
or O O
leuprolide O O
acetate O O
injection O O
. O O
To O O
isolate O O
this O O
gene O O
, O O
a O O
P-1 O S-GENE
artificial O O
chromosome O O
( O O
PAC O S-GENE
) O O
library O O
was O O
screened O O
with O O
a O O
full B-GENE O
length I-GENE O
UGT2B7 E-GENE O
probe O O
and O O
a O O
clone O O
of O O
approximately O O
100 O O
kb O O
in O O
length O O
was O O
isolated O O
. O O
Age O O
> O O
/= O O
50 O O
years O O
( O O
odds O O
ratio O O
[ O O
OR O O
] O O
, O O
14.1 O O
) O O
, O O
BMI O O
> O O
/= O O
28 O O
kg O O
/ O O
m(2 O O
) O O
( O O
OR O O
, O O
5.7 O O
) O O
, O O
triglycerides O O
> O O
/= O O
1.7 O O
mmol O O
/ O O
L O O
( O O
OR O O
, O O
5 O O
) O O
, O O
and O O
alanine B-GENE B-GENE
aminotransferase E-GENE E-GENE
( O O
ALT S-GENE O
) O O
> O O
/= O O
2N O O
( O O
OR O O
, O O
4.6 O O
) O O
were O O
independently O O
associated O O
with O O
septal O O
fibrosis O O
. O O
Biologically O O
significant O O
amounts O O
of O O
platelet B-GENE B-GENE
activating I-GENE I-GENE
factor E-GENE E-GENE
were O O
eluted O O
from O O
the O O
sorbent O O
during O O
the O O
entire O O
treatment O O
time O O
. O O
However O O
, O O
the O O
elderly O O
group O O
showed O O
significantly O O
longer O O
mean O O
residence O O
times O O
( O O
MRTs O O
) O O
and O O
lower O O
plasma O O
clearance O O
of O O
lidocaine O O
during O O
the O O
period O O
compared O O
with O O
the O O
adult O O
group O O
( O O
P O O
< O O
.05 O O
) O O
. O O

Here O O
, O O
we O O
show O O
that O O
the O O
zinc B-GENE B-GENE
finger I-GENE I-GENE
protein I-GENE I-GENE
Gis1 E-GENE E-GENE
acts O O
as O O
a O O
dosage O O
- O O
dependent O O
suppressor O O
of O O
the O O
rim15Delta S-GENE O
defect O O
in O O
nutrient O O
limitation O O
- O O
induced O O
transcriptional O O
derepression O O
of O O
SSA3 S-GENE S-GENE
. O O
The O O
so O O
- O O
called O O
" B-GENE O
SH3 I-GENE S-GENE
" I-GENE O
segment E-GENE O
of O O
the O O
linker O O
domain O O
, O O
in O O
contrast O O
, O O
shows O O
species O O
- O O
specific O O
sequence O O
identity O O
in O O
all O O
but O O
one O O
amino O O
acid O O
residues O O
in O O
both O O
factors O O
, O O
in O O
cattle O O
, O O
human O O
, O O
and O O
mouse O O
. O O
No O O
differences O O
in O O
total O O
cholesterol O O
levels O O
were O O
observed O O
between O O
mapuches O O
and O O
aymaras O O
. O O

Up O O
to O O
95% O O
of O O
the O O
total O O
UV O O
exposure O O
received O O
is O O
in O O
the O O
UV O O
- O O
A O O
waveband O O
( O O
320 O O
- O O
400 O O
nm O O
) O O
. O O

To O O
begin O O
to O O
characterize O O
the O O
role O O
of O O
the O O
RNA O B-GENE
subunits O E-GENE
in O O
enzyme O O
function O O
and O O
substrate O O
specificity O O
, O O
we O O
swapped O O
two O O
hairpin O O
structures O O
( O O
MRP3 O S-GENE
and O O
P3 O O
) O O
between O O
RNase B-GENE B-GENE
MRP I-GENE I-GENE
RNA E-GENE E-GENE
and O O
RNase B-GENE B-GENE
P I-GENE I-GENE
RNA I-GENE E-GENE
of I-GENE O
S. I-GENE O
cerevisiae E-GENE O
. O O
Among O O
genes O O
induced O O
by O O
added O O
pMesogenin1 S-GENE O
is O O
Xwnt-8 S-GENE O
, O O
a O O
signaling O O
factor O O
that O O
induces O O
a O O
similar O O
repertoire O O
of O O
marker O O
genes O O
and O O
a O O
similar O O
cellular O O
phenotype O O
. O O
Accordingly O O
, O O
no O O
Ha B-GENE B-GENE
- I-GENE I-GENE
ras I-GENE E-GENE
codon I-GENE O
12 E-GENE O
mutations O O
are O O
found O O
in O O
the O O
EtNU O O
- O O
induced O O
mammary O O
tumors O O
. O O
False O O
positive O O
PET O O
FDG O O
corresponded O O
to O O
lung O O
infection O O
, O O
degenerative O O
bone O O
disease O O
, O O
and O O
reconstruction O O
artifact O O
. O O

Tumor O O
stages O O
were O O
IIB O O
( O O
T3 O O
N0 O O
) O O
in O O
52% O O
, O O
IIIA O O
in O O
15% O O
, O O
and O O
IIIB O O
in O O
27% O O
of O O
patients O O
. O O

Similarly O O
, O O
comparison O O
of O O
percentage O O
reductions O O
of O O
heart O O
rate O O
at O O
supine O O
, O O
sitting O O
and O O
exercise O O
by O O
repeated O O
measure O O
analysis O O
showed O O
the O O
Malays O O
to O O
have O O
significantly O O
higher O O
change O O
compared O O
to O O
the O O
Chinese O O
( O O
p O O
= O O
0.040 O O
) O O
. O O

Consistent O O
with O O
our O O
model O O
, O O
CTCF S-GENE O
binding O O
is O O
abolished O O
by O O
DNA O O
methylation O O
. O O
OBJECTIVE O O
: O O
To O O
determine O O
the O O
efficacy O O
and O O
safety O O
of O O
amphotericin O O
B O O
oral O O
suspension O O
( O O
ABOS O O
) O O
for O O
the O O
treatment O O
of O O
fluconazole O O
refractory O O
oral O O
candidiasis O O
in O O
persons O O
with O O
HIV O O
infection O O
. O O

Mucin B-GENE B-GENE
gene E-GENE E-GENE
expression O O
has O O
been O O
shown O O
to O O
be O O
altered O O
in O O
many O O
intestinal O O
diseases O O
and O O
especially O O
cancers O O
of O O
the O O
gastrointestinal O O
tract O O
. O O
The O O
experimentally O O
mapped O O
regions O O
of O O
RPB5 S-GENE S-GENE
involved O O
in O O
these O O
interactions O O
correspond O O
to O O
distinct O O
and O O
surface O O
- O O
exposed O O
alpha O O
- O O
helical O O
structures O O
. O O
The O O
model O O
indicates O O
that O O
a O O
0.076% O O
reduction O O
in O O
cigarette O O
consumption O O
is O O
associated O O
with O O
the O O
availability O O
of O O
nicotine O O
patches O O
after O O
1992 O O
. O O

Paper O O
alert O O
. O O

The O O
tryptase B-GENE B-GENE
locus E-GENE E-GENE
also O O
contains O O
at O O
least O O
four O O
tryptase B-GENE B-GENE
- I-GENE I-GENE
like I-GENE I-GENE
pseudogenes E-GENE E-GENE
, O O
including O O
mastin S-GENE S-GENE
, O O
a O O
gene O O
expressed O O
in O O
dogs O O
but O O
not O O
in O O
humans O O
. O O
The O O
cellular O O
part O O
of O O
the O O
third O O
chimeric O O
clone O O
shows O O
significant O O
homology O O
to O O
an O O
exon O O
of O O
the O O
human B-GENE B-GENE
tyrosine I-GENE I-GENE
phosphatase I-GENE I-GENE
1 I-GENE I-GENE
gene E-GENE E-GENE
, O O
although O O
oriented O O
in O O
the O O
antisense O O
direction O O
compared O O
to O O
the O O
adjacent O O
LTR O O
. O O
OBJECTIVE O O
: O O
This O O
study O O
was O O
conducted O O
to O O
assess O O
the O O
relative O O
roles O O
of O O
99mTc O O
- O O
sestamibi O O
scintimammography O O
and O O
sonography O O
in O O
the O O
evaluation O O
of O O
breast O O
lesions O O
that O O
are O O
indeterminate O O
or O O
suspicious O O
on O O
mammography O O
or O O
clinical O O
examination O O
. O O

Mutational O O
analyses O O
showed O O
that O O
in O O
- O O
frame O O
stop O O
codons O O
introduced O O
into O O
five O O
of O O
seven O O
RNA B-GENE B-GENE
2 I-GENE I-GENE
ORFs E-GENE E-GENE
did O O
not O O
affect O O
accumulation O O
of O O
progeny O O
LIYV B-GENE B-GENE
RNA I-GENE I-GENE
1 E-GENE E-GENE
or O O
RNA O B-GENE
2 O E-GENE
, O O
confirming O O
that O O
RNA O O
2 O O
does O O
not O O
encode O O
proteins O O
necessary O O
for O O
LIYV O B-GENE
RNA O I-GENE
replication O E-GENE
. O O
Role O O
of O O
NH(2)- O S-GENE
and O O
COOH O O
- O O
terminal O O
domains O O
of O O
the O O
P B-GENE B-GENE
protein E-GENE E-GENE
of O O
human O B-GENE
parainfluenza O I-GENE
virus O I-GENE
type O I-GENE
3 O E-GENE
in O O
transcription O O
and O O
replication O O
. O O
Phosphorylation O O
of O O
tyrosine O O
residues O O
in O O
the O O
kinase O B-GENE
domain O E-GENE
and O O
juxtamembrane O O
region O O
regulates O O
the O O
biological O O
and O O
catalytic O O
activities O O
of O O
Eph B-GENE B-GENE
receptors E-GENE E-GENE
. O O
RESULTS O O
: O O
Fournier O O
's O O
gangrene O O
occurs O O
worldwide O O
. O O

Genomic O O
DNA O O
sequencing O O
in O O
the O O
vicinity O O
of O O
methylmalonyl B-GENE B-GENE
- I-GENE I-GENE
CoA I-GENE I-GENE
mutase I-GENE I-GENE
gene E-GENE E-GENE
( O O
mutAB S-GENE S-GENE
) O O
from O O
a O O
rifamycin O O
SV O O
- O O
producing O O
Amycolatopsis O B-GENE
mediterranei O I-GENE
U32 O E-GENE
allowed O O
us O O
to O O
clone O O
, O O
sequence O O
, O O
and O O
identify O O
a O O
gene O O
encoding O O
a O O
novel O O
serine B-GENE B-GENE
/ I-GENE I-GENE
threonine I-GENE I-GENE
protein I-GENE I-GENE
kinase E-GENE E-GENE
( O O
amk S-GENE O
) O O
. O O
IL-2 S-GENE S-GENE
is O O
accepted O O
as O O
a O O
standard O O
treatment O O
used O O
alone O O
, O O
or O O
in O O
combination O O
with O O
chemotherapy O O
or O O
biotherapy O O
in O O
the O O
management O O
of O O
metastatic O O
melanoma O O
and O O
metastatic O O
renal O O
cell O O
carcinoma O O
. O O
Moreover O O
, O O
expression O O
of O O
antisense B-GENE B-GENE
Ha I-GENE I-GENE
- I-GENE I-GENE
Ras E-GENE E-GENE
or O O
dominant B-GENE O
negative I-GENE O
Raf-1 E-GENE S-GENE
abrogated O O
the O O
mitogenic O O
effect O O
of O O
TGF B-GENE B-GENE
- I-GENE I-GENE
beta1 E-GENE E-GENE
in O O
TSU O S-GENE
- O O
Pr1 O S-GENE
, O O
and O O
the O O
TGF O B-GENE
- O I-GENE
beta1 O E-GENE
inhibition O O
of O O
DU145 O S-GENE
was O O
switched O O
to O O
stimulation O O
by O O
V12Ha B-GENE B-GENE
- I-GENE I-GENE
Ras E-GENE I-GENE
transfection O E-GENE
. O O
Taken O O
together O O
, O O
our O O
data O O
suggest O O
that O O
prostate O O
carcinomas O O
with O O
the O O
Ras S-GENE S-GENE
/ O O
MAPK S-GENE S-GENE
pathway O O
activation O O
might O O
have O O
a O O
selective O O
growth O O
advantage O O
by O O
autocrine O O
TGF B-GENE B-GENE
- I-GENE I-GENE
beta1 E-GENE E-GENE
production O O
. O O
Vbeta S-GENE O
segments O O
are O O
appended O O
to O O
DJbeta S-GENE O
rearrangements O O
, O O
with O O
little O O
or O O
no O O
direct O O
Vbeta O O
to O O
Jbeta O O
joining O O
, O O
despite O O
12/23 O O
compatibility O O
of O O
Vbeta B-GENE O
23-RSSs E-GENE O
and O O
Jbeta12-RSSs S-GENE O
. O O
For O O
oral O O
administration O O
, O O
AUC0-infinity O O
was O O
58.47 O O
+ O O
/- O O
16.37 O O
microg O O
x O O
h O O
/ O O
ml O O
, O O
t1/2beta O O
was O O
18.39 O O
+ O O
/- O O
0.06 O O
hours O O
, O O
maximum O O
concentration O O
( O O
Cmax O O
) O O
was O O
2.12 O O
+ O O
/- O O
00.51 O O
microg O O
/ O O
ml O O
, O O
time O O
to O O
Cmax O O
was O O
2.20 O O
+ O O
/- O O
2.17 O O
hours O O
, O O
mean O O
absorption O O
time O O
was O O
2.09 O O
+ O O
/- O O
0.51 O O
hours O O
, O O
and O O
bioavailability O O
was O O
42 O O
+ O O
/- O O
0.42% O O
. O O

In O O
experiment O O
2 O O
, O O
no O O
difference O O
in O O
gastric O O
emptying O O
of O O
40% O O
peptone O O
or O O
25% O O
glucose O O
was O O
found O O
between O O
rats O O
receiving O O
TPN O O
and O O
those O O
receiving O O
intragastric O O
nutrition O O
for O O
10 O O
to O O
12 O O
days O O
. O O

In O O
contrast O O
, O O
H B-GENE O
- I-GENE O
NS E-GENE O
negative O O
regulation O O
operated O O
only O O
in O O
the O O
absence O O
of O O
Fur S-GENE O
. O O
Thus O O
, O O
SAG S-GENE S-GENE
appears O O
to O O
control O O
cell O O
cycle O O
progression O O
in O O
yeast O O
by O O
promoting O O
ubiquitination O O
and O O
degradation O O
of O O
cell O O
cycle O O
regulatory O O
proteins O O
. O O
E2F B-GENE S-GENE
-1 E-GENE O
is O O
a O O
transcription O O
factor O O
that O O
regulates O O
cell O O
cycle O O
progression O O
into O O
S O O
- O O
phase O O
. O O
It O O
brings O O
about O O
fatigue O O
, O O
negative O O
moods O O
, O O
and O O
impaired O O
health O O
, O O
sleep O O
, O O
safety O O
, O O
and O O
working O O
capacity O O
. O O

This O O
demonstrates O O
that O O
treatment O O
of O O
the O O
graft O O
recipient O O
for O O
a O O
relatively O O
short O O
period O O
during O O
and O O
after O O
surgery O O
has O O
a O O
favorable O O
effect O O
on O O
the O O
survival O O
of O O
grafted O O
dopaminergic O O
neurons O O
. O O

The O O
relationships O O
among O O
blood O O
concentrations O O
of O O
thyroid O O
hormones O O
and O O
selenium O O
, O O
zinc O O
, O O
retinol O O
, O O
and O O
alpha O O
- O O
tocopherol O O
were O O
studied O O
in O O
44 O O
healthy O O
Northern O O
Italian O O
oldest O O
- O O
old O O
subjects O O
( O O
age O O
range O O
, O O
90 O O
- O O
107 O O
yr O O
) O O
, O O
selected O O
by O O
the O O
criteria O O
of O O
the O O
SENIEUR O O
protocol O O
. O O

Chinese O O
Spring O O
( O O
CS O O
) O O
carrying O O
the O O
Q B-GENE B-GENE
gene E-GENE E-GENE
to O O
those O O
of O O
a O O
chromosome O O
deletion O O
line O O
of O O
CS O S-GENE
, O O
namely O O
, O O
q5 O O
, O O
which O O
lacks O O
15% O O
of O O
5AL O S-GENE
including O O
the O O
Q O B-GENE
gene O E-GENE
. O O
Investigations O O
using O O
hippocampal O O
slices O O
maintained O O
in O O
vitro O O
have O O
demonstrated O O
that O O
bursts O O
of O O
oscillatory O O
field O O
potentials O O
in O O
the O O
gamma O O
frequency O O
range O O
( O O
30 O O
- O O
80 O O
Hz O O
) O O
are O O
followed O O
by O O
a O O
slower O O
oscillation O O
in O O
the O O
beta O O
1 O O
range O O
( O O
12 O O
- O O
20 O O
Hz O O
) O O
. O O

Karger O O
AG O O
, O O
Basel O O

During O O
surgery O O
bone O O
cysts O O
were O O
excised O O
and O O
filled O O
by O O
bone O O
grafts O O
. O O

Urinary O O
LTE4 O O
increased O O
after O O
both O O
challenges O O
the O O
rise O O
being O O
higher O O
following O O
oral O O
as O O
compared O O
to O O
inhalation O O
provocation O O
( O O
p=0.0001 O O
) O O
. O O

Basal O O
FVR O S-GENE
was O O
reduced O O
by O O
approximately O O
18% O O
by O O
ERT O O
and O O
HRT O O
, O O
but O O
FVR O O
responses O O
to O O
noradrenaline O O
, O O
angiotensin B-GENE B-GENE
II E-GENE E-GENE
, O O
acetylcholine O O
and O O
nitroprusside O O
were O O
unaffected O O
. O O
Three O O
FGF B-GENE B-GENE
- I-GENE I-GENE
AS I-GENE I-GENE
cDNAs E-GENE E-GENE
were O O
isolated O O
; O O
the O O
full B-GENE O
- I-GENE O
length I-GENE O
FGF I-GENE B-GENE
- I-GENE I-GENE
AS I-GENE I-GENE
mRNA E-GENE E-GENE
and O O
two O O
alternative O O
splice O O
variants O O
lacking O O
exon O O
2 O O
or O O
exons O O
2 O O
and O O
3 O O
of O O
the O O
FGF B-GENE B-GENE
- I-GENE I-GENE
AS I-GENE I-GENE
sequence E-GENE E-GENE
. O O
Taken O O
together O O
, O O
these O O
results O O
indicate O O
that O O
MAP B-GENE B-GENE
kinase E-GENE E-GENE
stimulates O O
the O O
hPL B-GENE B-GENE
- I-GENE I-GENE
B I-GENE I-GENE
enhancer E-GENE E-GENE
by O O
an O O
NF O B-GENE
- O I-GENE
IL-6-dependent O E-GENE
pathway O O
. O O
Characterization O O
of O O
polymorphic O O
TNRs O S-GENE
in O O
novel O O
and O O
even O O
known O O
genes O O
expressed O O
in O O
human O O
spinal O O
cord O O
is O O
likely O O
to O O
help O O
in O O
the O O
identification O O
of O O
new O O
candidates O O
for O O
genes O O
involved O O
in O O
neurodegenerative O O
disorders O O
. O O

Finally O O
, O O
in O O
situ O O
RNA O O
hybridization O O
studies O O
revealed O O
a O O
very O O
specific O O
pattern O O
of O O
EphA8 B-GENE B-GENE
gene E-GENE E-GENE
expression O O
restricted O O
to O O
the O O
rostral O O
region O O
of O O
midbrain O O
tectum O O
during O O
embryonic O O
development O O
. O O
Transfection O O
of O O
cDNAs O O
for O O
three O O
mutant O O
enzymes O O
into O O
FPGS S-GENE S-GENE
- O O
null O O
Chinese O O
hamster O O
ovary O O
cells O O
restored O O
a O O
reduced O O
level O O
of O O
clonal O O
growth O O
, O O
whereas O O
a O O
T339I O B-GENE
mutant O E-GENE
supported O O
growth O O
at O O
a O O
level O O
comparable O O
to O O
that O O
of O O
the O O
wild O B-GENE
- O I-GENE
type O I-GENE
enzyme O E-GENE
. O O
SETTING O O
: O O
University O O
of O O
Paris O O
VII O O
hospital O O
. O O
Patient(s O O
) O O
: O O
Nine O O
women O O
had O O
embolization O O
for O O
symptomatic O O
myoma O O
, O O
with O O
12 O O
pregnancies O O
observed O O
. O O

Improving O O
fissure O O
sealant O O
quality O O
: O O
mechanical O O
preparation O O
and O O
filling O O
level O O
. O O

The O O
Menopause O O
- O O
Rating O O
- O O
Scale O O
( O O
MRS O O
I O O
) O O
was O O
used O O
in O O
clinical O O
practice O O
since O O
1992 O O
. O O

The O O
MRS O O
II O O
meets O O
a O O
high O O
methodological O O
standard O O
as O O
an O O
instrument O O
standardized O O
in O O
the O O
population O O
. O O

The O O
protein O O
encoded O O
by O O
the O O
fruA B-GENE B-GENE
transcript E-GENE E-GENE
is O O
well O O
conserved O O
with O O
the O O
D. B-GENE B-GENE
melanogaster I-GENE I-GENE
type I-GENE I-GENE
A I-GENE I-GENE
protein E-GENE E-GENE
, O O
particularly O O
the O O
BTB B-GENE B-GENE
protein E-GENE I-GENE
- O I-GENE
protein O I-GENE
- O I-GENE
binding O I-GENE
domain O E-GENE
, O O
which O O
is O O
encoded O O
by O O
exons O O
I O S-GENE
and O O
II O S-GENE
and O O
is O O
100% O O
conserved O O
. O O
In O O
addition O O
, O O
the O O
mouse O O
ortholog O O
( O O
Mharp S-GENE S-GENE
/ O O
Smarcal1 S-GENE S-GENE
) O O
was O O
cloned O O
, O O
and O O
the O O
Caenorhabditis O O
elegans O O
ortholog O O
( O O
CEHARP S-GENE S-GENE
) O O
was O O
identified O O
in O O
the O O
GenBank O O
database O O
. O O
Sparfloxacin O O
and O O
clinafloxacin O O
were O O
evaluated O O
against O O
Enterococcus O O
faecium O O
SF2149 O O
and O O
Enterococcus O O
faecalis O O
WH245 O O
, O O
respectively O O
. O O

ECP S-GENE S-GENE
and O O
tryptase S-GENE S-GENE
levels O O
in O O
serum O O
were O O
measured O O
before O O
and O O
after O O
the O O
last O O
oral O O
challenge O O
. O O
Tolterodine O O
users O O
were O O
7.5 O O
times O O
more O O
likely O O
to O O
have O O
received O O
another O O
spasmolytic O O
drug O O
( O O
RR O O
7.5 O O
, O O
95% O O
CI O O
4.8 O O
to O O
11.9 O O
) O O
. O O

For O O
an O O
unsupervised O O
program O O
, O O
the O O
costs O O
were O O
estimated O O
at O O
$ O O
311 O O
for O O
the O O
first O O
year O O
and O O
$ O O
73 O O
for O O
all O O
additional O O
years O O
. O O

The O O
presence O O
of O O
such O O
a O O
putative O O
RNA- O B-GENE
binding O I-GENE
domain O E-GENE
suggests O O
a O O
mechanism O O
for O O
the O O
observed O O
autoregulation O O
of O O
bacteriophage O B-GENE
T4 B-GENE I-GENE
DNA I-GENE I-GENE
polymerase E-GENE E-GENE
synthesis O O
by O O
binding O O
to O O
its O O
own O O
mRNA O O
. O O
Deletion O O
and O O
mutational O O
analyses O O
revealed O O
two O O
positive O O
cis O O
- O O
regulatory O O
elements O O
in O O
this O O
region O O
that O O
are O O
essential O O
for O O
CSX1 S-GENE S-GENE
expression O O
in O O
cardiomyocytes O O
. O O
Functional O O
studies O O
which O O
introduced O O
a O O
mutation O O
in O O
the O O
AP2 B-GENE B-GENE
core I-GENE I-GENE
binding I-GENE I-GENE
region E-GENE E-GENE
as O O
well O O
as O O
cotransfection O O
experiments O O
using O O
an O O
AP2 O S-GENE
expression O O
vector O O
revealed O O
that O O
AP2 O S-GENE
exerts O O
a O O
repressive O O
role O O
on O O
the O O
HGF B-GENE B-GENE
gene I-GENE I-GENE
promoter E-GENE E-GENE
activity O O
. O O
Using O O
adenoviral O O
transfer O O
of O O
IkappaBalpha S-GENE S-GENE
( O O
IkappaBalpha O S-GENE
overexpression O O
) O O
, O O
the O O
production O O
of O O
TNF B-GENE B-GENE
- I-GENE I-GENE
alpha E-GENE E-GENE
induced O O
by O O
whole O O
GBS O S-GENE
was O O
inhibited O O
by O O
only O O
20% O O
. O O
In O O
reconstitution O O
experiments O O
, O O
we O O
first O O
showed O O
that O O
expression O O
in O O
the O O
RAW O O
264.7 O O
cell O O
line O O
of O O
C B-GENE B-GENE
- I-GENE I-GENE
terminal I-GENE I-GENE
Src I-GENE I-GENE
kinase E-GENE E-GENE
( O O
Csk S-GENE S-GENE
) O O
inhibited O O
and O O
that O O
of O O
a O O
membrane O O
- O O
anchored O O
, O O
gain O O
- O O
of O O
- O O
function O O
Csk O O
abolished O O
the O O
Fc B-GENE B-GENE
gamma I-GENE I-GENE
R E-GENE E-GENE
- O O
mediated O O
signaling O O
that O O
leads O O
to O O
phagocytosis O O
in O O
a O O
kinase O O
- O O
dependent O O
manner O O
. O O
In O O
contrast O O
, O O
c B-GENE B-GENE
- I-GENE I-GENE
Src I-GENE E-GENE
- I-GENE O
derived I-GENE O
construct E-GENE O
( O O
a B-GENE O
- I-GENE O
Src E-GENE S-GENE
) O O
, O O
that O O
was O O
excluded O O
from O O
detergent O O
- O O
resistant O O
membranes O O
, O O
could O O
not O O
restore O O
the O O
series O O
of O O
phagocytosis O O
signaling O O
. O O
The O O
delta B-GENE B-GENE
srb10 I-GENE I-GENE
mutation E-GENE E-GENE
also O O
influenced O O
on O O
the O O
transcript O O
levels O O
of O O
meiosis O B-GENE
- O I-GENE
inducing O I-GENE
genes O E-GENE
called O O
IME1 S-GENE S-GENE
and O O
IME2 S-GENE S-GENE
: O O
the O O
mutation O O
elevated O O
the O O
transcript O O
level O O
of O O
IME1 O S-GENE
but O O
reduced O O
that O O
of O O
IME2 O S-GENE
, O O
resulting O O
in O O
partial O O
defects O O
in O O
premeiotic O O
DNA O O
synthesis O O
and O O
meiosis O O
. O O
We O O
also O O
found O O
that O O
environmental O O
conditions O O
for O O
meiosis O O
finely O O
regulate O O
the O O
transcript O O
levels O O
of O O
KIN28 S-GENE S-GENE
and O O
CCL1 S-GENE S-GENE
, O O
such O O
that O O
nitrogen O O
starvation O O
first O O
elevates O O
them O O
but O O
subsequent O O
alkalization O O
of O O
medium O O
decreases O O
them O O
. O O
The O O
pJR O S-GENE
vectors O O
differ O O
among O O
them O O
in O O
: O O
( O O
a O O
) O O
the O O
selectable O O
marker O O
( O O
Saccharomyces O B-GENE
cerevisiae O I-GENE
LEU B-GENE I-GENE
2 I-GENE I-GENE
gene E-GENE E-GENE
, O O
which O O
complements O O
S. B-GENE B-GENE
pombe I-GENE I-GENE
leu1- I-GENE I-GENE
gene E-GENE E-GENE
and O O
S. O B-GENE
pombe O I-GENE
ura4 B-GENE I-GENE
+ E-GENE E-GENE
and O O
his3 B-GENE B-GENE
+ I-GENE I-GENE
genes E-GENE E-GENE
) O O
; O O
( O O
b O O
) O O
the O O
thiamine O B-GENE
- O I-GENE
repressible O I-GENE
nmt1 B-GENE I-GENE
promoter E-GENE E-GENE
( O O
3X O O
, O O
41X O S-GENE
and O O
81X O S-GENE
with O O
extremely O O
high O O
, O O
moderate O O
or O O
low O O
transcription O O
efficiency O O
, O O
respectively O O
) O O
; O O
and O O
( O O
c O O
) O O
the O O
multiple O O
cloning O O
site O O
( O O
two O O
multiple O O
cloning O O
sites O O
, O O
with O O
12 O O
restriction O O
sites O O
each O O
) O O
. O O
( O O
GUT)Sera O O
of O O
30 O O
montoux O O
negative O O
healthy O O
adults O O
( O O
age O O
/ O O
sex O O
matched O O
) O O
were O O
taken O O
as O O
control O O
by O O
detecting O O
IgG B-GENE B-GENE
anti I-GENE E-GENE
bodies E-GENE O
to O O
A60 B-GENE B-GENE
antigen E-GENE E-GENE
. O O
The O O
effect O O
of O O
acute O O
, O O
mid O O
- O O
cervical O O
spinal O O
cord O O
lesions O O
on O O
neuronal O O
and O O
reflex O O
activity O O
evoked O O
by O O
the O O
noxious O O
visceral O O
stimulus O O
, O O
colorectal O O
distension O O
( O O
CRD O O
; O O
80 O O
mmHg O O
, O O
20 O O
s O O
) O O
, O O
was O O
determined O O
in O O
halothane O O
- O O
anesthetized O O
rats O O
. O O

Franz O O
Schubert O O
-- O O
his O O
life O O
, O O
music O O
and O O
diseases O O

The O O
results O O
suggest O O
that O O
the O O
role O O
of O O
S. O O
argyrostoma O O
in O O
the O O
dissemination O O
of O O
Trichinella O O
larvae O O
in O O
nature O O
is O O
limited O O
in O O
comparison O O
to O O
the O O
role O O
played O O
by O O
mammals O O
with O O
scavenger O O
and O O
cannibalistic O O
behavior O O
. O O

The O O
equilibrium O O
dissociation O O
binding O O
constant O O
for O O
the O O
interaction O O
of O O
TnrA S-GENE S-GENE
with O O
the O O
nrgAB B-GENE B-GENE
promoter I-GENE E-GENE
fragment E-GENE O
was O O
7.7 O O
nM O O
under O O
the O O
conditions O O
used O O
here O O
. O O
These O O
results O O
demonstrate O O
that O O
N O B-GENE
- O I-GENE
glycans O I-GENE
flanking O E-GENE
the O O
receptor O B-GENE
- O I-GENE
binding O I-GENE
site O E-GENE
of O O
the O O
HA B-GENE S-GENE
molecule E-GENE O
are O O
potent O O
regulators O O
of O O
influenza O O
virus O O
growth O O
, O O
with O O
the O O
glycan O O
at O O
Asn149 O O
being O O
dominant O O
and O O
that O O
at O O
Asn123 O O
being O O
less O O
effective O O
. O O
RESULTS O O
: O O
The O O
introduction O O
of O O
the O O
PAIP O O
resulted O O
in O O
a O O
significant O O
( O O
p<0.001 O O
) O O
reduction O O
in O O
contaminating O O
WBCs O O
( O O
median O O
, O O
30,000 O O
) O O
from O O
the O O
numbers O O
seen O O
with O O
FIP O O
( O O
median O O
, O O
2,300,000 O O
) O O
while O O
maintaining O O
the O O
separation O O
efficacy O O
( O O
47% O O
) O O
and O O
separation O O
time O O
. O O

All O O
were O O
tested O O
for O O
serum O B-GENE
ferritin S-GENE E-GENE
( O O
SF S-GENE S-GENE
) O O
, O O
hemoglobin S-GENE S-GENE
( O O
Hb S-GENE S-GENE
) O O
level O O
and O O
asked O O
for O O
detailed O O
histories O O
of O O
donations O O
and O O
iron O O
supplementation O O
. O O
Vascular B-GENE B-GENE
endothelial I-GENE I-GENE
growth I-GENE I-GENE
factor E-GENE E-GENE
( O O
VEGF S-GENE S-GENE
) O O
, O O
a O O
potent O O
agonist O O
secreted O O
by O O
virtually O O
all O O
cells O O
, O O
controls O O
migration O O
and O O
division O O
of O O
vascular O O
endothelial O O
cells O O
. O O
The O O
antioxidant O B-GENE
agent O I-GENE
pyrrolidine O I-GENE
dithiocarbamate O E-GENE
( O O
PDTC O S-GENE
) O O
has O O
been O O
shown O O
to O O
protect O O
endothelial O O
cells O O
( O O
EC O O
) O O
from O O
pro O O
- O O
inflammatory O O
- O O
induced O O
and O O
pro O O
- O O
oxidant O O
- O O
induced O O
NF B-GENE B-GENE
- I-GENE I-GENE
kappaB E-GENE I-GENE
activation O E-GENE
. O O
We O O
further O O
studied O O
the O O
effects O O
of O O
SIE-1 S-GENE B-GENE
hypermethylation O E-GENE
on O O
p21WAF1 S-GENE S-GENE
induction O O
by O O
STAT S-GENE B-GENE
activation O E-GENE
. O O
Phd S-GENE B-GENE
antibody O I-GENE
- O I-GENE
immunoreactive O I-GENE
peptides O E-GENE
are O O
seen O O
in O O
light O O
- O O
adapted O O
mouse O O
retinal O O
cytosolic O O
and O O
nuclear O O
extracts O O
. O O
In O O
the O O
pRb(- B-GENE S-GENE
) E-GENE O
SAOS-2 O S-GENE
cell O O
line O O
transiently O O
transfected O O
with O O
a O O
reporter O O
plasmid O O
containing O O
six O O
tal-1 B-GENE B-GENE
binding I-GENE I-GENE
site E-GENE E-GENE
, O O
pRb O S-GENE
enhances O O
the O O
transcriptional O O
activity O O
of O O
tal-1-E12-Lmo2 O S-GENE
and O O
tal-1-E12-Lmo2-Ldb1 O S-GENE
complexes O O
but O O
not O O
that O O
of O O
a O O
tal-1-E12 O B-GENE
heterodimer O E-GENE
. O O
This O O
effect O O
was O O
not O O
seen O O
in O O
conjunction O O
with O O
oxycodone O O
, O O
a O O
morphine B-GENE O
- I-GENE O
like I-GENE O
mu I-GENE B-GENE
- I-GENE I-GENE
receptor E-GENE E-GENE
agonist O O
. O O
In O O
contrast O O
to O O
the O O
morphological O O
criteria O O
, O O
the O O
few O O
data O O
available O O
from O O
recent O O
studies O O
at O O
the O O
genetic O O
level O O
have O O
suggested O O
that O O
EPVs O O
infecting O O
different O O
insect O O
orders O O
are O O
phylogenetically O O
distant O O
. O O

Neurofibromatosis O O
of O O
the O O
breast O O
in O O
a O O
patient O O
with O O
Morbus O O
von O O
Recklinghausen O O

In O O
the O O
premating O O
period O O
male O O
rate O O
of O O
aggression O O
was O O
not O O
significantly O O
correlated O O
with O O
testosterone O O
level O O
. O O

These O O
results O O
support O O
the O O
hypothesis O O
that O O
in O O
the O O
presence O O
of O O
tryptophan O O
the O O
ribosome O O
translating O O
tnaC S-GENE S-GENE
blocks O O
Rho S-GENE O
's O O
access O O
to O O
the O O
boxA S-GENE S-GENE
and O O
rut B-GENE B-GENE
sites E-GENE E-GENE
, O O
thereby O O
preventing O O
transcription O O
termination O O
. O O
In O O
situ O O
hybridization O O
with O O
the O O
antisense O O
RNA O O
probes O O
further O O
supported O O
the O O
expression O O
changes O O
of O O
these O O
six O O
clones O O
and O O
localized O O
the O O
changes O O
in O O
multiple O O
germ O O
cell O O
stages O O
as O O
well O O
as O O
other O O
cell O O
types O O
( O O
Sertoli O O
, O O
interstitial O O
and O O
peritubular O O
cells O O
) O O
. O O

The O O
administration O O
of O O
the O O
GnRH S-GENE O
agonist O O
reduced O O
the O O
bone O O
mineral O O
density O O
in O O
the O O
whole O O
femur O O
to O O
91.0% O O
of O O
that O O
in O O
the O O
control O O
group O O
. O O
Prevention O O
, O O
differential O O
diagnosis O O
and O O
therapy O O
of O O
travel O O
diarrhea O O

This O O
study O O
shows O O
that O O
C B-GENE O
/ I-GENE O
EBPbeta E-GENE O
is O O
the O O
predominant O O
C B-GENE O
/ I-GENE O
EBP I-GENE B-GENE
isoform E-GENE E-GENE
found O O
in O O
activated O O
stellate O O
cells O O
and O O
that O O
increased O O
C B-GENE B-GENE
/ I-GENE I-GENE
EBPbeta I-GENE I-GENE
protein E-GENE E-GENE
and O O
C O O
/ O O
EBPbeta O S-GENE
binding O O
to O O
a O O
proximal O O
C B-GENE O
/ I-GENE O
EBP I-GENE B-GENE
binding I-GENE I-GENE
site E-GENE E-GENE
in O O
the O O
promoter O O
mediates O O
the O O
activating O O
effect O O
of O O
acetaldehyde O O
. O O
Mutation O O
analysis O O
demonstrates O O
that O O
the O O
motif O O
TCCCCT O S-GENE
is O O
critical O O
for O O
PyRo1 S-GENE S-GENE
interaction O O
. O O
As O O
with O O
VP16 S-GENE S-GENE
, O O
the O O
transactivation O O
function O O
of O O
Luman S-GENE S-GENE
is O O
also O O
regulated O O
by O O
HCF S-GENE S-GENE
. O O
After O O
two O O
successive O O
rounds O O
of O O
selection O O
by O O
focus O O
formation O O
assay O O
, O O
a O O
transforming O O
ribozyme O O
( O O
Rz007 S-GENE O
) O O
was O O
identified O O
. O O
G. O O
, O O
and O O
Hyde O O
, O O
C. O O

Our O O
results O O
suggest O O
that O O
proteasome O O
inhibition O O
leads O O
to O O
upregulation O O
of O O
specific O O
members O O
of O O
transcription O O
factor O O
families O O
controlling O O
cellular O O
stress O O
response O O
and O O
proliferation O O
. O O

The O O
ATR O O
- O O
X O O
syndrome O O
results O O
from O O
mutations O O
of O O
the O O
XH2 B-GENE B-GENE
gene E-GENE E-GENE
, O O
located O O
on O O
the O O
X O O
chromosome O O
( O O
Xq13.3 O O
) O O
and O O
coding O O
for O O
a O O
transacting O B-GENE
factor O I-GENE
which O I-GENE
regulates O I-GENE
gene O E-GENE
expression O O
. O O
AIMS O S-GENE
: O O
To O O
evaluate O O
the O O
role O O
of O O
environmental O O
intra O O
- O O
uterine O O
factors O O
in O O
determining O O
the O O
birthweights O O
of O O
twins O O
with O O
increased O O
susceptibility O O
to O O
diabetes O O
and O O
discordant O O
for O O
abnormal O O
responses O O
to O O
the O O
oral O O
glucose O O
tolerance O O
test O O
( O O
OGTT O O
) O O
and O O
verify O O
the O O
possible O O
association O O
of O O
within O O
- O O
pair O O
birthweight O O
differences O O
and O O
metabolic O O
abnormalities O O
in O O
adult O O
life O O
. O O

In O O
NASCIS O B-GENE
III O E-GENE
, O O
a O O
randomization O O
imbalance O O
occurred O O
that O O
allocated O O
a O O
disproportionate O O
number O O
of O O
patients O O
with O O
no O O
motor O O
deficit O O
( O O
and O O
therefore O O
no O O
chance O O
for O O
recovery O O
) O O
to O O
the O O
lower O O
dose O O
control O O
group O O
. O O

Penicillin B-GENE O
acylase E-GENE O
( O O
PA S-GENE O
) O O
from O O
Escherichia O B-GENE
coli O I-GENE
ATCC11105 O E-GENE
is O O
a O O
periplasmic O O
heterodimer O O
consisting O O
of O O
a O O
24 O O
kDa O O
small O O
subunit O O
and O O
a O O
65 O O
kDa O O
large O O
subunit O O
. O O
A O O
murine O O
expressed O O
sequence O O
tag O O
( O O
EST O O
) O O
showing O O
homology O O
with O O
erythropoietin B-GENE B-GENE
receptor E-GENE E-GENE
( O O
EPOR S-GENE S-GENE
) O O
was O O
identified O O
in O O
the O O
EST O O
database O O
. O O
When O O
the O O
LCx O O
was O O
partially O O
occluded O O
, O O
mild O O
PM O O
- O O
induced O O
tachycardia O O
resulted O O
in O O
decreased O O
AoP O O
( O O
P=0.045 O O
) O O
as O O
well O O
as O O
in O O
decreased O O
SV O O
( O O
P=0.048 O O
) O O
; O O
the O O
LVEDP O O
remained O O
high O O
( O O
P=0.002 O O
) O O
. O O

Activation O O
of O O
nuclear B-GENE B-GENE
factor I-GENE E-GENE
( I-GENE O
NF)-kappaB E-GENE S-GENE
and O O
subsequent O O
proinflammatory O O
gene O O
expression O O
in O O
human O O
airway O O
epithelial O O
cells O O
can O O
be O O
evoked O O
by O O
oxidative O O
stress O O
. O O
GAP O O
JUNCTIONS O O
IN O O
THE O O
BRAIN O O
: O O
PREFACE O O
. O O

We O O
have O O
isolated O O
and O O
functionally O O
characterized O O
the O O
mouse O B-GENE
gene O E-GENE
for O O
the O O
C2 O B-GENE
subunit O E-GENE
of O O
the O O
20S B-GENE B-GENE
proteasome E-GENE E-GENE
. O O
Furthermore O O
, O O
as O O
in O O
the O O
human O B-GENE
gene O E-GENE
, O O
the O O
3 O O
' O O
end O O
of O O
the O O
Cacna1f B-GENE B-GENE
gene E-GENE E-GENE
maps O O
within O O
5 O O
kb O O
of O O
the O O
5 O O
' O O
end O O
of O O
the O O
mouse B-GENE B-GENE
synaptophysin I-GENE I-GENE
gene E-GENE E-GENE
in O O
a O O
region O O
orthologous O O
to O O
Xp11.23 O S-GENE
. O O
With O O
the O O
human B-GENE B-GENE
Rhotekin I-GENE I-GENE
cDNA E-GENE E-GENE
as O O
a O O
probe O O
, O O
Northern O O
hybridization O O
revealed O O
that O O
a O O
4.0-kb O O
transcript O O
was O O
expressed O O
at O O
a O O
high O O
level O O
in O O
prostate O O
and O O
at O O
a O O
middle O O
level O O
in O O
13 O O
of O O
16 O O
tissues O O
examined O O
, O O
but O O
it O O
can O O
not O O
be O O
detected O O
in O O
liver O O
and O O
lung O O
tissues O O
. O O
Similarly O O
, O O
co O O
- O O
expression O O
of O O
a O O
dominant O O
- O O
negative O O
mutant O O
of O O
p38alpha S-GENE S-GENE
, O O
but O O
not O O
of O O
ERK1 S-GENE S-GENE
, O O
ERK2 S-GENE S-GENE
, O O
JNK1 S-GENE S-GENE
, O O
or O O
JNK2 S-GENE O
, O O
reduces O O
basal O O
and O O
cadmium O O
- O O
induced O O
pE1-luc S-GENE O
activity O O
. O O
BACKGROUND O O
: O O
Gamma O O
knife O O
radiosurgery O O
( O O
GKR O O
) O O
is O O
a O O
safe O O
and O O
effective O O
alternative O O
to O O
surgery O O
for O O
intracranial O O
lesions O O
. O O

In O O
hemodialyzed O O
patients O O
( O O
Epo S-GENE S-GENE
and O O
Non O O
- O O
Epo O S-GENE
group O O
) O O
leptin S-GENE O
levels O O
were O O
significantly O O
higher O O
when O O
compared O O
to O O
CAPD O O
patients O O
( O O
Epo O S-GENE
and O O
Non O O
- O O
Epo O S-GENE
group O O
, O O
respectively O O
) O O
. O O
It O O
is O O
mainly O O
transcribed O O
in O O
neural O O
structures O O
and O O
in O O
developing O O
organs O O
characterized O O
by O O
epithelial O O
- O O
mesenchymal O O
interactions O O
. O O

CONCLUSION O O
: O O
The O O
alpha2-adrenergic O O
antagonist O O
idazoxan O O
increases O O
glucose O O
- O O
induced O O
sympathetic O O
activity O O
but O O
not O O
energy O O
expenditure O O
in O O
obese O O
subjects O O
. O O

ID O B-GENE
- O I-GENE
PaGIA O I-GENE
diphtheria B-GENE I-GENE
toxin E-GENE E-GENE
polymer O O
particle O O
diagnostic O O
agent O O
manufactured O O
by O O
DiaMed O B-GENE
AG O E-GENE
, O O
Switzerland O O
, O O
was O O
tried O O
at O O
bacteriological O O
laboratory O O
of O O
Institute O O
of O O
Childhood O O
Infections O O
in O O
St. O O
Next O O
, O O
we O O
show O O
that O O
two O O
EMS O S-GENE
- O O
induced O O
mutations O O
, O O
previously O O
shown O O
to O O
interact O O
genetically O O
with O O
zipper(Ebr O S-GENE
) O O
, O O
disrupt O O
the O O
RhoA B-GENE B-GENE
locus E-GENE E-GENE
. O O
Therefore O O
, O O
the O O
results O O
indicate O O
that O O
repeated O O
exposure O O
to O O
amphetamine O O
or O O
apomorphine O O
overcomes O O
the O O
context O O
- O O
dependent O O
component O O
of O O
sensitization O O
of O O
amphetamine- O O
or O O
apomorphine O O
- O O
induced O O
stereotyped O O
behavior O O
. O O

Testing O O
for O O
serum B-GENE B-GENE
IgM E-GENE E-GENE
binding O O
to O O
GM1 O B-GENE
ganglioside O E-GENE
in O O
clinical O O
practice O O
. O O
Objective O O
responses O O
also O O
occurred O O
in O O
studies O O
that O O
explored O O
sequential O O
use O O
of O O
exemestane O O
after O O
failure O O
of O O
aminoglutethimide O O
( O O
26% O O
with O O
exemestane O O
200 O O
mg O O
/ O O
day O O
) O O
or O O
other O O
nonsteroidal O O
aromatase S-GENE O
inhibitors O O
( O O
6.6% O O
with O O
exemestane O O
25 O O
mg O O
/ O O
day O O
) O O
. O O
Topics O O
reviewed O O
here O O
include O O
: O O
data O O
supporting O O
the O O
association O O
of O O
myositis O O
with O O
cancer O O
and O O
the O O
appropriate O O
evaluations O O
for O O
malignancy O O
in O O
a O O
myositis O O
patient O O
; O O
an O O
approach O O
to O O
the O O
assessment O O
of O O
patients O O
with O O
dermatomyositis O O
sine O O
myositis O O
; O O
the O O
usefulness O O
of O O
the O O
clinicopathological O O
and O O
serological O O
classifications O O
; O O
a O O
discussion O O
of O O
whether O O
childhood O O
and O O
adult O O
myositis O O
are O O
the O O
same O O
or O O
different O O
entities O O
; O O
a O O
review O O
of O O
those O O
prognostic O O
factors O O
to O O
consider O O
in O O
the O O
clinical O O
management O O
of O O
myositis O O
patients O O
; O O
current O O
approaches O O
and O O
their O O
limitations O O
for O O
assessing O O
disease O O
activity O O
and O O
damage O O
. O O

The O O
science O O
of O O
tissue O O
engineering O O
. O O

Endonuclease B-GENE O
III E-GENE S-GENE
( O O
Nth S-GENE S-GENE
) O O
of O O
Escherichia O O
coli O O
is O O
a O O
DNA B-GENE O
glycosylase E-GENE O
essential O O
for O O
the O O
removal O O
of O O
oxidised O O
pyrimidine O O
base O O
residues O O
from O O
DNA O O
. O O
The O O
duration O O
of O O
reactive O O
hyperemia O O
decreased O O
with O O
aging O O
, O O
but O O
the O O
difference O O
between O O
males O O
and O O
females O O
was O O
not O O
significant O O
at O O
any O O
age O O
. O O

Acquired O O
bile O O
duct O O
blockage O O
: O O
entry O O
of O O
hepatobiliary O O
agent O O
into O O
an O O
intrahepatic O O
abscess O O
. O O

Furthermore O O
, O O
this O O
study O O
looks O O
at O O
the O O
impact O O
of O O
synthesis O O
conditions O O
on O O
block O O
length O O
and O O
crystallinity O O
, O O
and O O
the O O
impact O O
of O O
the O O
blocking O O
on O O
both O O
, O O
crystallinity O O
and O O
solubility O O
of O O
the O O
polymers O O
. O O

However O O
, O O
little O O
was O O
understood O O
about O O
the O O
normal O O
function O O
of O O
CREB-2 S-GENE O
in O O
mammalian O O
development O O
or O O
organ O O
physiology O O
. O O
The O O
outer O O
diameter O O
and O O
the O O
thickness O O
of O O
the O O
rotor O O
are O O
60 O O
mm O O
and O O
8 O O
mm O O
, O O
respectively O O
. O O

Both O O
the O O
MVBF O O
and O O
the O O
maximum O O
EMG O O
activity O O
in O O
the O O
right O O
masseter O O
and O O
the O O
left O O
anterior O O
temporalis O O
muscles O O
were O O
significantly O O
decreased O O
during O O
muscle O O
pain O O
when O O
the O O
subjects O O
bit O O
on O O
the O O
painful O O
side O O
. O O

CONCLUSIONS O O
: O O
There O O
is O O
a O O
relation O O
in O O
the O O
topography O O
of O O
some O O
visual O O
field O O
areas O O
assessed O O
by O O
SWAP O O
and O O
the O O
inferotemporal O O
neuroretinal O O
rim O O
area O O
, O O
which O O
may O O
play O O
a O O
role O O
in O O
the O O
diagnosis O O
and O O
follow O O
- O O
up O O
of O O
suspected O O
glaucoma O O
. O O

The O O
total O O
alkaloids O O
contained O O
in O O
the O O
peel O O
of O O
Atzimba O O
, O O
Lopez O O
, O O
Marciana O O
, O O
Montsama O O
, O O
Murca O O
, O O
and O O
Puebla O O
was O O
lower O O
than O O
the O O
limits O O
recommended O O
for O O
food O O
safety O O
. O O

The O O
detection O O
success O O
rate O O
was O O
determined O O
for O O
different O O
markers O O
using O O
this O O
MEK S-GENE S-GENE
. O O
Herein O O
, O O
we O O
show O O
that O O
Smad3 S-GENE S-GENE
physically O O
interacts O O
with O O
the O O
HMG S-GENE B-GENE
box O I-GENE
domain O E-GENE
of O O
LEF1 S-GENE S-GENE
and O O
that O O
TGFbeta S-GENE S-GENE
and O O
Wnt S-GENE S-GENE
pathways O O
synergize O O
to O O
activate O O
transcription O O
of O O
the O O
Xenopus O B-GENE
homeobox O I-GENE
gene O E-GENE
twin S-GENE O
( O O
Xtwn S-GENE S-GENE
) O O
. O O
The O O
transmembrane O O
topology O O
of O O
Na(+)/H(+ O S-GENE
) O O
exchanger O O
NHE3 S-GENE S-GENE
has O O
been O O
studied O O
using O O
in O O
vitro O O
transcription O O
/ O O
translation O O
of O O
two O O
types O O
of O O
fusion O O
vectors O O
designed O O
to O O
test O O
membrane O O
insertion O O
properties O O
of O O
cDNA O O
sequences O O
encoding O O
putative O O
NHE3 O S-GENE
membrane O O
spanning O O
domains O O
( O O
msds O S-GENE
) O O
. O O
ACE-2 S-GENE S-GENE
has O O
a O O
hydrophobic O O
C O O
terminus O O
of O O
H O B-GENE
type O E-GENE
. O O
Members O O
of O O
the O O
titin S-GENE B-GENE
/ O I-GENE
myosin B-GENE I-GENE
light I-GENE I-GENE
chain I-GENE I-GENE
kinase E-GENE I-GENE
family O E-GENE
play O O
an O O
essential O O
role O O
in O O
the O O
organization O O
of O O
the O O
actin S-GENE B-GENE
/ O I-GENE
myosin O I-GENE
cytoskeleton O E-GENE
, O O
especially O O
in O O
sarcomere O O
assembly O O
and O O
function O O
. O O
We O O
concluded O O
that O O
activation O O
of O O
c B-GENE B-GENE
- I-GENE I-GENE
fosER E-GENE E-GENE
mediated O O
transcriptional O O
inhibition O O
of O O
p21(Cip1/WAF1 O S-GENE
) O O
through O O
a O O
previously O O
uncharacterized O O
AP-1 B-GENE B-GENE
site E-GENE E-GENE
, O O
revealing O O
an O O
important O O
role O O
for O O
c O B-GENE
- O I-GENE
fos O E-GENE
in O O
negative O O
control O O
of O O
cell O O
cycle O O
regulatory O O
genes O O
. O O
Furthermore O O
, O O
a O O
pTyr317 B-GENE B-GENE
Shc I-GENE E-GENE
phosphopeptide E-GENE O
selectively O O
recognized O O
Grb2 S-GENE S-GENE
, O O
Sos1 S-GENE S-GENE
, O O
SHIP S-GENE S-GENE
, O O
and O O
the O O
p85 B-GENE B-GENE
subunit E-GENE E-GENE
of O O
phosphatidylinositol B-GENE B-GENE
3 I-GENE I-GENE
' I-GENE I-GENE
kinase E-GENE E-GENE
from O O
mast O O
cells O O
, O O
as O O
characterized O O
by O O
mass O O
spectrometry O O
. O O
Although O O
increased O O
expression O O
of O O
the O O
HMG B-GENE B-GENE
- I-GENE I-GENE
I I-GENE I-GENE
/ I-GENE I-GENE
Y I-GENE I-GENE
proteins E-GENE E-GENE
is O O
associated O O
with O O
cellular O O
proliferation O O
, O O
neoplastic O O
transformation O O
, O O
and O O
several O O
human O O
cancers O O
, O O
the O O
role O O
of O O
these O O
proteins O O
in O O
the O O
pathogenesis O O
of O O
malignancy O O
remains O O
unclear O O
. O O
The O O
naltrexone O O
/ O O
lofexidine O O
combination O O
was O O
associated O O
with O O
a O O
more O O
rapid O O
resolution O O
of O O
the O O
opiate O O
withdrawal O O
syndrome O O
than O O
a O O
7-day O O
lofexidine O O
- O O
only O O
treatment O O
schedule O O
, O O
without O O
substantial O O
increases O O
in O O
withdrawal O O
symptoms O O
or O O
hypotensive O O
side O O
- O O
effects O O
. O O

The O O
first O O
symptoms O O
of O O
enzootic O O
calcinosis O O
were O O
noted O O
in O O
March O O
1998 O O
, O O
when O O
some O O
of O O
the O O
cows O O
developed O O
locomotor O O
abnormalities O O
. O O

Screening O O
, O O
counseling O O
, O O
and O O
treatment O O
for O O
alcohol O O
and O O
illicit O O
drug O O
use O O
should O O
be O O
essential O O
components O O
in O O
comprehensive O O
HBP O O
care O O
. O O

Transcriptional O O
regulation O O
of O O
the O O
mouse B-GENE B-GENE
cytosolic I-GENE I-GENE
chaperonin I-GENE I-GENE
subunit I-GENE I-GENE
gene E-GENE I-GENE
Ccta B-GENE I-GENE
/ I-GENE I-GENE
t I-GENE I-GENE
- I-GENE I-GENE
complex I-GENE I-GENE
polypeptide I-GENE I-GENE
1 E-GENE E-GENE
by O O
selenocysteine B-GENE B-GENE
tRNA I-GENE I-GENE
gene I-GENE I-GENE
transcription I-GENE I-GENE
activating I-GENE I-GENE
factor I-GENE I-GENE
family I-GENE I-GENE
zinc I-GENE I-GENE
finger I-GENE I-GENE
proteins E-GENE E-GENE
. O O
The O O
unfolded O O
protein O O
response O O
regulates O O
multiple O O
aspects O O
of O O
secretory O O
and O O
membrane O O
protein O O
biogenesis O O
and O O
endoplasmic O O
reticulum O O
quality O O
control O O
. O O

PNRC S-GENE S-GENE
: O O
a O O
proline O B-GENE
- O I-GENE
rich O I-GENE
nuclear O I-GENE
receptor O I-GENE
coregulatory O I-GENE
protein O E-GENE
that O O
modulates O O
transcriptional O O
activation O O
of O O
multiple O B-GENE
nuclear O I-GENE
receptors O I-GENE
including O I-GENE
orphan O I-GENE
receptors O I-GENE
SF1 S-GENE E-GENE
( O O
steroidogenic B-GENE B-GENE
factor I-GENE I-GENE
1 E-GENE E-GENE
) O O
and O O
ERRalpha1 S-GENE S-GENE
( O O
estrogen B-GENE B-GENE
related I-GENE I-GENE
receptor I-GENE I-GENE
alpha-1 E-GENE E-GENE
) O O
. O O
Studies O O
using O O
a O O
reporter O O
plasmid O O
with O O
a O O
functionally O O
disrupted O O
sterol O B-GENE
- O I-GENE
responsive O I-GENE
element O E-GENE
( O O
SRE)-1 O S-GENE
revealed O O
a O O
reduced O O
stimulatory O O
response O O
to O O
IL-6 S-GENE S-GENE
. O O
However O O
, O O
there O O
is O O
still O O
a O O
subset O O
of O O
tumors O O
that O O
displayed O O
no O O
changes O O
in O O
these O O
genes O O
. O O

We O O
have O O
shown O O
that O O
the O O
epidural O O
( O O
EPI O O
) O O
delivery O O
of O O
morphine O O
encapsulated O O
in O O
multivesicular O O
liposomes O O
( O O
DepoFoam O O
drug O O
delivery O O
system O O
) O O
produces O O
a O O
sustained O O
clearance O O
of O O
morphine O O
and O O
a O O
prolonged O O
analgesia O O
. O O

Following O O
EPI O O
- O O
C0401 O O
, O O
but O O
not O O
saline O O
or O O
DepoFoam O O
vehicle O O
, O O
there O O
were O O
transient O O
( O O
< O O
72 O O
hr O O
) O O
decreases O O
in O O
food O O
consumption O O
, O O
arousal O O
, O O
hindlimb O O
muscle O O
tone O O
, O O
and O O
body O O
temperature O O
. O O

Bailey O O
Instruments O O
and O O
Owen O O
Mumford O O
filaments O O
were O O
the O O
most O O
accurate O O
with O O
100% O O
buckling O O
within O O
+ O O
/-1.0 O O
g O O
of O O
10 O O
g. O O

PARTICIPANTS O O
: O O
Convenience O O
sample O O
of O O
ambulatory O O
outpatients O O
with O O
hereditary O O
motor O O
and O O
sensory O O
neuropathy O O
, O O
type O O
I O O
( O O
n O O
= O O
9 O O
) O O
, O O
myotonic O O
muscular O O
dystrophy O O
( O O
n O O
= O O
10 O O
) O O
, O O
and O O
able O O
- O O
bodied O O
controls O O
( O O
n O O
= O O
11 O O
) O O
. O O

The O O
effect O O
of O O
water O O
deprivation O O
for O O
19 O O
h O O
on O O
renal O O
Na O O
excretion O O
of O O
conscious O O
adrenalectomized O O
( O O
ADX O O
) O O
sheep O O
maintained O O
on O O
a O O
constant O O
intravenous O O
infusion O O
of O O
aldosterone O O
and O O
cortisol O O
( O O
ADX O O
- O O
constant O O
steroid O O
sheep O O
) O O
was O O
investigated O O
. O O

Neither O O
is O O
it O O
a O O
major O O
cause O O
of O O
rehydration O O
- O O
induced O O
renal O O
Na O O
retention O O
. O O

CONCLUSION O O
: O O
Rheumatic O O
fever O O
in O O
the O O
Nazareth O O
area O O
is O O
still O O
manifest O O
. O O

Antithrombin B-GENE B-GENE
III E-GENE E-GENE
deficiency O O
: O O
when O O
substitute O O
, O O
when O O
heparin O O
? O O
Thrombosis O O
ABC O O
, O O
3 O O
: O O
The O O
role O O
of O O
antithrombin B-GENE B-GENE
III E-GENE I-GENE
Specific O I-GENE
class B-GENE I-GENE
I I-GENE E-GENE
and I-GENE O
II I-GENE B-GENE
histone I-GENE I-GENE
deacetylases E-GENE E-GENE
( O O
HDACs S-GENE S-GENE
) O O
interact O O
in O O
vivo O O
with O O
BCoR S-GENE S-GENE
, O O
suggesting O O
that O O
BCoR O S-GENE
may O O
functionally O O
link O O
these O O
two O O
classes O O
of O O
HDACs O S-GENE
. O O
This O O
is O O
the O O
first O O
example O O
of O O
a O O
eukaryotic O B-GENE
transcription O I-GENE
factor O E-GENE
complex O O
containing O O
both O O
a O O
MADS B-GENE B-GENE
- I-GENE I-GENE
box E-GENE E-GENE
and O O
a O O
forkhead B-GENE B-GENE
protein E-GENE E-GENE
, O O
and O O
it O O
has O O
important O O
implications O O
for O O
the O O
regulation O O
of O O
mammalian O B-GENE
gene O E-GENE
expression O O
. O O
After O O
screening O O
the O O
Berkeley O B-GENE
Drosophila O I-GENE
Genome O I-GENE
Project O E-GENE
database O O
with O O
sequences O O
from O O
a O O
recently O O
characterized O O
Leu B-GENE O
- I-GENE O
rich I-GENE O
repeats I-GENE O
- I-GENE O
containing I-GENE O
G I-GENE B-GENE
protein I-GENE I-GENE
- I-GENE I-GENE
coupled I-GENE I-GENE
receptor E-GENE E-GENE
( O O
LGR S-GENE S-GENE
) O O
from O O
Drosophila O O
( O O
DLGR-1 S-GENE S-GENE
) O O
, O O
we O O
identified O O
a O O
second O O
gene O O
for O O
a O O
different O O
LGR O S-GENE
( O O
DLGR-2 S-GENE S-GENE
) O O
and O O
cloned O O
its O O
cDNA O O
. O O
Degenerate O O
primers O O
homologous O O
to O O
highly O O
conserved O O
regions O O
of O O
known O O
CYP3A B-GENE S-GENE
sequences E-GENE O
were O O
used O O
for O O
initial O O
RT O B-GENE
- O I-GENE
PCRs O E-GENE
. O O
When O O
cells O O
were O O
microinjected O O
with O O
TFOs O S-GENE
designed O O
to O O
bind O O
to O O
a O O
30-bp O O
polypurine O O
site O O
situated O O
between O O
the O O
two O O
TK B-GENE B-GENE
genes E-GENE E-GENE
, O O
recombination O O
was O O
observed O O
at O O
frequencies O O
in O O
the O O
range O O
of O O
1% O O
, O O
2,500-fold O O
above O O
the O O
background O O
. O O
Methyllevamisole O O
was O O
used O O
as O O
the O O
internal O O
standard O O
. O O

Resistance O O
ratios O O
for O O
the O O
other O O
field O O
strains O O
obtained O O
by O O
comparison O O
with O O
the O O
R5 O O
strain O O
ranged O O
from O O
24.5 O O
to O O
239 O O
for O O
topical O O
application O O
and O O
from O O
1.2 O O
to O O
9.8 O O
for O O
the O O
glass O O
jar O O
method O O
. O O

Only O O
transcripts O O
specific O O
for O O
TSGF-2 S-GENE S-GENE
are O O
detected O O
in O O
ovary O O
and O O
testes O O
tissues O O
of O O
adults O O
as O O
well O O
as O O
in O O
puparia O O
, O O
while O O
neither O O
gene O O
is O O
expressed O O
during O O
the O O
larval O O
developmental O O
stages O O
. O O
In O O
a O O
gel O O
retardation O O
assay O O
using O O
HepG2 O O
nuclear O O
extracts O O
, O O
the O O
5 O O
' O O
flanking O O
sequence O O
from O O
-74 O O
to O O
-46 O O
showed O O
a O O
shifted O O
band O O
. O O

Reliability O O
of O O
cervical O O
range O O
of O O
motion O O
using O O
the O O
OSI O O
CA O O
6000 O O
spine O O
motion O O
analyser O O
on O O
asymptomatic O O
and O O
symptomatic O O
subjects O O
. O O

Coimmunoprecipitation O O
experiments O O
performed O O
in O O
transfected O O
cells O O
showed O O
that O O
BCMA S-GENE S-GENE
associates O O
with O O
TNFR B-GENE B-GENE
- I-GENE I-GENE
associated I-GENE I-GENE
factor I-GENE E-GENE
( I-GENE O
TRAF I-GENE S-GENE
) I-GENE O
1 E-GENE O
, O O
TRAF2 S-GENE S-GENE
, O O
and O O
TRAF3 B-GENE B-GENE
adaptor I-GENE I-GENE
proteins E-GENE E-GENE
. O O
Since O O
the O O
RINX B-GENE B-GENE
gene E-GENE E-GENE
is O O
likely O O
an O O
ortholog O O
of O O
the O O
goldfish B-GENE B-GENE
Vsx1 I-GENE I-GENE
gene E-GENE E-GENE
, O O
it O O
has O O
been O O
named O O
VSX1 S-GENE S-GENE
by O O
the O O
Human O B-GENE
Gene O I-GENE
Nomenclature O E-GENE
Committee O O
. O O
The O O
chromosomal O O
localization O O
on O O
distal O O
chromosome O O
7 O O
places O O
it O O
in O O
a O O
cluster O O
of O O
imprinted O O
genes O O
, O O
flanked O O
by O O
the O O
previously O O
described O O
Tapa1 S-GENE S-GENE
and O O
Kcnq1 B-GENE B-GENE
genes E-GENE E-GENE
. O O
Activation O O
of O O
PKA S-GENE S-GENE
by O O
8-bromo O B-GENE
- O I-GENE
cyclic O I-GENE
AMP O E-GENE
or O O
forskolin O O
, O O
and O O
inhibition O O
of O O
PKC S-GENE S-GENE
by O O
calphostin O B-GENE
C O E-GENE
, O O
resulted O O
in O O
a O O
significant O O
decrease O O
in O O
3TP S-GENE S-GENE
activity O O
as O O
well O O
as O O
in O O
vitro O O
ERK B-GENE B-GENE
kinase E-GENE E-GENE
activity O O
in O O
CRAC O S-GENE
. O O
The O O
present O O
study O O
was O O
designed O O
to O O
evaluate O O
the O O
sensitivity O O
and O O
specificity O O
of O O
AMP O O
CT O O
( O O
Gen O O
- O O
Probe O O
Incorporated O O
, O O
San O O
Diego O O
, O O
CA O O
, O O
USA O O
) O O
on O O
urogenital O O
specimens O O
taken O O
from O O
symptomatic O O
patients O O
and O O
on O O
first O O
void O O
urine O O
( O O
FVU O O
) O O
specimens O O
from O O
asymptomatic O O
patients O O
. O O

Mus81p S-GENE O
also O O
shares O O
homology O O
with O O
motifs O O
found O O
in O O
the O O
XPF B-GENE B-GENE
endonuclease I-GENE I-GENE
superfamily E-GENE E-GENE
. O O
Double O B-GENE
mutant O E-GENE
analysis O O
suggests O O
that O O
Rad54p S-GENE S-GENE
and O O
Mus81p S-GENE S-GENE
act O O
in O O
one O O
pathway O O
for O O
the O O
repair O O
of O O
, O O
or O O
tolerance O O
to O O
, O O
UV O O
- O O
induced O O
DNA O O
damage O O
. O O
The O O
linear O O
plasmid O O
pCLU1 O S-GENE
from O O
the O O
yeast O O
Kluyveromyces O O
lactis O O
normally O O
replicates O O
in O O
the O O
cytoplasm O O
, O O
with O O
the O O
aid O O
of O O
the O O
helper O O
linear O O
plasmid O O
pGKL2 O S-GENE
, O O
using O O
terminal B-GENE O
protein E-GENE O
( O O
TP S-GENE S-GENE
) O O
as O O
a O O
primer O O
. O O
The O O
repetitive O O
ETn S-GENE S-GENE
( O O
early B-GENE O
transposon E-GENE O
) O O
family O O
of O O
sequences O O
represents O O
an O O
active O O
" O O
mobile O O
mutagen O O
" O O
in O O
the O O
mouse O O
genome O O
. O O
The O O
two O O
main O O
experimental O O
variables O O
were O O
the O O
attended O O
hemifield O O
( O O
left O O
or O O
right O O
) O O
and O O
the O O
proportion O O
of O O
trials O O
requiring O O
a O O
shift O O
within O O
that O O
hemifield O O
( O O
20% O O
or O O
80% O O
) O O
. O O

The O O
measurement O O
of O O
NO O O
in O O
biological O O
systems O O
using O O
chemiluminescence O O
. O O

Biochemical O O
examinations O O
of O O
calcium O O
- O O
phosphorus O O
metabolism O O
included O O
ions O O
and O O
PTH S-GENE S-GENE
concentrations O O
in O O
blood O O
serum O O
, O O
and O O
the O O
activity O O
of O O
bone O B-GENE
isoenzyme O E-GENE
of O O
AP S-GENE S-GENE
. O O
Atorvastatin O O
was O O
the O O
most O O
cost O O
- O O
effective O O
HMG B-GENE B-GENE
- I-GENE I-GENE
CoA I-GENE I-GENE
reductase E-GENE I-GENE
inhibitor O E-GENE
. O O
Pharmacoeconomic O S-GENE
assessment O O
of O O
HMG B-GENE B-GENE
- I-GENE I-GENE
CoA I-GENE I-GENE
reductase E-GENE E-GENE
inhibitor O O
therapy O O
: O O
an O O
analysis O O
based O O
on O O
the O O
CURVES O O
study O O
. O O
Interestingly O O
, O O
although O O
E O O
domains O O
of O O
these O O
two O O
receptors O O
are O O
much O O
less O O
conserved O O
, O O
replacement O O
of O O
this O O
domain O O
in O O
rtER S-GENE S-GENE
by O O
its O O
human O O
counterpart O O
resulted O O
in O O
higher O O
estradiol O O
sensitivity O O
but O O
no O O
increase O O
in O O
the O O
magnitude O O
of O O
transactivation O O
. O O
G O O
- O O
DNA O O
is O O
a O O
four O O
- O O
stranded O O
DNA O O
structure O O
with O O
diverse O O
putative O O
biological O O
roles O O
. O O

The O O
effectiveness O O
of O O
NRT O O
appears O O
to O O
be O O
largely O O
independent O O
of O O
the O O
intensity O O
of O O
additional O O
support O O
provided O O
to O O
the O O
smoker O O
. O O

SELECTION O O
CRITERIA O O
: O O
All O O
controlled O O
trials O O
where O O
adults O O
with O O
schizophrenia O O
or O O
similar O O
illnesses O O
were O O
randomised O O
to O O
quetiapine O O
, O O
placebo O O
or O O
other O O
neuroleptic O O
drugs O O
and O O
where O O
clinically O O
relevant O O
outcomes O O
were O O
reported O O
. O O

8% O O
( O O
95% O O
CI O O
, O O
21.3 O O
- O O
44.3% O O
) O O
. O O

In O O
contrast O O
, O O
the O O
action O O
of O O
GLP-1 S-GENE S-GENE
at O O
the O O
CRE O O
was O O
not O O
blocked O O
by O O
cotransfection O O
with O O
M1-CREB S-GENE S-GENE
, O O
an O O
isoform O O
that O O
lacks O O
a O O
consensus O O
serine O O
residue O O
serving O O
as O O
substrate O O
for O O
PKA S-GENE B-GENE
- O I-GENE
mediated O I-GENE
phosphorylation O E-GENE
. O O
Because O O
all O O
PDGFbetaR B-GENE S-GENE
fusions E-GENE O
described O O
thus O O
far O O
result O O
in O O
splicing O O
to O O
a O O
common O O
exon O O
of O O
this O O
gene O O
, O O
we O O
performed O O
5'-rapid O O
amplification O O
of O O
cDNA O O
ends O O
PCR O O
on O O
patient O O
RNA O O
. O O
CONCLUSIONS O O
: O O
In O O
essential O O
hypertension O O
an O O
acute O O
protein O O
load O O
induces O O
a O O
decrease O O
in O O
GFR O O
that O O
may O O
normalize O O
under O O
antihypertensive O O
treatment O O
. O O

This O O
finding O O
suggested O O
that O O
the O O
PI3K S-GENE B-GENE
- O I-GENE
Akt S-GENE E-GENE
activation O O
pathway O O
plays O O
some O O
role O O
in O O
the O O
antiapoptotic O O
effect O O
of O O
EPO S-GENE S-GENE
. O O
Nine O O
DNA O O
fragments O O
that O O
were O O
specifically O O
recognized O O
and O O
bound O O
by O O
histidine O O
- O O
tagged O O
AdpA S-GENE S-GENE
were O O
isolated O O
by O O
cycles O O
of O O
a O O
gel O O
mobility O O
shift O O
- O O
PCR O O
method O O
. O O
To O O
determine O O
whether O O
the O O
NTP O B-GENE
- O I-GENE
binding O I-GENE
motif O E-GENE
is O O
important O O
for O O
Rad24 S-GENE S-GENE
function O O
, O O
we O O
mutated O O
the O O
conserved O O
lysine(115 O O
) O O
residue O O
in O O
this O O
motif O O
. O O
The O O
carboxyl O O
- O O
terminal O O
proline O O
- O O
rich O O
domain O O
of O O
SOS1 S-GENE S-GENE
is O O
involved O O
in O O
the O O
interaction O O
with O O
the O O
PLC B-GENE B-GENE
- I-GENE I-GENE
gamma1 E-GENE I-GENE
SH3 B-GENE I-GENE
domain E-GENE E-GENE
. O O
From O O
transient O O
expression O O
studies O O
, O O
we O O
could O O
demonstrate O O
that O O
the O O
SH3 B-GENE B-GENE
domain E-GENE E-GENE
of O O
PLC B-GENE B-GENE
- I-GENE I-GENE
gamma1 E-GENE E-GENE
is O O
necessary O O
for O O
the O O
association O O
with O O
SOS1 S-GENE S-GENE
in O O
vivo O O
. O O
Six O O
distinct O O
Ets B-GENE B-GENE
mRNAs E-GENE E-GENE
were O O
identified O O
: O O
Ets2 S-GENE S-GENE
, O O
Fli1 S-GENE S-GENE
, O O
GABPalpha S-GENE S-GENE
, O O
SAP1 S-GENE S-GENE
, O O
Elk1 S-GENE S-GENE
, O O
and O O
PE1 S-GENE S-GENE
. O O
A O O
2 O O
kb O O
transcript O O
was O O
isolated O O
from O O
brain O O
that O O
encodes O O
a O O
approximately O O
57 O O
kDa O B-GENE
protein O E-GENE
; O O
the O O
predicted O O
protein O O
contains O O
the O O
known O O
N B-GENE B-GENE
- I-GENE I-GENE
terminal I-GENE I-GENE
Ets I-GENE I-GENE
domain E-GENE E-GENE
of O O
PE1 S-GENE S-GENE
and O O
a O O
novel O O
C O B-GENE
- O I-GENE
terminal O I-GENE
domain O E-GENE
with O O
signficant O O
homology O O
to O O
murine B-GENE O
ERF E-GENE S-GENE
. O O
Twenty O O
eligible O O
patients O O
with O O
cirrhosis O O
were O O
randomized O O
into O O
two O O
groups O O
: O O
10 O O
patients O O
treated O O
with O O
6 O O
million O O
units O O
of O O
natural O O
IFN B-GENE B-GENE
- I-GENE I-GENE
beta E-GENE E-GENE
twice O O
a O O
week O O
for O O
36 O O
months O O
and O O
10 O O
patients O O
without O O
IFN O S-GENE
therapy O O
. O O
Wnt-1 S-GENE O
overexpression O O
in O O
mammary O O
epithelial O O
cells O O
induced O O
cyclin B-GENE B-GENE
D1 I-GENE I-GENE
mRNA E-GENE E-GENE
and O O
targeted O O
overexpression O O
of O O
Wnt-1 O S-GENE
in O O
the O O
mammary O O
gland O O
of O O
transgenic O O
mice O O
increased O O
both O O
ILK S-GENE O
activity O O
and O O
cyclin O B-GENE
D1 O E-GENE
levels O O
. O O
Intravenous O O
versus O O
oral O O
administration O O
of O O
amitriptyline O O
in O O
patients O O
with O O
major O O
depression O O
. O O

Deletion O O
of O O
the O O
RVH B-GENE B-GENE
domain E-GENE E-GENE
resulted O O
in O O
loss O O
of O O
Ca(2+)-dependent O O
activation O O
. O O
Logistic O O
regression O O
analysis O O
revealed O O
that O O
physicians O O
were O O
3.6 O O
times O O
more O O
likely O O
to O O
detect O O
thin O O
lesions O O
( O O
< O O
/=0.75 O O
mm O O
) O O
compared O O
with O O
nonphysician O O
detectors O O
( O O
95% O O
confidence O O
interval O O
[ O O
95% O O
CI O O
] O O
, O O
2.1 O O
, O O
6.5 O O
; O O
P O O
= O O
0.0001 O O
) O O
. O O

Erythema O O
exsudativum O O
multiforme O O
induced O O
by O O
granulocyte B-GENE B-GENE
colony I-GENE I-GENE
- I-GENE I-GENE
stimulating I-GENE I-GENE
factor E-GENE E-GENE
in O O
an O O
allogeneic O O
peripheral O O
blood O O
stem O O
cell O O
donor O O
. O O
VaI O O
and O O
VaII O O
co O O
- O O
immunoprecipitated O O
with O O
ErbB2 S-GENE S-GENE
, O O
but O O
not O O
with O O
ErbB1 S-GENE S-GENE
, O O
ErbB3 S-GENE S-GENE
, O O
or O O
ErbB4 S-GENE O
. O O
While O O
interactions O O
of O O
WT O O
and O O
variant O O
TGF B-GENE B-GENE
- I-GENE I-GENE
alpha E-GENE E-GENE
with O O
the O O
ErbBs S-GENE S-GENE
all O O
result O O
in O O
ErbB2 S-GENE S-GENE
activation O O
, O O
they O O
produce O O
different O O
biological O O
consequences O O
, O O
suggesting O O
that O O
the O O
various O O
TGF B-GENE B-GENE
- I-GENE I-GENE
alpha I-GENE I-GENE
precursors E-GENE I-GENE
differentially O I-GENE
modulate O I-GENE
ErbB O I-GENE
signaling O E-GENE
. O O
It O O
is O O
now O O
well O O
accepted O O
that O O
the O O
p53 B-GENE B-GENE
C I-GENE E-GENE
- I-GENE O
terminus E-GENE O
plays O O
a O O
central O O
role O O
in O O
controlling O O
the O O
activity O O
of O O
the O O
wild O B-GENE
- O I-GENE
type O I-GENE
molecule O E-GENE
. O O
In O O
contrast O O
to O O
full B-GENE O
- I-GENE O
length I-GENE O
E2F-3 E-GENE O
, O O
which O O
is O O
expressed O O
only O O
at O O
the O O
G1/S O O
boundary O O
, O O
E2F-3B S-GENE S-GENE
is O O
detected O O
throughout O O
the O O
cell O O
cycle O O
with O O
peak O O
levels O O
in O O
GO O O
where O O
it O O
is O O
associated O O
with O O
Rb S-GENE O
. O O
The O O
transcription O B-GENE
factor O I-GENE
Jun S-GENE E-GENE
( O O
c B-GENE B-GENE
- I-GENE I-GENE
Jun E-GENE E-GENE
) O O
functions O O
as O O
a O O
recipient O O
of O O
extracellular O O
growth O O
signals O O
and O O
converts O O
them O O
into O O
patterns O O
of O O
gene O O
expression O O
. O O
Developmental O O
toxicity O O
of O O
the O O
class O O
III O O
antiarrhythmic O O
agent O O
almokalant O O
in O O
mice O O
. O O

This O O
compound O O
is O O
the O O
main O O
bioactive O O
metabolite O O
of O O
trimebutine O O
II O O
( O O
Debridat O O
, O O
CAS O O
39133 O O
- O O
31 O O
- O O
8 O O
) O O
, O O
an O O
antispasmodic O O
widely O O
used O O
for O O
intestinal O O
diseases O O
since O O
1969 O O
. O O

In O O
addition O O
to O O
its O O
effect O O
in O O
augmenting O O
the O O
neutrophil O O
response O O
to O O
eccentric O O
exercise O O
, O O
vitamin O O
E O O
causes O O
a O O
greater O O
increase O O
in O O
circulating O B-GENE
creatine B-GENE I-GENE
kinase E-GENE E-GENE
activity O O
, O O
perhaps O O
indicating O O
increased O O
skeletal O O
muscle O O
repair O O
. O O
This O O
enabled O O
the O O
formation O O
of O O
stem O O
- O O
loop O O
templates O O
with O O
the O O
fusion O O
point O O
of O O
the O O
chimeric O B-GENE
transcript O E-GENE
in O O
the O O
loop O O
and O O
the O O
use O O
of O O
MLL S-GENE O
primers O O
in O O
two O O
- O O
sided O O
PCR O O
. O O
CONCLUSION O O
: O O
The O O
authors O O
emphasize O O
that O O
the O O
initial O O
management O O
of O O
primary O O
STS O O
should O O
be O O
adequate O O
and O O
suggest O O
that O O
safty O O
margin O O
of O O
> O O
or O O
= O O
2 O O
cm O O
should O O
be O O
adhered O O
to O O
. O O

Measurements O O
were O O
compared O O
with O O
two O O
computerised O O
treatment O O
planning O O
systems O O
-- O O
Theraplan O O
VO5B O O
and O O
ADAC O O
Pinnacle3 O O
V4.0b O O
. O O

Activation O O
was O O
biphasic O O
; O O
peaking O O
at O O
5 O O
- O O
10 O O
min O O
and O O
24 O O
h O O
after O O
treatment O O
. O O

Whereas O O
MARTA1 S-GENE S-GENE
is O O
clearly O O
detectable O O
in O O
crude O O
lysates O O
, O O
cytosolic O O
and O O
ribosomal O O
salt O O
- O O
wash O O
fractions O O
, O O
and O O
in O O
nuclear O O
extracts O O
, O O
MARTA2 S-GENE S-GENE
is O O
preferentially O O
found O O
in O O
the O O
ribosomal O O
salt O O
- O O
wash O O
preparation O O
. O O
It O O
contains O O
25 O O
exons O O
coding O O
for O O
a O O
4.7 O O
kb O O
transcript O O
including O O
large O O
5'- O O
and O O
3'- O O
( O O
1218bp O O
and O O
701bp O O
, O O
respectively O O
) O O
untranslated O O
regions O O
( O O
UTRs O O
) O O
. O O

Five O O
of O O
the O O
PDP1 B-GENE B-GENE
isoforms E-GENE E-GENE
differ O O
by O O
the O O
substitution O O
or O O
insertion O O
of O O
amino O O
acids O O
at O O
or O O
near O O
the O O
N O O
- O O
terminal O O
of O O
the O O
protein O O
. O O
The O O
optimum O O
technique O O
for O O
the O O
pathological O O
examination O O
of O O
sentinel O O
lymph O O
nodes O O
( O O
SLNs O O
) O O
is O O
still O O
under O O
debate O O
. O O

Partial O O
correction O O
of O O
anemia O O
with O O
recombinant B-GENE B-GENE
human I-GENE I-GENE
erythropoietin E-GENE E-GENE
likely O O
reduces O O
left O O
ventricular O O
mass O O
and O O
volume O O
. O O
This O O
study O O
demonstrated O O
that O O
the O O
PFA-100 O S-GENE
analyzer O O
can O O
accurately O O
assess O O
vWF S-GENE B-GENE
- O I-GENE
dependent O I-GENE
platelet O E-GENE
function O O
and O O
detect O O
other O O
platelet O O
defects O O
under O O
high O O
shear O O
stress O O
in O O
complex O O
patient O O
populations O O
. O O
We O O
recently O O
reported O O
the O O
molecular O O
cloning O O
of O O
a O O
PL B-GENE B-GENE
scramblase E-GENE E-GENE
of O O
human O O
( O O
HuPLSCR1 S-GENE S-GENE
) O O
and O O
mouse O O
origin O O
, O O
respectively O O
. O O
To O O
analyze O O
the O O
regulatory O O
activity O O
of O O
Gtx S-GENE S-GENE
, O O
we O O
first O O
identified O O
the O O
optimal O O
Gtx B-GENE B-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
sequence E-GENE E-GENE
using O O
an O O
in O O
vitro O O
DNA O O
- O O
binding O O
assay O O
. O O
Using O O
an O O
oligomer O O
duplex O O
5'-A(GGGTTA)(5)-3'/5'-(TAACCC)(5)T-3 O S-GENE
' O O
as O O
a O O
template O O
- O O
primer O O
, O O
we O O
show O O
that O O
both O O
the O O
Klenow B-GENE O
fragment I-GENE O
of I-GENE O
Escherichia I-GENE B-GENE
coli I-GENE I-GENE
DNA I-GENE I-GENE
polymerase I-GENE I-GENE
I E-GENE E-GENE
and O O
HIV B-GENE B-GENE
reverse I-GENE I-GENE
transcriptase E-GENE E-GENE
could O O
expand O O
telomere O O
DNA O O
sequences O O
as O O
well O O
, O O
giving O O
products O O
greater O O
than O O
the O O
size O O
of O O
the O O
template O O
DNA O O
. O O
Cdk2 S-GENE S-GENE
and O O
MAPK S-GENE S-GENE
precipitates O O
from O O
untreated O O
tumor O B-GENE
lysates O I-GENE
phosphorylated O I-GENE
recombinant B-GENE I-GENE
wild I-GENE I-GENE
- I-GENE I-GENE
type I-GENE I-GENE
p27 E-GENE E-GENE
but O O
not O O
the O O
T187A O B-GENE
mutant O E-GENE
in O O
vitro O O
. O O
The O O
loss O O
of O O
avirulence O O
activity O O
because O O
of O O
mutations O O
in O O
the O O
acidic O O
transcriptional O O
activation O O
domain O O
was O O
restored O O
by O O
addition O O
of O O
the O O
activation O O
domain O O
from O O
the O O
herpes B-GENE B-GENE
simplex I-GENE I-GENE
viral I-GENE I-GENE
protein I-GENE I-GENE
VP16 E-GENE E-GENE
. O O
Mutations O O
in O O
the O O
RP2 B-GENE B-GENE
locus I-GENE E-GENE
at I-GENE O
Xp11.3 E-GENE O
were O O
found O O
in O O
a O O
further O O
10 O O
- O O
20% O O
of O O
XLRP O O
patients O O
, O O
as O O
predicted O O
from O O
linkage O O
studies O O
. O O
The O O
limit O O
between O O
the O O
cecum O O
and O O
the O O
ascending O O
colon O O
was O O
externally O O
marked O O
by O O
the O O
sulcus O O
cecocolicus O O
dorsalis O O
and O O
ventralis O O
. O O

Subsequently O O
, O O
HD O O
inhibited O O
healing O O
because O O
it O O
significantly O O
delayed O O
epithelialization O O
and O O
caused O O
protracted O O
inflammation O O
. O O

The O O
effectiveness O O
of O O
the O O
haemodialysate O O
Solcoseryl O O
for O O
second O O
- O O
intention O O
wound O O
healing O O
in O O
horses O O
and O O
ponies O O
. O O

Although O O
there O O
is O O
little O O
evidence O O
that O O
diet O O
composition O O
plays O O
a O O
clinically O O
important O O
role O O
in O O
the O O
absorption O O
or O O
expenditure O O
of O O
energy O O
, O O
it O O
does O O
appear O O
to O O
play O O
a O O
role O O
in O O
food O O
intake O O
. O O

These O O
findings O O
were O O
reinforced O O
by O O
an O O
analysis O O
that O O
was O O
restricted O O
to O O
living O O
donor O O
transplants O O
without O O
acute O O
rejection O O
. O O

These O O
results O O
further O O
support O O
an O O
important O O
role O O
for O O
CBF2 S-GENE S-GENE
in O O
mediating O O
EBNA2 S-GENE B-GENE
transactivation O E-GENE
; O O
they O O
identify O O
the O O
hnRNP B-GENE B-GENE
protein I-GENE I-GENE
AUF1 E-GENE E-GENE
as O O
a O O
major O O
component O O
of O O
CBF2 O S-GENE
and O O
are O O
also O O
the O O
first O O
evidence O O
of O O
a O O
cis O O
- O O
acting O O
sequence O O
other O O
than O O
a O O
CBF1 B-GENE B-GENE
binding I-GENE I-GENE
element E-GENE E-GENE
that O O
is O O
able O O
to O O
confer O O
responsiveness O O
to O O
EBNA2 O S-GENE
. O O
The O O
genome O O
of O O
the O O
human O B-GENE
herpesvirus O I-GENE
8 O E-GENE
( O O
HHV-8 O S-GENE
) O O
contains O O
a O O
cluster O O
of O O
open O O
reading O O
frames O O
( O O
ORFs O O
) O O
encoding O O
proteins O O
with O O
homology O O
to O O
the O O
cellular O B-GENE
transcription O I-GENE
factors O E-GENE
of O O
the O O
interferon B-GENE B-GENE
regulatory I-GENE I-GENE
factor E-GENE E-GENE
( O O
IRF S-GENE S-GENE
) O O
family O O
. O O
Despite O O
these O O
limitations O O
the O O
CHIME O O
monitor O O
provides O O
an O O
opportunity O O
to O O
record O O
physiological O O
data O O
previously O O
unavailable O O
in O O
the O O
home O O
. O O

DATA O O
SYNTHESIS O O
: O O
Intracoronary O O
ultrasound O O
has O O
been O O
shown O O
to O O
improve O O
upon O O
demonstrated O O
weaknesses O O
of O O
coronary O O
angiography O O
. O O

TB O O
bone O O
area O O
( O O
p O O
< O O
0.001 O O
) O O
, O O
height O O
( O O
p O O
< O O
0.01 O O
) O O
, O O
years O O
in O O
present O O
colony O O
( O O
p O O
= O O
0.03 O O
) O O
, O O
and O O
menses O O
( O O
p O O
< O O
0.01 O O
) O O
predicted O O
TB O O
BMC O O
. O O

CREST O O
syndrome O O
; O O
a O O
changing O O
clinical O O
significance O O

Troglitazone O O
also O O
induced O O
an O O
endogenous B-GENE O
PPARgamma I-GENE B-GENE
target I-GENE I-GENE
gene E-GENE E-GENE
in O O
T24 O S-GENE
cells O O
, O O
adipocyte B-GENE B-GENE
- I-GENE I-GENE
type I-GENE I-GENE
fatty I-GENE I-GENE
acid I-GENE I-GENE
binding I-GENE I-GENE
protein E-GENE E-GENE
( O O
A B-GENE O
- I-GENE O
FABP E-GENE S-GENE
) O O
, O O
the O O
expression O O
of O O
which O O
correlates O O
with O O
bladder O O
cancer O O
differentiation O O
. O O
Viruses O O
were O O
isolated O O
from O O
9 O O
lungs O O
: O O
7 O O
with O O
PI-3V O O
, O O
1 O O
with O O
NCP O O
BVDV O O
type O O
1 O O
, O O
and O O
1 O O
with O O
both O O
BVHV-1 O O
and O O
BVDV O O
. O O

The O O
RS447 S-GENE O
human B-GENE O
megasatellite I-GENE O
tandem I-GENE O
repetitive I-GENE O
sequence E-GENE O
encodes O O
a O O
novel O O
deubiquitinating O O
enzyme O O
with O O
a O O
functional O O
promoter O O
. O O
Previous O O
experience O O
and O O
contextual O O
cues O O
are O O
essential O O
elements O O
in O O
the O O
generation O O
of O O
a O O
subjective O O
prediction O O
. O O

To O O
characterize O O
this O O
effect O O
, O O
we O O
looked O O
for O O
targets O O
of O O
NS1 B-GENE B-GENE
influenza I-GENE I-GENE
virus I-GENE I-GENE
protein E-GENE I-GENE
among O I-GENE
cellular O I-GENE
translation O I-GENE
factors O E-GENE
. O O
Collectively O O
, O O
these O O
and O O
previously O O
published O O
data O O
suggest O O
a O O
model O O
where O O
NS1 S-GENE O
recruits O O
eIF4GI S-GENE S-GENE
specifically O O
to O O
the O O
5 O O
' O O
untranslated O O
region O O
( O O
5 O O
' O O
UTR O O
) O O
of O O
the O O
viral O B-GENE
mRNA O E-GENE
, O O
allowing O O
for O O
the O O
preferential O O
translation O O
of O O
the O O
influenza O O
virus O O
messengers O O
. O O
Eukaryotic B-GENE B-GENE
translation I-GENE I-GENE
initiation I-GENE I-GENE
factor I-GENE I-GENE
4GI E-GENE E-GENE
is O O
a O O
cellular O O
target O O
for O O
NS1 B-GENE B-GENE
protein E-GENE E-GENE
, O O
a O O
translational O O
activator O O
of O O
influenza O O
virus O O
. O O
Splicing O O
of O O
the O O
K B-GENE B-GENE
- I-GENE I-GENE
SAM E-GENE E-GENE
alternative O O
exon O O
of O O
the O O
fibroblast B-GENE B-GENE
growth I-GENE I-GENE
factor I-GENE I-GENE
receptor I-GENE I-GENE
2 I-GENE I-GENE
gene E-GENE E-GENE
is O O
heavily O O
dependent O O
on O O
the O O
U O O
- O O
rich O O
sequence O O
IAS1 S-GENE S-GENE
lying O O
immediately O O
downstream O O
from O O
its O O
5 O O
' O O
splice O O
site O O
. O O
( O O
iii O O
) O O
In O O
these O O
cells O O
, O O
PKCbeta S-GENE S-GENE
plays O O
a O O
unique O O
Ras S-GENE S-GENE
- O O
independent O O
role O O
in O O
mediating O O
insulin S-GENE S-GENE
but O O
not O O
EGF S-GENE S-GENE
or O O
other O O
growth O B-GENE
factor O I-GENE
mitogenic O I-GENE
signals O E-GENE
. O O
However O O
, O O
it O O
is O O
not O O
known O O
whether O O
the O O
recently O O
identified O O
isoforms O B-GENE
Vav2 S-GENE E-GENE
and O O
Vav3 S-GENE S-GENE
, O O
which O O
are O O
broadly O O
expressed O O
, O O
can O O
couple O O
with O O
similar O O
classes O O
of O O
receptors O O
, O O
nor O O
is O O
it O O
known O O
whether O O
all O O
Vav B-GENE B-GENE
isoforms E-GENE E-GENE
possess O O
identical O O
functional O O
activities O O
. O O
Transcriptional O O
regulation O O
of O O
fbp1 B-GENE B-GENE
promoter I-GENE E-GENE
constructs E-GENE O
containing O O
only O O
UAS1 O S-GENE
or O O
UAS2 O S-GENE
confirms O O
that O O
the O O
PKA S-GENE S-GENE
and O O
MAPK S-GENE S-GENE
regulation O O
is O O
targeted O O
to O O
both O O
sites O O
. O O
X O O
- O O
ray O O
crystallographic O O
data O O
show O O
that O O
the O O
PLZF S-GENE B-GENE
BTB S-GENE E-GENE
/ O O
POZ O O
domain O O
forms O O
an O O
obligate O O
homodimer O O
via O O
an O O
extensive O O
interface O O
. O O
The O O
ability O O
of O O
SMRT S-GENE S-GENE
to O O
associate O O
with O O
these O O
transcription O O
factors O O
and O O
thereby O O
to O O
mediate O O
repression O O
is O O
strongly O O
inhibited O O
by O O
activation O O
of O O
tyrosine B-GENE B-GENE
kinase E-GENE E-GENE
signaling O O
pathways O O
, O O
such O O
as O O
that O O
represented O O
by O O
the O O
epidermal B-GENE B-GENE
growth I-GENE I-GENE
factor I-GENE I-GENE
receptor E-GENE E-GENE
. O O
In O O
addition O O
, O O
the O O
ketamine O O
- O O
treated O O
rats O O
had O O
more O O
neurons O O
and O O
glial O O
cells O O
surrounding O O
the O O
ventricles O O
. O O

The O O
differences O O
were O O
as O O
follows O O
: O O
for O O
overall O O
response O O
rate O O
p O O
= O O
0.004 O O
; O O
power O O
( O O
for O O
p O O
= O O
0.05 O O
) O O
85% O O
; O O
for O O
survival O O
p O O
= O O
0.09 O O
; O O
for O O
grade O O
IV O O
granulocytopenia O O
p O O
= O O
0.3 O O
; O O
and O O
for O O
febrile O O
neutropenia O O
p O O
= O O
0.61 O O
. O O

Patients O O
were O O
randomly O O
assigned O O
to O O
treatment O O
with O O
the O O
ACE S-GENE B-GENE
inhibitor O I-GENE
perindopril O E-GENE
( O O
and O O
the O O
diuretic O O
indapamide O O
for O O
those O O
with O O
no O O
definite O O
indication O O
for O O
or O O
contraindication O O
to O O
treatment O O
with O O
a O O
diuretic O O
) O O
or O O
matching O O
placebo(s O O
) O O
. O O
The O O
results O O
indicate O O
that O O
the O O
open O O
- O O
section O O
effect O O
decreases O O
the O O
torsional O O
stiffness O O
and O O
stress O O
concentration O O
effects O O
decrease O O
the O O
torsional O O
strength O O
of O O
a O O
long O O
bone O O
with O O
a O O
longitudinal O O
defect O O
. O O

These O O
regions O O
may O O
be O O
differentially O O
involved O O
in O O
tissue O O
- O O
specificity O O
, O O
and/or O O
circadian O O
regulation O O
, O O
of O O
the O O
human B-GENE B-GENE
hPer1 I-GENE I-GENE
gene E-GENE I-GENE
transcription O E-GENE
. O O
Additionally O O
, O O
putative O O
CF1/USP O S-GENE
and O O
Broad B-GENE O
Complex I-GENE O
Z2 E-GENE B-GENE
transcription O I-GENE
factor O E-GENE
elements O O
were O O
found O O
in O O
the O O
upstream O O
regions O O
of O O
MIH S-GENE S-GENE
and O O
MO B-GENE B-GENE
- I-GENE I-GENE
IH E-GENE I-GENE
genes O E-GENE
respectively O O
. O O
Sequence O O
analysis O O
reveals O O
that O O
the O O
newly O O
discovered O O
oasA2 B-GENE B-GENE
gene E-GENE E-GENE
represents O O
a O O
pseudogene O O
that O O
is O O
still O O
transcribed O O
, O O
but O O
is O O
not O O
functionally O O
translated O O
. O O
Genomic O O
and O O
functional O O
characterization O O
of O O
the O O
oas B-GENE B-GENE
gene I-GENE I-GENE
family E-GENE I-GENE
encoding O I-GENE
O B-GENE I-GENE
- I-GENE I-GENE
acetylserine I-GENE E-GENE
( I-GENE O
thiol I-GENE O
) I-GENE O
lyases E-GENE O
, O O
enzymes O O
catalyzing O O
the O O
final O O
step O O
in O O
cysteine O O
biosynthesis O O
in O O
Arabidopsis O B-GENE
thaliana O E-GENE
. O O
Two O O
distinct O O
recessive O O
susceptibility O O
loci O O
for O O
vasculitis O O
were O O
mapped O O
on O O
chromosome O O
( O O
Chr O O
) O O
4 O O
at O O
D4Mit89 S-GENE O
and O O
D4Mit147 S-GENE S-GENE
in O O
both O O
progenies O O
. O O
During O O
treatment O O
, O O
the O O
phosphorylation O O
state O O
of O O
Rb S-GENE S-GENE
shifted O O
to O O
a O O
hypophosphorylated O O
form O O
. O O
mRNA O O
for O O
the O O
HPV O B-GENE
E6/E7 O I-GENE
genes O E-GENE
decreased O O
; O O
however O O
, O O
significant O O
changes O O
in O O
the O O
E7 B-GENE B-GENE
protein E-GENE E-GENE
were O O
not O O
observed O O
, O O
while O O
increased O O
levels O O
of O O
Rb O B-GENE
immunoprecipitated O E-GENE
with O O
anti B-GENE B-GENE
- I-GENE I-GENE
E7 I-GENE I-GENE
antibodies E-GENE E-GENE
were O O
observed O O
. O O
Further O O
characterization O O
of O O
these O O
putative O O
Hoxa-1 B-GENE B-GENE
target I-GENE I-GENE
genes E-GENE E-GENE
will O O
aid O O
in O O
delineating O O
the O O
functions O O
of O O
the O O
Hoxa-1 B-GENE B-GENE
protein E-GENE E-GENE
in O O
the O O
differentiation O O
processes O O
which O O
occur O O
during O O
embryogenesis O O
. O O
The O O
ability O O
of O O
U6-U57 O B-GENE
mutants O E-GENE
to O O
influence O O
the O O
fidelity O O
of O O
both O O
branch O O
site O O
and O O
3 O O
' O O
splice O O
site O O
recognition O O
suggests O O
that O O
this O O
nucleotide O O
may O O
participate O O
in O O
the O O
formation O O
of O O
the O O
active O O
site(s O O
) O O
of O O
the O O
spliceosome O O
. O O
We O O
have O O
determined O O
the O O
structure O O
of O O
the O O
WNT-2B B-GENE B-GENE
gene E-GENE E-GENE
. O O
The O O
role O O
of O O
daunorubicin O O
in O O
induction O O
therapy O O
for O O
adult O O
acute O O
myeloid O O
leukemia O O

Five O O
of O O
the O O
Aeromonas O O
strains O O
and O O
one O O
of O O
V O O
cholerae O O
non O O
- O O
O1 O O
were O O
positive O O
for O O
enterotoxin O O
activity O O
. O O

TNF B-GENE B-GENE
- I-GENE I-GENE
alpha E-GENE E-GENE
induced O O
a O O
dose- O O
and O O
time O O
- O O
dependent O O
increase O O
in O O
cyclooxygenase-2 S-GENE O
( O O
COX-2 S-GENE S-GENE
) O O
expression O O
and O O
PGE2 O O
formation O O
in O O
human O B-GENE
NCI O I-GENE
- O I-GENE
H292 O E-GENE
epithelial O O
cells O O
. O O
The O O
therapy O O
time O O
to O O
deliver O O
the O O
NCS O O
therapeutic O O
dose O O
of O O
10000 O O
RBE O O
- O O
cGy O O
, O O
is O O
27 O O
times O O
longer O O
when O O
157Gd O O
is O O
used O O
instead O O
of O O
10B. O O

Mis3 S-GENE O
is O O
needed O O
for O O
the O O
formation O O
of O O
18S B-GENE B-GENE
ribosome I-GENE I-GENE
RNA E-GENE E-GENE
, O O
and O O
may O O
hence O O
direct O O
the O O
level O O
of O O
proteins O O
required O O
for O O
the O O
coupling O O
. O O
Losartan O O
Intervention O O
For O O
Endpoint O O
. O O

CONCLUSION O O
: O O
Vitrectomy O O
for O O
vitreous O O
hemorrhage O O
in O O
Terson O O
syndrome O O
is O O
a O O
safe O O
and O O
effective O O
procedure O O
, O O
offering O O
a O O
rapid O O
and O O
prolonged O O
improvement O O
in O O
vision O O
. O O

RNA O O
in O O
situ O O
hybridization O O
on O O
brain O O
sections O O
of O O
normal O O
human O O
embryos O O
revealed O O
a O O
strong O O
labeling O O
in O O
restricted O O
areas O O
of O O
the O O
cerebral O O
cortex O O
. O O

To O O
facilitate O O
manipulation O O
of O O
large O O
genomic O O
sequences O O
, O O
we O O
developed O O
a O O
method O O
of O O
converting O O
Escherichia O O
coli O O
P1 O O
artificial O O
chromosomes O O
( O O
PACs O O
) O O
into O O
yeast O O
artificial O O
chromosomes O O
( O O
YACs O O
) O O
. O O

After O O
gamma O O
- O O
irradiation O O
, O O
the O O
majority O O
of O O
F9 O O
cells O O
undergo O O
apoptosis O O
implying O O
that O O
wt B-GENE O
- I-GENE O
p53 E-GENE S-GENE
likely O O
triggers O O
pro O B-GENE
- O I-GENE
apoptotic O I-GENE
gene O E-GENE
expression O O
in O O
DNA O O
damaged O O
cells O O
. O O
Mobilization O O
with O O
cyclophosphamide O O
and O O
granulocyte B-GENE B-GENE
- I-GENE I-GENE
colony I-GENE I-GENE
stimulating I-GENE I-GENE
factor E-GENE E-GENE
was O O
effective O O
in O O
terms O O
of O O
CD34 B-GENE O
+ E-GENE O
cell O O
shift O O
to O O
peripheral O O
blood O O
and O O
the O O
good O O
quality O O
autograft O O
reliably O O
led O O
to O O
haematopoetic O O
recovery O O
after O O
megachemotherapy O O
. O O
This O O
suggests O O
that O O
cardiovascular O O
magnetic O O
resonance O O
is O O
the O O
preferred O O
technique O O
for O O
volume O O
and O O
ejection O O
fraction O O
estimation O O
in O O
heart O O
failure O O
patients O O
, O O
because O O
of O O
its O O
3D O O
approach O O
for O O
non O O
- O O
symmetric O O
ventricles O O
and O O
superior O O
image O O
quality O O
. O O

A O O
degenerate O O
DNA O O
transposon O O
, O O
Pat S-GENE S-GENE
, O O
was O O
identified O O
in O O
the O O
genomes O O
of O O
various O O
wild O O
- O O
type O O
strains O O
of O O
the O O
filamentous O O
fungus O O
Podospora O B-GENE
anserina O E-GENE
. O O
However O O
, O O
the O O
presence O O
of O O
Tax B-GENE B-GENE
I E-GENE E-GENE
increased O O
the O O
extent O O
and O O
altered O O
the O O
profile O O
of O O
proteins O B-GENE
binding O I-GENE
TRE-2 S-GENE E-GENE
in O O
vivo O O
. O O
We O O
have O O
also O O
identified O O
a O O
functional O O
domain O O
in O O
the O O
ORF O B-GENE
50 O I-GENE
protein O E-GENE
, O O
an O O
immediate B-GENE B-GENE
- I-GENE I-GENE
early I-GENE I-GENE
gene I-GENE I-GENE
product E-GENE E-GENE
that O O
is O O
mainly O O
encoded O O
by O O
ORF O O
50 O O
. O O
A O O
2.3-kb O O
full O O
- O O
length O O
cDNA O O
clone O O
of O O
an O O
Atlantic B-GENE B-GENE
halibut I-GENE I-GENE
Mx I-GENE I-GENE
gene E-GENE E-GENE
was O O
isolated O O
from O O
a O O
liver O O
cDNA O O
library O O
. O O
PLUS-3 O O
is O O
a O O
new O O
Swedish O O
protocol O O
of O O
natural O O
speech O O
in O O
3-year O O
- O O
old O O
children O O
. O O

Once O O
HIT O O
II O O
is O O
suspected O O
, O O
heparin O O
( O O
and O O
low O O
- O O
molecular O O
- O O
weight O O
heparins O O
) O O
should O O
be O O
stopped O O
immediately O O
. O O

The O O
reduced O O
efficiency O O
in O O
the O O
glycosylase S-GENE O
activity O O
is O O
also O O
reflected O O
in O O
a O O
reduced O O
ability O O
of O O
S120 B-GENE B-GENE
K I-GENE I-GENE
MutY E-GENE E-GENE
to O O
prevent O O
DNA O O
mutations O O
in O O
vivo O O
. O O
METHODS O O
AND O O
RESULTS O O
: O O
We O O
prospectively O O
compared O O
the O O
automated O O
measurements O O
of O O
left O O
ventricular O O
ejection O O
fraction O O
( O O
LVEF O O
) O O
and O O
volumes O O
from O O
rest O O
- O O
injected O O
gated O O
Technetium O O
99 O O
m O O
( O O
Tc99 O O
m O O
) O O
perfusion O O
SPECT O O
with O O
equilibrium O O
radionuclide O O
angiocardiography O O
( O O
ERNA O O
) O O
in O O
62 O O
patients O O
and O O
the O O
assessment O O
of O O
regional O O
function O O
with O O
echocardiography O O
in O O
22 O O
patients O O
. O O

The O O
2 O B-GENE
cDNAs O E-GENE
differed O O
in O O
the O O
length O O
of O O
their O O
respective O O
3 O O
' O O
untranslated O O
regions O O
, O O
of O O
577 O O
bp O O
in O O
Cp B-GENE O
. I-GENE O
F6 E-GENE S-GENE
and O O
72 O O
bp O O
in O O
Cp B-GENE O
. I-GENE O
F10 E-GENE S-GENE
, O O
in O O
both O O
of O O
which O O
a O O
putative O O
polyadenylation O O
signal O O
was O O
identified O O
. O O
This O O
intracellular O O
signaling O O
, O O
known O O
as O O
the O O
unfolded O O
protein O O
response O O
( O O
UPR O O
) O O
, O O
is O O
mediated O O
by O O
the O O
cis O O
- O O
acting O O
ER O O
stress O O
response O O
element O O
( O O
ERSE O O
) O O
in O O
mammals O O
. O O

A O O
Y. B-GENE O
lipolytica I-GENE B-GENE
Kar2p I-GENE I-GENE
mutant E-GENE E-GENE
was O O
isolated O O
that O O
restored O O
interaction O O
with O O
an O O
Sls1p B-GENE B-GENE
mutant E-GENE E-GENE
, O O
suggesting O O
that O O
the O O
interaction O O
with O O
Sls1p O S-GENE
could O O
be O O
nucleotide O O
and/or O O
conformation O O
dependent O O
. O O
We O O
have O O
carried O O
out O O
a O O
comprehensive O O
and O O
systematic O O
mutagenesis O O
of O O
the O O
Cse4p B-GENE O
N I-GENE O
terminus E-GENE O
to O O
analyze O O
its O O
function O O
. O O
The O O
spacing O O
of O O
the O O
essential O O
N O O
- O O
terminal O O
domain O O
( O O
END O O
) O O
relative O O
to O O
the O O
HFD S-GENE O
can O O
be O O
changed O O
significantly O O
without O O
an O O
apparent O O
effect O O
on O O
Cse4p S-GENE O
function O O
. O O
The O O
bases O O
of O O
this O O
comparison O O
are O O
reviewed O O
and O O
discussed O O
. O O

In O O
invertebrates O O
, O O
Fhit S-GENE O
is O O
encoded O O
as O O
a O O
fusion O O
protein O O
with O O
Nit S-GENE S-GENE
, O O
a O O
member O O
of O O
the O O
nitrilase B-GENE B-GENE
superfamily E-GENE E-GENE
. O O
Platelet O S-GENE
counts O O
and O O
function O O
as O O
well O O
as O O
fibrinogen S-GENE S-GENE
and O O
von B-GENE B-GENE
Willebrand I-GENE I-GENE
factor E-GENE E-GENE
( O O
vWF S-GENE O
) O O
levels O O
were O O
determined O O
in O O
each O O
sample O O
. O O
The O O
manifestations O O
often O O
include O O
a O O
moderate O O
thrombocytopenia O O
and O O
, O O
less O O
commonly O O
, O O
hemolysis O O
. O O

A O O
beta2 B-GENE O
RARE I-GENE O
reporter I-GENE O
construct E-GENE O
in O O
which O O
the O O
methylation O O
- O O
susceptible O O
cytosines O O
in O O
the O O
sense O O
strand O O
were O O
replaced O O
by O O
thymine O O
displayed O O
marked O O
loss O O
of O O
activity O O
in O O
a O O
replicated O O
chromatin O O
- O O
dependent O O
manner O O
. O O
Non O O
- O O
poliomyelitis O O
AFP O O
rate O O
had O O
increased O O
from O O
0.9 O O
in O O
1997 O O
to O O
2.8 O O
in O O
1998 O O
. O O

Consciousness O O
is O O
connected O O
with O O
attention O O
, O O
working O O
memory O O
and O O
perception O O
. O O

Multiparity O O
had O O
a O O
protective O O
effect O O
with O O
0.66 O O
less O O
risk O O
( O O
95% O O
CI O O
0.44 O O
- O O
0.99 O O
) O O
. O O

Picture O O
the O O
smell O O
. O O

The O O
aim O O
of O O
our O O
study O O
was O O
to O O
evaluate O O
the O O
level O O
of O O
oxidative O O
stress O O
in O O
healthy O O
controls O O
( O O
CTL O O
) O O
compared O O
with O O
CRF O O
and O O
HD O O
patients O O
before O O
( O O
pre O O
- O O
HD O O
) O O
and O O
after O O
( O O
post O O
- O O
HD O O
) O O
the O O
dialysis O O
session O O
, O O
carried O O
out O O
on O O
a O O
high O O
biocompatible O O
polyacrylonitrile O O
membrane O O
AN69 O O
. O O

Indirect O O
plasma O O
parameters O O
such O O
as O O
vitamin O O
E O O
, O O
thiol O O
and O O
uric O O
acid O O
levels O O
were O O
also O O
quantified O O
. O O

Only O O
two O O
of O O
27 O O
participants O O
( O O
7.4% O O
) O O
with O O
definite O O
POAG O O
had O O
been O O
previously O O
diagnosed O O
and O O
treated O O
, O O
and O O
66.7% O O
of O O
the O O
previously O O
undiagnosed O O
had O O
IOP O O
less O O
than O O
22 O O
mmHg O O
. O O

Taken O O
together O O
, O O
they O O
uphold O O
the O O
emerging O O
concern O O
that O O
women O O
with O O
ER(+ B-GENE O
) E-GENE O
cancers O O
may O O
not O O
benefit O O
significantly O O
from O O
endocrine O O
treatment O O
if O O
the O O
tumors O O
also O O
overexpress O O
HER-2 S-GENE S-GENE
. O O
Promoter O O
activity O O
was O O
dose O O
- O O
dependently O O
inhibited O O
by O O
cotransfection O O
with O O
either O O
ras S-GENE S-GENE
or O O
mos B-GENE B-GENE
oncogenes E-GENE E-GENE
, O O
but O O
oncogene O O
inhibition O O
was O O
reversed O O
and O O
the O O
overall O O
activity O O
increased O O
when O O
cells O O
were O O
treated O O
with O O
the O O
MAP B-GENE B-GENE
kinase I-GENE I-GENE
kinase E-GENE E-GENE
( O O
MKK S-GENE S-GENE
) O O
inhibitor O O
PD98059 O S-GENE
. O O
Our O O
results O O
indicate O O
that O O
the O O
expression O O
of O O
Cktsf1b1 S-GENE S-GENE
, O O
a O O
gene O O
associated O O
with O O
early O O
development O O
and O O
cell O O
transformation O O
, O O
is O O
sensitive O O
to O O
MKK S-GENE S-GENE
levels O O
and O O
may O O
be O O
regulated O O
via O O
multiple O O
transcription O B-GENE
factor O I-GENE
complexes O E-GENE
. O O
INTERVENTIONS O O
: O O
Subcutaneous O O
tissue O O
PO2 O O
and O O
PCO2 O O
tensions O O
were O O
measured O O
directly O O
in O O
patients O O
with O O
necrotising O O
fasciitis O O
and O O
in O O
healthy O O
volunteers O O
during O O
normobaric O O
and O O
hyperbaric O O
conditions O O
. O O

Because O O
GH S-GENE B-GENE
- O I-GENE
induced O I-GENE
Akt S-GENE E-GENE
activation O O
was O O
completely O O
inhibited O O
in O O
both O O
cells O O
by O O
the O O
same O O
concentration O O
of O O
LY294002 O S-GENE
, O O
these O O
findings O O
indicate O O
that O O
the O O
wortmannin O O
sensitivity O O
of O O
both O O
the O O
IRS-1-independent O O
and O O
-dependent O O
GH O S-GENE
- O O
induced O O
MAP B-GENE B-GENE
kinase E-GENE E-GENE
activation O O
may O O
reflect O O
the O O
activity O O
of O O
another O O
wortmannin O O
- O O
sensitive O O
target(s O O
) O O
in O O
addition O O
to O O
PI3 B-GENE B-GENE
K E-GENE E-GENE
in O O
mediation O O
of O O
GH O B-GENE
- O I-GENE
induced O I-GENE
MAP O I-GENE
kinase O E-GENE
activation O O
in O O
these O O
cells O O
. O O
Insulin O B-GENE
receptor O I-GENE
substrate-1-mediated O E-GENE
enhancement O O
of O O
growth B-GENE B-GENE
hormone E-GENE I-GENE
- O I-GENE
induced O I-GENE
mitogen B-GENE I-GENE
- I-GENE I-GENE
activated I-GENE I-GENE
protein I-GENE I-GENE
kinase E-GENE I-GENE
activation O E-GENE
. O O
Functional O O
magnetic O O
resonance O O
imaging O O
( O O
fMRI O S-GENE
) O O
has O O
been O O
increasingly O O
used O O
in O O
studying O O
human O O
brain O O
function O O
given O O
its O O
non O O
- O O
invasive O O
feature O O
and O O
good O O
spatial O O
resolution O O
. O O

After O O
declamping O O
of O O
the O O
aorta O O
, O O
there O O
were O O
also O O
severe O O
edema O O
, O O
local O O
fibre O O
necrosis O O
, O O
and O O
adhesion O O
of O O
leucocytes O O
, O O
whereas O O
muscle O O
fibre O O
areas O O
became O O
3,935.18 O O
micro O O
531 O O
microm(2 O O
) O O
for O O
type O O
I O O
and O O
5,804 O O
+ O O
/- O O
1,075 O O
microm(2 O O
) O O
for O O
type O O
II O O
. O O

The O O
results O O
indicate O O
that O O
the O O
relationship O O
between O O
comprehension O O
and O O
production O O
is O O
different O O
at O O
different O O
stages O O
in O O
development O O
. O O

It O O
was O O
found O O
that O O
increase O O
in O O
the O O
RH O O
level O O
boosts O O
the O O
current O O
values O O
by O O
2 O O
- O O
3 O O
orders O O
of O O
magnitude O O
; O O
contrariwise O O
, O O
the O O
voltage O O
values O O
rise O O
by O O
about O O
three O O
times O O
with O O
drop O O
in O O
the O O
RH O O
. O O

On O O
long O O
- O O
term O O
follow O O
- O O
up O O
, O O
there O O
was O O
no O O
significant O O
difference O O
in O O
the O O
incidence O O
of O O
hospitalizations O O
( O O
1 O O
per O O
2.1 O O
vs. O O

Genomic O O
libraries O O
were O O
stored O O
as O O
frozen O O
cultures O O
in O O
a O O
96-well O O
format O O
, O O
each O O
well O O
containing O O
approximately O O
300 O O
- O O
600 O O
colonies O O
( O O
12 O O
plates O O
for O O
small O O
library O O
, O O
four O O
for O O
medium O O
- O O
size O O
library O O
and O O
four O O
for O O
large O O
library O O
) O O
. O O

In O O
several O O
cell O O
lines O O
, O O
mTOR S-GENE S-GENE
or O O
its O O
downstream O O
targets O O
can O O
be O O
regulated O O
by O O
phosphatidylinositol B-GENE O
( I-GENE O
PI I-GENE S-GENE
) I-GENE O
3-kinase E-GENE B-GENE
; O I-GENE
protein B-GENE I-GENE
kinases I-GENE E-GENE
A I-GENE O
, I-GENE O
B I-GENE S-GENE
, I-GENE O
and I-GENE O
C E-GENE O
; O O
heterotrimeric B-GENE O
G I-GENE B-GENE
- I-GENE I-GENE
proteins E-GENE E-GENE
; O O
a O O
PD98059-sensitive O B-GENE
kinase O E-GENE
or O O
calcium O O
; O O
as O O
well O O
as O O
by O O
amino O O
acids O O
. O O
The O O
tumor B-GENE B-GENE
- I-GENE I-GENE
suppressor I-GENE I-GENE
protein I-GENE I-GENE
p53 E-GENE E-GENE
is O O
involved O O
in O O
maintaining O O
genomic O O
stability O O
. O O
Abrogation O O
of O O
p53 S-GENE S-GENE
function O O
by O O
E6 S-GENE O
resulted O O
in O O
an O O
increase O O
in O O
the O O
spontaneous O O
mutation O O
frequencies O O
at O O
the O O
heterozygous O B-GENE
thymidine B-GENE I-GENE
kinase E-GENE E-GENE
( O O
TK S-GENE S-GENE
) O O
locus O O
but O O
not O O
at O O
the O O
hemizygous O B-GENE
hypoxanthine B-GENE I-GENE
phosphoribosyl I-GENE I-GENE
transferase E-GENE E-GENE
( O O
HPRT S-GENE S-GENE
) O O
locus O O
. O O
Cytogenetic O O
analysis O O
of O O
LOH O B-GENE
mutants O E-GENE
by O O
chromosome O O
painting O O
indicated O O
a O O
mosaic O O
of O O
chromosomal O O
aberrations O O
involving O O
chromosome O O
17 O O
, O O
in O O
which O O
partial O O
chromosome O O
deletions O O
, O O
amplifications O O
, O O
and O O
multiple O O
translocations O O
appeared O O
heterogeneously O O
in O O
a O O
single O O
mutant O O
. O O

These O O
results O O
support O O
a O O
model O O
in O O
which O O
p53 B-GENE B-GENE
protein E-GENE E-GENE
contributes O O
to O O
the O O
maintenance O O
of O O
genomic O O
integrity O O
through O O
recombinational O O
repair O O
. O O
The O O
importance O O
of O O
this O O
new O O
epidemiological O O
profile O O
of O O
schistosomiasis O O
in O O
the O O
State O O
of O O
Pernambuco O O
relies O O
on O O
the O O
fact O O
that O O
it O O
can O O
be O O
related O O
with O O
the O O
drastic O O
human O O
interference O O
on O O
the O O
environment O O
. O O

In O O
patients O O
with O O
type O O
II O O
tumors O O
, O O
the O O
pattern O O
of O O
lymphatic O O
spread O O
was O O
primarily O O
directed O O
toward O O
the O O
paracardial O O
, O O
lesser O O
curvature O O
, O O
and O O
left O O
gastric O O
artery O O
nodes O O
; O O
esophagectomy O O
offered O O
no O O
survival O O
benefit O O
over O O
extended O O
gastrectomy O O
in O O
these O O
patients O O
. O O

RESULTS O O
: O O
No O O
significant O O
deformation O O
in O O
vertebral O O
artery O O
flow O O
was O O
noted O O
in O O
the O O
flexion O O
- O O
distraction O O
Stage O O
I O O
injuries O O
within O O
the O O
physiologic O O
range O O
of O O
cervical O O
flexion O O
. O O

We O O
screened O O
a O O
K562 O B-GENE
cDNA O E-GENE
library O O
and O O
identified O O
novel O O
transcripts O O
, O O
MZF1B S-GENE S-GENE
and O O
MZF1C. O S-GENE
The O O
human O B-GENE
cDNA O E-GENE
clone O O
NFBD1 O S-GENE
( O O
previously O O
designated O O
KIAA0170 O S-GENE
) O O
encodes O O
a O O
novel O O
protein O O
( O O
2089 O O
amino O O
acids O O
in O O
length O O
; O O
calculated O O
molecular O O
mass O O
226,440 O O
D O O
) O O
with O O
possible O O
BRCT B-GENE O
domains E-GENE O
at O O
its O O
carboxy O O
terminus O O
( O O
amino O O
acid O O
residues O O
1894 O O
- O O
2089 O O
) O O
. O O
RESULTS O O
: O O
Neither O O
basal O O
FSH S-GENE S-GENE
level O O
nor O O
stimulated O O
FSH O S-GENE
level O O
alone O O
were O O
statistically O O
significant O O
predictors O O
of O O
IVF O O
success O O
; O O
however O O
, O O
no O O
patient O O
with O O
a O O
day O O
3 O O
FSH O O
level O O
> O O
11.1 O O
mIU O O
/ O O
ml O O
or O O
a O O
stimulated O O
day O O
10 O O
FSH O O
level O O
> O O
13.5 O O
mIU O O
/ O O
ml O O
conceived O O
and O O
carried O O
a O O
pregnancy O O
. O O
Parathyroid B-GENE B-GENE
hormone E-GENE E-GENE
regulation O O
of O O
bone B-GENE B-GENE
sialoprotein E-GENE E-GENE
( O O
BSP S-GENE S-GENE
) O O
gene O O
transcription O O
is O O
mediated O O
through O O
a O O
pituitary B-GENE B-GENE
- I-GENE I-GENE
specific I-GENE I-GENE
transcription I-GENE I-GENE
factor-1 E-GENE E-GENE
( O O
Pit-1 S-GENE S-GENE
) O O
motif O O
in O O
the O O
rat B-GENE B-GENE
BSP I-GENE I-GENE
gene I-GENE I-GENE
promoter E-GENE E-GENE
. O O
Recent O O
target O O
BP O O
goals O O
promulgated O O
by O O
the O O
Sixth O O
Report O O
from O O
the O O
Joint O O
National O O
Committee O O
( O O
JNC O O
VI O O
) O O
are O O
based O O
on O O
the O O
premise O O
that O O
the O O
intensity O O
of O O
treatment O O
directly O O
corresponds O O
to O O
the O O
magnitude O O
of O O
pretreatment O O
risk O O
. O O

Linking O O
continuous O O
community O O
- O O
based O O
morbidity O O
recording O O
of O O
influenza O O
- O O
like O O
illness O O
( O O
ILI O O
) O O
with O O
virological O O
sampling O O
has O O
consistently O O
proved O O
its O O
value O O
as O O
one O O
of O O
the O O
earliest O O
indicators O O
of O O
circulating O O
influenza O O
activity O O
. O O

The O O
muskox O O
is O O
a O O
new O O
host O O
record O O
for O O
T. O O
gondii O O
. O O

These O O
include O O
NPF O B-GENE
repeats O E-GENE
, O O
a O O
leucine O O
heptad O O
repeat O O
enriched O O
in O O
charged O O
residues O O
, O O
and O O
a O O
proline O O
- O O
rich O O
SH3-like S-GENE S-GENE
and/or O O
WW O B-GENE
domain O I-GENE
- O I-GENE
binding O I-GENE
site O E-GENE
in O O
the O O
N O B-GENE
- O I-GENE
terminal O I-GENE
domain O E-GENE
, O O
which O O
is O O
followed O O
by O O
a O O
membrane O O
core O O
containing O O
four O O
putative O O
transmembrane O O
spans O O
and O O
three O O
amphiphilic O O
segments O O
that O O
are O O
the O O
most O O
highly O O
conserved O O
structural O O
elements O O
. O O
We O O
show O O
here O O
that O O
this O O
difference O O
is O O
due O O
to O O
the O O
presence O O
of O O
a O O
Mot3 B-GENE O
binding I-GENE O
site E-GENE O
in O O
OpA. O O
The O O
article O O
deals O O
with O O
the O O
diagnosing O O
and O O
correction O O
of O O
reversible O O
ischemia O O
of O O
the O O
intestine O O
. O O

Mucosal O O
application O O
of O O
NCX-4016 O O
, O O
however O O
, O O
did O O
not O O
cause O O
PD O O
reduction O O
and O O
luminal O O
H+ O O
loss O O
, O O
but O O
produced O O
a O O
marked O O
hyperemia O O
, O O
resulting O O
in O O
no O O
damage O O
in O O
the O O
stomach O O
of O O
both O O
normal O O
and O O
STZ O O
- O O
diabetic O O
rats O O
. O O

Functional O O
recognition O O
of O O
5 O O
' O O
splice O O
site O O
by O O
U4/U6.U5 O B-GENE
tri O I-GENE
- O I-GENE
snRNP O E-GENE
defines O O
a O O
novel O O
ATP O O
- O O
dependent O O
step O O
in O O
early O O
spliceosome O O
assembly O O
. O O
As O O
control O O
, O O
the O O
cells O O
were O O
transfected O O
with O O
DNA O O
mixtures O O
containing O O
vector O O
mU6-C1 O O
or O O
mU6-C2 O O
. O O

The O O
amino O O
acid O O
sequence O O
of O O
matrilysin-2 S-GENE O
also O O
contains O O
a O O
threonine O O
residue O O
adjacent O O
to O O
the O O
Zn O B-GENE
- O I-GENE
binding O I-GENE
site O E-GENE
that O O
has O O
been O O
defined O O
as O O
a O O
specific O O
feature O O
of O O
matrilysin O S-GENE
. O O
In O O
this O O
regard O O
, O O
we O O
have O O
recently O O
observed O O
that O O
a O O
constitutively O O
active O O
G B-GENE B-GENE
protein I-GENE I-GENE
- I-GENE I-GENE
coupled I-GENE I-GENE
receptor E-GENE E-GENE
( O O
GPCR S-GENE S-GENE
) O O
encoded O O
by O O
the O O
Kaposi O S-GENE
's O O
sarcoma O O
- O O
associated O O
herpes O O
virus O O
( O O
KSHV)/human O O
herpes O O
virus O O
8 O O
is O O
oncogenic O O
and O O
stimulates O O
angiogenesis O O
by O O
increasing O O
the O O
secretion O O
of O O
vascular B-GENE B-GENE
endothelial I-GENE I-GENE
growth I-GENE I-GENE
factor E-GENE E-GENE
( O O
VEGF S-GENE S-GENE
) O O
, O O
which O O
is O O
a O O
key O O
angiogenic O O
stimulator O O
and O O
a O O
critical O O
mitogen O O
for O O
the O O
development O O
of O O
Kaposi O O
's O O
sarcoma O O
. O O
No O O
specific O O
subgroup O O
of O O
clients O O
benefited O O
more O O
from O O
URD O O
, O O
although O O
a O O
prospective O O
study O O
employing O O
random O O
assignment O O
might O O
be O O
more O O
successful O O
in O O
identifying O O
such O O
a O O
group O O
. O O

In O O
the O O
lattice O O
, O O
23% O O
of O O
the O O
sites O O
are O O
occupied O O
, O O
95% O O
of O O
the O O
atoms O O
are O O
in O O
the O O
lowest O O
energy O O
magnetic O O
sublevel O O
, O O
and O O
37% O O
are O O
in O O
the O O
lowest O O
3D O O
vibrational O O
state O O
. O O

Coexisting O O
vertical O O
and O O
horizontal O O
one O O
and O O
a O O
half O O
syndromes O O
. O O

As O O
in O O
the O O
other O O
three O O
members O O
whose O O
gene O O
expression O O
is O O
altered O O
during O O
tumorigenesis O O
, O O
PI12 S-GENE S-GENE
expression O O
was O O
found O O
to O O
be O O
down O O
- O O
regulated O O
in O O
tumor O O
brain O O
tissues O O
and O O
in O O
two O O
brain O O
cancer O O
cell O O
lines O O
: O O
U-87 O O
MG O O
and O O
H4 O O
. O O
Regarding O O
" O O
the O O
relation O O
between O O
sexual O O
orientation O O
and O O
penile O O
size O O
, O O
" O O
by O O
A. O O

This O O
slope O O
was O O
further O O
significantly O O
decreased O O
at O O
5 O O
min O O
ischemia O O
( O O
-26.5 O O
+ O O
/- O O
8.8 O O
microm O O
/ O O
mmHg O O
) O O
but O O
returned O O
toward O O
control O O
values O O
in O O
short O O
- O O
term O O
hibernating O O
myocardium O O
at O O
90 O O
min O O
ischemia O O
( O O
-17.2 O O
+ O O
/- O O
6.6 O O
microm O O
/ O O
mmHg O O
) O O
. O O

Whereas O O
both O O
MAP O O
and O O
MSNA O O
increase O O
during O O
SHG O O
, O O
the O O
transition O O
from O O
SHG O O
to O O
PHI O O
is O O
characterized O O
by O O
a O O
transient O O
reduction O O
in O O
MAP O O
but O O
sustained O O
elevation O O
in O O
MSNA O O
, O O
facilitating O O
separation O O
of O O
these O O
factors O O
in O O
vivo O O
. O O

Analysis O O
of O O
Standard O O
Reference O O
Material O O
1846 O O
, O O
Infant O O
Formula O O
, O O
gave O O
a O O
mean O O
value O O
of O O
0.95 O O
+ O O
/- O O
0.088 O O
mg O O
vitamin O O
K O O
/ O O
kg O O
( O O
K O O
or O O
K1 O O
? O O
) O O
( O O
n O O
= O O
31 O O
) O O
with O O
a O O
coefficient O O
of O O
variation O O
of O O
9.26 O O
. O O

We O O
have O O
recently O O
discovered O O
that O O
CCAAAT B-GENE B-GENE
/ I-GENE I-GENE
enhancer I-GENE I-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
protein I-GENE I-GENE
- I-GENE I-GENE
beta E-GENE E-GENE
( O O
C B-GENE B-GENE
/ I-GENE I-GENE
EBP I-GENE I-GENE
- I-GENE I-GENE
beta E-GENE I-GENE
) O I-GENE
induces O I-GENE
gene O E-GENE
transcription O O
through O O
a O O
novel O O
IFN B-GENE S-GENE
response I-GENE O
element E-GENE O
called O O
the O O
gamma B-GENE B-GENE
- I-GENE I-GENE
IFN I-GENE I-GENE
- I-GENE I-GENE
activated I-GENE I-GENE
transcriptional I-GENE I-GENE
element E-GENE E-GENE
Northern O O
blot O O
analysis O O
demonstrated O O
that O O
the O O
STORP B-GENE B-GENE
gene E-GENE E-GENE
has O O
a O O
ubiquitous O O
pattern O O
of O O
expression O O
similar O O
to O O
that O O
of O O
the O O
PML B-GENE B-GENE
gene E-GENE E-GENE
. O O
In O O
the O O
TLE O O
patients O O
the O O
NAA O O
: O O
Cr O O
ratios O O
were O O
reduced O O
in O O
the O O
seizure O O
focus O O
, O O
while O O
in O O
the O O
FLE O O
patients O O
they O O
were O O
not O O
always O O
reduced O O
in O O
the O O
seizure O O
focus O O
. O O

The O O
Spo0F B-GENE O
residues E-GENE O
making O O
up O O
the O O
hydrophobic O O
patch O O
are O O
very O O
similar O O
in O O
all O O
response O O
regulators O O
suggesting O O
that O O
the O O
binding O O
is O O
initiated O O
through O O
the O O
same O O
residues O O
in O O
all O O
interacting O O
response O O
regulator O B-GENE
- O I-GENE
kinase O E-GENE
pairs O O
. O O
The O O
psychologic O O
factors O O
associated O O
wth O O
serious O O
illness O O
, O O
terminal O O
prognoses O O
, O O
and O O
dying O O
complicate O O
the O O
scenario O O
even O O
more O O
as O O
compared O O
with O O
that O O
of O O
nonmalignant O O
pain O O
. O O

However O O
, O O
if O O
the O O
spatial O O
resolution O O
is O O
not O O
critical O O
and O O
interest O O
is O O
to O O
compare O O
a O O
pathologic O O
area O O
with O O
a O O
contralateral O O
VOI O O
, O O
then O O
the O O
acquisition O O
of O O
two O O
single O O
- O O
voxel O O
spectra O O
may O O
be O O
preferred O O
. O O

Quantitative O O
evaluation O O
of O O
magneto O O
- O O
optical O O
parameters O O
is O O
necessary O O
in O O
order O O
to O O
apply O O
scanning O O
near O O
- O O
field O O
optical O O
microscope O O
( O O
SNOM O O
) O O
technology O O
to O O
the O O
study O O
of O O
magnetism O O
on O O
the O O
mesoscopic O O
scale O O
. O O

We O O
found O O
that O O
the O O
amplitude O O
of O O
the O O
cortical O O
evoked O O
potentials O O
( O O
amplitude O O
of O O
the O O
N2/P2 O O
peak O O
) O O
increased O O
from O O
5.1 O O
+ O O
/- O O
0.7 O O
microV O O
at O O
5 O O
mA O O
to O O
16.3 O O
+ O O
/- O O
1.1 O O
microV O O
at O O
20 O O
mA. O O

While O O
mutations O O
in O O
K B-GENE B-GENE
- I-GENE I-GENE
Rev E-GENE E-GENE
that O O
inactivate O O
any O O
one O O
of O O
these O O
properties O O
also O O
blocked O O
K O B-GENE
- O I-GENE
Rev O I-GENE
- O I-GENE
dependent O I-GENE
nuclear O I-GENE
RNA O E-GENE
export O O
, O O
several O O
K B-GENE B-GENE
- I-GENE I-GENE
Rev I-GENE I-GENE
mutants E-GENE E-GENE
were O O
comparable O O
to O O
wild O O
type O O
when O O
assayed O O
for O O
any O O
of O O
these O O
individual O O
activities O O
yet O O
nevertheless O O
defective O O
for O O
RNA O B-GENE
export O E-GENE
. O O
LMP-1 S-GENE S-GENE
is O O
targeted O O
to O O
the O O
plasma O B-GENE
membrane O E-GENE
, O O
where O O
it O O
binds O O
TRAF S-GENE S-GENE
, O O
TRADD S-GENE S-GENE
, O O
and O O
JAK B-GENE S-GENE
molecules E-GENE O
to O O
activate O O
NF O B-GENE
- O I-GENE
kappaB- O E-GENE
, O O
AP-1- O S-GENE
, O O
and O O
STAT S-GENE S-GENE
- O O
dependent O O
pathways O O
as O O
does O O
CD40 S-GENE S-GENE
. O O
Identification O O
of O O
an O O
enhancer O O
and O O
an O O
alternative O O
promoter O O
in O O
the O O
first O O
intron O O
of O O
the O O
alpha B-GENE B-GENE
- I-GENE I-GENE
fetoprotein I-GENE I-GENE
gene E-GENE E-GENE
. O O
Studying O O
intracellular O O
signaling O O
pathways O O
, O O
which O O
may O O
be O O
involved O O
in O O
malignant O O
transformation O O
of O O
Ret-9bp S-GENE B-GENE
expressing O I-GENE
NIH3T3 O E-GENE
cells O O
, O O
we O O
could O O
demonstrate O O
Ret-9bp O O
dependent O O
phosphorylation O O
of O O
insulin B-GENE B-GENE
receptor I-GENE I-GENE
substrate-2 E-GENE E-GENE
( O O
IRS-2 S-GENE S-GENE
) O O
with O O
consecutive O O
activation O O
of O O
phosphatidylinositol B-GENE B-GENE
3-kinase E-GENE E-GENE
( O O
PI B-GENE B-GENE
3-kinase E-GENE E-GENE
) O O
and O O
protein B-GENE B-GENE
kinase I-GENE I-GENE
B E-GENE E-GENE
( O O
PKB S-GENE S-GENE
/ O O
AKT S-GENE S-GENE
) O O
. O O
METHODS O O
: O O
In O O
the O O
current O O
study O O
the O O
authors O O
reported O O
on O O
PPB O O
cases O O
from O O
a O O
national O O
retrospective O O
search O O
performed O O
in O O
18 O O
Italian O O
Associations O O
for O O
Pediatric O O
Hematology O O
and O O
Oncology O O
centers O O
. O O

Phylogenetic O O
analysis O O
showed O O
that O O
the O O
ToLCV O O
isolates O O
from O O
Bangalore O O
constitute O O
a O O
group O O
of O O
viruses O O
separated O O
from O O
those O O
of O O
Northern O O
India O O
. O O

Mutating O O
the O O
Fcp1p S-GENE B-GENE
- O I-GENE
binding O I-GENE
motif O I-GENE
KEFGK O E-GENE
in O O
the O O
RAP74 S-GENE S-GENE
( O O
Tfg1p S-GENE S-GENE
) O O
subunit O O
of O O
TFIIF S-GENE S-GENE
to O O
EEFGE O S-GENE
led O O
to O O
both O O
synthetic O O
phenotypes O O
in O O
certain O O
fcp1 S-GENE B-GENE
tfg1 S-GENE I-GENE
double O I-GENE
mutants O E-GENE
and O O
a O O
reduced O O
ability O O
of O O
Fcp1p O S-GENE
to O O
activate O O
transcription O O
when O O
it O O
is O O
artificially O O
tethered O O
to O O
a O O
promoter O O
. O O
These O O
results O O
suggest O O
that O O
Cdc42p S-GENE S-GENE
is O O
in O O
fact O O
required O O
for O O
pheromone O O
response O O
and O O
that O O
interaction O O
with O O
the O O
PAK S-GENE B-GENE
Ste20p S-GENE E-GENE
is O O
critical O O
for O O
that O O
role O O
. O O
Deletion O O
of O O
an O O
intergenic O O
DNA O O
- O O
binding O O
site O O
for O O
this O O
complex O O
from O O
a O O
human B-GENE B-GENE
beta I-GENE I-GENE
- I-GENE I-GENE
globin I-GENE I-GENE
locus I-GENE E-GENE
construct E-GENE O
results O O
in O O
delayed O O
human B-GENE B-GENE
gamma- I-GENE E-GENE
to I-GENE O
beta I-GENE B-GENE
- I-GENE I-GENE
globin E-GENE E-GENE
switching O O
in O O
transgenic O O
mice O O
, O O
suggesting O O
that O O
the O O
PYR B-GENE B-GENE
complex E-GENE E-GENE
acts O O
to O O
facilitate O O
the O O
switch O O
. O O
The O O
product O O
of O O
rat B-GENE B-GENE
gene I-GENE E-GENE
33 E-GENE O
was O O
identified O O
as O O
an O O
ErbB-2-interacting B-GENE B-GENE
protein E-GENE E-GENE
in O O
a O O
two O O
- O O
hybrid O O
screen O O
employing O O
the O O
ErbB-2 B-GENE B-GENE
juxtamembrane I-GENE E-GENE
and I-GENE O
kinase I-GENE B-GENE
domains E-GENE E-GENE
as O O
bait O O
. O O
Studies O O
suggest O O
that O O
the O O
DGOR O O
without O O
acid O O
reflux O O
may O O
result O O
in O O
symptoms O O
but O O
unless O O
acid O O
reflux O O
is O O
present O O
simultaneously O O
, O O
it O O
does O O
not O O
cause O O
oesophagitis O O
. O O

Symptoms O O
, O O
however O O
, O O
appear O O
to O O
correlate O O
poorly O O
with O O
oesophagitis O O
; O O
hence O O
, O O
severe O O
symptoms O O
do O O
not O O
indicate O O
there O O
is O O
greater O O
oesophageal O O
damage O O
. O O

OBJECTIVE O O
: O O
To O O
evaluate O O
the O O
relationship O O
between O O
blood O O
flow O O
in O O
the O O
tumor O O
assessed O O
by O O
color O O
Doppler O O
ultrasound O O
, O O
microvessel O O
density O O
, O O
and O O
vascular B-GENE B-GENE
endothelial I-GENE I-GENE
growth I-GENE I-GENE
factor E-GENE E-GENE
levels O O
in O O
endometrial O O
carcinoma O O
. O O
These O O
results O O
demonstrate O O
Ras- O S-GENE
and O O
Raf S-GENE B-GENE
- O I-GENE
independent O I-GENE
ERK S-GENE I-GENE
MAPK O E-GENE
activation O O
maintains O O
cell O O
viability O O
following O O
heat O O
shock O O
. O O
Three O O
cDNAs O B-GENE
encoding O I-GENE
basic B-GENE I-GENE
leucine I-GENE I-GENE
zipper I-GENE E-GENE
( I-GENE O
bZIP)-type I-GENE B-GENE
ABRE I-GENE I-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
proteins E-GENE E-GENE
were O O
isolated O O
by O O
using O O
the O O
yeast O O
one O O
- O O
hybrid O O
system O O
and O O
were O O
designated O O
AREB1 S-GENE S-GENE
, O O
AREB2 S-GENE S-GENE
, O O
and O O
AREB3 S-GENE S-GENE
( O O
ABA B-GENE B-GENE
- I-GENE I-GENE
responsive I-GENE I-GENE
element I-GENE I-GENE
binding I-GENE I-GENE
protein E-GENE E-GENE
) O O
. O O
Recombinant O O
AROM S-GENE B-GENE
- O I-GENE
p64 S-GENE E-GENE
displayed O O
high O O
binding O O
to O O
single O O
- O O
stranded O O
DNA O O
and O O
poly(A O O
) O O
homopolymers O O
suggesting O O
that O O
this O O
protein O O
could O O
play O O
a O O
role O O
in O O
mRNA O O
maturation O O
/ O O
metabolism O O
. O O
The O O
protein B-GENE B-GENE
- I-GENE I-GENE
tyrosine I-GENE I-GENE
kinase E-GENE I-GENE
fer S-GENE E-GENE
associates O O
with O O
signaling O O
complexes O O
containing O O
insulin B-GENE B-GENE
receptor I-GENE I-GENE
substrate-1 E-GENE E-GENE
and O O
phosphatidylinositol B-GENE B-GENE
3-kinase E-GENE E-GENE
. O O
The O O
variable O O
phenotype O O
of O O
the O O
allotetraploids O O
could O O
not O O
be O O
explained O O
by O O
cytological O O
abnormalities O O
. O O

In O O
the O O
PMR O O
target O O
area O O
but O O
not O O
in O O
the O O
nontreated O O
area O O
an O O
improvement O O
in O O
regional O O
myocardial O O
flow O O
reserve O O
occurs O O
in O O
wall O O
segments O O
with O O
initially O O
severely O O
or O O
moderately O O
reduced O O
stress O O
perfusion O O
. O O

Analysis O O
of O O
intron O O
/ O O
exon O O
boundaries O O
of O O
the O O
genomic O O
BAC O S-GENE
clones O O
demonstrate O O
that O O
junctin S-GENE S-GENE
, O O
junctate S-GENE O
, O O
and O O
aspartyl B-GENE B-GENE
beta I-GENE I-GENE
- I-GENE I-GENE
hydroxylase E-GENE E-GENE
result O O
from O O
alternative O O
splicing O O
of O O
the O O
same O O
gene O O
. O O
It O O
is O O
now O O
estimated O O
that O O
inactivation O O
mutants O O
of O O
PTEN S-GENE S-GENE
exist O O
in O O
60% O O
of O O
all O O
forms O O
of O O
solid O O
tumors O O
. O O
We O O
have O O
demonstrated O O
that O O
the O O
activity O O
of O O
ILK S-GENE S-GENE
is O O
constitutively O O
elevated O O
in O O
PTEN B-GENE B-GENE
mutant E-GENE E-GENE
cells O O
. O O
The O O
growth B-GENE B-GENE
factor I-GENE I-GENE
receptor I-GENE I-GENE
- I-GENE I-GENE
bound I-GENE I-GENE
protein I-GENE I-GENE
2 E-GENE E-GENE
( O O
Grb2 S-GENE S-GENE
) O O
adaptor O O
when O O
complexed O O
with O O
Sos S-GENE O
( O O
Son B-GENE S-GENE
of I-GENE O
sevenless E-GENE O
) O O
, O O
the O O
exchange O B-GENE
factor O E-GENE
of O O
Ras S-GENE S-GENE
, O O
conveys O O
the O O
signal O O
induced O O
by O O
tyrosine B-GENE B-GENE
kinase I-GENE I-GENE
- I-GENE I-GENE
activated I-GENE I-GENE
receptor E-GENE E-GENE
to O O
Ras O S-GENE
by O O
recruiting O O
Sos O O
to O O
the O O
membrane O O
, O O
allowing O O
activation O O
of O O
Ras O S-GENE
. O O
Mutations O O
in O O
genes O O
encoding O O
PR65/A B-GENE S-GENE
subunits E-GENE O
have O O
been O O
identified O O
in O O
several O O
different O O
human O O
cancers O O
and O O
the O O
PP2A S-GENE B-GENE
inhibitor O E-GENE
, O O
termed O O
fostriecin O O
, O O
is O O
being O O
tested O O
as O O
an O O
anticancer O O
drug O O
. O O
For O O
this O O
purpose O O
, O O
a O O
segment O O
of O O
dxr S-GENE O
was O O
amplified O O
from O O
Synechococcus O O
leopoliensis O O
SAUG O O
1402 O O
- O O
1 O O
DNA O O
via O O
PCR O O
using O O
oligonucleotides O O
for O O
conserved O O
regions O O
. O O
Perceptual O O
learning O O
for O O
a O O
pattern O O
discrimination O O
task O O
. O O

The O O
detector O O
has O O
the O O
advantage O O
of O O
finding O O
both O O
ST O O
segment O O
deviations O O
and O O
entire O O
ST O O
- O O
T O O
complex O O
changes O O
thereby O O
providing O O
a O O
wider O O
characterization O O
of O O
the O O
potential O O
ischemic O O
events O O
. O O

While O O
this O O
Saccharomyces O B-GENE
cerevisiae O I-GENE
SIN4 B-GENE I-GENE
gene I-GENE I-GENE
product E-GENE E-GENE
is O O
a O O
component O O
of O O
a O O
mediator O O
complex O O
associated O O
with O O
RNA B-GENE B-GENE
polymerase I-GENE I-GENE
II E-GENE E-GENE
, O O
various O O
studies O O
suggest O O
the O O
involvement O O
of O O
Sin4 S-GENE S-GENE
in O O
the O O
alteration O O
of O O
higher O O
- O O
order O O
chromatin O O
structure O O
. O O
Primary O O
adrenal O O
hypersensitivity O O
to O O
ACTH S-GENE S-GENE
drive O O
in O O
obesity O O
has O O
also O O
been O O
suggested O O
. O O
In O O
addition O O
, O O
a O O
noncanonical O O
C B-GENE O
/ I-GENE O
EBP I-GENE B-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
site E-GENE E-GENE
within O O
the O O
Gadd45gamma B-GENE B-GENE
promoter E-GENE E-GENE
where O O
C B-GENE O
/ I-GENE O
EBPbeta E-GENE S-GENE
and O O
C B-GENE O
/ I-GENE O
EBPdelta E-GENE S-GENE
could O O
bind O O
, O O
was O O
identified O O
by O O
electrophoretic O O
mobility O O
shift O O
assay O O
( O O
EMSA O S-GENE
) O O
and O O
reporter O O
gene O O
analysis O O
. O O
Src S-GENE S-GENE
activation O O
induced O O
by O O
FGF1 S-GENE S-GENE
was O O
blocked O O
by O O
the O O
SH2 B-GENE B-GENE
domain E-GENE E-GENE
of O O
Src O S-GENE
and O O
PP2 S-GENE S-GENE
, O O
a O O
specific O O
inhibitor O O
of O O
Src O S-GENE
. O O
The O O
use O O
of O O
the O O
PLCgamma B-GENE B-GENE
inhibitory I-GENE I-GENE
peptide E-GENE E-GENE
, O O
neomycin O O
and O O
the O O
calcium O O
chelator O O
BAPTA O B-GENE
- O I-GENE
AM O E-GENE
on O O
oocytes O O
expressing O O
FGFR1 S-GENE S-GENE
or O O
the O O
stimulation O O
by O O
PDGF B-GENE B-GENE
- I-GENE I-GENE
BB E-GENE E-GENE
of O O
oocytes O O
expressing O O
PDGFR S-GENE S-GENE
- O O
FGFR1 O S-GENE
mutated O O
on O O
the O O
PLCgamma B-GENE B-GENE
binding I-GENE I-GENE
site E-GENE E-GENE
, O O
prevented O O
GVBD O S-GENE
and O O
ERK2 S-GENE S-GENE
phosphorylation O O
. O O
Multiple O O
transcription O O
start O O
sites O O
were O O
revealed O O
by O O
primer O O
extension O O
analysis O O
of O O
the O O
mouse O B-GENE
gene O E-GENE
, O O
and O O
transfection O O
constructs O O
containing O O
the O O
prospective O O
promoter O O
generated O O
transcriptional O O
activity O O
comparable O O
to O O
that O O
of O O
the O O
SV40 B-GENE B-GENE
promoter E-GENE E-GENE
. O O
From O O
two O O
inhibitor O O
scaffolds O O
, O O
we O O
have O O
identified O O
potent O O
and O O
selective O O
inhibitors O O
for O O
sensitized O O
kinases O O
from O O
five O O
distinct O O
subfamilies O O
. O O

To O O
determine O O
whether O O
interaction O O
of O O
arsenite O O
with O O
the O O
hormone O B-GENE
- O I-GENE
binding O I-GENE
domain O E-GENE
results O O
in O O
receptor O O
activation O O
, O O
COS-1 O S-GENE
cells O O
were O O
transiently O O
cotransfected O O
with O O
the O O
chimeric B-GENE B-GENE
receptors I-GENE I-GENE
GAL I-GENE I-GENE
- I-GENE I-GENE
ER E-GENE E-GENE
, O O
which O O
contains O O
the O O
hormone O B-GENE
- O I-GENE
binding O I-GENE
domain O E-GENE
of O O
ERalpha S-GENE S-GENE
and O O
the O O
DNA O B-GENE
- O I-GENE
binding O I-GENE
domain O E-GENE
of O O
the O O
transcription O B-GENE
factor O I-GENE
GAL4 S-GENE E-GENE
, O O
and O O
a O O
GAL4-responsive O B-GENE
CAT B-GENE I-GENE
reporter I-GENE I-GENE
gene E-GENE E-GENE
. O O
By O O
progressive O O
5'-deletion O O
studies O O
, O O
we O O
have O O
identified O O
a O O
248-bp O O
DNA O O
fragment O O
( O O
-1018 O O
to O O
-771 O O
, O O
relative O O
to O O
the O O
translation O O
start O O
site O O
) O O
at O O
the O O
5'-flanking O O
region O O
of O O
the O O
human B-GENE B-GENE
GnRHR I-GENE I-GENE
gene E-GENE E-GENE
that O O
is O O
responsible O O
for O O
the O O
GnRHa O S-GENE
- O O
mediated O O
down O O
- O O
regulation O O
of O O
human B-GENE B-GENE
GnRHR I-GENE I-GENE
promoter E-GENE E-GENE
activity O O
. O O
The O O
mean O O
day O O
of O O
diagnosis O O
of O O
periventricular O O
echodensities O O
was O O
3 O O
+ O O
/- O O
2 O O
days O O
( O O
range O O
1 O O
- O O
11 O O
days O O
) O O
, O O
and O O
of O O
cystic O O
PVL O O
21 O O
+ O O
/- O O
8 O O
days O O
( O O
range O O
2 O O
- O O
47 O O
days O O
) O O
. O O

The O O
LAMMER S-GENE B-GENE
protein O I-GENE
kinase O E-GENE
encoded O O
by O O
the O O
Doa B-GENE B-GENE
locus E-GENE E-GENE
of O O
Drosophila O O
is O O
required O O
in O O
both O O
somatic O O
and O O
germline O O
cells O O
and O O
is O O
expressed O O
as O O
both O O
nuclear O O
and O O
cytoplasmic O O
isoforms O O
throughout O O
development O O
. O O
We O O
have O O
mutated O O
to O O
cysteine O O
, O O
one O O
at O O
a O O
time O O
, O O
21 O O
consecutive O O
residues O O
in O O
the O O
fourth O O
TMS O O
( O O
TM4 O O
) O O
. O O

( O O
1995 O O
) O O
J. O O

HYPOTHESIS O O
: O O
The O O
aim O O
of O O
this O O
study O O
was O O
to O O
investigate O O
the O O
oxidative O O
susceptibility O O
of O O
apolipoprotein B-GENE B-GENE
B I-GENE I-GENE
- I-GENE I-GENE
containing I-GENE I-GENE
lipoproteins E-GENE E-GENE
and O O
antioxidant O O
status O O
in O O
patients O O
with O O
acute O O
coronary O O
syndromes O O
and O O
chronic O O
stable O O
angina O O
pectoris O O
. O O
In O O
group O O
B O O
37 O O
MBq O O
in O O
150 O O
microL O O
of O O
99mTc O O
- O O
HSA O O
nanocolloid O O
was O O
additionally O O
injected O O
intradermally O O
18 O O
h O O
before O O
surgery O O
( O O
3 O O
- O O
6 O O
aliquots O O
injected O O
perilesionally O O
) O O
. O O

Post O O
- O O
operative O O
functional O O
outcome O O
is O O
related O O
to O O
pre O O
- O O
operative O O
functional O O
status O O
. O O

We O O
cloned O O
a O O
DNA O O
fragment O O
encoding O O
the O O
N O O
- O O
terminal O O
part O O
of O O
a O O
protein O O
with O O
significant O O
similarity O O
to O O
members O O
of O O
the O O
LysR B-GENE B-GENE
family I-GENE E-GENE
of I-GENE O
transcriptional I-GENE O
regulators E-GENE O
( O O
LTTRs S-GENE S-GENE
) O O
. O O
AGO1 S-GENE S-GENE
is O O
similar O O
to O O
QDE-2 S-GENE S-GENE
required O O
for O O
quelling O O
and O O
RDE-1 S-GENE S-GENE
required O O
for O O
RNAi O S-GENE
. O O
Intracellular O O
localization O O
studies O O
using O O
the O O
mDAP-3/EGFP O B-GENE
fusion O I-GENE
protein O E-GENE
, O O
cell O O
fractionation O O
and O O
protease O O
protection O O
experiments O O
localized O O
mDAP-3 O S-GENE
to O O
the O O
mitochondrial O O
matrix O O
. O O
We O O
could O O
demonstrate O O
the O O
involvement O O
of O O
cAMP B-GENE B-GENE
- I-GENE I-GENE
dependent I-GENE I-GENE
protein I-GENE I-GENE
kinase E-GENE E-GENE
( O O
PKA S-GENE S-GENE
) O O
in O O
the O O
phosphorylation O O
of O O
CDC25Mm S-GENE S-GENE
in O O
fibroblasts O O
overexpressing O O
this O O
RasGEF S-GENE S-GENE
as O O
well O O
as O O
in O O
mouse O O
brain O O
synaptosomal O O
membranes O O
. O O
Reporter O B-GENE
gene O E-GENE
expression O O
analyses O O
indicate O O
that O O
both O O
WASP B-GENE S-GENE
promoters E-GENE O
show O O
high O O
levels O O
of O O
expression O O
in O O
different O O
hematopoietic O O
cell O O
lines O O
. O O
We O O
find O O
that O O
3T1 O B-GENE
- O I-GENE
3T2 O E-GENE
mixing O O
has O O
a O O
pronounced O O
effect O O
on O O
the O O
line O O
shape O O
and O O
radiative O O
decay O O
rate O O
of O O
emission O O
from O O
the O O
3T2 O O
state O O
and O O
that O O
the O O
extent O O
of O O
mixing O O
depends O O
critically O O
on O O
the O O
magnitude O O
of O O
nontetrahedral O O
distortions O O
. O O

A O O
total O O
of O O
576 O O
1-day O O
- O O
old O O
Ross O O
broiler O O
chicks O O
were O O
housed O O
in O O
six O O
treatment O O
groups O O
[ O O
six O O
replicates O O
of O O
16 O O
each O O
; O O
control O O
, O O
CLI O O
( O O
15 O O
g O O
kg(-1)diet O O
) O O
, O O
50 O O
parts O O
per O O
billion O O
( O O
ppb O O
) O O
AF S-GENE O
, O O
50 O O
ppb O O
AF O O
plus O O
CLI O O
, O O
100 O O
ppb O O
AF O O
, O O
100 O O
ppb O O
AF O O
plus O O
CLI O O
] O O
for O O
42 O O
days O O
. O O
The O O
cost O O
per O O
test O O
is O O
less O O
than O O
those O O
for O O
CC O O
, O O
kEIA O O
and O O
PACE2 O O
. O O

Altogether O O
these O O
results O O
suggest O O
that O O
, O O
in O O
KG1a O S-GENE
cells O O
, O O
TNFalpha S-GENE O
can O O
stimulate O O
in O O
parallel O O
PC B-GENE B-GENE
- I-GENE I-GENE
PLC E-GENE E-GENE
and O O
PLD S-GENE S-GENE
, O O
whose O O
lipid O O
products O O
activate O O
in O O
turn O O
mitogen B-GENE B-GENE
- I-GENE I-GENE
activated I-GENE I-GENE
protein I-GENE I-GENE
kinase E-GENE E-GENE
( O O
MAP B-GENE B-GENE
kinase E-GENE E-GENE
) O O
and O O
NF B-GENE B-GENE
- I-GENE I-GENE
kappaB E-GENE E-GENE
signalling O O
respectively O O
. O O
Concurrently O O
, O O
we O O
monitored O O
weather O O
conditions O O
and O O
used O O
time O O
- O O
activity O O
budget O O
data O O
of O O
free O O
- O O
living O O
birds O O
and O O
laboratory O O
data O O
on O O
resting O O
metabolic O O
rate O O
to O O
construct O O
time O O
- O O
activity O O
laboratory O O
( O O
TAL O O
) O O
estimates O O
of O O
daily O O
energy O O
expenditure O O
( O O
DEE O O
) O O
and O O
to O O
partition O O
the O O
verdins O O
' O O
energy O O
budget O O
into O O
thermoregulatory O O
, O O
activity O O
and O O
basal O O
components O O
. O O

L O O
/ O O
H O O
> O O
0.61 O O
( O O
chi(2)=10.8 O O
; O O
P:<0.001 O O
) O O
and O O
a O O
restrictive O O
filling O O
pattern O O
( O O
chi(2)=3.6 O O
; O O
P:<0.05 O O
) O O
were O O
independent O O
predictors O O
of O O
events O O
. O O

The O O
high O O
selectivity O O
of O O
arrestins S-GENE O
for O O
this O O
particular O O
functional O O
form O O
of O O
receptor O O
ensures O O
their O O
timely O O
binding O O
and O O
dissociation O O
. O O
When O O
cotransfected O O
in O O
fibroblasts O O
with O O
a O O
C B-GENE O
/ I-GENE O
EBP I-GENE B-GENE
alpha E-GENE E-GENE
expression O O
vector O O
, O O
reporter O B-GENE
gene O E-GENE
expression O O
increased O O
3-fold O O
only O O
in O O
the O O
wild O B-GENE
- O I-GENE
type O I-GENE
constructs O E-GENE
. O O
Expression O O
of O O
a O O
dominant B-GENE O
negative I-GENE O
Smad2 E-GENE S-GENE
significantly O O
reduces O O
the O O
level O O
of O O
luciferase B-GENE B-GENE
reporter E-GENE E-GENE
activity O O
induced O O
by O O
nodal O O
treatment O O
. O O
Normal O O
alpha1(I B-GENE O
) I-GENE O
collagen I-GENE B-GENE
mRNA E-GENE E-GENE
showed O O
no O O
significant O O
reduction O O
when O O
AR O O
or O O
IR O O
was O O
expressed O O
from O O
the O O
pHbetaAPr-1-neo O O
vector O O
and O O
a O O
small O O
( O O
10 O O
- O O
20% O O
) O O
but O O
significant O O
reduction O O
when O O
either O O
ribozyme O O
was O O
expressed O O
from O O
the O O
pCI.neo O O
vector O O
. O O
Nature O O
398 O O
, O O
828 O O
- O O
830 O O
) O O
that O O
the O O
amino O O
acid O O
sequences O O
of O O
peptide O O
fragments O O
obtained O O
from O O
a O O
polypeptide O O
found O O
in O O
a O O
complex O O
of O O
proteins O O
that O O
alters O O
chromatin O O
structure O O
( O O
ARC S-GENE O
) O O
are O O
identical O O
to O O
portions O O
of O O
the O O
deduced O O
open O O
reading O O
frame O O
of O O
TIG-1 B-GENE B-GENE
mRNA E-GENE E-GENE
. O O
Abnormalities O O
of O O
plasma B-GENE B-GENE
cholecystokinin E-GENE E-GENE
were O O
observed O O
only O O
in O O
patients O O
with O O
delayed O O
gastric O O
emptying O O
. O O
5 O O
( O O
Sunset O O
Yellow O O
FCF O O
) O O
were O O
determined O O
using O O
liquid O O
chromatography O O
/ O O
mass O O
spectrometry O O
( O O
LC O O
/ O O
MS O O
) O O
with O O
electrospray O O
ionization O O
. O O

Polysome O O
and O O
40S B-GENE O
ribosome E-GENE O
fractions O O
were O O
severely O O
decreased O O
in O O
the O O
krr1 B-GENE B-GENE
mutant E-GENE E-GENE
and O O
Kri1p S-GENE S-GENE
- O O
depleted O O
cells O O
. O O
They O O
also O O
negatively O O
modulate O O
the O O
PI B-GENE B-GENE
3-kinase E-GENE I-GENE
catalytic O E-GENE
activity O O
but O O
to O O
different O O
extents O O
, O O
dependent O O
on O O
the O O
unique O O
N O O
- O O
terminal O O
structure O O
of O O
each O O
isoform O O
. O O
Cam B-GENE B-GENE
kinase I-GENE I-GENE
II E-GENE E-GENE
induces O O
in O O
vivo O O
phosphorylation O O
of O O
Smad2 S-GENE S-GENE
and O O
Smad4 S-GENE S-GENE
and O O
, O O
to O O
a O O
lesser O O
extent O O
, O O
Smad3 S-GENE S-GENE
. O O
The O O
Drosophila B-GENE B-GENE
melanogaster I-GENE I-GENE
suppressor I-GENE E-GENE
of I-GENE O
sable I-GENE B-GENE
gene E-GENE E-GENE
, O O
su(s B-GENE S-GENE
) E-GENE O
, O O
encodes O O
a O O
novel O O
, O O
150-kDa O B-GENE
nuclear O I-GENE
RNA O I-GENE
binding O I-GENE
protein O E-GENE
, O O
SU(S B-GENE S-GENE
) E-GENE O
, O O
that O O
negatively O O
regulates O O
RNA O O
accumulation O O
from O O
mutant O O
alleles O O
of O O
other O O
genes O O
that O O
have O O
transposon O O
insertions O O
in O O
the O O
5 O O
' O O
transcribed O O
region O O
. O O
As O O
a O O
result O O
, O O
we O O
have O O
defined O O
two O O
arginine O O
- O O
rich O O
motifs O O
( O O
ARM1 O S-GENE
and O O
ARM2 O S-GENE
) O O
that O O
mediate O O
the O O
RNA O O
binding O O
activity O O
of O O
SU(S B-GENE S-GENE
) E-GENE O
. O O
This O O
interaction O O
inhibits O O
the O O
histone B-GENE B-GENE
acetyltransferase E-GENE E-GENE
activity O O
of O O
p300 S-GENE S-GENE
, O O
resulting O O
in O O
drastic O O
reduction O O
of O O
nucleosomal O B-GENE
histone O I-GENE
acetylation O E-GENE
and O O
alteration O O
of O O
chromatin O O
structure O O
. O O
Recombinant B-GENE B-GENE
BRI1-KD E-GENE I-GENE
autophosphorylated O E-GENE
on O O
serine O O
( O O
Ser O O
) O O
and O O
threonine O O
( O O
Thr O O
) O O
residues O O
with O O
p O O
- O O
Ser O O
predominating O O
. O O
Flow O O
cytomery O O
was O O
used O O
for O O
cell O O
cycle O O
analysis O O
. O O

Further O O
research O O
is O O
required O O
to O O
better O O
measure O O
treatment O O
effects O O
, O O
modification O O
of O O
MS O O
natural O O
history O O
, O O
and O O
net O O
societal O O
costs O O
of O O
IFN B-GENE B-GENE
beta-1b E-GENE E-GENE
in O O
RRMS O O
. O O
Cost O O
- O O
effectiveness O O
of O O
interferon B-GENE O
beta-1b E-GENE O
in O O
slowing O O
multiple O O
sclerosis O O
disability O O
progression O O
. O O
Both O O
the O O
Cmax O O
and O O
AUC O O
values O O
were O O
almost O O
doubled O O
with O O
doubling O O
the O O
dose O O
. O O

Hyperactivation O O
of O O
Cdc2 S-GENE O
in O O
fission O O
yeast O O
causes O O
cells O O
to O O
undergo O O
a O O
lethal O O
premature O O
mitosis O O
called O O
mitotic O O
catastrophe O O
. O O
Diary O O
. O O

Cells O O
differentiate O O
in O O
response O O
to O O
various O O
extracellular O O
stimuli O O
. O O

Transforming B-GENE B-GENE
growth I-GENE I-GENE
factor I-GENE I-GENE
- I-GENE I-GENE
beta1 E-GENE E-GENE
( O O
TGF B-GENE B-GENE
- I-GENE I-GENE
beta1 E-GENE E-GENE
) O O
can O O
act O O
as O O
a O O
tumor O O
suppressor O O
or O O
a O O
tumor O O
promoter O O
depending O O
on O O
the O O
characteristics O O
of O O
the O O
malignant O O
cell O O
. O O
Vasoactive B-GENE O
intestinal I-GENE O
peptide E-GENE O
and O O
pituitary B-GENE B-GENE
adenylate I-GENE I-GENE
cyclase I-GENE I-GENE
- I-GENE I-GENE
activating I-GENE I-GENE
polypeptide E-GENE I-GENE
inhibit O I-GENE
nuclear B-GENE I-GENE
factor I-GENE I-GENE
- I-GENE I-GENE
kappa I-GENE I-GENE
B I-GENE I-GENE
- I-GENE I-GENE
dependent I-GENE I-GENE
gene E-GENE E-GENE
activation O O
at O O
multiple O O
levels O O
in O O
the O O
human O O
monocytic O O
cell O O
line O O
THP-1 O S-GENE
. O O
Mn2 O O
+ O O
increased O O
both O O
the O O
junction O O
binding O O
and O O
cleaving O O
activities O O
of O O
the O O
mutant O O
proteins O O
. O O

While O O
Pt;cycH;1 S-GENE S-GENE
and O O
Os;cycH;1 S-GENE S-GENE
were O O
expressed O O
in O O
all O O
tissues O O
examined O O
, O O
the O O
transcripts O O
accumulated O O
abundantly O O
in O O
dividing O O
cells O O
. O O
Moreover O O
, O O
an O O
in O O
vitro O O
pull O O
- O O
down O O
assay O O
showed O O
that O O
Os;CycH;1 S-GENE S-GENE
specifically O O
bound O O
to O O
R2 S-GENE O
but O O
not O O
to O O
other O O
rice B-GENE B-GENE
CDKs E-GENE E-GENE
. O O
In O O
transient O O
analysis O O
using O O
particle O O
bombardment O O
of O O
tobacco O O
leaf O O
sections O O
, O O
a O O
tetramer O O
of O O
the O O
distB O B-GENE
ABRE O E-GENE
( O O
abscisic O B-GENE
acid O I-GENE
- O I-GENE
responsive O I-GENE
element O E-GENE
) O O
mediated O O
transactivation O O
by O O
ABI3 S-GENE S-GENE
and O O
ABI3-dependent O O
response O O
to O O
ABA O S-GENE
, O O
whereas O O
a O O
tetramer O O
of O O
the O O
composite O O
RY O O
/ O O
G O O
complex O O
, O O
containing O O
RY O O
repeats O O
and O O
a O O
G O O
- O O
box O O
, O O
mediated O O
only O O
ABA O O
- O O
independent O O
transactivation O O
by O O
ABI3 O S-GENE
. O O
The O O
major O O
neurological O O
manifestations O O
of O O
brain O O
injury O O
in O O
these O O
babies O O
are O O
spastic O O
motor O O
deficits O O
. O O

Spores O O
from O O
Rhizopus O O
stolonifer O O
were O O
suspended O O
in O O
distilled O O
water O O
( O O
1 O O
x O O
10(6 O O
) O O
spores O O
/ O O
mL O O
) O O
and O O
used O O
as O O
starter O O
. O O

Overexpression O O
of O O
Trdpm1 S-GENE S-GENE
in O O
a O O
dpm1(+)::his7/dpm1(+ O O
) O O
S.pombe O O
diploid O O
resulted O O
in O O
a O O
4-fold O O
increase O O
in O O
specific O O
DPM B-GENE B-GENE
synthase E-GENE E-GENE
activity O O
. O O
The O O
LMW B-GENE B-GENE
FGF-2 E-GENE E-GENE
up O O
- O O
regulated O O
the O O
PKC B-GENE B-GENE
epsilon E-GENE E-GENE
levels O O
by O O
1.6-fold O O
; O O
by O O
contrast O O
the O O
HMW B-GENE B-GENE
isoform E-GENE E-GENE
down O O
- O O
regulated O O
the O O
level O O
of O O
this O O
PKC B-GENE B-GENE
isotype E-GENE E-GENE
by O O
about O O
3-fold O O
and O O
increased O O
the O O
amount O O
of O O
PKC B-GENE B-GENE
delta E-GENE E-GENE
by O O
1.7-fold O O
. O O
Helicobacter O O
pylori O O
and O O
stomach O O
diseases O O
: O O
from O O
clinical O O
point O O
of O O
view O O

For O O
this O O
purpose O O
, O O
the O O
writhing O O
test O O
, O O
capsaicin O O
and O O
formalin O O
induced O O
- O O
pain O O
in O O
mice O O
were O O
used O O
. O O

2000 O O
update O O
of O O
recommendations O O
for O O
the O O
use O O
of O O
hematopoietic B-GENE B-GENE
colony I-GENE I-GENE
- I-GENE I-GENE
stimulating I-GENE I-GENE
factors E-GENE E-GENE
: O O
evidence O O
- O O
based O O
, O O
clinical O O
practice O O
guidelines O O
. O O
Prominent O O
findings O O
were O O
chronic O O
pancreatitis O O
with O O
acinar O O
and O O
ductal O O
plugs O O
, O O
granulomatous O O
and O O
necrotizing O O
peripancreatic O O
steatitis O O
, O O
degenerative O O
myopathy O O
, O O
testicular O O
atrophy O O
, O O
candidiasis O O
and O O
bacterial O O
necrotizing O O
glossitis O O
. O O

Taken O O
together O O
, O O
our O O
data O O
indicate O O
that O O
multiple O O
survival O O
pathways O O
are O O
triggered O O
via O O
this O O
receptor O O
, O O
whereas O O
NF B-GENE B-GENE
- I-GENE I-GENE
kappaB E-GENE I-GENE
/ O I-GENE
Rel S-GENE E-GENE
and O O
PI-3 B-GENE B-GENE
K E-GENE E-GENE
are O O
crucial O O
for O O
CD40-induced O S-GENE
proliferation O O
. O O
In O O
vitro O O
, O O
Arix S-GENE S-GENE
and O O
NBPhox S-GENE S-GENE
form O O
DNA O O
- O O
independent O O
multimers O O
and O O
exhibit O O
cooperative O O
binding O O
to O O
the O O
DB1 B-GENE B-GENE
regulatory I-GENE I-GENE
element E-GENE E-GENE
, O O
which O O
contains O O
two O O
homeodomain B-GENE B-GENE
recognition I-GENE I-GENE
sites E-GENE E-GENE
. O O
We O O
conclude O O
from O O
this O O
study O O
that O O
Arix S-GENE S-GENE
and O O
NBPhox S-GENE S-GENE
exhibit O O
indistinguishable O O
and O O
independent O O
transcriptional O O
regulatory O O
properties O O
on O O
the O O
DBH B-GENE B-GENE
promoter E-GENE E-GENE
. O O
METHODS O O
AND O O
RESULTS O O
: O O
Studies O O
were O O
undertaken O O
in O O
9 O O
isolated O O
guinea O O
pig O O
hearts O O
, O O
which O O
demonstrated O O
reverse O O
use O O
- O O
dependent O O
prolongation O O
of O O
cardiac O O
repolarization O O
by O O
100 O O
nmol O O
/ O O
L O O
domperidone O O
. O O

The O O
N O O
- O O
terminal O O
small O O
segment O O
of O O
yeast B-GENE O
TAF145 E-GENE S-GENE
( O O
yTAF145 S-GENE S-GENE
) O O
binds O O
to O O
TBP S-GENE S-GENE
and O O
thereby O O
inhibits O O
TBP O S-GENE
function O O
. O O
OBJECTIVE O O
: O O
To O O
evaluate O O
the O O
overall O O
performance O O
of O O
a O O
new O O
oscillometric O O
wrist O O
blood O O
pressure O O
monitor O O
( O O
Braun O O
PrecisionSensor O O
, O O
Braun O O
GmbH O O
, O O
Kronberg O O
, O O
Germany O O
) O O
as O O
defined O O
by O O
the O O
ANSI O O
/ O O
AAMI O O
SP10 O O
- O O
1992 O O
guidelines O O
, O O
and O O
to O O
analyze O O
the O O
data O O
for O O
the O O
optimized O O
selection O O
of O O
the O O
algorithm O O
that O O
derives O O
the O O
blood O O
pressure O O
values O O
from O O
the O O
oscillometric O O
blood O O
pressure O O
curves O O
. O O

Following O O
the O O
results O O
of O O
toxicological O O
experiments O O
in O O
the O O
target O O
animals O O
" O O
Toxicological O O
Drinking O O
Water O O
Standards O O
for O O
Animals O O
" O O
can O O
be O O
established O O
. O O

An O O
increase O O
in O O
hypothalamic O O
expression O O
of O O
at O O
least O O
two O O
of O O
the O O
erbB B-GENE B-GENE
receptors E-GENE E-GENE
is O O
initiated O O
before O O
the O O
pubertal O O
augmentation O O
of O O
gonadal O O
steroid O O
secretion O O
and O O
is O O
completed O O
on O O
the O O
day O O
of O O
the O O
first O O
preovulatory O O
surge O O
of O O
gonadotropins S-GENE S-GENE
. O O
Dsh S-GENE S-GENE
is O O
required O O
for O O
two O O
different O O
pathways O O
, O O
the O O
Wnt S-GENE O
pathway O O
and O O
planar O O
polarity O O
pathway O O
in O O
Drosophila O O
. O O
Catch O O
- O O
up O O
growth O O
and O O
craniofacial O O
dimensions O O
following O O
administration O O
of O O
the O O
antineoplastic O O
agent O O
vincristine O O
to O O
young O O
rats O O
. O O

CONCLUSIONS O O
: O O
LSCC O O
malformation O O
, O O
like O O
other O O
inner O O
ear O O
malformations O O
such O O
as O O
large O O
vestibular O O
aqueduct O O
and O O
X O O
- O O
linked O O
mixed O O
deafness O O
with O O
perilymph O O
gusher O O
, O O
can O O
be O O
associated O O
with O O
CHL O O
, O O
SNHL O O
, O O
or O O
normal O O
hearing O O
. O O

Escalation O O
to O O
180 O O
mg O O
/ O O
m2 O O
was O O
to O O
be O O
carried O O
out O O
if O O
white O O
blood O O
cell O O
nadir O O
count O O
was O O
> O O
2.0 O O
x O O
10(9)/l O O
and O O
platelet O O
nadir O O
count O O
was O O
> O O
75 O O
x O O
10(9)/l O O
. O O

Methyl O O
formate O O
was O O
used O O
as O O
the O O
solvent O O
of O O
biodegradable O O
oligoesters O O
for O O
the O O
fabrication O O
of O O
microspheres O O
with O O
encapsulated O O
bovine B-GENE O
serum I-GENE B-GENE
albumin E-GENE E-GENE
( O O
BSA S-GENE S-GENE
) O O
. O O
The O O
small B-GENE O
monomeric I-GENE O
GTP I-GENE B-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
proteins E-GENE E-GENE
of O O
the O O
RAB B-GENE S-GENE
subfamily E-GENE O
are O O
key O O
regulatory O O
elements O O
of O O
the O O
machinery O O
that O O
controls O O
membrane O O
traffic O O
in O O
eukaryotic O O
cells O O
. O O
Furthermore O O
, O O
loss O O
of O O
methylation O O
also O O
greatly O O
reduced O O
the O O
association O O
of O O
another O O
yeast O O
B O B-GENE
- O I-GENE
type O I-GENE
subunit O E-GENE
, O O
Rts1p S-GENE S-GENE
. O O
Thus O O
, O O
methylation O O
of O O
Pph21p S-GENE S-GENE
is O O
important O O
for O O
formation O O
of O O
PP2A B-GENE B-GENE
trimeric I-GENE E-GENE
and I-GENE O
dimeric I-GENE O
complexes E-GENE O
, O O
and O O
consequently O O
, O O
for O O
PP2A O S-GENE
function O O
. O O
The O O
purpose O O
of O O
this O O
study O O
was O O
to O O
analyze O O
the O O
temporal O O
characteristics O O
and O O
the O O
spatial O O
mapping O O
of O O
the O O
independent O O
components O O
identified O O
by O O
ICA O O
when O O
the O O
subject O O
performs O O
a O O
finger O O
- O O
tapping O O
task O O
. O O

The O O
authors O O
present O O
the O O
only O O
two O O
studies O O
that O O
have O O
proved O O
successful O O
in O O
treating O O
animal O O
models O O
of O O
osteoarthritis O O
using O O
gene O O
therapy O O
, O O
and O O
propose O O
an O O
overview O O
of O O
several O O
strategies O O
for O O
the O O
development O O
of O O
gene O O
therapy O O
in O O
osteoarthritis O O
treatment O O
in O O
the O O
future O O
. O O

Together O O
, O O
these O O
results O O
indicate O O
that O O
IL-1 B-GENE B-GENE
beta E-GENE E-GENE
induces O O
VEGF B-GENE B-GENE
gene E-GENE E-GENE
expression O O
at O O
both O O
transcriptional O O
and O O
post O O
- O O
transcriptional O O
levels O O
, O O
and O O
IL-1 O B-GENE
beta O E-GENE
evokes O O
p38 S-GENE B-GENE
MAPK O E-GENE
and O O
JNK S-GENE B-GENE
signalings O E-GENE
, O O
which O O
in O O
turn O O
stimulate O O
the O O
transcription O O
of O O
the O O
VEGF O B-GENE
gene O E-GENE
through O O
Sp1-binding B-GENE B-GENE
sites E-GENE E-GENE
. O O
Binding O O
of O O
NusA S-GENE S-GENE
to O O
RNA O O
in O O
the O O
presence O O
of O O
alpha O O
or O O
N O O
involves O O
an O O
amino B-GENE O
- I-GENE O
terminal I-GENE O
S1 I-GENE O
homology I-GENE O
region E-GENE O
that O O
is O O
otherwise O O
inactive O O
in O O
full O O
- O O
length O O
NusA. O O
The O O
subjects O O
were O O
diagnosed O O
on O O
the O O
basis O O
of O O
DSM O O
- O O
IV O O
pathological O O
gambling O O
criteria O O
and O O
completed O O
the O O
Turkish O O
Version O O
of O O
South O O
Oaks O O
Gambling O O
Screen O O
( O O
SOGS O O
) O O
. O O

Lys(193 O O
) O O
and O O
Arg(194 O O
) O O
, O O
located O O
at O O
the O O
COOH O O
- O O
terminal O O
end O O
of O O
HD S-GENE O
, O O
are O O
essential O O
for O O
dimerization O O
. O O
Elevation O O
of O O
intracellular O O
Ca(2 O S-GENE
+ O O
) O O
levels O O
are O O
also O O
involved O O
because O O
treatment O O
with O O
receptor O B-GENE
- O I-GENE
associated O I-GENE
protein O E-GENE
, O O
nifedipine O O
, O O
MK801 O S-GENE
, O O
removal O O
of O O
Ca(2 O B-GENE
+ O E-GENE
) O O
from O O
the O O
medium O O
and O O
dantrolene O O
all O O
served O O
to O O
inhibit O O
calcium O O
elevation O O
and O O
attenuate O O
the O O
activation O O
of O O
CREB S-GENE S-GENE
. O O
The O O
present O O
study O O
shows O O
that O O
phosphatidylinositol B-GENE B-GENE
3-kinase E-GENE I-GENE
- O I-GENE
dependent O I-GENE
p38 B-GENE I-GENE
kinase E-GENE I-GENE
activation O I-GENE
regulates O I-GENE
Akt S-GENE E-GENE
phosphorylation O O
and O O
activity O O
in O O
human O O
neutrophils O O
. O O
When O O
BFDS O O
was O O
taken O O
as O O
the O O
reference O O
, O O
W O O
/ O O
A O O
Z O O
scores O O
showed O O
consistent O O
positive O O
increments O O
, O O
from O O
birth O O
in O O
girls O O
and O O
1 O O
mo O O
in O O
boys O O
. O O

These O O
probable O O
border O O
sequences O O
are O O
closely O O
related O O
to O O
those O O
of O O
other O O
known O O
T O O
- O O
regions O O
and O O
define O O
a O O
second O O
T O O
- O O
region O O
of O O
pTiChry5 O O
, O O
called O O
T O O
- O O
right O O
( O O
TR O O
) O O
, O O
that O O
confers O O
production O O
of O O
the O O
Amadoriopines O O
. O O

Using O O
purified O O
recombinant B-GENE O
HMG I-GENE B-GENE
I E-GENE E-GENE
, O O
we O O
have O O
identified O O
several O O
high O O
- O O
affinity O O
binding O O
sites O O
which O O
overlap O O
important O O
transcription O B-GENE
factor O I-GENE
binding O I-GENE
sites O E-GENE
. O O
High B-GENE B-GENE
- I-GENE I-GENE
mobility I-GENE I-GENE
- I-GENE I-GENE
group I-GENE I-GENE
protein I-GENE I-GENE
I E-GENE E-GENE
can O O
modulate O O
binding O O
of O O
transcription O O
factors O O
to O O
the O O
U5 B-GENE O
region E-GENE O
of O O
the O O
human B-GENE B-GENE
immunodeficiency I-GENE I-GENE
virus I-GENE I-GENE
type I-GENE I-GENE
1 I-GENE I-GENE
proviral I-GENE I-GENE
promoter E-GENE E-GENE
. O O
Another O O
cis O O
- O O
acting O O
element O O
, O O
exonic O O
splicing O O
suppressor O O
1 O O
( O O
ESS1 O O
) O O
, O O
represses O O
use O O
of O O
the O O
nt O O
3225 O O
3 O O
' O O
splice O O
site O O
. O O

Leptinaemia O O
does O O
not O O
correlate O O
with O O
the O O
actual O O
or O O
mean O O
blood O O
pressure O O
reading O O
nor O O
with O O
stage O O
of O O
hypertension O O
according O O
to O O
the O O
WHO O O
classification O O
. O O

5'-RACE O O
analysis O O
suggested O O
a O O
single O O
transcription O O
initiation O O
site O O
187 O O
bp O O
upstream O O
from O O
the O O
translational O O
start O O
site O O
. O O

Thus O O
, O O
diamide O O
treatment O O
of O O
nuclear O O
extracts O O
strongly O O
reduces O O
the O O
binding O O
of O O
NFI B-GENE B-GENE
proteins E-GENE E-GENE
, O O
and O O
the O O
addition O O
of O O
higher O O
concentrations O O
of O O
dithiothreitol O O
to O O
nuclear O O
extracts O O
from O O
TG S-GENE O
- O O
treated O O
cells O O
restores O O
NFI B-GENE S-GENE
- I-GENE O
DNA E-GENE O
binding O O
to O O
levels O O
in O O
extracts O O
from O O
untreated O O
cells O O
. O O
LMP2A S-GENE S-GENE
enhances O O
Lyn S-GENE S-GENE
and O O
Syk S-GENE B-GENE
ubiquitination O E-GENE
in O O
vivo O O
in O O
a O O
fashion O O
that O O
depends O O
on O O
the O O
activity O O
of O O
Nedd4 S-GENE B-GENE
family O E-GENE
members O O
and O O
correlates O O
with O O
destabilization O O
of O O
the O O
Lyn B-GENE B-GENE
tyrosine I-GENE I-GENE
kinase E-GENE E-GENE
. O O
Further O O
, O O
Tax S-GENE O
- O O
mediated O O
apoptosis O O
was O O
effectively O O
prevented O O
by O O
ectopic O O
expression O O
of O O
the O O
p300 B-GENE B-GENE
coactivator E-GENE E-GENE
. O O
Our O O
results O O
, O O
however O O
, O O
were O O
obtained O O
for O O
Z O O
itself O O
and O O
not O O
for O O
[ O O
Z O O
] O O
. O O

Fisher O O
's O O
exact O O
test O O
or O O
Pearson O O
's O O
chi2 O O
test O O
were O O
used O O
for O O
statistical O O
analysis O O
. O O

RESULTS O O
: O O
In O O
the O O
pregnant O O
group O O
, O O
serum O B-GENE
PP14 S-GENE E-GENE
concentrations O O
were O O
markedly O O
increased O O
after O O
ET O O
, O O
and O O
a O O
significant O O
difference O O
between O O
the O O
pregnant O O
group O O
and O O
the O O
nonpregnant O O
group O O
was O O
observed O O
8 O O
days O O
following O O
ET O O
( O O
p O O
< O O
0.01 O O
) O O
. O O
Thromboelastography O O
is O O
a O O
test O O
that O O
could O O
potentially O O
correlate O O
with O O
the O O
degree O O
of O O
anticoagulation O O
produced O O
by O O
low O O
molecular O O
weight O O
heparin O O
. O O

High O O
expression O O
of O O
the O O
peroxisome B-GENE B-GENE
proliferator I-GENE I-GENE
- I-GENE I-GENE
activated I-GENE I-GENE
receptor I-GENE I-GENE
alpha E-GENE E-GENE
( O O
PPARalpha S-GENE S-GENE
) O O
differentiates O O
brown O O
fat O O
from O O
white O O
, O O
and O O
is O O
related O O
to O O
its O O
high O O
capacity O O
of O O
lipid O O
oxidation O O
. O O
This O O
-2485/-2458 O B-GENE
element O I-GENE
bound O I-GENE
PPARalpha S-GENE E-GENE
and O O
PPARgamma S-GENE S-GENE
from O O
brown O O
fat O O
nuclei O O
. O O
These O O
results O O
provide O O
direct O O
evidence O O
for O O
differential O O
susceptibility O O
to O O
endonuclease O O
- O O
mediated O O
mRNA O O
decay O O
resulting O O
from O O
the O O
differential O O
affinity O O
of O O
a O O
RNA O B-GENE
- O I-GENE
binding O I-GENE
protein O E-GENE
for O O
cis O O
- O O
acting O O
stability O O
determinants O O
. O O

RESULTS O O
: O O
Twenty O O
- O O
two O O
( O O
26% O O
) O O
patients O O
had O O
PHG O O
before O O
( O O
group O O
A O O
) O O
and O O
64 O O
( O O
74% O O
) O O
developed O O
PHG O O
after O O
variceal O O
eradication O O
( O O
group O O
B O O
) O O
. O O

Response O O
was O O
extremely O O
poor O O
in O O
African O O
Americans O O
and O O
those O O
with O O
HCV O O
genotype O O
1 O O
. O O

Aspirin O O
causes O O
peptic O O
ulcers O O
predominately O O
by O O
reducing O O
gastric B-GENE O
mucosal I-GENE O
cyclooxygenase E-GENE O
( O O
COX S-GENE O
) O O
activity O O
and O O
prostaglandin O O
synthesis O O
. O O
A O O
total O O
of O O
1060 O O
clones O O
were O O
randomly O O
selected O O
for O O
sequencing O O
of O O
one O O
end O O
. O O

Expression O O
of O O
a O O
hybrid O O
protein O O
containing O O
the O O
cytoplasmic O O
C O O
- O O
terminal O O
half O O
of O O
UhpB S-GENE S-GENE
fused O O
to O O
glutathione B-GENE B-GENE
S I-GENE I-GENE
- I-GENE I-GENE
transferase E-GENE E-GENE
( O O
GST S-GENE S-GENE
) O O
also O O
interfered O O
with O O
Uhp O B-GENE
signaling O E-GENE
. O O
CONCLUSIONS O O
: O O
The O O
surgical O O
or O O
multimodality O O
treatment O O
of O O
MSGT O O
has O O
provided O O
a O O
good O O
locoregional O O
control O O
( O O
78% O O
) O O
and O O
68% O O
10-year O O
survival O O
in O O
a O O
series O O
of O O
patients O O
treated O O
at O O
the O O
oncology O O
department O O
of O O
a O O
general O O
hospital O O
in O O
Quito O O
, O O
Ecuador O O
. O O

RESULTS O O
: O O
Glaucoma O O
suspects O O
were O O
divided O O
into O O
two O O
groups O O
according O O
to O O
their O O
SWAP O O
results O O
: O O
high O O
risk O O
( O O
with O O
SWAP O O
abnormalities O O
) O O
and O O
low O O
risk O O
( O O
with O O
normal O O
SWAP O O
result O O
) O O
. O O

The O O
gene O O
is O O
separated O O
into O O
four O O
exons O O
by O O
three O O
short O O
introns O O
, O O
and O O
the O O
open O O
reading O O
frame O O
consists O O
of O O
6660 O O
base O O
pairs O O
( O O
bp O O
) O O
capable O O
of O O
encoding O O
a O O
polypeptide O O
of O O
2220 O O
amino O O
acid O O
residues O O
. O O

Like O O
the O O
p190-B S-GENE B-GENE
exon O E-GENE
, O O
the O O
first O O
exon O O
of O O
p190-A S-GENE S-GENE
is O O
extremely O O
large O O
( O O
3.7 O O
kb O O
in O O
length O O
) O O
, O O
encoding O O
both O O
the O O
GTPase S-GENE S-GENE
and O O
middle O O
domains O O
( O O
residues O O
1 O O
- O O
1228 O O
) O O
, O O
but O O
not O O
the O O
remaining O O
GAP B-GENE B-GENE
domain E-GENE E-GENE
, O O
suggesting O O
a O O
high O O
conservation O O
of O O
genomic O O
structure O O
between O O
two O O
p190 B-GENE B-GENE
genes E-GENE E-GENE
. O O
The O O
entire O O
human B-GENE B-GENE
teneurin-1 E-GENE E-GENE
( O O
TEN1 S-GENE S-GENE
) O O
gene O O
is O O
contained O O
in O O
eight O O
PAC O S-GENE
clones O O
representing O O
part O O
of O O
the O O
chromosomal O B-GENE
locus O I-GENE
Xq25 O E-GENE
. O O
The O O
plexiform O O
neurofibroma O O
and O O
multiple O O
localized O O
neurofibromas O O
are O O
characteristic O O
of O O
NF1 S-GENE O
. O O
In O O
general O O
lookback O O
, O O
all O O
patients O O
who O O
received O O
blood O O
before O O
being O O
tested O O
for O O
hepatitis O O
C O O
are O O
advised O O
to O O
undergo O O
testing O O
. O O

The O O
proposed O O
algorithm O O
consists O O
of O O
several O O
steps O O
. O O

It O O
contained O O
seven O O
extra O O
amino O O
acids O O
of O O
FVVLNLQ O S-GENE
; O O
this O O
short O O
stretch O O
of O O
extra O O
sequence O O
was O O
found O O
between O O
Gln(421 O O
) O O
and O O
Phe(422 O O
) O O
within O O
the O O
SET S-GENE O
( O O
Suvar3 B-GENE O
- I-GENE O
9 E-GENE O
, O O
Enhancer B-GENE O
- I-GENE O
of I-GENE O
- I-GENE O
zeste E-GENE O
, O O
Trithorax S-GENE S-GENE
) O O
interacting O O
domain O O
( O O
SID O S-GENE
) O O
of O O
rMTM S-GENE S-GENE
. O O
MED1 S-GENE S-GENE
has O O
a O O
weak O O
glycosylase S-GENE O
activity O O
on O O
the O O
mutagenic O O
adduct O O
3,N(4)-ethenocytosine O O
, O O
a O O
metabolite O O
of O O
vinyl O O
chloride O O
and O O
ethyl O O
carbamate O O
. O O
There O O
were O O
no O O
instances O O
of O O
major O O
flap O O
necrosis O O
although O O
two O O
flaps O O
showed O O
tip O O
ischaemia O O
. O O

These O O
results O O
suggest O O
that O O
XAB1 S-GENE S-GENE
is O O
a O O
novel O O
cytoplasmic B-GENE O
GTPase E-GENE S-GENE
involved O O
in O O
nuclear O O
localization O O
of O O
XPA S-GENE S-GENE
. O O
One O O
of O O
these O O
factors O O
, O O
IRF-2 S-GENE S-GENE
, O O
was O O
initially O O
cloned O O
as O O
an O O
antagonistic O O
counterpart O O
to O O
IRF-1 S-GENE S-GENE
with O O
oncogenic O O
potential O O
. O O
Among O O
the O O
total O O
CDSs O O
, O O
8.8% O O
match O O
sequences O O
of O O
proteins O O
found O O
only O O
in O O
Bacillus O O
subtilis O O
and O O
66.7% O O
are O O
widely O O
conserved O O
in O O
comparison O O
with O O
the O O
proteins O O
of O O
various O O
organisms O O
, O O
including O O
B.subtilis O O
. O O

Tobramycin O O
- O O
loaded O O
SLN O O
administered O O
i.v O O
. O O
showed O O
a O O
prolonged O O
circulation O O
time O O
compared O O
to O O
the O O
i.v O O
. O O
administered O O
tobramycin O O
solution O O
. O O

Bacteriol O O
. O O

Terminal B-GENE O
deoxynucleotidyl I-GENE O
transferase E-GENE O
- O O
mediated O O
nick O O
end O O
labeling O O
assays O O
revealed O O
that O O
hormonal O O
activation O O
of O O
the O O
PAX3 B-GENE B-GENE
repressors E-GENE E-GENE
induced O O
extensive O O
apoptosis O O
that O O
correlated O O
with O O
down O O
- O O
regulation O O
of O O
BCL B-GENE B-GENE
- I-GENE I-GENE
X(L I-GENE E-GENE
) E-GENE O
expression O O
. O O
VEGF B-GENE B-GENE
promoter E-GENE E-GENE
activity O O
in O O
transient O O
transfections O O
was O O
decreased O O
by O O
either O O
pharmacological O O
or O O
genetic O O
inhibition O O
of O O
EGFR S-GENE S-GENE
, O O
Ras S-GENE S-GENE
, O O
or O O
phosphatidylinositol B-GENE B-GENE
3'-kinase E-GENE E-GENE
[ B-GENE O
PI(3 I-GENE S-GENE
) I-GENE O
kinase I-GENE B-GENE
] E-GENE E-GENE
. O O
Epidermal B-GENE B-GENE
growth I-GENE I-GENE
factor I-GENE I-GENE
receptor E-GENE I-GENE
transcriptionally O I-GENE
up O I-GENE
- O I-GENE
regulates O I-GENE
vascular B-GENE I-GENE
endothelial I-GENE I-GENE
growth I-GENE I-GENE
factor E-GENE E-GENE
expression O O
in O O
human O O
glioblastoma O O
cells O O
via O O
a O O
pathway O O
involving O O
phosphatidylinositol B-GENE B-GENE
3'-kinase E-GENE E-GENE
and O O
distinct O O
from O O
that O O
induced O O
by O O
hypoxia O O
. O O
Thus O O
, O O
IHHNV O O
is O O
closely O O
related O O
to O O
densoviruses O O
of O O
the O O
genus O O
Brevidensovirus O O
in O O
the O O
family O O
Parvoviridae O O
, O O
and O O
we O O
therefore O O
propose O O
to O O
rename O O
this O O
virus O O
Penaeus O O
stylirostris O O
densovirus O O
( O O
PstDNV O O
) O O
. O O

Stress B-GENE B-GENE
- I-GENE I-GENE
activated I-GENE I-GENE
protein I-GENE I-GENE
kinase I-GENE I-GENE
1 E-GENE E-GENE
( O O
SAPK1 S-GENE S-GENE
) O O
, O O
also O O
called O O
c B-GENE B-GENE
- I-GENE I-GENE
Jun I-GENE I-GENE
N I-GENE I-GENE
- I-GENE I-GENE
terminal I-GENE I-GENE
kinase E-GENE E-GENE
( O O
JNK S-GENE S-GENE
) O O
, O O
becomes O O
activated O O
in O O
vivo O O
in O O
response O O
to O O
pro O B-GENE
- O I-GENE
inflammatory O I-GENE
cytokines O E-GENE
or O O
cellular O O
stresses O O
. O O
Catalytic O O
activation O O
of O O
mitogen B-GENE B-GENE
- I-GENE I-GENE
activated I-GENE I-GENE
protein I-GENE E-GENE
( I-GENE O
MAP I-GENE S-GENE
) I-GENE O
kinase I-GENE B-GENE
phosphatase-1 E-GENE E-GENE
by O O
binding O O
to O O
p38 B-GENE B-GENE
MAP I-GENE I-GENE
kinase E-GENE E-GENE
: O O
critical O O
role O O
of O O
the O O
p38 B-GENE B-GENE
C I-GENE I-GENE
- I-GENE I-GENE
terminal I-GENE I-GENE
domain E-GENE E-GENE
in O O
its O O
negative O O
regulation O O
. O O
Thus O O
, O O
the O O
class B-GENE B-GENE
C E-GENE I-GENE
- O I-GENE
Vps S-GENE I-GENE
complex O E-GENE
directs O O
multiple O O
reactions O O
during O O
the O O
docking O O
and O O
fusion O O
of O O
vesicles O O
with O O
the O O
vacuole O O
, O O
each O O
of O O
which O O
contributes O O
to O O
the O O
overall O O
specificity O O
and O O
efficiency O O
of O O
this O O
transport O O
process O O
. O O
Combined O O
intravenous O O
and O O
intra O B-GENE
- O I-GENE
arterial O I-GENE
recombinant O I-GENE
tissue B-GENE I-GENE
plasminogen I-GENE I-GENE
activator E-GENE E-GENE
in O O
acute O O
ischemic O O
stroke O O
. O O
To O O
begin O O
to O O
understand O O
this O O
role O O
, O O
we O O
overexpressed O O
ATF-2 S-GENE S-GENE
in O O
a O O
human O O
cancer O O
cell O O
line O O
. O O
Signal O O
transduction O O
via O O
modulation O O
of O O
phosphorylation O O
after O O
selective O O
inhibition O O
of O O
protein B-GENE B-GENE
phosphatase I-GENE E-GENE
( I-GENE O
PP I-GENE S-GENE
) I-GENE O
1 E-GENE O
and/or O O
PP2A S-GENE S-GENE
appears O O
to O O
play O O
a O O
role O O
in O O
okadaic O O
acid O O
( O O
OA)-mediated O O
effects O O
. O O
Botulinum B-GENE B-GENE
toxin I-GENE E-GENE
A E-GENE O
in O O
the O O
treatment O O
of O O
hemiplegic O O
spastic O O
foot O O
drop O O
-- O O
clinical O O
and O O
functional O O
outcomes O O
. O O
Exon O O
A O O
is O O
located O O
approximately O O
7 O O
kb O O
5 O O
' O O
to O O
the O O
HSL B-GENE B-GENE
translation I-GENE I-GENE
start I-GENE I-GENE
site E-GENE E-GENE
. O O
NF B-GENE B-GENE
- I-GENE I-GENE
kappaB E-GENE E-GENE
is O O
a O O
redox O B-GENE
- O I-GENE
sensitive O I-GENE
transcription O I-GENE
factor O E-GENE
known O O
to O O
be O O
activated O O
by O O
oxidative O O
stress O O
as O O
well O O
as O O
chemical O O
and O O
biological O O
reductants O O
. O O
Cardiovascular O O
risk O O
factors O O
and O O
antihypertensive O O
treatment O O
. O O

What O O
to O O
look O O
for O O
during O O
a O O
compliance O O
review O O
: O O
10 O O
common O O
mistakes O O
made O O
by O O
SNFs O O
. O O

CONCLUSIONS O O
: O O
EBCT O O
technology O O
allows O O
minimally O O
invasive O O
evaluation O O
of O O
intramyocardial O O
microcirculatory O O
function O O
and O O
permits O O
assessment O O
of O O
microvascular O O
BV O O
distribution O O
in O O
different O O
functional O O
components O O
. O O

These O O
two O O
mAbs O O
used O O
the O O
same O O
V(H O O
) O O
and O O
J(H O O
) O O
gene O O
segments O O
, O O
but O O
different O O
D O O
, O O
Vkappa O O
, O O
and O O
Jkappa O O
genes O O
. O O

SSF O O
experiments O O
were O O
carried O O
out O O
in O O
bench O O
- O O
scale O O
bioreactors O O
( O O
equipped O O
with O O
CO2 O O
and O O
volatile O O
organic O O
traps O O
) O O
containing O O
a O O
mixture O O
of O O
lignocellulosic O O
materials O O
and O O
a O O
radiolabeled O O
pesticide O O
. O O

Characterization O O
of O O
a O O
Xenopus B-GENE B-GENE
laevis I-GENE I-GENE
CXC I-GENE I-GENE
chemokine I-GENE I-GENE
receptor I-GENE E-GENE
4 E-GENE O
: O O
implications O O
for O O
hematopoietic O O
cell O O
development O O
in O O
the O O
vertebrate O O
embryo O O
. O O
Patients O O
had O O
to O O
have O O
adequate O O
liver O O
, O O
renal O O
, O O
and O O
marrow O O
functions O O
. O O

Inhibition O O
of O O
RNA2 S-GENE S-GENE
translation O O
was O O
selective O O
, O O
with O O
no O O
effect O O
on O O
general O O
cellular O O
translation O O
or O O
translation O O
of O O
BMV O B-GENE
RNA1-encoded O I-GENE
replication B-GENE I-GENE
factor I-GENE I-GENE
1a E-GENE E-GENE
, O O
and O O
was O O
independent O O
of O O
p20 S-GENE O
, O O
a O O
cellular O O
antagonist O O
of O O
DED1 S-GENE S-GENE
function O O
in O O
translation O O
. O O
Abbreviations O O
: O O
CAS S-GENE S-GENE
, O O
CRK B-GENE S-GENE
- I-GENE O
associated I-GENE O
substrate E-GENE O
; O O
CH S-GENE S-GENE
, O O
calponin B-GENE B-GENE
- I-GENE I-GENE
homology I-GENE I-GENE
domain E-GENE E-GENE
; O O
CSK S-GENE S-GENE
, O O
C B-GENE B-GENE
- I-GENE I-GENE
terminal I-GENE I-GENE
SRC I-GENE I-GENE
kinase E-GENE E-GENE
; O O
E6 S-GENE S-GENE
, O O
Papillomavirus B-GENE B-GENE
E6 I-GENE I-GENE
protein E-GENE E-GENE
; O O
FAK S-GENE S-GENE
, O O
focal B-GENE B-GENE
adhesion I-GENE I-GENE
kinase E-GENE E-GENE
; O O
GIT S-GENE S-GENE
, O O
GRK B-GENE S-GENE
interacter E-GENE O
; O O
GPCR S-GENE S-GENE
, O O
heterotrimeric B-GENE B-GENE
- I-GENE I-GENE
G I-GENE I-GENE
- I-GENE I-GENE
protein I-GENE I-GENE
- I-GENE I-GENE
coupled I-GENE I-GENE
receptor E-GENE E-GENE
; O O
GRK O S-GENE
, O O
G B-GENE B-GENE
- I-GENE I-GENE
protein I-GENE I-GENE
- I-GENE I-GENE
coupled I-GENE I-GENE
- I-GENE I-GENE
receptor I-GENE I-GENE
kinase E-GENE E-GENE
; O O
MAPK S-GENE S-GENE
, O O
mitogen B-GENE B-GENE
- I-GENE I-GENE
activated I-GENE I-GENE
protein I-GENE I-GENE
kinase E-GENE E-GENE
( O O
ERK S-GENE S-GENE
, O O
p38 S-GENE S-GENE
, O O
JNK S-GENE S-GENE
) O O
; O O
PAK S-GENE S-GENE
, O O
p21-activated B-GENE B-GENE
kinase E-GENE E-GENE
; O O
PBS S-GENE S-GENE
, O O
paxillin B-GENE B-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
subdomain E-GENE E-GENE
; O O
PIX S-GENE S-GENE
, O O
PAK B-GENE B-GENE
- I-GENE I-GENE
interacting I-GENE I-GENE
exchange I-GENE I-GENE
factor E-GENE E-GENE
; O O
PKL S-GENE S-GENE
, O O
paxillin B-GENE B-GENE
kinase I-GENE E-GENE
linker E-GENE O
; O O
POR1 S-GENE S-GENE
, O O
partner B-GENE O
of I-GENE O
Rac E-GENE S-GENE
; O O
PS O O
, O O
phosphoserine O O
; O O
PT O O
, O O
phosphothreonine O O
; O O
PY O S-GENE
, O O
phosphotyrosine O O
; O O
RTK S-GENE S-GENE
, O O
growth B-GENE B-GENE
factor I-GENE I-GENE
receptor I-GENE I-GENE
tyrosine I-GENE I-GENE
kinase E-GENE E-GENE
; O O
SH S-GENE S-GENE
, O O
SRC B-GENE B-GENE
- I-GENE I-GENE
homology I-GENE I-GENE
domain E-GENE E-GENE
. O O
In O O
15 O O
ventilator O O
- O O
dependent O O
, O O
SB O O
, O O
and O O
actively O O
expiring O O
patients O O
, O O
we O O
found O O
that O O
the O O
difference O O
PEEP(i),dyn O O
- O O
Pga O O
, O O
total O O
decay O O
( O O
mean O O
+ O O
/- O O
SD O O
, O O
5.7 O O
+ O O
/- O O
1.9 O O
cm O O
H(2)O O O
) O O
was O O
quite O O
similar O O
to O O
PEEP(i),dyn O O
ref O O
( O O
5.3 O O
+ O O
/- O O
1.9 O O
cm O O
H(2)O O O
) O O
. O O

Of O O
208 O O
eligible O O
subjects O O
, O O
82 O O
received O O
supervised O O
IPT O O
at O O
a O O
dose O O
of O O
900 O O
mg O O
twice O O
weekly O O
for O O
6 O O
mo O O
( O O
Regimen O O
A O O
) O O
, O O
73 O O
received O O
unsupervised O O
IPT O O
900 O O
mg O O
twice O O
weekly O O
for O O
6 O O
mo O O
( O O
Regimen O O
B O O
) O O
, O O
and O O
53 O O
received O O
unsupervised O O
IPT O O
300 O O
mg O O
daily O O
for O O
6 O O
mo O O
( O O
Regimen O O
C O O
) O O
. O O

There O O
were O O
122 O O
cases O O
of O O
tuberculosis O O
over O O
an O O
average O O
10.3 O O
yr O O
of O O
follow O O
- O O
up O O
( O O
crude O O
annual O O
incidence O O
, O O
76.2/100,000 O O
) O O
. O O

These O O
results O O
suggested O O
that O O
BACH1 B-GENE S-GENE
t E-GENE O
recruits O O
BACH1 O S-GENE
to O O
the O O
nucleus O O
through O O
BTB S-GENE S-GENE
domain O O
- O O
mediated O O
interaction O O
. O O
The O O
U17/U16 O S-GENE
and O O
the O O
U16 B-GENE B-GENE
+ I-GENE I-GENE
gene I-GENE I-GENE
products E-GENE I-GENE
transactivated O E-GENE
the O O
HIV B-GENE B-GENE
LTR E-GENE E-GENE
. O O
Transcription O O
of O O
the O O
six O O
EBNA B-GENE B-GENE
genes E-GENE E-GENE
, O O
which O O
are O O
expressed O O
in O O
EBV O O
- O O
immortalized O O
primary O O
B O O
cells O O
, O O
arises O O
from O O
one O O
of O O
two O O
promoters O O
, O O
Cp S-GENE O
and O O
Wp S-GENE S-GENE
, O O
located O O
near O O
the O O
left O O
end O O
of O O
the O O
viral O O
genome O O
. O O
The O O
Cili-2 B-GENE O
sequences E-GENE O
possess O O
similarity O O
to O O
the O O
RNaseH B-GENE B-GENE
domain E-GENE E-GENE
of O O
Lian S-GENE B-GENE
- O I-GENE
Aa1 S-GENE E-GENE
, O O
a O O
mosquito B-GENE O
non I-GENE O
- I-GENE O
LTR I-GENE O
retrotransposon E-GENE O
. O O
This O O
dynamic O O
response O O
strongly O O
suggests O O
that O O
the O O
p53 S-GENE S-GENE
and O O
Rb S-GENE B-GENE
tumor O I-GENE
suppressor O E-GENE
pathways O O
are O O
intact O O
in O O
HeLa O O
cells O O
and O O
that O O
repression O O
of O O
HPV B-GENE B-GENE
E6 E-GENE E-GENE
and O O
E7 S-GENE S-GENE
mobilizes O O
these O O
pathways O O
in O O
an O O
orderly O O
fashion O O
to O O
deliver O O
growth O O
inhibitory O O
signals O O
to O O
the O O
cells O O
. O O
Thus O O
, O O
blocks O O
in O O
the O O
RARalpha S-GENE S-GENE
- O O
specific O O
pathway O O
of O O
retinoid O O
- O O
induced O O
differentiation O O
may O O
be O O
bypassed O O
during O O
retinoid O O
induction O O
of O O
FR B-GENE B-GENE
- I-GENE I-GENE
beta E-GENE E-GENE
expression O O
. O O
Is O O
more O O
better O O
? O O
About O O
dose O O
levels O O
of O O
ACE S-GENE S-GENE
inhibitors O O
in O O
chronic O O
heart O O
failure O O
. O O
To O O
test O O
whether O O
or O O
not O O
SOCS-3 S-GENE O
also O O
binds O O
to O O
the O O
IGFIR S-GENE S-GENE
, O O
we O O
cloned O O
human B-GENE O
SOCS-3 E-GENE S-GENE
by O O
reverse O B-GENE
transcription O I-GENE
- O I-GENE
polymerase O I-GENE
chain O I-GENE
reaction O I-GENE
from O I-GENE
human O I-GENE
skeletal O I-GENE
muscle O I-GENE
mRNA O E-GENE
. O O
A O O
protein O O
lacking O O
the O O
SH2 S-GENE S-GENE
and O O
RING O O
finger O O
domains O O
has O O
no O O
activity O O
, O O
but O O
a O O
chimeric O O
protein O O
with O O
the O O
SH2 O S-GENE
and O O
RING O O
finger O O
domains O O
of O O
SLI-1 S-GENE S-GENE
replaced O O
by O O
the O O
equivalent O O
domains O O
of O O
c B-GENE B-GENE
- I-GENE I-GENE
Cbl E-GENE E-GENE
has O O
activity O O
. O O
To O O
evaluate O O
the O O
effects O O
of O O
HRT O O
on O O
those O O
factors O O
in O O
end O O
- O O
stage O O
renal O O
disease O O
( O O
ESRD O O
) O O
patients O O
, O O
we O O
evaluated O O
the O O
changes O O
of O O
lipid O O
profile O O
, O O
coagulation O O
and O O
fibrinolysis O O
markers O O
, O O
and O O
plasma O O
homocysteine O O
levels O O
after O O
treatment O O
. O O

There O O
was O O
a O O
weak O O
significant O O
correlation O O
between O O
TGF B-GENE B-GENE
beta I-GENE I-GENE
1 E-GENE E-GENE
levels O O
and O O
normal O O
cell O O
radiosensitivity O O
( O O
lymphocyte O O
SF2 O O
) O O
. O O
Acute O O
feasibility O O
and O O
safety O O
of O O
a O O
smoking O O
reduction O O
strategy O O
for O O
smokers O O
with O O
schizophrenia O O
. O O

Tightly O O
ordered O O
proteasomal O O
degradation O O
of O O
proteins O O
critical O O
for O O
cell O O
cycle O O
control O O
implies O O
a O O
role O O
of O O
the O O
proteasome O O
in O O
maintaining O O
cell O O
proliferation O O
and O O
cell O O
survival O O
. O O

The O O
sixth O O
nucleotide O O
was O O
bulged O O
out O O
to O O
allow O O
stacking O O
of O O
this O O
U.G O O
pair O O
on O O
the O O
adjacent O O
helical O O
region O O
. O O

Functional O O
analysis O O
of O O
the O O
mutant S-GENE B-GENE
desmin S-GENE E-GENE
in O O
SW13 O S-GENE
( O O
vim- O O
) O O
cells O O
showed O O
aggregation O O
of O O
abnormal O O
coarse O O
clumps O O
of O O
desmin O O
positive O O
material O O
dispersed O O
throughout O O
the O O
cytoplasm O O
. O O
Patients O O
with O O
lesions O O
affecting O O
the O O
PRC O O
but O O
sparing O O
the O O
PHC O O
, O O
and O O
patients O O
with O O
lesions O O
affecting O O
both O O
PRC O O
and O O
PHC O O
, O O
performed O O
an O O
oculomotor O O
delayed O O
response O O
task O O
with O O
unpredictably O O
varied O O
memory O O
delays O O
of O O
up O O
to O O
30 O O
s. O O

In O O
addition O O
, O O
26 O O
amino O O
acid O O
residues O O
, O O
K69 O O
, O O
D88 O O
, O O
E94 O O
, O O
D134 O O
, O O
R154 O O
, O O
K169 O O
, O O
H197 O O
, O O
D233 O O
, O O
G235 O O
, O O
G236 O O
, O O
G237 O O
, O O
F238 O O
, O O
E274 O O
, O O
G276 O O
, O O
R277 O O
, O O
Y278 O O
, O O
K294 O O
, O O
Y323 O O
, O O
Y331 O O
, O O
D332 O O
, O O
C360 O O
, O O
D361 O O
, O O
D364 O O
, O O
G387 O O
, O O
Y389 O O
, O O
and O O
F397 O O
( O O
mouse O O
ODC S-GENE O
numbering O O
) O O
, O O
all O O
of O O
which O O
are O O
implicated O O
in O O
the O O
formation O O
of O O
the O O
pyridoxal O B-GENE
phosphate O I-GENE
- O I-GENE
binding O I-GENE
domain O E-GENE
and O O
the O O
substrate O B-GENE
- O I-GENE
binding O I-GENE
domain O E-GENE
and O O
in O O
dimer O O
stabilization O O
with O O
the O O
eukaryotic O O
ODCs S-GENE S-GENE
, O O
were O O
also O O
conserved O O
in O O
S. O O
ruminantium O O
LDC S-GENE S-GENE
. O O
The O O
Psc2 B-GENE B-GENE
cDNA E-GENE E-GENE
contained O O
an O O
open O O
reading O O
frame O O
homologous O O
to O O
CP2 B-GENE B-GENE
family I-GENE I-GENE
proteins E-GENE E-GENE
. O O
Our O O
results O O
indicate O O
that O O
Shh S-GENE S-GENE
can O O
drive O O
continued O O
cycling O O
in O O
immature O O
, O O
proliferating O O
CGNPs O S-GENE
. O O
The O O
QT O O
interval O O
was O O
related O O
to O O
various O O
components O O
of O O
the O O
insulin S-GENE S-GENE
resistance O O
syndrome O O
, O O
including O O
BP O O
and O O
insulin O S-GENE
sensitivity O O
. O O
The O O
wavenumbers O O
corresponding O O
to O O
the O O
normal O O
modes O O
of O O
vibration O O
were O O
calculated O O
using O O
the O O
DFT O O
( O O
B3LYP/6 O O
- O O
31 O O
G O O
* O O
* O O
) O O
approximation O O
and O O
their O O
agreement O O
with O O
the O O
measured O O
values O O
improved O O
after O O
scaling O O
of O O
the O O
associated O O
force O O
field O O
. O O

The O O
data O O
provide O O
strong O O
evidence O O
that O O
ThlA S-GENE S-GENE
is O O
involved O O
in O O
the O O
metabolism O O
of O O
both O O
acid O O
and O O
solvent O O
formation O O
, O O
whereas O O
the O O
physiological O O
function O O
of O O
ThlB S-GENE S-GENE
has O O
yet O O
to O O
be O O
elucidated O O
. O O
In O O
addition O O
, O O
npm3 S-GENE O
, O O
which O O
is O O
usually O O
coactivated O O
with O O
fgf8 S-GENE S-GENE
by O O
MMTV O O
insertion O O
, O O
was O O
not O O
up O O
- O O
regulated O O
by O O
androgens O O
in O O
SC-3 O S-GENE
cells O O
. O O
Experiments O O
with O O
epitope O O
- O O
tagged O O
proteins O O
show O O
that O O
UEV1A S-GENE S-GENE
is O O
a O O
nuclear O O
protein O O
, O O
whereas O O
both O O
Kua S-GENE S-GENE
and O O
Kua O S-GENE
- O O
UEV O S-GENE
localize O O
to O O
cytoplasmic O O
structures O O
, O O
indicating O O
that O O
the O O
Kua B-GENE S-GENE
domain E-GENE O
determines O O
the O O
cytoplasmic O O
localization O O
of O O
Kua O B-GENE
- O I-GENE
UEV O E-GENE
. O O
Stoichiometric O O
phosphorylation O O
of O O
human S-GENE B-GENE
p53 S-GENE E-GENE
at O O
Ser315 O B-GENE
stimulates O I-GENE
p53-dependent O I-GENE
transcription O E-GENE
. O O
p53 B-GENE B-GENE
protein E-GENE E-GENE
activity O O
as O O
a O O
transcription O B-GENE
factor O E-GENE
can O O
be O O
activated O O
in O O
vivo O O
by O O
antibodies O O
that O O
target O O
its O O
C O B-GENE
- O I-GENE
terminal O I-GENE
negative O I-GENE
regulatory O I-GENE
domain O E-GENE
suggesting O O
that O O
cellular O O
enzymes O O
that O O
target O O
this O O
domain O O
may O O
play O O
a O O
role O O
in O O
stimulating O B-GENE
p53-dependent O I-GENE
gene O E-GENE
expression O O
. O O
Interestingly O O
, O O
this O O
mutant O O
cell O O
line O O
lacks O O
expression O O
of O O
the O O
IKK B-GENE B-GENE
regulatory I-GENE I-GENE
protein E-GENE E-GENE
, O O
IKKgamma S-GENE S-GENE
. O O
The O O
Tax S-GENE O
/ O O
IKKgamma S-GENE S-GENE
interaction O O
serves O O
to O O
recruit O O
Tax O O
to O O
the O O
IKK B-GENE B-GENE
catalytic I-GENE I-GENE
subunits E-GENE E-GENE
, O O
IKKalpha S-GENE S-GENE
and O O
IKKbeta S-GENE S-GENE
, O O
and O O
this O O
recruitment O O
appears O O
to O O
be O O
an O O
essential O O
mechanism O O
by O O
which O O
Tax O O
stimulates O O
the O O
activity O O
of O O
IKK O O
. O O
An O O
anchored O O
AFLP- O O
and O O
retrotransposon O O
- O O
based O O
map O O
of O O
diploid O O
Avena O O
. O O

In O O
addition O O
, O O
we O O
identified O O
a O O
novel O O
type O O
of O O
inhibitory O O
domain O O
in O O
the O O
N O O
- O O
terminal O O
60 O O
amino O O
acids O O
of O O
IRF-1 S-GENE S-GENE
which O O
strongly O O
inhibits O O
its O O
transcriptional O O
activity O O
. O O
Effects O O
of O O
spatial O O
and O O
temporal O O
smoothing O O
on O O
stimulated O O
brillouin O O
scattering O O
in O O
the O O
independent O O
- O O
hot O O
- O O
spot O O
model O O
limit O O
The O O
influence O O
of O O
laser O O
beam O O
smoothing O O
on O O
stimulated O O
Brillouin O O
backscattering O O
( O O
SBBS O O
) O O
is O O
studied O O
analytically O O
in O O
the O O
limit O O
of O O
the O O
independent O O
hot O O
spot O O
model O O
. O O

Simultaneous O O
determination O O
of O O
theophylline O O
and O O
its O O
metabolites O O
by O O
HPLC O O
] O O
A O O
high O O
performance O O
liquid O O
chromatography O O
( O O
HPLC O O
) O O
method O O
has O O
been O O
developed O O
for O O
the O O
simultaneous O O
determination O O
of O O
theophylline O O
and O O
its O O
metabolites O O
, O O
with O O
caffeine O O
and O O
its O O
metabolites O O
. O O

Ten O O
males O O
performed O O
both O O
test O O
conditions O O
and O O
oxygen O O
uptake O O
VO2 O O
, O O
heart O O
rate O O
, O O
minute O O
ventilation O O
VE O O
, O O
perceived O O
exertion O O
and O O
spinal O O
shrinkage O O
were O O
recorded O O
. O O

CONCLUSION O O
: O O
SPT O O
is O O
more O O
useful O O
than O O
WST O O
in O O
differentiating O O
patients O O
predisposed O O
to O O
aspiration O O
. O O

Studied O O
groups O O
were O O
( O O
1 O O
) O O
untreated O O
control O O
, O O
n O O
= O O
12 O O
; O O
( O O
2 O O
) O O
FK-1 O O
, O O
n O O
= O O
8 O O
; O O
( O O
3 O O
) O O
FK-3 O O
, O O
n O O
= O O
8 O O
. O O

DNA O O
binding O O
and O O
glutathione B-GENE B-GENE
S I-GENE I-GENE
- I-GENE I-GENE
transferase E-GENE E-GENE
pull O O
- O O
down O O
assays O O
demonstrate O O
that O O
binding O O
requires O O
Elk-1(1 B-GENE S-GENE
- I-GENE O
212 I-GENE O
) E-GENE O
but O O
not O O
the O O
C O B-GENE
- O I-GENE
terminal O I-GENE
transactivation O I-GENE
domain O E-GENE
. O O
Unexpectedly O O
, O O
ALK7 S-GENE S-GENE
signaling O O
produced O O
a O O
remarkable O O
change O O
in O O
cell O O
morphology O O
characterized O O
by O O
cell O O
flattening O O
and O O
elaboration O O
of O O
blunt O O
, O O
short O O
cell O O
processes O O
. O O
The O O
swa2 B-GENE B-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
allele E-GENE E-GENE
recovered O O
from O O
the O O
original O O
screen O O
carries O O
a O O
point O O
mutation O O
in O O
its O O
tetratricopeptide O O
repeat O O
( O O
TPR O S-GENE
) O O
domain O O
, O O
a O O
motif O O
not O O
found O O
in O O
auxilin S-GENE O
but O O
known O O
in O O
other O O
proteins O O
to O O
mediate O O
interaction O O
with O O
heat B-GENE B-GENE
- I-GENE I-GENE
shock I-GENE I-GENE
proteins E-GENE E-GENE
. O O
Association O O
of O O
stress O O
during O O
delivery O O
with O O
increased O O
numbers O O
of O O
nucleated O O
cells O O
and O O
hematopoietic O O
progenitor O O
cells O O
in O O
umbilical O O
cord O O
blood O O
. O O

In O O
slightly O O
older O O
embryos O O
, O O
the O O
expression O O
was O O
skewed O O
to O O
one O O
side O O
of O O
the O O
embryo O O
and O O
by O O
E6.5 O O
, O O
at O O
the O O
onset O O
of O O
gastrulation O O
, O O
expression O O
was O O
seen O O
in O O
the O O
epiblast O O
, O O
visceral O O
endoderm O O
, O O
nascent O O
mesoderm O O
, O O
and O O
the O O
primitive O O
streak O O
. O O

Transformation O O
of O O
the O O
sconC3 B-GENE B-GENE
mutant E-GENE E-GENE
with O O
sconB+ S-GENE O
restores O O
the O O
wild O B-GENE
- O I-GENE
type O I-GENE
phenotype O E-GENE
. O O
The O O
authors O O
proposed O O
that O O
the O O
highly O O
convergent O O
inputs O O
to O O
the O O
entorhinal O O
cortex O O
indicate O O
this O O
region O O
may O O
be O O
particularly O O
important O O
for O O
selecting O O
or O O
compressing O O
information O O
. O O

Influence O O
of O O
oil O O
emulsions O O
and O O
diphenyl O O
on O O
post O O
- O O
harvest O O
physiconutritional O O
changes O O
in O O
Kagzi O O
limes O O
( O O
Citrus O O
aurantifolia O O
) O O
was O O
studied O O
. O O

Detailed O O
analysis O O
of O O
alpha1,3GT B-GENE B-GENE
transcripts E-GENE E-GENE
revealed O O
two O O
major O O
alternative O O
splicing O O
patterns O O
in O O
the O O
5'-untranslated O O
region O O
( O O
5'-UTR O S-GENE
) O O
and O O
evidence O O
for O O
minor O O
splicing O O
activity O O
that O O
occurs O O
in O O
a O O
tissue O O
- O O
specific O O
manner O O
. O O
A O O
thermal O O
Kubo O O
- O O
Martin O O
- O O
Schwinger O O
condition O O
arises O O
due O O
to O O
the O O
coupling O O
of O O
a O O
computer O O
to O O
a O O
strong O O
periodic O O
source O O
, O O
namely O O
, O O
the O O
daily O O
and O O
weekly O O
usage O O
patterns O O
of O O
the O O
system O O
. O O

The O O
non O O
- O O
homologous O O
sequences O O
in O O
the O O
5 O O
' O O
untranslated O O
regions O O
might O O
be O O
acquired O O
at O O
or O O
after O O
transcription O O
during O O
retrotransposition O O
of O O
the O O
ATLN O O
elements O O
. O O

The O O
time O O
course O O
of O O
RNA1 S-GENE O
replication O O
and O O
RNA3 S-GENE S-GENE
synthesis O O
in O O
induced O O
yeast O O
paralleled O O
that O O
in O O
yeast O O
transfected O O
with O O
natural O O
FHV O B-GENE
virion O I-GENE
RNA O E-GENE
. O O
The O O
transcription O O
and O O
alternative O O
splicing O O
of O O
human B-GENE B-GENE
ORL1 E-GENE E-GENE
and O O
GAIP S-GENE S-GENE
are O O
cell O O
- O O
type O O
specific O O
. O O
RESULTS O O
: O O
The O O
main O O
effect O O
of O O
muscle O O
pain O O
, O O
compared O O
to O O
non O O
- O O
painful O O
stimulation O O
, O O
was O O
a O O
significant O O
and O O
long O O
- O O
lasting O O
increase O O
of O O
delta O O
( O O
1 O O
- O O
3 O O
Hz O O
) O O
power O O
and O O
an O O
alpha-1 O O
( O O
9 O O
- O O
11 O O
Hz O O
) O O
power O O
increase O O
over O O
the O O
contralateral O O
parietal O O
locus O O
. O O

The O O
extraction O O
was O O
subsequently O O
rated O O
as O O
' O O
easy O O
' O O
or O O
' O O
difficult'.Taking O O
Pell O O
- O O
Gregory O O
class O O
C O O
as O O
a O O
predictor O O
of O O
a O O
' O O
difficult O O
' O O
extraction O O
, O O
specificity O O
was O O
88% O O
but O O
sensitivity O O
was O O
low O O
at O O
15% O O
. O O

In O O
addition O O
, O O
our O O
results O O
show O O
that O O
ERKs S-GENE S-GENE
and O O
PI3Ks S-GENE S-GENE
can O O
synergise O O
to O O
convert O O
ectoderm O O
into O O
mesoderm O O
. O O
Based O O
on O O
16S B-GENE B-GENE
rRNA I-GENE I-GENE
gene I-GENE E-GENE
sequence E-GENE O
analysis O O
, O O
the O O
11 O O
species O O
having O O
two O O
tuf B-GENE B-GENE
genes E-GENE E-GENE
all O O
have O O
a O O
common O O
ancestor O O
, O O
while O O
the O O
six O O
species O O
having O O
only O O
one O O
copy O O
diverged O O
from O O
the O O
enterococcal O O
lineage O O
before O O
that O O
common O O
ancestor O O
. O O
Nevertheless O O
, O O
protein B-GENE B-GENE
kinase I-GENE E-GENE
A E-GENE O
stimulation O O
induces O O
CREMalpha S-GENE S-GENE
to O O
activate O O
the O O
complex O B-GENE
native O I-GENE
promoter O E-GENE
in O O
the O O
phosphoenolpyruvate B-GENE B-GENE
carboxykinase E-GENE E-GENE
( O O
PEPCK S-GENE B-GENE
) O I-GENE
gene O E-GENE
. O O
Another O O
putative O O
HNF3 B-GENE B-GENE
site E-GENE E-GENE
in O O
close O O
apposition O O
to O O
a O O
NF1/CTF O B-GENE
site O E-GENE
was O O
localized O O
upstream O O
of O O
the O O
silencer O B-GENE
- O I-GENE
like O I-GENE
element O E-GENE
. O O
This O O
transcriptional O O
regulation O O
occurs O O
through O O
modulation O O
of O O
the O O
forkhead B-GENE B-GENE
transcription I-GENE I-GENE
factor E-GENE I-GENE
FKHR B-GENE I-GENE
- I-GENE I-GENE
L1 E-GENE E-GENE
, O O
and O O
IL-3 S-GENE S-GENE
inhibited O O
FKHR O S-GENE
- O O
L1 O O
activity O O
in O O
a O O
PI3K S-GENE S-GENE
- O O
dependent O O
manner O O
. O O
Taken O O
together O O
, O O
these O O
observations O O
indicate O O
that O O
inhibition O O
of O O
p27(KIP1 O S-GENE
) O O
transcription O O
through O O
PI3K S-GENE S-GENE
- O O
induced O O
FKHR B-GENE S-GENE
- I-GENE O
L1 E-GENE O
phosphorylation O O
provides O O
a O O
novel O O
mechanism O O
of O O
regulating O O
cytokine O O
- O O
mediated O O
survival O O
and O O
proliferation O O
. O O
DNase B-GENE B-GENE
I E-GENE E-GENE
genomic O O
footprinting O O
revealed O O
that O O
the O O
c B-GENE B-GENE
- I-GENE I-GENE
Myb I-GENE I-GENE
site E-GENE E-GENE
is O O
occupied O O
in O O
a O O
tissue O O
- O O
specific O O
fashion O O
in O O
vivo O O
. O O
We O O
conclude O O
that O O
c B-GENE B-GENE
- I-GENE I-GENE
Myb E-GENE E-GENE
regulates O O
the O O
RAG-2 B-GENE B-GENE
promoter E-GENE E-GENE
in O O
T O O
cells O O
by O O
binding O O
to O O
this O O
consensus B-GENE O
c I-GENE B-GENE
- I-GENE I-GENE
Myb I-GENE I-GENE
binding I-GENE I-GENE
site E-GENE E-GENE
. O O
A O O
recently O O
reported O O
new O O
member O O
of O O
the O O
Vav B-GENE B-GENE
family I-GENE I-GENE
proteins E-GENE E-GENE
, O O
Vav3 S-GENE S-GENE
has O O
been O O
identified O O
as O O
a O O
Ros S-GENE B-GENE
receptor B-GENE I-GENE
protein I-GENE I-GENE
tyrosine I-GENE I-GENE
kinase E-GENE E-GENE
( O O
RPTK S-GENE S-GENE
) O O
interacting O O
protein O O
by O O
yeast O O
two O O
- O O
hybrid O O
screening O O
. O O
Subsequently O O
, O O
we O O
show O O
that O O
the O O
reexpression O O
of O O
the O O
r B-GENE B-GENE
- I-GENE I-GENE
PTPeta I-GENE I-GENE
gene E-GENE E-GENE
in O O
highly O O
malignant O O
rat O O
thyroid O O
cells O O
transformed O O
by O O
retroviruses O O
carrying O O
the O O
v B-GENE B-GENE
- I-GENE I-GENE
mos E-GENE E-GENE
and O O
v B-GENE B-GENE
- I-GENE I-GENE
ras I-GENE I-GENE
- I-GENE I-GENE
Ki I-GENE I-GENE
oncogenes E-GENE E-GENE
suppresses O O
their O O
malignant O O
phenotype O O
. O O
Induced O O
expression O O
of O O
Rnd3 S-GENE S-GENE
is O O
associated O O
with O O
transformation O O
of O O
polarized O O
epithelial O O
cells O O
by O O
the O O
Raf S-GENE B-GENE
- O I-GENE
MEK S-GENE I-GENE
- O I-GENE
extracellular O I-GENE
signal O I-GENE
- O I-GENE
regulated O I-GENE
kinase O E-GENE
pathway O O
. O O
The O O
activity O O
of O O
the O O
transcription B-GENE B-GENE
factor I-GENE I-GENE
CREB E-GENE E-GENE
is O O
regulated O O
by O O
extracellular O O
stimuli O O
that O O
result O O
in O O
its O O
phosphorylation O O
at O O
a O O
critical O O
serine O O
residue O O
, O O
Ser133 O O
. O O
RESULTS O O
: O O
Average O O
age O O
at O O
symptom O O
onset O O
was O O
41.2 O O
years O O
. O O

When O O
10 O O
fields O O
were O O
analysed O O
, O O
a O O
strong O O
relationship O O
was O O
found O O
between O O
the O O
presence O O
of O O
bacteria O O
on O O
Gram O O
staining O O
and O O
the O O
final O O
diagnosis O O
of O O
VAP O O
( O O
for O O
PSB O O
and O O
PTC O O
respectively O O
: O O
sensitivity O O
74 O O
and O O
81% O O
, O O
specificity O O
94 O O
and O O
100% O O
, O O
positive O O
predictive O O
value O O
91 O O
and O O
100% O O
, O O
negative O O
predictive O O
value O O
82 O O
and O O
88% O O
) O O
. O O

Unlike O O
the O O
mammalian O B-GENE
proteins O E-GENE
, O O
XFGF3 S-GENE S-GENE
is O O
efficiently O O
secreted O O
as O O
a O O
Mr O B-GENE
31,000 O I-GENE
glycoprotein O E-GENE
, O O
gp31 S-GENE S-GENE
, O O
which O O
undergoes O O
proteolytic O O
cleavage O O
to O O
produce O O
an O O
NH2-terminally O B-GENE
truncated O I-GENE
product O E-GENE
, O O
gp27 S-GENE S-GENE
. O O
NH2-terminal O O
trimming O O
of O O
Xenopus O O
and O O
mammalian B-GENE O
FGF3s E-GENE S-GENE
may O O
therefore O O
be O O
a O O
prerequisite O O
of O O
optimal O O
biological O O
activity O O
. O O
Here O O
, O O
we O O
identified O O
three O O
cis O O
- O O
elements O O
required O O
for O O
replication O O
within O O
the O O
200 O O
bp O O
promoter O O
, O O
using O O
autonomously O O
replicating O O
plasmids O O
carrying O O
various O O
mutations O O
and O O
deletions O O
. O O

Tranilast O O
in O O
the O O
Therapy O O
of O O
Coronary O O
Artery O O
Disease O O
. O O

The O O
objectives O O
of O O
the O O
present O O
study O O
were O O
to O O
evaluate O O
the O O
effects O O
of O O
adding O O
Equex O O
to O O
a O O
TRIS O O
- O O
extender O O
, O O
diluting O O
the O O
semen O O
in O O
1 O O
or O O
2 O O
steps O O
, O O
freezing O O
according O O
to O O
2 O O
methods O O
, O O
thawing O O
at O O
2 O O
rates O O
, O O
and O O
the O O
interactions O O
between O O
these O O
treatments O O
, O O
on O O
the O O
post O O
- O O
thaw O O
survival O O
of O O
dog O O
spermatozoa O O
at O O
38 O O
degrees O O
C. O O

This O O
study O O
is O O
a O O
further O O
and O O
more O O
extensive O O
validation O O
of O O
the O O
clinician O O
rated O O
NIMH O O
- O O
LCM O O
- O O
p O O
. O O

The O O
Aie1 B-GENE B-GENE
locus E-GENE E-GENE
was O O
mapped O O
to O O
mouse O O
chromosome O O
7A2-A3 O S-GENE
by O O
fluorescent O O
in O O
situ O O
hybridization O O
. O O
Psychiatric O O
disorders O O
in O O
children O O
and O O
adolescents O O
carry O O
considerable O O
morbidity O O
, O O
impede O O
development O O
, O O
and O O
carry O O
a O O
significant O O
mortality O O
by O O
suicide O O
. O O

Molecular O O
cloning O O
and O O
expression O O
of O O
human B-GENE B-GENE
UDP I-GENE I-GENE
- I-GENE I-GENE
d I-GENE I-GENE
- I-GENE I-GENE
Xylose I-GENE E-GENE
: I-GENE O
proteoglycan I-GENE B-GENE
core I-GENE I-GENE
protein E-GENE I-GENE
beta B-GENE I-GENE
- I-GENE I-GENE
d I-GENE I-GENE
- I-GENE I-GENE
xylosyltransferase E-GENE E-GENE
and O O
its O O
first O O
isoform B-GENE O
XT I-GENE B-GENE
- I-GENE I-GENE
II E-GENE E-GENE
. O O
Thyrotoxicosis O O
due O O
to O O
amiodarone O O
is O O
difficult O O
to O O
treat O O
and O O
is O O
further O O
complicated O O
by O O
the O O
pro O O
- O O
arrhythmic O O
potential O O
of O O
thyrotoxicosis O O
and O O
the O O
fading O O
antiarrhythmic O O
effect O O
after O O
amiodarone O O
withdrawal O O
. O O

Chaperones O O
/ O O
HSPs S-GENE S-GENE
thus O O
play O O
important O O
roles O O
within O O
cell O O
cycle O O
processes O O
. O O
Oncogenic O O
signalling O O
by O O
E2F1 S-GENE S-GENE
has O O
recently O O
been O O
linked O O
to O O
stabilization O O
and O O
activation O O
of O O
the O O
tumour O B-GENE
suppressor O I-GENE
p53 S-GENE E-GENE
( O O
refs O O
1,3,4 O S-GENE
) O O
. O O
This O O
study O O
allows O O
us O O
to O O
draw O O
conclusions O O
about O O
the O O
identity O O
of O O
proteins O O
required O O
for O O
the O O
development O O
of O O
the O O
nervous O O
system O O
in O O
Drosophila O O
and O O
provides O O
an O O
example O O
of O O
a O O
molecular O O
approach O O
to O O
characterize O O
en O O
masse O O
transposon O O
- O O
tagged O O
mutations O O
identified O O
in O O
genetic O O
screens O O
. O O

We O O
describe O O
the O O
identification O O
and O O
initial O O
characterization O O
of O O
neurobeachin S-GENE O
, O O
a O O
neuron O O
- O O
specific O O
multidomain O O
protein O O
of O O
327 O O
kDa O O
with O O
a O O
high O O
- O O
affinity O O
binding O O
site O O
( O O
K(d O S-GENE
) O O
, O O
10 O O
nm O O
) O O
for O O
the O O
type B-GENE O
II I-GENE B-GENE
regulatory I-GENE I-GENE
subunit I-GENE E-GENE
of I-GENE O
protein I-GENE B-GENE
kinase I-GENE E-GENE
A E-GENE O
( O O
PKA B-GENE B-GENE
RII E-GENE E-GENE
) O O
. O O
Children O O
with O O
ADD O O
showed O O
an O O
attenuated O O
frontal O O
CNV-1 O O
amplitude O O
and O O
a O O
trend O O
towards O O
increased O O
CNV-1 O O
and O O
CNV-2 O O
occipital O O
amplitudes O O
. O O

Where O O
UMDNJ O O
is O O
headed O O
. O O

Overexpression O O
of O O
c B-GENE B-GENE
- I-GENE I-GENE
Myc E-GENE E-GENE
in O O
serum O B-GENE
- O I-GENE
starved O I-GENE
human O E-GENE
or O O
mouse O O
embryonic O O
cells O O
leads O O
to O O
apoptosis O O
which O O
is O O
significantly O O
reduced O O
in O O
the O O
presence O O
of O O
growth O B-GENE
factor O I-GENE
- O I-GENE
containing O I-GENE
serum O E-GENE
. O O
c O B-GENE
- O I-GENE
Myc O E-GENE
- O O
induced O O
apoptosis O O
appears O O
to O O
be O O
deficient O O
in O O
bax S-GENE B-GENE
- O I-GENE
null O E-GENE
as O O
compared O O
with O O
bax O B-GENE
- O I-GENE
wild O I-GENE
- O I-GENE
type O I-GENE
mouse O I-GENE
embryonic O I-GENE
fibroblasts O E-GENE
. O O
Antimicrobial O O
Susceptibility O O
of O O
Klebsiella O B-GENE
pneumoniae O I-GENE
Producing O I-GENE
Extended B-GENE I-GENE
- I-GENE I-GENE
Spectrum I-GENE I-GENE
beta I-GENE I-GENE
- I-GENE I-GENE
lactamase E-GENE E-GENE
( O O
ESBL S-GENE S-GENE
) O O
Isolated O O
in O O
Hospitals O O
in O O
Brazil O O
. O O
CONCLUSION O O
: O O
Our O O
results O O
suggest O O
that O O
AIF O S-GENE
peak O O
saturation O O
leads O O
to O O
a O O
significant O O
systematic O O
error O O
in O O
the O O
determination O O
of O O
CBV O O
and O O
CBF O O
values O O
and O O
has O O
necessarily O O
to O O
be O O
taken O O
into O O
account O O
for O O
dynamic O O
contrast O O
- O O
enhanced O O
MR O O
perfusion O O
studies O O
. O O

METHODS O O
: O O
T2 O O
* O O
-weighted O O
, O O
three O O
- O O
dimensional O O
gradient O O
- O O
echo O O
images O O
were O O
acquired O O
by O O
exploiting O O
the O O
magnetic O O
susceptibility O O
difference O O
between O O
oxygenated O O
and O O
deoxygenated O B-GENE
hemoglobin S-GENE E-GENE
in O O
the O O
vasculature O O
and O O
microvasculature O O
. O O
In O O
the O O
COPD O O
patients O O
, O O
the O O
variability O O
of O O
Delta O O
- O O
inst O O
Rrs O O
( O O
30% O O
) O O
was O O
greater O O
than O O
that O O
of O O
FOT O O
Rrs O O
( O O
21% O O
) O O
. O O

Toward O O
this O O
end O O
, O O
we O O
prepared O O
synthetic O O
proteins O O
with O O
either O O
the O O
catalytic O O
domain O O
of O O
FAP-1 B-GENE S-GENE
( I-GENE O
C I-GENE O
- I-GENE O
terminal I-GENE O
399 I-GENE O
amino I-GENE O
acids I-GENE O
) E-GENE O
or O O
its O O
inactive O O
form O O
( O O
Cys2408 O B-GENE
- O I-GENE
->Ser O E-GENE
) O O
fused O O
to O O
glutathione B-GENE B-GENE
- I-GENE I-GENE
S I-GENE I-GENE
- I-GENE I-GENE
transferase E-GENE E-GENE
( O O
GST S-GENE S-GENE
) O O
. O O
Thus O O
, O O
Pet111p S-GENE S-GENE
could O O
play O O
dual O O
roles O O
in O O
both O O
membrane O O
localization O O
and O O
regulation O O
of O O
Cox2p S-GENE S-GENE
synthesis O O
within O O
mitochondria O O
. O O
Furthermore O O
, O O
transfection O O
of O O
cells O O
with O O
the O O
spacer O O
- O O
RING O O
domain O O
alone O O
suppressed O O
the O O
antiapoptotic O O
function O O
of O O
the O O
N O B-GENE
- O I-GENE
terminal O I-GENE
BIR S-GENE I-GENE
domain O E-GENE
of O O
c B-GENE B-GENE
- I-GENE I-GENE
IAP1 E-GENE E-GENE
and O O
induced O O
apoptosis O O
. O O
The O O
determination O O
of O O
the O O
double O O
bounds O O
in O O
blood O O
serum O O
lipids O O
by O O
titration O O
with O O
ozone O O
: O O
the O O
pathophysiology O O
and O O
diagnostic O O
significance O O
] O O
In O O
this O O
article O O
the O O
method O O
of O O
definition O O
of O O
double O O
binders O O
in O O
lipids O O
of O O
blood O O
serum O O
in O O
patients O O
with O O
different O O
diseases O O
basically O O
atherosclerosis O O
and O O
ischemic O O
heart O O
disease O O
, O O
with O O
use O O
titration O O
by O O
ozone O O
is O O
given O O
. O O

Ang B-GENE B-GENE
II E-GENE I-GENE
- O I-GENE
induced O I-GENE
fibronectin B-GENE I-GENE
mRNA E-GENE E-GENE
was O O
not O O
affected O O
by O O
PKC S-GENE S-GENE
inhibitors O O
or O O
PKC O S-GENE
depletion O O
, O O
whereas O O
specific O O
inhibition O O
of O O
EGF B-GENE O
- I-GENE O
R E-GENE O
function O O
by O O
a O O
dominant B-GENE O
negative I-GENE O
EGF I-GENE O
- I-GENE O
R I-GENE O
mutant E-GENE O
and O O
tyrphostin O O
AG1478 O O
abolished O O
induction O O
of O O
fibronectin O O
mRNA O O
. O O
Acoust O O
. O O

Video O O
images O O
of O O
the O O
nostrils O O
were O O
captured O O
and O O
then O O
analyzed O O
for O O
area O O
, O O
perimeter O O
, O O
centroid O O
, O O
principal O O
axis O O
, O O
moments O O
about O O
the O O
major O O
and O O
minor O O
axes O O
( O O
I11 O O
, O O
I22 O O
) O O
, O O
anisometry O O
, O O
bulkiness O O
, O O
lateral O O
offset O O
, O O
internostril O O
angle O O
, O O
and O O
rotational O O
angle O O
. O O

MS O O
characteristics O O
of O O
coumarins O O
, O O
psoralens O O
and O O
polymethoxylated O O
flavones O O
with O O
different O O
substitution O O
patterns O O
were O O
determined O O
on O O
the O O
basis O O
of O O
the O O
response O O
obtained O O
with O O
the O O
APcI O O
interface O O
. O O

Young O O
fish O O
( O O
Oreochromis O O
mossambicus O O
) O O
were O O
exposed O O
to O O
microgravity O O
( O O
micro O O
g O O
) O O
for O O
9 O O
to O O
10 O O
days O O
during O O
space O O
missions O O
STS-55 O O
and O O
STS-84 O O
, O O
or O O
to O O
hypergravity O O
( O O
hg O O
) O O
for O O
9 O O
days O O
. O O

S6K2 S-GENE S-GENE
is O O
highly O O
homologous O O
to O O
S6K1 S-GENE S-GENE
in O O
the O O
core O B-GENE
kinase O E-GENE
and O O
linker O O
regulatory O O
domains O O
but O O
differs O O
from O O
S6K1 O S-GENE
in O O
the O O
N- O O
and O O
C O O
- O O
terminal O O
regions O O
and O O
is O O
differently O O
localized O O
primarily O O
to O O
the O O
nucleus O O
because O O
of O O
a O O
C O O
- O O
terminal O O
nuclear O O
localization O O
signal O O
unique O O
to O O
S6K2 O S-GENE
. O O
Pretreatment O O
of O O
cells O O
with O O
the O O
mitogen B-GENE B-GENE
- I-GENE I-GENE
activated I-GENE I-GENE
protein I-GENE I-GENE
- I-GENE I-GENE
extracellular I-GENE I-GENE
signal I-GENE I-GENE
- I-GENE I-GENE
regulated I-GENE I-GENE
kinase I-GENE I-GENE
kinase E-GENE E-GENE
( O O
MEK S-GENE S-GENE
) O O
inhibitor O O
U0126 O S-GENE
inhibited O O
S6K2 S-GENE S-GENE
activation O O
to O O
a O O
greater O O
extent O O
than O O
S6K1 S-GENE S-GENE
. O O
T O O
cells O O
express O O
two O O
isoforms O O
of O O
S6k1 S-GENE S-GENE
: O O
a O O
70 O O
kDa O B-GENE
cytoplasmic O I-GENE
kinase O E-GENE
and O O
an O O
85 O O
kDa O O
isoform O O
that O O
has O O
a O O
classic O O
nuclear O O
localisation O O
. O O
Ketanserin O O
, O O
a O O
hypotensive O O
drug O O
with O O
5-HT2 B-GENE B-GENE
receptor E-GENE E-GENE
antagonism O O
, O O
when O O
administered O O
by O O
topical O O
infusion O O
of O O
a O O
0.25% O O
w O O
/ O O
v O O
solution O O
by O O
corneal O O
and O O
scleral O O
applications O O
, O O
was O O
found O O
to O O
lower O O
intraocular O O
pressure O O
with O O
four O O
times O O
more O O
activity O O
than O O
its O O
metabolite O O
, O O
ketanserinol O O
. O O
A O O
prospectively O O
gated O O
2D O O
axial O O
sequence O O
with O O
velocity O O
encoding O O
in O O
the O O
craniocaudal O O
direction O O
in O O
the O O
cervical O O
region O O
was O O
set O O
at O O
a O O
velocity O O
of O O
+ O O
/- O O
10 O O
cm O O
/ O O
s O O
. O O

It O O
was O O
subsequently O O
shown O O
that O O
Tip60 S-GENE B-GENE
had O I-GENE
histone B-GENE I-GENE
acetyltransferase E-GENE E-GENE
( O O
HAT S-GENE S-GENE
) O O
activity O O
. O O
Our O O
data O O
show O O
that O O
multiple O O
MLSN1 B-GENE B-GENE
transcripts E-GENE E-GENE
, O O
both O O
constitutively O O
expressed O O
and O O
inducible O O
, O O
are O O
present O O
in O O
cultured O O
pigmented O O
melanoma O O
cells O O
, O O
and O O
suggest O O
that O O
MLSN1 O S-GENE
expression O O
can O O
be O O
regulated O O
at O O
the O O
level O O
of O O
both O O
transcription O O
and O O
mRNA O O
processing O O
. O O
Copyright O O
2000 O O
Academic O O
Press O O
. O O

Plectin S-GENE O
and O O
desmoplakin S-GENE O
have O O
GSR O S-GENE
- O O
containing O O
domains O O
at O O
their O O
C O O
- O O
termini O O
and O O
we O O
further O O
demonstrate O O
that O O
the O O
GSR O S-GENE
- O O
containing O O
domain O O
of O O
plectin S-GENE O
, O O
but O O
not O O
desmoplakin O O
, O O
can O O
bind O O
to O O
MTs O S-GENE
in O O
vivo O O
. O O
Characterization O O
of O O
the O O
microtubule O B-GENE
binding O I-GENE
domain O E-GENE
of O O
microtubule B-GENE B-GENE
actin I-GENE I-GENE
crosslinking I-GENE I-GENE
factor E-GENE E-GENE
( O O
MACF S-GENE S-GENE
) O O
: O O
identification O O
of O O
a O O
novel O O
group O O
of O O
microtubule B-GENE B-GENE
associated I-GENE I-GENE
proteins E-GENE E-GENE
. O O
These O O
results O O
also O O
suggest O O
the O O
involvement O O
of O O
additional O O
elements O O
in O O
the O O
UPR O O
. O O

We O O
show O O
that O O
in O O
contrast O O
to O O
SRC1 S-GENE S-GENE
, O O
direct O O
binding O O
of O O
CBP S-GENE S-GENE
to O O
the O O
estrogen B-GENE B-GENE
receptor E-GENE E-GENE
is O O
weak O O
, O O
suggesting O O
that O O
SRC1 O S-GENE
functions O O
primarily O O
as O O
an O O
adaptor O O
to O O
recruit O O
CBP O S-GENE
and O O
p300 S-GENE S-GENE
. O O
Remarkably O O
, O O
a O O
construct O O
corresponding O O
to O O
residues O O
631 O O
to O O
970 O O
, O O
which O O
contains O O
only O O
the O O
LXXLL O S-GENE
motifs O O
and O O
the O O
AD1 O S-GENE
region O O
of O O
SRC1 S-GENE S-GENE
, O O
retained O O
strong O O
coactivator O O
activity O O
in O O
our O O
assays O O
. O O
Since O O
MEK S-GENE S-GENE
acts O O
as O O
a O O
cytoplasmic O O
anchor O O
for O O
the O O
ERKs S-GENE S-GENE
, O O
the O O
lack O O
of O O
a O O
MEK O S-GENE
interaction O O
resulted O O
in O O
the O O
aberrant O O
nuclear O O
localization O O
of O O
ERK2-Delta19 O B-GENE
- O I-GENE
25 O I-GENE
mutants O E-GENE
in O O
serum O B-GENE
- O I-GENE
starved O E-GENE
cells O O
. O O
Pmt2 S-GENE S-GENE
is O O
a O O
member O O
of O O
a O O
six O B-GENE
- O I-GENE
protein O I-GENE
family O E-GENE
in O O
yeast O O
that O O
catalyzes O O
the O O
first O O
step O O
in O O
O O O
mannosylation O O
of O O
target O O
proteins O O
. O O
Fecal O O
samples O O
were O O
collected O O
at O O
the O O
beginning O O
and O O
end O O
of O O
each O O
trial O O
period O O
and O O
were O O
analyzed O O
for O O
gastrointestinal O O
nematode O O
eggs O O
and O O
Giardia O O
cyst O O
. O O

The O O
aim O O
of O O
this O O
study O O
was O O
to O O
determine O O
the O O
risk O O
factors O O
for O O
background O O
diabetic O O
retinopathy O O
( O O
BDR O O
) O O
and O O
PDR O O
by O O
following O O
394 O O
Japanese O O
patients O O
with O O
early O O
- O O
onset O O
type O O
2 O O
diabetes O O
diagnosed O O
before O O
30 O O
years O O
of O O
age O O
( O O
mean O O
age O O
27 O O
, O O
mean O O
blood O O
pressure O O
at O O
entry O O
116/73 O O
mm O O
Hg O O
) O O
. O O

Of O O
the O O
21 O O
quadrants O O
positive O O
in O O
the O O
controls O O
, O O
17 O O
were O O
correlated O O
with O O
previously O O
detected O O
jaw O O
pathoses O O
. O O

Four O O
cases O O
of O O
synovial O O
chondromatosis O O
are O O
presented O O
. O O

Previous O O
studies O O
have O O
shown O O
that O O
the O O
pro O B-GENE
- O I-GENE
inflammatory O I-GENE
cytokines O I-GENE
tumor B-GENE I-GENE
necrosis I-GENE I-GENE
factor I-GENE I-GENE
alpha E-GENE E-GENE
and O O
interferon B-GENE B-GENE
gamma E-GENE E-GENE
reduce O O
the O O
expression O O
of O O
the O O
cystic B-GENE O
fibrosis I-GENE O
transmembrane I-GENE O
conductance I-GENE O
regulator E-GENE O
( O O
CFTR S-GENE S-GENE
) O O
gene O O
( O O
CFTR O S-GENE
) O O
in O O
HT-29 O S-GENE
and O O
T84 O S-GENE
cells O O
by O O
acting O O
post O O
- O O
transcriptionally O O
. O O
Regulation O O
of O O
RhoA S-GENE S-GENE
is O O
required O O
to O O
maintain O O
adhesion O O
in O O
stationary O O
cells O O
, O O
but O O
is O O
also O O
critical O O
for O O
cell O O
spreading O O
and O O
migration O O
[ O O
3 O O
] O O
. O O
Here O O
we O O
show O O
in O O
mouse O O
fibroblasts O O
stably O O
transformed O O
by O O
v B-GENE B-GENE
- I-GENE I-GENE
Src E-GENE E-GENE
that O O
mRNA O S-GENE
and O O
protein O O
levels O O
of O O
p21 S-GENE S-GENE
( O O
WAF1/CIP1 O S-GENE
) O O
, O O
cyclin B-GENE B-GENE
D1 E-GENE E-GENE
, O O
and O O
cyclin B-GENE B-GENE
E E-GENE E-GENE
are O O
elevated O O
. O O
ORFA O S-GENE
and O O
ccdA S-GENE S-GENE
were O O
constitutively O O
cotranscribed O O
as O O
determined O O
by O O
primer O O
extension O O
analysis O O
. O O
Mouse B-GENE O
Impact E-GENE O
is O O
a O O
paternally O O
expressed O O
gene O O
encoding O O
an O O
evolutionarily O O
conserved O O
protein O O
of O O
unknown O O
function O O
. O O
These O O
cells O O
produced O O
P2Y(11 B-GENE S-GENE
) I-GENE O
mRNA E-GENE O
during O O
culture O O
. O O
Coexpression O O
studies O O
indicate O O
that O O
insulin S-GENE S-GENE
and O O
PKB S-GENE S-GENE
suppress O O
transactivation O O
by O O
C B-GENE O
/ I-GENE O
EBPbeta E-GENE S-GENE
, O O
but O O
not O O
C B-GENE O
/ I-GENE O
EBPalpha E-GENE S-GENE
, O O
and O O
that O O
N O O
- O O
terminal O O
transactivation O O
domains O O
in O O
C O O
/ O O
EBPbeta O S-GENE
are O O
required O O
. O O
Among O O
eight O O
graminaceous O O
species O O
tested O O
, O O
Ids3 S-GENE S-GENE
expression O O
was O O
observed O O
only O O
in O O
Fe O O
- O O
deficient O O
roots O O
of O O
H. O O
vulgare O O
and O O
Secale O B-GENE
cereale O E-GENE
. O O
which O O
not O O
only O O
secrete O O
2'-deoxymugineic O O
acid O O
( O O
DMA O S-GENE
) O O
, O O
but O O
also O O
mugineic O O
acid O O
( O O
MA O O
) O O
and O O
3-epihydroxymugineic O O
acid O O
( O O
epiHMA O O
, O O
H. O O
vulgare O O
) O O
, O O
and O O
3-hydroxymugineic O O
acid O O
( O O
HMA O O
, O O
S. O O
cereale O O
) O O
. O O
In O O
contrast O O
, O O
high O O
COUP B-GENE B-GENE
- I-GENE I-GENE
TFI E-GENE E-GENE
expression O O
impeded O O
the O O
neuronal O O
differentiation O O
of O O
P19 O S-GENE
cells O O
induced O O
with O O
RA O O
, O O
resulting O O
in O O
cell O O
cultures O O
lacking O O
neurons O O
. O O
Because O O
PET O O
is O O
also O O
useful O O
for O O
the O O
pretreatment O O
and O O
follow O O
- O O
up O O
evaluation O O
, O O
the O O
use O O
of O O
stereotactic O O
PET O O
in O O
these O O
patients O O
can O O
enable O O
an O O
accurate O O
comparison O O
of O O
PET O O
- O O
based O O
metabolic O O
data O O
with O O
MR O O
- O O
based O O
anatomical O O
data O O
. O O

Therefore O O
, O O
in O O
our O O
in O O
vitro O O
model O O
, O O
the O O
localization O O
of O O
the O O
mutation O O
in O O
the O O
K B-GENE B-GENE
- I-GENE I-GENE
ras I-GENE I-GENE
gene E-GENE E-GENE
predisposes O O
to O O
a O O
different O O
level O O
of O O
aggressiveness O O
in O O
the O O
transforming O O
phenotype O O
. O O
Here O O
, O O
we O O
describe O O
the O O
isolation O O
of O O
MdPin1 S-GENE S-GENE
, O O
a O O
Pin1 O O
homologue O O
from O O
the O O
plant O O
species O O
apple O O
( O O
Malus O O
domestica O O
) O O
and O O
show O O
that O O
it O O
has O O
the O O
same O O
phosphorylation O O
- O O
specific O O
substrate O O
specificity O O
and O O
can O O
be O O
inhibited O O
by O O
juglone O O
in O O
vitro O O
, O O
as O O
is O O
the O O
case O O
for O O
Pin1 O O
. O O
Differential O O
association O O
of O O
products O O
of O O
alternative O O
transcripts O O
of O O
the O O
candidate O O
tumor B-GENE O
suppressor I-GENE O
ING1 E-GENE S-GENE
with O O
the O O
mSin3/HDAC1 O B-GENE
transcriptional O I-GENE
corepressor O I-GENE
complex O E-GENE
. O O
These O O
and O O
other O O
data O O
presented O O
suggest O O
that O O
TAg S-GENE O
' O O
re O O
- O O
models O O
' O O
host O O
cell O O
transcription O O
factors O O
that O O
are O O
used O O
early O O
in O O
viral O O
infection O O
, O O
and O O
thereby O O
mimics O O
an O O
event O O
that O O
naturally O O
occurs O O
during O O
transformation O O
. O O
This O O
sensitivity O O
analysis O O
showed O O
that O O
the O O
practical O O
limits O O
of O O
the O O
accuracy O O
of O O
the O O
used O O
screening O O
test O O
jeopardize O O
the O O
estimation O O
of O O
the O O
true O O
herd O O
prevalence O O
within O O
reasonable O O
confidence O O
limits O O
, O O
because O O
the O O
within O O
- O O
herd O O
PTB O O
true O O
prevalence O O
was O O
low O O
. O O
For O O
this O O
reason O O
we O O
augmented O O
the O O
herd O O
specificity O O
for O O
herds O O
with O O
larger O O
adult O O
herd O O
size O O
( O O
> O O
5 O O
) O O
. O O

ORFK10.5 S-GENE O
encodes O O
a O O
protein O O
, O O
latency B-GENE O
- I-GENE O
associated I-GENE O
nuclear I-GENE B-GENE
antigen I-GENE I-GENE
2 E-GENE E-GENE
( O O
LANA2 S-GENE S-GENE
) O O
, O O
which O O
is O O
expressed O O
in O O
KSHV O O
- O O
infected O O
hematopoietic O O
tissues O O
, O O
including O O
PEL O S-GENE
and O O
CD O O
but O O
not O O
KS O O
lesions O O
. O O
As O O
hypothesized O O
, O O
believers O O
showed O O
relatively O O
higher O O
right O O
hemispheric O O
activation O O
and O O
reduced O O
hemispheric O O
asymmetry O O
of O O
functional O O
complexity O O
. O O

In O O
Xenopus O O
, O O
BMPs S-GENE S-GENE
act O O
as O O
epidermal O O
inducers O O
and O O
also O O
as O O
negative O O
regulators O O
of O O
neurogenesis O O
. O O
Presently O O
four O O
unique O O
variants O O
carrying O O
distinct O O
GAF B-GENE S-GENE
sequences E-GENE O
in O O
the O O
N O O
- O O
terminal O O
region O O
have O O
been O O
identified O O
. O O
Genomic O O
organization O O
of O O
the O O
human O B-GENE
phosphodiesterase B-GENE I-GENE
PDE11A I-GENE I-GENE
gene E-GENE E-GENE
. O O
The O O
present O O
findings O O
revealed O O
that O O
the O O
rib-2 B-GENE B-GENE
protein E-GENE E-GENE
was O O
a O O
unique O O
alpha1,4-N B-GENE B-GENE
- I-GENE I-GENE
acetylglucosaminyltransferase E-GENE E-GENE
involved O O
in O O
the O O
biosynthetic O O
initiation O O
and O O
elongation O O
of O O
heparan O B-GENE
sulfate O E-GENE
. O O
Inhibition O O
of O O
the O O
Mek S-GENE B-GENE
/ O I-GENE
Erk S-GENE E-GENE
pathway O O
in O O
Rat1/ras O S-GENE
cells O O
, O O
using O O
the O O
Mek O B-GENE
inhibitor O E-GENE
, O O
PD98059 O S-GENE
, O O
resulted O O
in O O
complete O O
cytoskeletal O O
recovery O O
, O O
indistinguishable O O
from O O
that O O
induced O O
by O O
HR12 O S-GENE
. O O
The O O
transcription O B-GENE
factor O I-GENE
CHOP S-GENE E-GENE
/ O O
GADD153 S-GENE B-GENE
gene O E-GENE
is O O
induced O O
by O O
cellular O O
stress O O
and O O
is O O
involved O O
in O O
mediating O O
apoptosis O O
. O O
Addition O O
of O O
synthetic O O
tyrosine O O
- O O
phosphorylated O O
peptides O O
derived O O
from O O
betac O B-GENE
cytoplasmic O I-GENE
tyrosines O E-GENE
prior O O
to O O
GM B-GENE B-GENE
- I-GENE I-GENE
CSF E-GENE E-GENE
stimulation O O
inhibited O O
the O O
in O O
vitro O O
activation O O
of O O
STAT5 S-GENE S-GENE
. O O
MAIN O O
OUTCOME O O
MEASURES O O
: O O
Percentage O O
change O O
in O O
the O O
apnea O O
- O O
hypopnea O O
index O O
( O O
AHI O O
; O O
apnea O O
events O O
+ O O
hypopnea O O
events O O
per O O
hour O O
of O O
sleep O O
) O O
and O O
odds O O
of O O
developing O O
moderate O O
- O O
to O O
- O O
severe O O
SDB O O
( O O
defined O O
by O O
an O O
AHI O O
> O O
or O O
= O O
15 O O
events O O
per O O
hour O O
of O O
sleep O O
) O O
, O O
with O O
respect O O
to O O
change O O
in O O
weight O O
. O O

Paraneoplastic O O
rheumatic O O
syndromes O O
. O O

This O O
article O O
reviews O O
recent O O
information O O
on O O
the O O
frequency O O
, O O
characteristics O O
, O O
and O O
possible O O
pathogenic O O
mechanisms O O
of O O
the O O
vasculitides O O
occurring O O
in O O
patients O O
with O O
the O O
main O O
connective O O
tissue O O
diseases O O
. O O

Tec B-GENE B-GENE
kinase E-GENE I-GENE
signaling O E-GENE
in O O
T O S-GENE
cells O O
is O O
regulated O O
by O O
phosphatidylinositol B-GENE B-GENE
3-kinase E-GENE E-GENE
and O O
the O O
Tec O B-GENE
pleckstrin B-GENE I-GENE
homology I-GENE I-GENE
domain E-GENE E-GENE
. O O
Current O O
evidence O O
for O O
this O O
type O O
of O O
DNA O O
supercoiling O O
- O O
dependent O O
transcriptional O O
coupling O O
, O O
based O O
largely O O
on O O
the O O
in O O
vivo O O
activities O O
of O O
promoters O O
contained O O
in O O
engineered O O
DNA O O
constructs O O
, O O
suggests O O
that O O
the O O
transcription O O
complex O O
must O O
be O O
physically O O
hindered O O
to O O
generate O O
DNA O O
supercoils O O
and O O
to O O
prevent O O
their O O
diffusion O O
throughout O O
the O O
DNA O O
duplex O O
. O O

The O O
structure O O
of O O
the O O
free O O
SH2 B-GENE B-GENE
domain E-GENE E-GENE
has O O
been O O
compared O O
to O O
that O O
of O O
the O O
SH2 O B-GENE
complexed O E-GENE
with O O
a O O
doubly O O
phosphorylated O O
peptide O O
derived O O
from O O
polyomavirus B-GENE O
middle I-GENE O
T I-GENE B-GENE
antigen E-GENE E-GENE
( O O
MT S-GENE S-GENE
) O O
. O O
We O O
have O O
identified O O
three O O
binding O O
sites O O
for O O
protein O O
complexes O O
: O O
a O O
palindrome O O
, O O
a O O
direct O O
repeat O O
, O O
and O O
a O O
C+T O O
sequence O O
that O O
corresponds O O
to O O
seven O O
GAGA O O
motifs O O
on O O
the O O
transcribed O O
strand O O
. O O

Copyright O O
2000 O O
Academic O O
Press O O
. O O

Nucleotide O O
sequence O O
, O O
genome O O
organization O O
and O O
phylogenetic O O
analysis O O
of O O
pineapple O O
mealybug O O
wilt O O
- O O
associated O O
virus-2 O O
. O O

Patients O O
underwent O O
pretreatment O O
cystoscopy O O
and O O
detailed O O
tumor O O
mapping O O
, O O
and O O
were O O
treated O O
with O O
75 O O
mg O O
. O O
/m.2 O O
cisplatin O O
on O O
day O O
1 O O
and O O
1 O O
gm./m.2 O O
daily O O
, O O
5-fluorouracil O O
on O O
days O O
1 O O
to O O
4 O O
and O O
definitive O O
radiotherapy O O
. O O

All O O
9 O O
untreated O O
patients O O
underwent O O
laparoscopy O O
, O O
which O O
identified O O
3 O O
intra O O
- O O
abdominal O O
, O O
3 O O
vanished O O
and O O
2 O O
peeping O O
testes O O
, O O
and O O
1 O O
atrophic O O
testis O O
in O O
the O O
inguinal O O
canal O O
. O O

This O O
philosophy O O
was O O
instituted O O
for O O
the O O
compound O O
RP O O
73401 O O
, O O
a O O
specific O O
phosphodiesterase B-GENE B-GENE
IV E-GENE I-GENE
inhibitor O E-GENE
, O O
that O O
was O O
being O O
developed O O
simultaneously O O
for O O
delivery O O
by O O
both O O
oral O O
and O O
pulmonary O O
routes O O
of O O
administration O O
. O O
Increased O O
levels O O
of O O
anticardiolipin B-GENE B-GENE
immunoglobulin I-GENE I-GENE
G E-GENE E-GENE
may O O
also O O
cause O O
bleeding O O
. O O
RESULTS O O
: O O
Prevalence O O
of O O
obesity O O
( O O
BMI O O
SDS>2.0 O O
) O O
was O O
< O O
2% O O
at O O
diagnosis O O
, O O
but O O
increased O O
to O O
16% O O
at O O
3y O O
. O O

One O O
of O O
the O O
sequelae O O
of O O
the O O
antiphospholipid O O
- O O
antibodies O O
is O O
an O O
impaired O O
uteroplacental O O
circulation O O
. O O

Bupropion O O
to O O
aid O O
smoking O O
cessation O O
. O O

Using O O
a O O
natural O O
dominant O O
negative O O
for O O
AP-1 S-GENE S-GENE
transcriptional O O
activity O O
in O O
ROS O B-GENE
17/2.8 O E-GENE
cells O O
, O O
we O O
then O O
showed O O
that O O
AP-1 B-GENE B-GENE
transcription I-GENE I-GENE
factors E-GENE E-GENE
mediated O O
TGF O B-GENE
- O I-GENE
beta1- O E-GENE
and O O
BMP-2-regulated O S-GENE
expression O O
of O O
the O O
( B-GENE O
alpha1 I-GENE S-GENE
) I-GENE O
collagen I-GENE B-GENE
I I-GENE I-GENE
gene E-GENE E-GENE
as O O
well O O
as O O
TGF O S-GENE
- O O
beta1-regulated O O
expression O O
of O O
the O O
parathyroid B-GENE B-GENE
hormone E-GENE E-GENE
( O O
PTH)/PTH O B-GENE
- O I-GENE
related O I-GENE
peptide O E-GENE
( O O
PTHrP O B-GENE
) O I-GENE
receptor O E-GENE
. O O
PM O O
12 O O
or O O
18 O O
mg O O
/ O O
kg O O
daily O O
plus O O
a O O
standard O O
dose O O
of O O
SB O O
for O O
21 O O
days O O
was O O
statistically O O
more O O
effective O O
than O O
SB O O
in O O
producing O O
a O O
final O O
cure O O
for O O
patients O O
with O O
VL O O
in O O
Bihar O O
, O O
India O O
. O O

Adjuvant O O
therapy O O
for O O
colon O O
cancer O O
] O O
Surgery O O
alone O O
may O O
fail O O
to O O
cure O O
a O O
considerable O O
number O O
of O O
locally O O
advanced O O
colon O O
cancers O O
. O O

There O O
were O O
significant O O
differences O O
( O O
p<0.05 O O
) O O
between O O
the O O
fracture O O
and O O
nonfracture O O
groups O O
in O O
the O O
total O O
femur O O
BMD O O
( O O
13% O O
) O O
, O O
trabecular O O
BMD O O
in O O
the O O
distal O O
radius O O
( O O
4% O O
) O O
, O O
and O O
the O O
fractal O O
dimension O O
in O O
the O O
radiographs O O
( O O
FD2 O O
) O O
( O O
3% O O
) O O
. O O

BACKGROUND O O
: O O
The O O
aim O O
of O O
this O O
study O O
was O O
to O O
determine O O
and O O
compare O O
interleukin-6 S-GENE O
( O O
IL-6 S-GENE S-GENE
) O O
levels O O
in O O
gingival O O
crevicular O O
fluid O O
( O O
GCF O S-GENE
) O O
and O O
clinical O O
periodontal O O
findings O O
in O O
patients O O
with O O
rheumatoid O O
arthritis O O
( O O
RA O O
) O O
and O O
adult O O
periodontitis O O
( O O
AP O O
) O O
. O O
In O O
a O O
prospective O O
, O O
multicentre O O
trial O O
the O O
efficacy O O
of O O
an O O
Vitex O O
agnus O O
castus O O
L O O
extract O O
Ze O O
440 O O
was O O
investigated O O
in O O
50 O O
patients O O
with O O
pre O O
- O O
menstrual O O
syndrome O O
( O O
PMS O O
) O O
. O O

Studies O O
are O O
necessary O O
to O O
assess O O
the O O
source O O
of O O
contamination O O
and O O
potential O O
role O O
of O O
MRSA O O
- O O
contaminated O O
milk O O
in O O
the O O
transmission O O
of O O
MRSA O O
to O O
neonates O O
. O O

Effects O O
of O O
Trypanosoma O O
vivax O O
on O O
pregnancy O O
of O O
Yankasa O O
sheep O O
and O O
the O O
results O O
of O O
homidum O O
chloride O O
chemotherapy O O
. O O

NF B-GENE B-GENE
kappa I-GENE I-GENE
B E-GENE E-GENE
was O O
activated O O
to O O
a O O
much O O
greater O O
extent O O
by O O
roscovitine O O
in O O
the O O
WT O O
cells O O
than O O
in O O
Y8 O O
cells O O
. O O
Depending O O
on O O
treatment O O
exposures O O
, O O
this O O
at O O
- O O
risk O O
population O O
may O O
experience O O
life O O
- O O
threatening O O
late O O
effects O O
, O O
such O O
as O O
cirrhosis O O
secondary O O
to O O
hepatitis O O
C O O
or O O
late O O
- O O
onset O O
anthracycline O O
- O O
induced O O
cardiomyopathy O O
, O O
or O O
life O O
- O O
changing O O
late O O
effects O O
, O O
such O O
as O O
cognitive O O
dysfunction O O
. O O

The O O
presence O O
of O O
locus O O
- O O
specific O O
residues O O
throughout O O
the O O
entire O O
promoter O O
region O O
strongly O O
suggests O O
that O O
the O O
various O O
HLA B-GENE B-GENE
class I-GENE I-GENE
I I-GENE I-GENE
loci E-GENE E-GENE
are O O
differentially O O
regulated O O
. O O
Because O O
the O O
number O O
of O O
parameters O O
required O O
by O O
a O O
Volterra O O
series O O
grows O O
rapidly O O
with O O
both O O
the O O
length O O
of O O
its O O
memory O O
and O O
the O O
order O O
of O O
its O O
nonlinearity O O
, O O
methods O O
for O O
identifying O O
these O O
models O O
from O O
measurements O O
of O O
input O O
/ O O
output O O
data O O
are O O
limited O O
to O O
low O O
- O O
order O O
systems O O
with O O
relatively O O
short O O
memories O O
. O O

The O O
standard O O
method O O
for O O
calculating O O
the O O
composite O O
score O O
on O O
the O O
S O O
- O O
B O O
IV O O
excludes O O
subtests O O
with O O
a O O
raw O O
score O O
of O O
0 O O
, O O
which O O
overestimates O O
cognitive O O
functioning O O
in O O
young O O
biologically O O
high O O
risk O O
children O O
. O O

NiCl(2)-induced O O
MCP-1 S-GENE S-GENE
synthesis O O
required O O
activation O O
of O O
NF B-GENE B-GENE
- I-GENE I-GENE
kappaB E-GENE E-GENE
since O O
mutation O O
of O O
NF B-GENE B-GENE
- I-GENE I-GENE
kappaB I-GENE I-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
sites E-GENE E-GENE
in O O
the O O
promoter O O
resulted O O
in O O
complete O O
loss O O
of O O
inducible O B-GENE
promoter O E-GENE
activity O O
. O O
Engagement O O
of O O
human B-GENE B-GENE
CD2 E-GENE E-GENE
by O O
mitogenic O O
pairs O O
of O O
anti B-GENE B-GENE
- I-GENE I-GENE
CD2 I-GENE I-GENE
mAb E-GENE E-GENE
induces O O
tyrosine O O
phosphorylation O O
of O O
a O O
number O O
of O O
intracellular O O
proteins O O
including O O
a O O
120 O O
kDa O O
phosphoprotein O O
that O O
we O O
identify O O
as O O
the O O
proto B-GENE B-GENE
- I-GENE I-GENE
oncogene I-GENE I-GENE
c I-GENE I-GENE
- I-GENE I-GENE
Cbl E-GENE E-GENE
. O O
Validity O O
of O O
NIR O O
spectroscopy O O
for O O
quantitatively O O
measuring O O
muscle O O
oxidative O O
metabolic O O
rate O O
in O O
exercise O O
. O O

Previous O O
studies O O
have O O
demonstrated O O
that O O
tissue O B-GENE
- O I-GENE
restricted O I-GENE
transcription O I-GENE
factors O E-GENE
including O O
PU.1 S-GENE S-GENE
and O O
PU.1 B-GENE S-GENE
interaction I-GENE O
partner E-GENE O
( O O
PIP S-GENE S-GENE
) O O
function O O
synergistically O O
with O O
c B-GENE B-GENE
- I-GENE I-GENE
Fos E-GENE I-GENE
plus O I-GENE
c B-GENE I-GENE
- I-GENE I-GENE
Jun E-GENE E-GENE
to O O
stimulate O O
the O O
kappaE3'-enhancer S-GENE S-GENE
in O O
3T3 O O
cells O O
. O O
The O O
murine B-GENE B-GENE
int-6 I-GENE I-GENE
locus E-GENE E-GENE
, O O
identified O O
as O O
a O O
frequent O O
integration O O
site O O
of O O
mouse O O
mammary O O
tumor O O
viruses O O
, O O
encodes O O
the O O
48-kDa B-GENE B-GENE
eIF3e I-GENE I-GENE
subunit I-GENE E-GENE
of I-GENE O
translation I-GENE B-GENE
initiation I-GENE I-GENE
factor I-GENE I-GENE
eIF3 E-GENE E-GENE
. O O
An O O
int6 B-GENE O
deletion E-GENE O
( O O
int6Delta S-GENE S-GENE
) O O
mutant O O
was O O
viable O O
but O O
grew O O
slowly O O
in O O
minimal O O
medium O O
. O O
Additionally O O
, O O
MIP-2A S-GENE S-GENE
antagonizes O O
cell O O
growth O O
regulatory O O
role O O
of O O
MBP-1 S-GENE S-GENE
. O O
We O O
produced O O
transgenic O O
plants O O
expressing O O
the O O
antisense B-GENE B-GENE
Arabidopsis I-GENE I-GENE
HD E-GENE E-GENE
( O O
AtHD1 S-GENE O
) O O
gene O O
. O O
3.04+/-1.2 O O
, O O
P<0.0001 O O
) O O
, O O
large O O
accelerations/30 O O
min O O
( O O
1.46+/-1.96 O O
vs. O O

Four O O
transcription O O
initiation O O
sites O O
have O O
been O O
identified O O
by O O
full O O
- O O
length O O
RNA B-GENE B-GENE
ligase E-GENE E-GENE
- O O
mediated O O
rapid O O
amplification O O
of O O
cDNA O O
ends O O
( O O
RLM O B-GENE
- O I-GENE
RACE O E-GENE
) O O
between O O
-61 O O
and O O
-32 O O
bp O O
from O O
the O O
translation O O
initiation O O
codon O O
. O O
Reverse O B-GENE
transcription O I-GENE
- O I-GENE
PCR O E-GENE
analysis O O
revealed O O
that O O
PFK B-GENE S-GENE
- I-GENE O
A E-GENE O
, O O
PFK B-GENE B-GENE
- I-GENE I-GENE
B E-GENE E-GENE
and O O
PFK B-GENE B-GENE
- I-GENE I-GENE
C I-GENE I-GENE
genes E-GENE E-GENE
were O O
expressed O O
, O O
in O O
all O O
mouse O O
tissues O O
tested O O
, O O
at O O
varying O O
levels O O
. O O
PFK B-GENE B-GENE
- I-GENE I-GENE
A E-GENE I-GENE
mRNA O E-GENE
was O O
more O O
abundantly O O
expressed O O
in O O
all O O
tissues O O
than O O
were O O
the O O
PFK B-GENE B-GENE
- I-GENE I-GENE
B E-GENE E-GENE
and O O
PFK B-GENE B-GENE
- I-GENE I-GENE
C I-GENE I-GENE
genes E-GENE E-GENE
. O O
We O O
used O O
the O O
Toshiba O O
IIDR O O
system O O
, O O
which O O
is O O
composed O O
of O O
an O O
X O O
- O O
ray O O
TV O O
system O O
and O O
a O O
digital O O
image O O
managing O O
circuit O O
. O O

In O O
whole O O
sardine O O
, O O
domoic O O
acid O O
was O O
detected O O
in O O
levels O O
exceeding O O
sometimes O O
the O O
regulatory O O
limit O O
. O O

In O O
addition O O
, O O
we O O
identified O O
two O O
mutations O O
, O O
Delta O O
M1281 O O
and O O
IVS51 O O
+ O O
5G-->A O O
, O O
in O O
a O O
German O O
USH1 S-GENE O
patient O O
. O O
Closeup O O
: O O
a O O
resource O O
for O O
nurses O O
who O O
smoke O O
. O O

[ O O
18F](+)-4-fluorobenzyltrozamicol O O
( O O
FBT O S-GENE
) O O
, O O
which O O
selectively O O
binds O O
to O O
the O O
vesicular O B-GENE
acetylcholine B-GENE I-GENE
transporter E-GENE E-GENE
in O O
the O O
presynaptic O O
cholinergic O O
neuron O O
, O O
has O O
previously O O
been O O
shown O O
to O O
be O O
a O O
useful O O
ligand O O
for O O
the O O
study O O
of O O
cholinergic O O
terminal O O
density O O
in O O
the O O
basal O O
ganglia O O
with O O
PET O O
. O O
We O O
demonstrate O O
that O O
the O O
protein O O
is O O
a O O
murine B-GENE O
homologue I-GENE O
of I-GENE O
SAF I-GENE S-GENE
- I-GENE O
A E-GENE O
which O O
has O O
been O O
shown O O
to O O
bind O O
selectively O O
to O O
MARs O S-GENE
and O O
is O O
responsible O O
for O O
the O O
satMa S-GENE B-GENE
- O I-GENE
binding O E-GENE
activity O O
in O O
the O O
chromatographic O O
fractions O O
. O O
The O O
molecular O O
associations O O
dictating O O
INCENP S-GENE S-GENE
behavior O O
during O O
mitosis O O
are O O
currently O O
unknown O O
. O O
Ang B-GENE B-GENE
II E-GENE E-GENE
significantly O O
induced O O
Ang2 B-GENE B-GENE
mRNA E-GENE E-GENE
accumulations O O
without O O
affecting O O
Ang1 S-GENE S-GENE
or O O
Tie2 S-GENE O
expression O O
, O O
which O O
was O O
inhibited O O
by O O
protein B-GENE B-GENE
kinase I-GENE I-GENE
C E-GENE E-GENE
inhibitors O O
and O O
by O O
intracellular O O
Ca(2 O S-GENE
+ O O
) O O
chelating O O
agents O O
. O O
Promoter O O
analysis O O
demonstrated O O
that O O
the O O
sequence O O
identical O O
to O O
consensus O O
cAMP O B-GENE
- O I-GENE
responsive O I-GENE
element O E-GENE
( O O
CRE O O
) O O
located O O
at O O
-481 O O
of O O
the O O
SMemb B-GENE B-GENE
promoter E-GENE E-GENE
was O O
critical O O
for O O
Hex S-GENE S-GENE
responsiveness O O
. O O
LH B-GENE B-GENE
/ I-GENE I-GENE
CG I-GENE I-GENE
receptor E-GENE E-GENE
activation O O
of O O
ARNO S-GENE S-GENE
is O O
not O O
mediated O O
by O O
activation O O
of O O
phosphatidylinositol B-GENE B-GENE
3-kinase E-GENE E-GENE
( O O
PI B-GENE B-GENE
3-kinase E-GENE E-GENE
) O O
or O O
by O O
G B-GENE B-GENE
protein I-GENE I-GENE
beta I-GENE I-GENE
gamma I-GENE I-GENE
subunits E-GENE E-GENE
. O O
Deletion O O
analysis O O
showed O O
that O O
the O O
-321/+41 O S-GENE
sequence O O
was O O
sufficient O O
for O O
both O O
the O O
constitutive O B-GENE
promoter O E-GENE
activity O O
and O O
auto O O
- O O
activation O O
and O O
electrophoretic O O
mobility O O
shift O O
assays O O
identified O O
the O O
interaction O O
of O O
C B-GENE O
/ I-GENE O
EBPs E-GENE S-GENE
and O O
Sp1 S-GENE S-GENE
to O O
this O O
region O O
. O O
Termination O O
of O O
induced O O
VT O O
on O O
the O O
first O O
attempt O O
was O O
comparable O O
with O O
BV O O
pacing O O
( O O
87.4% O O
) O O
versus O O
RV O O
pacing O O
( O O
89.6% O O
) O O
. O O

We O O
compare O O
the O O
results O O
of O O
this O O
algorithm O O
with O O
the O O
results O O
obtained O O
with O O
two O O
other O O
algorithms O O
, O O
the O O
optimal O O
algorithm O O
for O O
monochannel O O
nonoverlapping O O
noise O O
and O O
the O O
optimal O O
algorithm O O
for O O
multichannel O O
additive O O
noise O O
, O O
and O O
we O O
show O O
that O O
in O O
both O O
cases O O
improvement O O
can O O
be O O
obtained O O
. O O

Changes O O
in O O
stimulation O O
levels O O
over O O
time O O
in O O
nucleus O O
22 O O
cochlear O O
implant O O
users O O
. O O

Nuclease O O
probing O O
and O O
structure O O
- O O
directed O O
mutagenesis O O
revealed O O
that O O
the O O
105-nt O O
TE O O
( O O
TE105 O O
) O O
forms O O
a O O
cruciform O O
secondary O O
structure O O
containing O O
four O O
helices O O
connected O O
by O O
single O O
- O O
stranded O O
regions O O
. O O

Tele O O
- O O
Talk O O
has O O
the O O
extra O O
capability O O
of O O
operating O O
in O O
live O O
conference O O
situations O O
using O O
microphone O O
input O O
. O O

A O O
marked O O
decrease O O
in O O
the O O
type B-GENE O
1 I-GENE O
insulin I-GENE B-GENE
- I-GENE I-GENE
like I-GENE I-GENE
growth I-GENE I-GENE
factor I-GENE E-GENE
( I-GENE O
IGF I-GENE S-GENE
) I-GENE O
receptor E-GENE S-GENE
( O O
IGF B-GENE B-GENE
- I-GENE I-GENE
IR E-GENE E-GENE
) O O
occurs O O
in O O
prostate O O
epithelial O O
cells O O
during O O
transformation O O
from O O
the O O
benign O O
to O O
the O O
metastatic O O
state O O
. O O
The O O
P69 O O
cell O O
line O O
was O O
derived O O
by O O
immortalization O O
of O O
human O O
primary O O
prostate O O
epithelial O O
cells O O
with O O
simian B-GENE B-GENE
virus-40 I-GENE I-GENE
T I-GENE I-GENE
antigen E-GENE E-GENE
and O O
is O O
rarely O O
tumorigenic O O
. O O
We O O
determined O O
whether O O
the O O
human B-GENE B-GENE
StAR I-GENE I-GENE
promoter E-GENE E-GENE
is O O
responsive O O
to O O
sterol B-GENE B-GENE
regulatory I-GENE I-GENE
element I-GENE I-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
proteins E-GENE E-GENE
( O O
SREBPs S-GENE S-GENE
) O O
. O O
Expression O O
of O O
SREBP-1a S-GENE S-GENE
stimulated O O
StAR B-GENE B-GENE
promoter E-GENE E-GENE
activity O O
in O O
the O O
context O O
of O O
COS-1 O O
cells O O
and O O
human O O
granulosa O O
- O O
lutein O O
cells O O
. O O
Because O O
the O O
high B-GENE B-GENE
- I-GENE I-GENE
density I-GENE I-GENE
lipoprotein I-GENE I-GENE
receptor E-GENE E-GENE
( O O
HDL B-GENE B-GENE
- I-GENE I-GENE
R E-GENE E-GENE
) O O
is O O
a O O
key O O
element O O
in O O
cholesterol O O
homeostasis O O
and O O
a O O
potential O O
therapeutic O O
target O O
for O O
hypercholesterolemic O O
drugs O O
, O O
an O O
understanding O O
of O O
HDL O B-GENE
- O I-GENE
R O E-GENE
regulation O O
is O O
essential O O
. O O
IFN B-GENE B-GENE
- I-GENE I-GENE
stimulated I-GENE I-GENE
gene I-GENE I-GENE
factor-3 E-GENE E-GENE
and O O
STAT1 B-GENE S-GENE
homodimers E-GENE O
formed O O
and O O
bound O O
an O O
IFN B-GENE B-GENE
- I-GENE I-GENE
stimulated I-GENE I-GENE
response I-GENE I-GENE
element E-GENE E-GENE
( O O
ISRE S-GENE S-GENE
) O O
and O O
gamma B-GENE B-GENE
- I-GENE I-GENE
activated I-GENE I-GENE
sequence E-GENE E-GENE
( O O
GAS S-GENE O
) O O
element O O
, O O
respectively O O
. O O
We O O
have O O
therefore O O
studied O O
the O O
molecular O O
mechanisms O O
of O O
TGF B-GENE B-GENE
- I-GENE I-GENE
beta1 E-GENE E-GENE
action O O
on O O
thyroglobulin S-GENE S-GENE
( O O
TG O S-GENE
) O O
gene O O
expression O O
by O O
focusing O O
our O O
attention O O
on O O
TGF O B-GENE
- O I-GENE
beta1 O E-GENE
regulation O O
of O O
thyroid O B-GENE
- O I-GENE
specific O I-GENE
transcription O I-GENE
factors O E-GENE
. O O
The O O
epitope O O
- O O
protected O O
lysine O O
( O O
K O S-GENE
) O O
was O O
present O O
in O O
a O O
30-aa B-GENE O
TPO I-GENE S-GENE
fragment E-GENE O
that O O
, O O
by O O
N O O
- O O
terminal O O
sequencing O O
, O O
was O O
found O O
to O O
be O O
K713 O S-GENE
. O O
To O O
understand O O
the O O
molecular O O
regulation O O
of O O
these O O
genes O O
in O O
thyroid O O
cells O O
, O O
the O O
effect O O
of O O
thyroid B-GENE B-GENE
transcription I-GENE I-GENE
factor I-GENE I-GENE
1 E-GENE E-GENE
( O O
TTF-1 S-GENE S-GENE
) O O
and O O
the O O
paired B-GENE O
domain I-GENE O
- I-GENE O
containing I-GENE O
protein I-GENE O
8 E-GENE O
( O O
Pax-8 S-GENE S-GENE
) O O
on O O
the O O
transcriptional O O
activity O O
of O O
the O O
deiodinase B-GENE B-GENE
promoters E-GENE E-GENE
were O O
studied O O
. O O
Regional O O
blood O O
blow O O
was O O
measured O O
by O O
means O O
of O O
microspheres O O
in O O
predefined O O
regions O O
of O O
the O O
C6 O O
, O O
T11 O O
, O O
and O O
L6 O O
vertebrae O O
. O O

Activation O O
of O O
transcription O O
through O O
the O O
AP-1 B-GENE B-GENE
site E-GENE E-GENE
in O O
Jurkat O O
cells O O
by O O
JunD S-GENE O
and/or O O
Fra-2 S-GENE S-GENE
was O O
weak O O
. O O
c B-GENE B-GENE
- I-GENE I-GENE
Jun E-GENE E-GENE
, O O
JunB S-GENE S-GENE
, O O
and O O
c B-GENE B-GENE
- I-GENE I-GENE
Fos E-GENE E-GENE
activation O O
was O O
greater O O
, O O
although O O
the O O
level O O
was O O
still O O
less O O
than O O
that O O
with O O
Tax S-GENE O
. O O
The O O
mechanism O O
of O O
ligand O B-GENE
- O I-GENE
activated O I-GENE
estrogen B-GENE I-GENE
receptor I-GENE I-GENE
alpha E-GENE E-GENE
( O O
ERalpha)-dependent O S-GENE
activation O O
of O O
gene O O
expression O O
through O O
the O O
SRE O S-GENE
was O O
determined O O
by O O
mutational O O
analysis O O
of O O
the O O
promoter O O
, O O
analysis O O
of O O
mitogen B-GENE B-GENE
- I-GENE I-GENE
activated I-GENE I-GENE
protein I-GENE I-GENE
kinase E-GENE E-GENE
( O O
MAPK S-GENE S-GENE
) O O
pathway O O
activation O O
by O O
E2 O O
, O O
and O O
transforming B-GENE B-GENE
growth I-GENE I-GENE
factor I-GENE I-GENE
alpha E-GENE E-GENE
( O O
TGF B-GENE B-GENE
- I-GENE I-GENE
alpha E-GENE E-GENE
) O O
as O O
a O O
positive O O
control O O
. O O
Perfusion O O
technique O O
for O O
perfusion O O
- O O
assisted O O
direct O O
coronary O O
artery O O
bypass O O
( O O
PADCAB O O
) O O
. O O

As O O
well O O
, O O
mixtures O O
of O O
( O O
LA)(12 O O
) O O
with O O
the O O
longer O O
chain O O
PEs O O
exhibit O O
unusual O O
biomodal O O
enthalpy O O
variations O O
, O O
suggesting O O
peptide O O
immiscibility O O
in O O
thicker O O
gel O O
state O O
bilayers O O
. O O

CONCLUSIONS O O
: O O
Under O O
current O O
immunization O O
practices O O
, O O
the O O
authors O O
estimate O O
that O O
nearly O O
13,000 O O
Asian O O
and O O
Pacific O O
Islander O O
children O O
living O O
in O O
the O O
United O O
States O O
today O O
will O O
become O O
infected O O
with O O
HBV O O
in O O
the O O
future O O
, O O
resulting O O
in O O
more O O
than O O
600 O O
liver O O
carcinoma O O
deaths O O
. O O

We O O
observed O O
NP S-GENE O
/ O O
NMP4/CIZ O S-GENE
expression O O
in O O
osteocytes O O
, O O
osteoblasts O O
, O O
and O O
chondrocytes O O
in O O
rat O O
bone O O
. O O
Chlamydia O O
and O O
cervical O O
cancer O O
: O O
a O O
real O O
association O O
? O O

A O O
novel O O
approach O O
was O O
developed O O
for O O
identifying O O
transcription O B-GENE
factor O E-GENE
activities O O
associated O O
with O O
NGF S-GENE B-GENE
- O I-GENE
activated O E-GENE
, O O
but O O
not O O
EGF S-GENE B-GENE
- O I-GENE
activated O E-GENE
, O O
signaling O O
, O O
using O O
random O O
oligonucleotide O O
clones O O
from O O
a O O
DNA O O
recognition O O
library O O
to O O
isolate O O
specific O O
DNA O O
binding O O
proteins O O
from O O
PC12 O B-GENE
nuclear O I-GENE
extracts O E-GENE
. O O
NGF S-GENE S-GENE
elicits O O
a O O
more O O
delayed O O
and O O
sustained O O
ERK S-GENE S-GENE
phosphorylation O O
than O O
EGF S-GENE S-GENE
, O O
consistent O O
with O O
previous O O
reports O O
. O O
NGF S-GENE S-GENE
, O O
but O O
not O O
EGF S-GENE S-GENE
, O O
enhances O O
the O O
upper O O
bands O O
, O O
corresponding O O
to O O
phosphorylated B-GENE O
Fra-2 E-GENE O
. O O
Energy O O
expenditure O O
was O O
obtained O O
using O O
a O O
primed O O
, O O
3-hour O O
infusion O O
of O O
NaH(13)CO(3 O O
' O O
) O O
, O O
breath O O
( O O
13)CO(2 O O
) O O
enrichment O O
determination O O
by O O
isotope O O
ratio O O
mass O O
spectroscopy O O
, O O
and O O
the O O
application O O
of O O
a O O
standard O O
regression O O
equation O O
. O O

Workload O O
, O O
UAPs O O
, O O
and O O
you O O
. O O

The O O
actA B-GENE B-GENE
gene E-GENE E-GENE
is O O
present O O
as O O
a O O
single O O
copy O O
in O O
the O O
genome O O
of O O
A. O O
chrysogenum O O
; O O
and O O
its O O
expression O O
level O O
, O O
opposite O O
to O O
pcbC S-GENE O
and O O
cefEF B-GENE B-GENE
cephalosporin I-GENE I-GENE
biosynthetic I-GENE I-GENE
genes E-GENE E-GENE
, O O
was O O
steady O O
during O O
cephalosporin O O
fermentation O O
, O O
showing O O
a O O
single O O
1.4-kb O O
transcript O O
. O O
Adding O O
10 O O
mmol O O
SDS O O
/ O O
l O O
led O O
to O O
transient O O
inhibition O O
of O O
acidification O O
, O O
metal O O
solubilization O O
and O O
sulfur O O
oxidation O O
. O O

We O O
have O O
investigated O O
the O O
role O O
of O O
NGF S-GENE S-GENE
in O O
regulating O O
gene O O
transcription O O
in O O
PC12 O S-GENE
and O O
INS-1 O S-GENE
cells O O
, O O
in O O
order O O
to O O
define O O
if O O
there O O
are O O
NGF O B-GENE
- O I-GENE
regulated O I-GENE
genes O E-GENE
per O O
se O O
. O O
Nine O O
animals O O
served O O
as O O
control O O
animals O O
, O O
whereas O O
20 O O
animals O O
received O O
a O O
focal O O
arachnoid O O
scar O O
at O O
C1-C2 O O
, O O
which O O
was O O
produced O O
by O O
placement O O
of O O
a O O
kaolin O O
- O O
soaked O O
fibrin S-GENE S-GENE
sponge O O
on O O
the O O
posterior O O
surface O O
of O O
the O O
spinal O O
cord O O
. O O
The O O
Schistosoma B-GENE B-GENE
mansoni I-GENE I-GENE
homologue E-GENE E-GENE
( O O
SmSmad2 S-GENE S-GENE
) O O
was O O
overexpressed O O
in O O
bacteria O O
as O O
a O O
Sj26-GST O B-GENE
fusion O I-GENE
protein O E-GENE
and O O
used O O
to O O
raise O O
specific O O
antibodies O O
. O O
These O O
data O O
indicate O O
that O O
the O O
SmSmad2 S-GENE S-GENE
responds O O
to O O
the O O
TGF B-GENE B-GENE
- I-GENE I-GENE
beta E-GENE E-GENE
signals O O
by O O
interaction O O
with O O
receptor B-GENE B-GENE
I E-GENE E-GENE
, O O
which O O
phosphorylates O O
it O O
, O O
whereupon O O
it O O
translocates O O
into O O
the O O
nucleus O O
presumably O O
to O O
regulate O O
target O O
gene O O
transcription O O
and O O
consequently O O
elicit O O
a O O
specific O O
TGF O B-GENE
- O I-GENE
beta O E-GENE
effect O O
. O O
Intact O O
Flag O B-GENE
- O I-GENE
tagged O I-GENE
protein O I-GENE
products O E-GENE
from O O
all O O
six O O
were O O
produced O O
from O O
genomic O O
expression O O
vectors O O
, O O
although O O
the O O
ORF40/41 O B-GENE
transcript O E-GENE
encoding O O
a O O
primase S-GENE B-GENE
- O I-GENE
helicase S-GENE E-GENE
component O O
proved O O
to O O
be O O
spliced O O
with O O
a O O
127-bp O B-GENE
intron O E-GENE
. O O
Expression O O
of O O
the O O
src B-GENE B-GENE
homology I-GENE I-GENE
3 E-GENE E-GENE
( O O
SH3)-encoding O S-GENE
, O O
expressed O O
in O O
tumorigenic O O
astrocytes O O
( O O
SETA S-GENE S-GENE
) O O
gene O O
is O O
associated O O
with O O
astrocyte O O
transformation O O
in O O
culture O O
and O O
tumors O O
in O O
the O O
adult O O
brain O O
. O O
Naltrexone O O
hydrochloride O O
is O O
a O O
synthetic O O
opioid B-GENE B-GENE
receptor E-GENE E-GENE
antagonist O O
recently O O
used O O
in O O
efforts O O
to O O
provide O O
rapid O O
opioid O O
detoxification O O
. O O
METHODS O O
: O O
One O O
hundred O O
fourteen O O
consecutive O O
patients O O
( O O
mean O O
age O O
61 O O
years O O
) O O
with O O
focal O O
pancreatic O O
masses O O
, O O
detected O O
on O O
CT O O
, O O
underwent O O
EUS O O
- O O
FNA O O
by O O
using O O
a O O
linear O O
- O O
array O O
echoendoscope O O
and O O
22-gauge O O
needles O O
. O O

METHODS O O
: O O
Thyroid O O
status O O
was O O
measured O O
at O O
baseline O O
( O O
1990 O O
- O O
93 O O
) O O
, O O
through O O
assessment O O
of O O
serum O B-GENE
antibodies O E-GENE
to O O
thyroid B-GENE B-GENE
peroxidase E-GENE E-GENE
( O O
TPO B-GENE B-GENE
- I-GENE I-GENE
Abs E-GENE E-GENE
, O O
positive O O
: O O
> O O
10 O O
IU O O
/ O O
ml O O
) O O
, O O
serum S-GENE B-GENE
TSH S-GENE E-GENE
levels O O
, O O
and O O
when O O
TSH O S-GENE
was O O
abnormal O O
( O O
< O O
0.4 O O
or O O
> O O
4.0 O O
mU O O
/ O O
l O O
) O O
, O O
serum B-GENE B-GENE
thyroxin E-GENE E-GENE
levels O O
( O O
T4 O O
) O O
. O O
We O O
suggest O O
that O O
ventriculopleural O O
shunting O O
should O O
be O O
considered O O
as O O
the O O
preferred O O
alternative O O
to O O
peritoneal O O
drainage O O
in O O
children O O
with O O
intra O O
- O O
abdominal O O
adhesions O O
or O O
with O O
a O O
history O O
of O O
recent O O
peritoneal O O
infection O O
. O O

Derivation O O
and O O
initial O O
characterization O O
of O O
a O O
mouse O O
mammary O O
tumor O O
cell O O
line O O
carrying O O
the O O
polyomavirus B-GENE O
middle I-GENE O
T I-GENE B-GENE
antigen E-GENE E-GENE
: O O
utility O O
in O O
the O O
development O O
of O O
novel O O
cancer O O
therapeutics O O
. O O
TBARS O O
levels O O
, O O
oxygen O O
- O O
radical O O
absorbing O O
capacity O O
assay O O
and O O
AFR O O
release O O
assessed O O
by O O
electron O O
paramagnetic O O
resonance O O
( O O
EPR O O
) O O
were O O
used O O
to O O
explore O O
the O O
existence O O
of O O
oxidative O O
stress O O
in O O
diabetes O O
. O O

Long O O
- O O
range O O
comparison O O
of O O
human B-GENE O
and I-GENE O
mouse I-GENE B-GENE
SCL I-GENE I-GENE
loci E-GENE E-GENE
: O O
localized O O
regions O O
of O O
sensitivity O O
to O O
restriction O O
endonucleases O O
correspond O O
precisely O O
with O O
peaks O O
of O O
conserved O O
noncoding O O
sequences O O
. O O
To O O
account O O
for O O
this O O
observation O O
, O O
other O O
possible O O
causes O O
include O O
increased O O
CSF O O
pulsation O O
in O O
children O O
creating O O
motion O O
artifact O O
, O O
changes O O
in O O
arterial O O
oxygen O O
concentration O O
intrinsic O O
to O O
propofol O O
or O O
related O O
to O O
the O O
supplemental O O
oxygen O O
normally O O
administered O O
, O O
or O O
changes O O
in O O
CSF O B-GENE
protein O E-GENE
levels O O
related O O
to O O
propofol O O
binding O O
to O O
proteins O O
for O O
uptake O O
into O O
CSF O O
. O O

The O O
utilities O O
measured O O
in O O
our O O
study O O
can O O
be O O
applied O O
directly O O
to O O
quality O O
- O O
of O O
- O O
life O O
determinations O O
in O O
clinical O O
trials O O
of O O
adjuvant O O
IFN B-GENE B-GENE
alpha-2b E-GENE E-GENE
to O O
measure O O
the O O
net O O
benefit O O
of O O
therapy O O
. O O
Serum B-GENE B-GENE
PTH E-GENE E-GENE
tended O O
to O O
increase O O
in O O
the O O
WL O O
group O O
but O O
not O O
in O O
the O O
WM O O
group O O
( O O
P O O
< O O
0.06 O O
) O O
. O O
Structure O O
of O O
the O O
EMAPII B-GENE B-GENE
domain E-GENE E-GENE
of O O
human B-GENE B-GENE
aminoacyl I-GENE I-GENE
- I-GENE I-GENE
tRNA I-GENE I-GENE
synthetase I-GENE E-GENE
complex E-GENE O
reveals O O
evolutionary O O
dimer O O
mimicry O O
. O O
Hypomorphic O B-GENE
dSLBP B-GENE I-GENE
alleles E-GENE E-GENE
support O O
zygotic O O
development O O
but O O
cause O O
female O O
sterility O O
. O O
We O O
mapped O O
the O O
DGCR6 B-GENE B-GENE
gene E-GENE E-GENE
to O O
chromosome O O
22q11 O O
within O O
a O O
low O O
copy O O
repeat O O
, O O
termed O O
sc11.1a O O
, O O
and O O
identified O O
a O O
second O O
copy O O
of O O
the O O
gene O O
, O O
DGCR6L S-GENE S-GENE
, O O
within O O
the O O
duplicate O O
locus O O
, O O
termed O O
sc11.1b O O
. O O
METHODS O O
: O O
The O O
passive O O
and O O
active O O
transport O O
of O O
fluorescein O O
through O O
the O O
BRB O O
was O O
quantitated O O
by O O
vitreous O O
fluorometry O O
. O O

Nerve B-GENE B-GENE
growth I-GENE I-GENE
factor E-GENE E-GENE
( O O
NGF S-GENE S-GENE
) O O
and O O
retinoic O O
acid O O
( O O
RA O S-GENE
) O O
exert O O
important O O
actions O O
on O O
PC12 O O
cells O O
. O O
Recruitment O O
of O O
an O O
RNA B-GENE B-GENE
polymerase I-GENE I-GENE
II I-GENE I-GENE
complex E-GENE E-GENE
is O O
mediated O O
by O O
the O O
constitutive O O
activation O O
domain O O
in O O
CREB S-GENE S-GENE
, O O
independently O O
of O O
CREB O S-GENE
phosphorylation O O
. O O
The O O
region O O
containing O O
both O O
serines O O
is O O
homologous O O
to O O
the O O
N O O
- O O
terminal O O
destruction O O
box O O
of O O
IkappaBalpha B-GENE S-GENE
, I-GENE O
-beta I-GENE O
, I-GENE O
and I-GENE O
-epsilon E-GENE O
. O O
This O O
function O O
requires O O
not O O
only O O
the O O
kinase O B-GENE
domain O E-GENE
of O O
Csk S-GENE S-GENE
, O O
but O O
also O O
its O O
Src B-GENE S-GENE
homology I-GENE O
3 E-GENE O
( O O
SH3 S-GENE S-GENE
) O O
and O O
SH2 S-GENE S-GENE
regions O O
. O O
Furthermore O O
, O O
we O O
showed O O
that O O
ERSF S-GENE S-GENE
including O O
NF B-GENE B-GENE
- I-GENE I-GENE
Y E-GENE E-GENE
and O O
ATF6alpha B-GENE S-GENE
and/or I-GENE O
beta E-GENE O
and O O
capable O O
of O O
binding O O
to O O
ERSE O S-GENE
is O O
indeed O O
formed O O
when O O
the O O
cellular O O
UPR O S-GENE
is O O
activated O O
. O O
The O O
observed O O
phenotypes O O
may O O
be O O
explained O O
by O O
( O O
i O O
) O O
a O O
selective O O
disruption O O
of O O
very B-GENE O
- I-GENE O
low I-GENE O
- I-GENE O
density I-GENE O
lipoprotein E-GENE O
secretion O O
due O O
to O O
decreased O O
expression O O
of O O
genes O B-GENE
encoding O I-GENE
apolipoprotein B-GENE I-GENE
B E-GENE E-GENE
and O O
microsomal B-GENE B-GENE
triglyceride I-GENE I-GENE
transfer I-GENE I-GENE
protein E-GENE E-GENE
, O O
( O O
ii O O
) O O
an O O
increase O O
in O O
hepatic O O
cholesterol O O
uptake O O
due O O
to O O
increased O O
expression O O
of O O
the O O
major O O
high B-GENE O
- I-GENE O
density I-GENE O
lipoprotein I-GENE B-GENE
receptor E-GENE E-GENE
, O O
scavenger B-GENE B-GENE
receptor I-GENE I-GENE
BI E-GENE E-GENE
, O O
and O O
( O O
iii O O
) O O
a O O
decrease O O
in O O
bile O O
acid O O
uptake O O
to O O
the O O
liver O O
due O O
to O O
down O O
- O O
regulation O O
of O O
the O O
major O O
basolateral B-GENE O
bile I-GENE O
acid I-GENE O
transporters I-GENE O
sodium I-GENE O
taurocholate I-GENE B-GENE
cotransporter I-GENE I-GENE
protein E-GENE E-GENE
and O O
organic B-GENE B-GENE
anion I-GENE I-GENE
transporter I-GENE I-GENE
protein I-GENE I-GENE
1 E-GENE E-GENE
. O O
These O O
effects O O
were O O
not O O
seen O O
with O O
SHIP2 S-GENE S-GENE
possessing O O
a O O
mutation O O
in O O
the O O
SH2 B-GENE B-GENE
domain E-GENE E-GENE
( O O
R47 B-GENE B-GENE
G E-GENE E-GENE
) O O
. O O
The O O
gonadotrope O O
- O O
specific O O
and O O
regulated O O
expression O O
of O O
the O O
GnRH B-GENE B-GENE
receptor E-GENE E-GENE
( O O
GnRH B-GENE B-GENE
- I-GENE I-GENE
R E-GENE I-GENE
) O I-GENE
gene O E-GENE
is O O
dependent O O
on O O
multiple O O
transcription O O
factors O O
that O O
interact O O
with O O
the O O
noncanonical B-GENE O
GnRH I-GENE B-GENE
- I-GENE I-GENE
R I-GENE I-GENE
activating I-GENE I-GENE
sequence E-GENE E-GENE
( O O
GRAS S-GENE S-GENE
) O O
, O O
the O O
activator B-GENE B-GENE
protein-1 E-GENE E-GENE
( O O
AP-1 S-GENE S-GENE
) O O
element O O
, O O
and O O
the O O
steroidogenic B-GENE B-GENE
factor-1 E-GENE E-GENE
( O O
SF-1 S-GENE B-GENE
) O I-GENE
binding O I-GENE
site O E-GENE
. O O
METHODS O O
: O O
A O O
structured O O
interview O O
was O O
undertaken O O
at O O
the O O
time O O
of O O
initial O O
consultation O O
and O O
at O O
subsequent O O
1-year O O
intervals O O
regarding O O
type O O
of O O
BHS O O
, O O
frequency O O
of O O
spells O O
, O O
associated O O
phenomenon O O
, O O
sequelae O O
, O O
family O O
history O O
, O O
and O O
age O O
at O O
termination O O
of O O
spells O O
. O O

In O O
three O O
cases O O
( O O
21.4% O O
) O O
, O O
the O O
MR O O
imaging O O
was O O
interpreted O O
as O O
negative O O
, O O
but O O
microscopic O O
tumor O O
was O O
shown O O
around O O
seroma O O
on O O
reexcision O O
. O O

Methylation O O
at O O
both O O
cytosine O O
residues O O
in O O
the O O
E2F S-GENE B-GENE
element O E-GENE
( O O
( O O
m)CG(m)CG O S-GENE
) O O
generated O O
a O O
new O O
methylcytosine O O
- O O
specific O O
DNA O B-GENE
- O I-GENE
protein O I-GENE
complex O E-GENE
. O O
These O O
mutations O O
, O O
when O O
placed O O
in O O
a O O
wild B-GENE O
- I-GENE O
type I-GENE O
fliF E-GENE O
background O O
, O O
had O O
no O O
mutant O O
phenotype O O
. O O
As O O
well O O
, O O
IFN B-GENE B-GENE
- I-GENE I-GENE
gamma E-GENE E-GENE
- O O
induced O O
expression O O
of O O
IRF-1 S-GENE S-GENE
and O O
its O O
binding O O
to O O
the O O
IRF B-GENE B-GENE
element E-GENE E-GENE
is O O
inhibited O O
. O O
This O O
molecule O O
, O O
wH22xeGFP S-GENE S-GENE
, O O
consists O O
of O O
the O O
entire B-GENE O
humanized I-GENE O
anti I-GENE B-GENE
- E-GENE I-GENE
FcgammaRI B-GENE I-GENE
mAb E-GENE I-GENE
H22 O E-GENE
with O O
eGFP O S-GENE
genetically O O
fused O O
to O O
the O O
C O O
- O O
terminal O O
end O O
of O O
each O O
CH3 B-GENE B-GENE
domain E-GENE E-GENE
. O O
wH22xeGFP O S-GENE
binds O O
within O O
the O O
ligand O O
- O O
binding O O
region O O
by O O
its O O
Fc O O
end O O
, O O
as O O
well O O
as O O
outside O O
the O O
ligand O O
- O O
binding O O
region O O
by O O
its O O
Fab S-GENE O
ends O O
, O O
thereby O O
cross O O
- O O
linking O O
FcgammaRI O S-GENE
. O O
Inactivity O O
of O O
the O O
human B-GENE B-GENE
cytomegalovirus I-GENE E-GENE
( I-GENE O
HCMV I-GENE S-GENE
) I-GENE O
major I-GENE O
immediate I-GENE O
- I-GENE O
early I-GENE O
regulatory I-GENE O
region E-GENE O
( O O
MIERR S-GENE S-GENE
) O O
, O O
which O O
is O O
composed O O
of O O
promoter O O
, O O
enhancer O O
, O O
unique O O
region O O
, O O
and O O
modulator O O
, O O
is O O
linked O O
to O O
lack O O
of O O
HCMV O O
replication O O
in O O
latently O O
infected O O
cells O O
and O O
in O O
other O O
nonpermissive O O
cell O O
types O O
, O O
including O O
human O O
embryonal O O
NTera2 O S-GENE
carcinoma O O
( O O
NT2 O S-GENE
) O O
cells O O
. O O
This O O
interaction O O
is O O
reciprocal O O
, O O
since O O
C B-GENE O
/ I-GENE O
EBP I-GENE O
dimer E-GENE O
binding O O
to O O
a O O
strong O O
C B-GENE O
/ I-GENE O
EBP I-GENE B-GENE
site E-GENE E-GENE
leads O O
to O O
enhanced O O
CREB-1 S-GENE S-GENE
recruitment O O
to O O
ATF S-GENE S-GENE
/ O O
CREB O B-GENE
sites O E-GENE
that O O
are O O
weakly O O
bound O O
by O O
CREB O S-GENE
. O O
The O O
metabolic O O
events O O
occurring O O
at O O
or O O
near O O
that O O
structure O O
and O O
involving O O
cyclin B-GENE B-GENE
D3 E-GENE E-GENE
cause O O
the O O
translocation O O
of O O
ICP0 S-GENE S-GENE
to O O
the O O
cytoplasm O O
. O O
Transient O O
transfections O O
showed O O
that O O
a O O
single O O
mutation O O
( O O
556 O O
M O O
) O O
decreased O O
TBLV B-GENE B-GENE
enhancer E-GENE E-GENE
activity O O
at O O
least O O
20-fold O O
in O O
two O O
different O O
T O O
- O O
cell O O
lines O O
. O O
Vector O O
stocks O O
containing O O
envelope B-GENE O
proteins E-GENE O
from O O
three O O
different O O
SIVmac O S-GENE
clones O O
, O O
namely O O
, O O
SIVmac239 O S-GENE
( O O
T O O
- O O
lymphocyte O O
tropic O O
[ O O
T O O
- O O
tropic O O
] O O
) O O
, O O
SIVmac316 O O
( O O
macrophage O O
tropic O O
[ O O
M O O
- O O
tropic O O
] O O
) O O
, O O
and O O
SIVmac1A11 O O
( O O
dualtropic O O
) O O
, O O
were O O
tested O O
. O O
Quantitative O O
PCR O O
studies O O
indicated O O
that O O
synthesis O O
and O O
transport O O
of O O
vector O O
DNA O O
into O O
the O O
nucleus O O
were O O
similar O O
for O O
macrophages O O
infected O O
with O O
the O O
clone O O
239 O O
and O O
316 O O
pseudotypes O O
, O O
suggesting O O
that O O
the O O
restriction O O
for O O
SIVmac239 O O
infection O O
is O O
after O O
reverse O O
transcription O O
and O O
nuclear O O
import O O
of O O
viral O O
DNA O O
. O O

Thus O O
, O O
the O O
anti B-GENE B-GENE
- I-GENE I-GENE
interferon E-GENE E-GENE
functions O O
of O O
vIRF-2 S-GENE S-GENE
may O O
contribute O O
to O O
the O O
establishment O O
of O O
a O O
chronic O O
or O O
latent O O
infection O O
. O O
Both O O
Z S-GENE O
and O O
R S-GENE O
expression O O
resulted O O
in O O
PML O O
dispersion O O
in O O
EBV O O
- O O
positive O O
cells O O
. O O
Interestingly O O
, O O
the O O
activity O O
of O O
IkappaB B-GENE B-GENE
kinase E-GENE E-GENE
( O O
IKK B-GENE B-GENE
- I-GENE I-GENE
beta E-GENE E-GENE
) O O
, O O
which O O
plays O O
an O O
essential O O
role O O
in O O
NF B-GENE B-GENE
- I-GENE I-GENE
kappaB E-GENE E-GENE
activation O O
through O O
IkappaB O S-GENE
phosphorylation O O
, O O
was O O
largely O O
enhanced O O
in O O
paclitaxel O O
- O O
treated O O
cells O O
, O O
detected O O
as O O
IkappaBalpha S-GENE B-GENE
phosphorylation O E-GENE
. O O
Immunofluorescence O O
studies O O
in O O
C2C12 O O
myotubes O O
show O O
that O O
Smad2 S-GENE S-GENE
and O O
MEF2A S-GENE S-GENE
co O O
- O O
localise O O
in O O
the O O
nucleus O O
of O O
multinuclear O O
myotubes O O
during O O
differentiation O O
. O O
We O O
propose O O
that O O
TFOs O S-GENE
represent O O
a O O
therapeutic O O
potential O O
to O O
specifically O O
diminish O O
the O O
expression O O
of O O
c B-GENE B-GENE
- I-GENE I-GENE
sis E-GENE I-GENE
/ O I-GENE
PDGF B-GENE I-GENE
- I-GENE I-GENE
B E-GENE I-GENE
proto O I-GENE
- O I-GENE
oncogene O E-GENE
in O O
various O O
pathologic O O
settings O O
where O O
constitutive O O
expression O O
of O O
this O O
gene O O
has O O
been O O
observed O O
. O O
Rapid O O
evolution O O
of O O
the O O
DNA O B-GENE
- O I-GENE
binding O I-GENE
site O E-GENE
in O O
LAGLIDADG B-GENE B-GENE
homing I-GENE I-GENE
endonucleases E-GENE E-GENE
. O O
Southern O O
blot O O
analysis O O
of O O
genomic O O
DNA O O
from O O
somatic O O
cell O O
hybrids O O
showed O O
that O O
endothelial B-GENE O
- I-GENE O
TACC I-GENE O
- I-GENE O
related I-GENE O
cDNA E-GENE O
maps O O
to O O
chromosome O O
10 O O
. O O
Copyright O O
2001 O O
Academic O O
Press O O
. O O

The O O
presence O O
of O O
truncated O B-GENE
receptor O I-GENE
isoforms O E-GENE
in O O
diverse O O
species O O
suggests O O
that O O
these O O
proteins O O
may O O
have O O
important O O
functional O O
roles O O
in O O
regulating O O
EGFR S-GENE S-GENE
activity O O
. O O
Interestingly O O
, O O
the O O
similarities O O
with O O
the O O
endophilin B-GENE B-GENE
proteins E-GENE E-GENE
cover O O
the O O
entire O O
sequence O O
of O O
the O O
SH3GLB B-GENE B-GENE
family E-GENE E-GENE
, O O
suggesting O O
a O O
common O O
fold O O
and O O
presumably O O
a O O
common O O
mode O O
of O O
action O O
. O O
Mental O O
rotation O O
of O O
paired O O
figures O O
engendered O O
activation O O
in O O
the O O
left O O
superior O O
parietal O O
lobule O O
and O O
the O O
right O O
frontal O O
medial O O
gyrus O O
. O O

We O O
also O O
reported O O
the O O
identification O O
of O O
three O O
corresponding O O
alternative O O
first O O
exons O O
and O O
an O O
intronic O O
promoter O O
in O O
the O O
human B-GENE B-GENE
PDE5A I-GENE I-GENE
gene E-GENE E-GENE
. O O
The O O
glucose O O
/ O O
insulin S-GENE S-GENE
stimulation O O
was O O
inhibited O O
by O O
the O O
addition O O
of O O
polyunsaturated O O
fatty O O
acids O O
. O O
The O O
continuing O O
development O O
of O O
ligands O O
that O O
function O O
as O O
selective O O
estrogens O O
or O O
antiestrogens O O
for O O
ERalpha S-GENE S-GENE
or O O
ERbeta S-GENE O
should O O
allow O O
optimized O O
tissue O O
selectivity O O
of O O
these O O
agents O O
for O O
menopausal O B-GENE
hormone O E-GENE
replacement O O
therapy O O
and O O
the O O
treatment O O
and O O
prevention O O
of O O
breast O O
cancer O O
. O O
Behavioural O O
tests O O
with O O
192 O O
specimen O O
of O O
the O O
roman O O
garden O O
snail O O
Helix O O
pomatia O O
L. O O
were O O
performed O O
in O O
order O O
to O O
clarify O O
whether O O
the O O
thermopreferendum O O
of O O
this O O
pulmonate O O
is O O
influenced O O
not O O
only O O
by O O
the O O
temperature O O
of O O
the O O
substratum O O
but O O
also O O
by O O
air O O
temperature O O
. O O

In O O
the O O
present O O
work O O
, O O
the O O
complete O O
genome O O
sequences O O
of O O
Pyrococcus O B-GENE
horikoshii O E-GENE
and O O
Pyrococcus O B-GENE
abyssi O E-GENE
, O O
two O O
species O O
in O O
a O O
genus O O
of O O
hyperthermophilic O O
archaeon O O
( O O
archaebacterium O O
) O O
, O O
were O O
compared O O
to O O
detect O O
large O O
genome O O
polymorphisms O O
linked O O
with O O
restriction O O
- O O
modification O O
gene O O
homologs O O
. O O

This O O
animal O O
model O O
of O O
dystonia O O
appears O O
to O O
be O O
a O O
model O O
of O O
NAD O O
in O O
man O O
from O O
the O O
viewpoint O O
of O O
treatment O O
- O O
response O O
. O O

Peripheral O O
and O O
preemptive O O
opioid O O
antinociception O O
in O O
a O O
mouse O O
visceral O O
pain O O
model O O
. O O

Twenty O O
- O O
six O O
( O O
55% O O
) O O
( O O
95% O O
CI O O
, O O
41 O O
- O O
69% O O
) O O
patients O O
experienced O O
> O O
or O O
= O O
grade O O
3 O O
acute O O
toxicity O O
( O O
RTOG O O
) O O
. O O

No O O
' O O
TATA O O
' O O
motif O O
was O O
identified O O
near O O
either O O
the O O
GABPalpha S-GENE O
or O O
ATPsynCF6 S-GENE B-GENE
transcription O I-GENE
start O I-GENE
sites O E-GENE
. O O
Significantly O O
higher O O
lung O O
function O O
parameters O O
were O O
obtained O O
in O O
extubated O O
recipients O O
of O O
LPD O O
preserved O O
grafts O O
2 O O
weeks O O
after O O
TX O O
. O O

Acquired O O
antithrombin S-GENE S-GENE
deficiency O O
in O O
sepsis O O
. O O
In O O
addition O O
, O O
we O O
have O O
isolated O O
a O O
genomic O O
fragment O O
containing O O
the O O
most O O
distal O O
5 O O
' O O
sequences O O
of O O
the O O
major O O
GGT B-GENE B-GENE
mRNA E-GENE E-GENE
in O O
HepG2 O O
cells O O
. O O
( O O
1997 O O
) O O
Nature O O
387 O O
, O O
370 O O
- O O
376 O O
) O O
] O O
, O O
we O O
suggest O O
that O O
the O O
metal O O
fluoride O O
ions O O
replaced O O
phosphate O O
at O O
the O O
two O O
ATP O B-GENE
- O I-GENE
binding O I-GENE
sites O E-GENE
of O O
the O O
iron O B-GENE
protein O E-GENE
, O O
Kp2 S-GENE S-GENE
. O O
Increased O B-GENE
erythropoietin S-GENE E-GENE
synthesis O O
in O O
patients O O
with O O
COLD O O
or O O
left O O
heart O O
failure O O
is O O
related O O
to O O
alterations O O
in O O
renal O O
haemodynamics O O
. O O
Expression O O
of O O
herpes B-GENE O
simplex I-GENE O
virus I-GENE O
type I-GENE O
2 I-GENE O
US3 E-GENE S-GENE
affects O O
the O O
Cdc42/Rac O O
pathway O O
and O O
attenuates O O
c B-GENE B-GENE
- I-GENE I-GENE
Jun I-GENE I-GENE
N I-GENE I-GENE
- I-GENE I-GENE
terminal I-GENE I-GENE
kinase E-GENE I-GENE
activation O E-GENE
. O O
If O O
you O O
think O O
education O O
is O O
expensive O O
-- O O
try O O
ignorance O O
-- O O
Bok O O
's O O
Law O O
. O O

To O O
study O O
the O O
in O O
vivo O O
role O O
of O O
p16.7 S-GENE O
, O O
a O O
phi29 O O
mutant O O
containing O O
a O O
suppressible O O
mutation O O
in O O
gene B-GENE O
16.7 E-GENE O
was O O
constructed O O
. O O
To O O
the O O
best O O
of O O
our O O
knowledge O O
, O O
SNTCS O O
is O O
highly O O
malignant O O
. O O

The O O
extraordinary O O
stability O O
of O O
peptide B-GENE O
-- I-GENE O
gp96 I-GENE O
complexes E-GENE O
and O O
the O O
plasticity O O
of O O
the O O
peptide O O
- O O
binding O O
pocket O O
support O O
the O O
proposed O O
relay O O
of O O
diverse O O
peptides O O
to O O
MHC S-GENE S-GENE
and/or O O
other O O
molecules O O
via O O
molecular O O
recognition O O
. O O
High O O
- O O
affinity O O
binding O O
of O O
NF-1 S-GENE S-GENE
to O O
PSE B-GENE B-GENE
- I-GENE I-GENE
B E-GENE E-GENE
, O O
but O O
not O O
to O O
PSE B-GENE S-GENE
- I-GENE O
A E-GENE O
, O O
was O O
confirmed O O
by O O
competition O O
of O O
DNA O B-GENE
- O I-GENE
protein O E-GENE
interactions O O
by O O
using O O
NF-1 O B-GENE
DNA O I-GENE
elements O E-GENE
and O O
antibodies O O
. O O
Coexpression O O
of O O
the O O
p120(ctn O B-GENE
) O I-GENE
protein O E-GENE
with O O
an O O
N O O
- O O
terminal O O
deletion O O
, O O
which O O
eliminates O O
some O O
potential O O
tyrosine O B-GENE
phosphorylation O I-GENE
sites O E-GENE
, O O
or O O
the O O
protein O O
with O O
a O O
single O O
amino O O
acid O O
substitution O O
( O O
tyrosine O O
at O O
217 O O
to O O
phenylalanine O O
) O O
resulted O O
in O O
an O O
increase O O
in O O
the O O
aggregation O O
of O O
v B-GENE B-GENE
- I-GENE I-GENE
Src E-GENE I-GENE
- O I-GENE
transformed O I-GENE
EL O E-GENE
and O O
EalphaCL O S-GENE
cells O O
. O O
We O O
show O O
that O O
p73 S-GENE S-GENE
can O O
transcriptionally O O
inhibit O O
a O O
number O O
of O O
cellular O O
and O O
viral O B-GENE
promoters O E-GENE
. O O
RESULTS O O
: O O
Of O O
the O O
24 O O
patients O O
, O O
6 O O
had O O
Grade O O
1 O O
pneumonitis O O
, O O
and O O
13 O O
had O O
Grade O O
2 O O
pneumonitis O O
. O O

In O O
contrast O O
, O O
we O O
did O O
not O O
detect O O
a O O
significant O O
correlation O O
between O O
plasma B-GENE B-GENE
TNFalpha E-GENE E-GENE
and O O
radiation O O
pneumonitis O O
. O O
Using O O
immunochemical O O
co O O
- O O
precipitation O O
methods O O
, O O
we O O
also O O
found O O
that O O
the O O
two O O
proteins O O
are O O
bound O O
in O O
vivo O O
. O O

METHODS O O
: O O
Sixteen O O
pigs O O
were O O
assigned O O
randomly O O
to O O
control O O
and O O
shock O O
groups O O
. O O

Identification O O
of O O
pulmonary O O
vein O O
stenosis O O
after O O
radiofrequency O O
ablation O O
for O O
atrial O O
fibrillation O O
using O O
MRI O O
. O O

Tumor O O
cell O O
lines O O
transduced O O
at O O
an O O
MOI O O
of O O
8 O O
for O O
3 O O
days O O
led O O
to O O
> O O
90% O O
gene O O
transfer O O
efficiency O O
. O O

Treatment O O
includes O O
both O O
medical O O
and O O
surgical O O
options O O
, O O
with O O
medical O O
therapy O O
further O O
subclassified O O
into O O
pharmacologic O O
and O O
pneumatic O O
dilation O O
. O O

Finally O O
, O O
we O O
compared O O
the O O
differential O O
screening O O
techniques O O
in O O
terms O O
of O O
sensitivity O O
, O O
efficiency O O
and O O
occurrence O O
of O O
false O O
positives O O
. O O

Serial O O
US O O
images O O
were O O
obtained O O
before O O
and O O
20 O O
, O O
30 O O
, O O
40 O O
, O O
50 O O
, O O
60 O O
, O O
90 O O
, O O
120 O O
, O O
150 O O
, O O
180 O O
, O O
240 O O
, O O
and O O
300 O O
s O O
after O O
intravenous O O
injection O O
of O O
2 O O
g O O
of O O
contrast O O
agent O O
using O O
conventional O O
and O O
harmonic O O
PD O O
US O O
. O O

To O O
investigate O O
the O O
effects O O
of O O
exogenous O O
hyaluronic O O
acid O O
, O O
the O O
development O O
of O O
port O O
- O O
site O O
metastasis O O
was O O
examined O O
using O O
mouse O O
adenocarcinoma O O
cell O O
- O O
line O O
colon O O
26 O O
cells O O
. O O

Cytomegalovirus O O
, O O
Chlamydia O O
pneumoniae O O
, O O
and O O
Helicobacter O B-GENE
pylori O I-GENE
IgG B-GENE I-GENE
antibodies E-GENE E-GENE
and O O
restenosis O O
after O O
stent O O
implantation O O
: O O
an O O
angiographic O O
and O O
intravascular O O
ultrasound O O
study O O
. O O
Responses O O
of O O
single O O
- O O
unit O O
carotid O O
body O O
chemoreceptors O O
in O O
adult O O
rats O O
. O O

Architecture O O
and O O
anatomy O O
of O O
the O O
genomic O O
locus O O
encoding O O
the O O
human O B-GENE
leukemia O I-GENE
- O I-GENE
associated O I-GENE
transcription O I-GENE
factor O I-GENE
RUNX1/AML1 O E-GENE
. O O
Therefore O O
, O O
we O O
suggested O O
that O O
both O O
proteins O O
might O O
belong O O
to O O
the O O
PLTP B-GENE B-GENE
family E-GENE E-GENE
. O O
In O O
this O O
paper O O
the O O
tyrosine O B-GENE
dephosphorylating O I-GENE
enzymes O E-GENE
, O O
the O O
protein B-GENE B-GENE
- I-GENE I-GENE
tyrosine I-GENE I-GENE
phosphatases E-GENE E-GENE
( O O
PTPs S-GENE S-GENE
) O O
, O O
are O O
studied O O
which O O
can O O
be O O
grouped O O
into O O
two O O
subfamilies O O
, O O
the O O
soluble B-GENE O
PTPs E-GENE S-GENE
and O O
the O O
receptor B-GENE B-GENE
PTPs E-GENE E-GENE
( O O
RPTPs S-GENE S-GENE
) O O
. O O
The O O
Ig S-GENE B-GENE
- O I-GENE
related O E-GENE
, O O
typical O O
metazoan O O
, O O
module O O
is O O
classified O O
to O O
the O O
disulphide O O
lacking O O
Ig B-GENE S-GENE
members E-GENE O
and O O
represents O O
the O O
phylogenetic O O
earliest O O
member O O
of O O
this O O
group O O
. O O
The O O
Sox B-GENE B-GENE
gene I-GENE I-GENE
family E-GENE E-GENE
( O O
Sry B-GENE B-GENE
like I-GENE I-GENE
HMG I-GENE I-GENE
box I-GENE I-GENE
gene E-GENE E-GENE
) O O
is O O
characterised O O
by O O
a O O
conserved O O
DNA O O
sequence O O
encoding O O
a O O
domain O O
of O O
approximately O O
80 O O
amino O O
acids O O
which O O
is O O
responsible O O
for O O
sequence O O
specific O O
DNA O O
binding O O
. O O
While O O
these O O
results O O
are O O
consistent O O
with O O
previously O O
reported O O
effects O O
of O O
the O O
C O B-GENE
- O I-GENE
terminal O I-GENE
domain O E-GENE
on O O
nucleotide O O
binding O O
, O O
they O O
also O O
demonstrate O O
that O O
interactions O O
with O O
the O O
N O O
- O O
terminal O O
domains O O
are O O
necessary O O
to O O
inhibit O O
proton O O
transport O O
. O O

Respiratory O O
parameters O O
suggested O O
that O O
M6 O O
G O O
produced O O
less O O
respiratory O O
depression O O
than O O
morphine O O
. O O

This O O
supports O O
previous O O
arguments O O
for O O
the O O
improbability O O
of O O
biological O O
effects O O
at O O
UHF O O
frequencies O O
unless O O
a O O
mechanism O O
can O O
be O O
found O O
for O O
accumulating O O
energy O O
over O O
time O O
and O O
space O O
and O O
focussing O O
it O O
. O O

To O O
assess O O
the O O
maximum O O
oxygen O O
uptake O O
( O O
V'O2 O O
max O O
) O O
of O O
Hong O O
Kong O O
Chinese O O
children O O
and O O
to O O
explore O O
its O O
association O O
with O O
respiratory O O
illnesses O O
, O O
we O O
conducted O O
the O O
Multistage O O
Fitness O O
Test O O
( O O
MFT O O
) O O
, O O
a O O
20-m O O
shuttle O O
run O O
test O O
, O O
in O O
1,427 O O
schoolchildren O O
aged O O
between O O
8 O O
- O O
12 O O
years O O
. O O

By O O
analyzing O O
5'-deletion O O
insulin B-GENE B-GENE
promoter I-GENE I-GENE
- I-GENE I-GENE
reporter I-GENE I-GENE
constructs E-GENE E-GENE
in O O
transient O O
transfections O O
of O O
clonal O O
INS-1 B-GENE B-GENE
beta E-GENE E-GENE
- O O
cells O O
, O O
we O O
located O O
activating O O
Hh S-GENE S-GENE
- O O
responsive O O
regions O O
within O O
the O O
rat B-GENE B-GENE
insulin I-GENE I-GENE
I I-GENE I-GENE
promoter E-GENE E-GENE
that O O
include O O
the O O
glucose O B-GENE
- O I-GENE
response O I-GENE
elements O I-GENE
Far O E-GENE
( O O
E2 O S-GENE
) O O
and O O
Flat O S-GENE
( O O
A2/A3 O S-GENE
) O O
. O O
The O O
androgen B-GENE B-GENE
receptor E-GENE E-GENE
( O O
AR S-GENE S-GENE
) O O
amino O O
- O O
terminus O O
imposes O O
androgen O O
- O O
specific O O
regulation O O
of O O
AR B-GENE B-GENE
gene E-GENE E-GENE
expression O O
via O O
an O O
exonic O O
enhancer O O
. O O
A O O
major O O
mechanism O O
by O O
which O O
estrogens O O
prevent O O
osteoporosis O O
seems O O
to O O
be O O
repression O O
of O O
transcription O O
of O O
NF B-GENE B-GENE
- I-GENE I-GENE
kappa I-GENE I-GENE
B I-GENE I-GENE
target I-GENE I-GENE
genes E-GENE E-GENE
, O O
such O O
as O O
the O O
osteoclast O B-GENE
- O I-GENE
activating O I-GENE
cytokines O I-GENE
interleukin-6 S-GENE E-GENE
and O O
interleukin-1 S-GENE S-GENE
. O O
To O O
identify O O
the O O
important O O
cis O O
- O O
DNA O O
regulatory O O
element(s O O
) O O
involved O O
in O O
the O O
tissue- O O
, O O
region- O O
, O O
and O O
cell O O
- O O
specific O O
expression O O
of O O
the O O
mE B-GENE B-GENE
- I-GENE I-GENE
RABP I-GENE I-GENE
gene E-GENE E-GENE
, O O
the O O
5-kb O O
DNA O O
fragment O O
was O O
sequenced O O
. O O
In O O
the O O
mouse O O
, O O
both O O
genes O O
reside O O
in O O
the O O
syntenic O O
region O O
8E1 O O
on O O
chromosome O O
8 O O
. O O

Analysis O O
of O O
the O O
genome O O
sequence O O
revealed O O
26,588 O B-GENE
protein O I-GENE
- O I-GENE
encoding O I-GENE
transcripts O E-GENE
for O O
which O O
there O O
was O O
strong O O
corroborating O O
evidence O O
and O O
an O O
additional O O
approximately O O
12,000 O O
computationally O O
derived O O
genes O O
with O O
mouse O O
matches O O
or O O
other O O
weak O O
supporting O O
evidence O O
. O O

The O O
corresponding O O
genotype O O
was O O
determined O O
with O O
a O O
restriction O O
enzyme O O
- O O
based O O
assay O O
. O O

An O O
additional O O
9 O O
patients O O
achieved O O
normal O O
levels O O
with O O
adjunctive O O
drug O O
therapy O O
. O O

By O O
Caveman O O
. O O

Multistage O O
models O O
and O O
the O O
A O O
- O O
bomb O O
survivor O O
data O O
: O O
implications O O
for O O
carcinogenic O O
mechanisms O O
? O O

The O O
revitalization O O
of O O
surgery O O
for O O
Parkinson O O
's O O
disease O O
( O O
PD O O
) O O
has O O
fueled O O
discussion O O
about O O
the O O
best O O
methodology O O
to O O
define O O
the O O
target O O
. O O

Corneal O O
scrapping O O
and O O
deep O O
stromal O O
biopsy O O
were O O
obtained O O
and O O
stained O O
for O O
microscopic O O
evaluation O O
with O O
periodic O O
acid O O
- O O
Schiff O O
, O O
Giemsa O O
, O O
and O O
Gomori O O
's O O
methenamine O O
silver O O
stains O O
. O O

These O O
results O O
indicate O O
that O O
BACM O O
has O O
antiplaque O O
and O O
stronger O O
antidegradation O O
effects O O
than O O
GLCM O O
. O O

Multidrug O O
resistance O O
in O O
Saccharomyces O O
cerevisiae O O
mainly O O
results O O
from O O
the O O
overexpression O O
of O O
genes O O
coding O O
for O O
the O O
membrane O O
efflux O O
pumps O O
, O O
the O O
major O O
facilitators O O
and O O
the O O
ABC B-GENE B-GENE
binding I-GENE I-GENE
cassette I-GENE I-GENE
transporters E-GENE E-GENE
, O O
under O O
the O O
control O O
of O O
key O O
transcription O O
regulators O O
encoded O O
by O O
the O O
PDR1 S-GENE S-GENE
and O O
PDR3 B-GENE B-GENE
genes E-GENE E-GENE
. O O
Susceptibility O O
to O O
ischemia O O
- O O
induced O O
arrhythmias O O
was O O
lower O O
in O O
1-week O O
diabetics O O
: O O
only O O
42 O O
% O O
of O O
diabetic O O
hearts O O
exhibited O O
ventricular O O
tachycardia O O
( O O
VT O O
) O O
and O O
16 O O
% O O
had O O
short O O
episodes O O
of O O
ventricular O O
fibrillation O O
( O O
VF O O
) O O
as O O
compared O O
to O O
VT O O
100 O O
% O O
and O O
VF O O
70 O O
% O O
( O O
including O O
sustained O O
VF O O
36 O O
% O O
) O O
in O O
the O O
non O O
- O O
diabetics O O
( O O
P<0.05 O O
) O O
. O O

A O O
picture O O
is O O
emerging O O
showing O O
a O O
gradient O O
of O O
function O O
among O O
p53 S-GENE S-GENE
, O O
p73 S-GENE S-GENE
, O O
p63 S-GENE O
ranging O O
from O O
tumor O O
suppression O O
to O O
development O O
. O O
This O O
could O O
lead O O
to O O
subsequent O O
outbreaks O O
if O O
Babesia O O
carrier O O
animals O O
were O O
to O O
be O O
introduced O O
into O O
the O O
herd O O
. O O

Contagious O O
bovine O O
pleuropneumonia O O
is O O
a O O
major O O
threat O O
for O O
cattle O O
in O O
Africa O O
. O O

Baseline O O
BMD O O
values O O
were O O
significantly O O
lower O O
in O O
the O O
oligo O O
- O O
amenorrheic O O
group O O
than O O
in O O
the O O
two O O
others O O
at O O
the O O
level O O
of O O
lumbar O O
spine O O
( O O
anteroposterior O O
view O O
: O O
0.941+/-0.039 O O
in O O
oligo O O
- O O
amenorrheic O O
vs O O
1.077+/-0.029 O O
or O O
1.051 O O
+ O O
/-0.017 O O
g O O
x O O
cm(-2 O O
) O O
, O O
P O O
< O O
0.005 O O
, O O
in O O
the O O
eumenorrheic O O
and O O
contraceptive O O
user O O
groups O O
, O O
respectively O O
) O O
but O O
not O O
in O O
weight O O
- O O
bearing O O
bone O O
such O O
as O O
proximal O O
and O O
midshaft O O
femur O O
. O O

The O O
distribution O O
of O O
red O O
rice O O
cultivation O O
in O O
Sri O O
Lanka O O
is O O
coincident O O
with O O
the O O
HIDD O O
villages O O
. O O

The O O
increase O O
in O O
number O O
of O O
terminal O O
hairs O O
, O O
which O O
are O O
defined O O
as O O
hairs O O
more O O
than O O
60 O O
microm O O
in O O
diameter O O
, O O
in O O
the O O
designated O O
area O O
( O O
0.5 O O
cm O O
square O O
= O O
0.25 O O
cm2 O O
area O O
) O O
of O O
the O O
procyanidin O O
B-2 O O
group O O
subjects O O
after O O
the O O
6-month O O
trial O O
was O O
significantly O O
greater O O
than O O
that O O
of O O
the O O
placebo O O
control O O
group O O
subjects O O
( O O
procyanidin O O
B-2 O O
, O O
1.99 O O
+ O O
/- O O
2.58 O O
( O O
mean O O
+ O O
/- O O
SD)/0.25 O O
cm2 O O
; O O
placebo O O
, O O
-0.82 O O
+ O O
/- O O
3.40 O O
( O O
mean O O
+ O O
/- O O
SD)/0.25 O O
cm2 O O
; O O
P O O
< O O
0.02 O O
, O O
two O O
- O O
sample O O
t O O
test O O
) O O
. O O

Ectopic O O
expression O O
of O O
the O O
dominant B-GENE O
mutant I-GENE O
Lg3 I-GENE B-GENE
allele E-GENE E-GENE
is O O
believed O O
to O O
cause O O
the O O
phenotype O O
. O O
High O B-GENE
plasma S-GENE I-GENE
AVP S-GENE E-GENE
levels O O
observed O O
in O O
the O O
two O O
cases O O
suggest O O
that O O
SSRIs O S-GENE
stimulate O O
AVP O S-GENE
secretion O O
, O O
thereby O O
causing O O
SIADH O S-GENE
. O O
Thus O O
, O O
in O O
T47D O O
breast O O
carcinoma O O
cells O O
, O O
IL-6 S-GENE S-GENE
acts O O
in O O
synergy O O
with O O
EGF B-GENE B-GENE
receptor E-GENE I-GENE
autocrine O E-GENE
activity O O
to O O
signal O O
through O O
the O O
MAPK S-GENE S-GENE
/ O O
PI3 B-GENE B-GENE
K E-GENE E-GENE
pathways O O
. O O
Human B-GENE B-GENE
homologue I-GENE E-GENE
of I-GENE O
yeast I-GENE B-GENE
Rad23 I-GENE I-GENE
protein I-GENE E-GENE
A E-GENE O
interacts O O
with O O
p300/cyclic O B-GENE
AMP O I-GENE
- O I-GENE
responsive O I-GENE
element O I-GENE
binding O E-GENE
( O O
CREB)-binding O B-GENE
protein O E-GENE
to O O
down O O
- O O
regulate O O
transcriptional O O
activity O O
of O O
p53 S-GENE S-GENE
. O O
For O O
immunological O O
methods O O
, O O
identification O O
of O O
such O O
antigens O O
with O O
intermolecular O O
variability O O
, O O
e.g. O O
, O O
the O O
structural O O
aescin O O
analogs O O
, O O
is O O
of O O
unknown O O
validity O O
. O O

Most O O
patients O O
harboring O O
metronidazole- O O
and O O
clarithromycin O O
- O O
resistant O O
strains O O
were O O
eradicated O O
at O O
an O O
equal O O
rate O O
by O O
each O O
of O O
the O O
three O O
regimens O O
. O O

Binding O O
of O O
cell O O
type O B-GENE
- O I-GENE
specific O I-GENE
nuclear O I-GENE
proteins O E-GENE
to O O
the O O
5'-flanking O O
region O O
of O O
maize B-GENE B-GENE
C4 I-GENE I-GENE
phosphoenolpyruvate I-GENE I-GENE
carboxylase I-GENE I-GENE
gene E-GENE E-GENE
confers O O
its O O
differential O O
transcription O O
in O O
mesophyll O O
cells O O
. O O
RESULTS O O
: O O
During O O
the O O
stabilization O O
period O O
, O O
PaCO2 O O
( O O
mean O O
+ O O
/- O O
SD O O
) O O
was O O
33 O O
+ O O
/- O O
5 O O
mm O O
Hg O O
, O O
and O O
arrhythmias O O
were O O
not O O
detected O O
. O O

BACKGROUND O O
: O O
Previous O O
studies O O
have O O
indicated O O
that O O
the O O
60- O O
, O O
30- O O
, O O
28- O O
and O O
12-item O O
versions O O
of O O
the O O
General O O
Health O O
Questionnaire O O
( O O
GHQ O O
) O O
are O O
liable O O
to O O
retest O O
effects O O
, O O
especially O O
when O O
administered O O
multiple O O
times O O
with O O
short O O
intervals O O
. O O

Acute O O
effects O O
of O O
LI O O
160 O O
( O O
extract O O
of O O
Hypericum O O
perforatum O O
, O O
St O O
John O O
's O O
wort O O
) O O
and O O
two O O
of O O
its O O
constituents O O
on O O
neuroendocrine O O
responses O O
in O O
the O O
rat O O
. O O

Decreased O O
serum B-GENE B-GENE
ceruloplasmin E-GENE E-GENE
and O O
copper O O
levels O O
in O O
cervical O O
dystonia O O
. O O
A O O
microsporidian O O
, O O
Nosema O O
algerae O O
Vavra O O
and O O
undeen O O
, O O
was O O
found O O
parasitizing O O
larvae O O
and O O
adults O O
of O O
a O O
laboratory O O
colony O O
of O O
Culex O O
pipiens O O
L. O O
originated O O
from O O
Gharbia O O
Governorate O O
. O O

Molecular O O
cloning O O
and O O
characterization O O
of O O
OsPSK S-GENE S-GENE
, O O
a O O
gene O O
encoding O O
a O O
precursor O O
for O O
phytosulfokine B-GENE B-GENE
- I-GENE I-GENE
alpha E-GENE E-GENE
, O O
required O O
for O O
rice O O
cell O O
proliferation O O
. O O
Blood O O
from O O
dams O O
was O O
collected O O
prior O O
to O O
inoculation O O
and O O
at O O
time O O
of O O
necropsy O O
for O O
measurement O O
of O O
IgM S-GENE O
and O O
IgG B-GENE B-GENE
antibodies E-GENE E-GENE
to O O
M. O O
pulmonis O O
. O O
Plasma O B-GENE
DHE O E-GENE
concentration O O
rose O O
promptly O O
above O O
5 O O
ng O O
/ O O
ml O O
after O O
the O O
application O O
of O O
the O O
PSA O O
tape O O
onto O O
the O O
damaged O O
skin O O
in O O
hairless O O
rat O O
. O O

Single O O
amino O O
acid O O
substitutions O O
at O O
the O O
acyl O B-GENE
- O I-GENE
CoA O I-GENE
- O I-GENE
binding O I-GENE
domain O E-GENE
interrupt O O
14[C]palmitoyl O B-GENE
- O I-GENE
CoA O E-GENE
binding O O
of O O
ACBP2 S-GENE S-GENE
, O O
an O O
Arabidopsis O B-GENE
acyl B-GENE I-GENE
- I-GENE I-GENE
CoA I-GENE I-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
protein E-GENE E-GENE
with O O
ankyrin S-GENE B-GENE
repeats O E-GENE
. O O
Implications O O
in O O
biomonitoring O O
of O O
the O O
observed O O
accumulation O O
patterns O O
, O O
especially O O
in O O
the O O
different O O
tissues O O
of O O
Posidonia O O
oceanica O O
, O O
are O O
discussed O O
. O O

Thus O O
, O O
Xlim-1 S-GENE O
not O O
only O O
contains O O
a O O
unique O O
tyrosine O O
- O O
rich O O
activation O O
domain O O
but O O
also O O
SP O O
contains O O
a O O
negative O O
regulatory O O
domain O O
in O O
CT239 O S-GENE
- O O
403 O O
, O O
suggesting O O
a O O
complex O O
regulatory O O
mechanism O O
SP O O
underlying O O
the O O
transcriptional O O
activity O O
of O O
Xlim-1 O O
in O O
the O O
organizer O O
. O O
After O O
allowing O O
time O O
for O O
absorption O O
, O O
participants O O
completed O O
a O O
bridge O O
simulator O O
task O O
. O O

The O O
bovine B-GENE B-GENE
PGHS-2 I-GENE I-GENE
cDNA E-GENE E-GENE
was O O
cloned O O
by O O
a O O
combination O O
of O O
reverse O B-GENE
transcription O I-GENE
- O I-GENE
polymerase O I-GENE
chain O I-GENE
reaction O E-GENE
and O O
cDNA O O
library O O
screening O O
. O O
The O O
regulation O O
of O O
PGHS-2 B-GENE B-GENE
mRNA E-GENE E-GENE
and O O
protein O O
was O O
studied O O
in O O
primary O O
cultures O O
of O O
bovine O O
uterine O O
stromal O O
cells O O
stimulated O O
with O O
phorbol O B-GENE
12-myristate O I-GENE
13-acetate O E-GENE
( O O
PMA O S-GENE
; O O
100 O O
nM O O
) O O
. O O
Functional O O
analysis O O
of O O
various O O
PTP S-GENE B-GENE
- O I-GENE
deficient O I-GENE
DT40 O I-GENE
B O E-GENE
cell O O
lines O O
stably O O
expressing O O
wild O B-GENE
- O I-GENE
type O I-GENE
chimeric O I-GENE
Fc B-GENE I-GENE
gamma I-GENE I-GENE
RIIB1-PECAM-1 I-GENE I-GENE
receptor E-GENE E-GENE
indicated O O
that O O
cytoplasmic B-GENE O
Src I-GENE B-GENE
homology I-GENE I-GENE
2-domain I-GENE I-GENE
- I-GENE I-GENE
containing I-GENE I-GENE
phosphatases E-GENE E-GENE
, O O
SHP-1 S-GENE S-GENE
and O O
SHP-2 S-GENE S-GENE
, O O
were O O
both O O
necessary O O
and O O
sufficient O O
to O O
deliver O O
inhibitory O O
negative O O
regulation O O
upon O O
coligation O O
of O O
BCR B-GENE B-GENE
complex E-GENE I-GENE
with O I-GENE
inhibitory O I-GENE
receptor O E-GENE
. O O
Anti B-GENE B-GENE
- I-GENE I-GENE
nucleolin I-GENE I-GENE
mAb E-GENE E-GENE
was O O
used O O
to O O
confirm O O
the O O
antigenic O O
properties O O
of O O
this O O
p95 B-GENE O
component E-GENE O
. O O
Furthermore O O
, O O
stable O O
expression O O
of O O
a O O
constitutively O O
active O O
form O O
of O O
chicken O B-GENE
Notch1 S-GENE E-GENE
or O O
Notch2 S-GENE S-GENE
in O O
a O O
B O O
cell O O
line O O
results O O
in O O
a O O
down O O
- O O
regulation O O
of O O
surface O O
IgM S-GENE S-GENE
expression O O
, O O
which O O
is O O
accompanied O O
by O O
the O O
reduction O O
of O O
IgH B-GENE B-GENE
gene I-GENE I-GENE
transcripts E-GENE E-GENE
. O O
Substitutions O O
in O O
the O O
YFV S-GENE B-GENE
Ag B-GENE I-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
region E-GENE E-GENE
( O O
ABR S-GENE S-GENE
) O O
occur O O
at O O
four O O
of O O
the O O
eight O O
highly O O
conserved O O
residues O O
that O O
are O O
essential O O
for O O
binding O O
of O O
peptide O B-GENE
- O I-GENE
Ag O E-GENE
in O O
the O O
class O B-GENE
Ia O I-GENE
molecules O E-GENE
. O O
Similarly O O
, O O
curcumin O O
( O O
diferuloylmethane O O
) O O
, O O
an O O
anti O O
- O O
inflammatory O O
agent O O
, O O
suppressed O O
OSM S-GENE S-GENE
- O O
stimulated O O
STAT1 S-GENE S-GENE
phosphorylation O O
, O O
DNA O O
- O O
binding O O
activity O O
of O O
STAT1 O S-GENE
, O O
and O O
c B-GENE B-GENE
- I-GENE I-GENE
Jun I-GENE I-GENE
N I-GENE I-GENE
- I-GENE I-GENE
terminal I-GENE I-GENE
kinase E-GENE E-GENE
activation O O
without O O
affecting O O
JAK1 S-GENE S-GENE
, O O
JAK2 S-GENE S-GENE
, O O
JAK3 S-GENE S-GENE
, O O
ERK1/2 S-GENE S-GENE
, O O
and O O
p38 S-GENE B-GENE
phosphorylation O E-GENE
. O O
In O O
contrast O O
, O O
the O O
failure O O
of O O
the O O
QKTT O B-GENE
motif O E-GENE
and O O
TGN46 O S-GENE
cytoplasmic O O
tail O O
to O O
induce O O
steady O O
- O O
state O O
ER O O
localization O O
of O O
vesicular B-GENE B-GENE
stomatitis I-GENE I-GENE
virus I-GENE I-GENE
glycoprotein E-GENE E-GENE
( O O
VSVG S-GENE S-GENE
) O O
chimeras O O
in O O
HeLa O O
and O O
NRK O S-GENE
cells O O
indicates O O
that O O
significant O O
differences O O
in O O
early O O
secretory O O
trafficking O O
also O O
exist O O
. O O
A O O
cDNA O O
clone O O
encoding O O
C2H2-type B-GENE B-GENE
zinc I-GENE I-GENE
finger I-GENE I-GENE
protein E-GENE E-GENE
, O O
SCOF-1 S-GENE S-GENE
, O O
was O O
isolated O O
from O O
soybean O O
. O O
Consistent O O
with O O
the O O
specificity O O
observed O O
for O O
the O O
interaction O O
of O O
DmCKIIalpha S-GENE S-GENE
with O O
these O O
bHLH B-GENE B-GENE
proteins E-GENE E-GENE
, O O
sequence O O
alignment O O
suggests O O
that O O
only O O
m5 S-GENE O
, O O
m7 S-GENE O
, O O
and O O
m8 S-GENE O
contain O O
a O O
consensus O O
site O O
for O O
phosphorylation O O
by O O
CKII O S-GENE
within O O
a O O
subdomain O O
unique O O
to O O
these O O
three O O
proteins O O
. O O
Apart O O
from O O
antimicrobial O O
properties O O
, O O
recent O O
data O O
indicate O O
that O O
PMN O S-GENE
also O O
exert O O
anti O O
- O O
inflammatory O O
effects O O
by O O
stimulation O O
and O O
release O O
of O O
cytokine O O
antagonists O O
such O O
as O O
interleukin-1 B-GENE B-GENE
receptor I-GENE E-GENE
antagonist E-GENE O
( O O
IL-1ra S-GENE S-GENE
) O O
. O O
The O O
purpose O O
of O O
this O O
investigation O O
was O O
to O O
study O O
the O O
morphological O O
characteristics O O
of O O
the O O
fibrous O O
tissue O O
capsule O O
resulting O O
from O O
the O O
implantation O O
of O O
aluminum O O
calcium O O
phosphate O O
( O O
ALCAP O O
) O O
and O O
hydroxyapetite O O
( O O
HA O O
) O O
bioceramics O O
. O O

Sevelamer O O
hydrochloride O O
( O O
Renagel O O
) O O
is O O
a O O
nonabsorbed O O
phosphate O O
- O O
binding O O
polymer O O
marketed O O
for O O
the O O
treatment O O
of O O
hyperphosphatemia O O
in O O
adult O O
patients O O
receiving O O
hemodialysis O O
. O O

The O O
pharmacokinetic O O
profiles O O
of O O
digoxin O O
and O O
warfarin O O
were O O
not O O
altered O O
by O O
the O O
simultaneous O O
and O O
continued O O
administration O O
of O O
sevelamer O O
. O O

Before O O
PO3 O O
administration O O
, O O
more O O
than O O
half O O
( O O
57.4% O O
) O O
of O O
the O O
patients O O
received O O
only O O
1 O O
or O O
2 O O
antituberculous O O
drugs O O
( O O
ethambutole O O
and O O
ethionamide O O
or O O
ethambutole O O
and O O
oprofloxacin O O
) O O
. O O

Can O O
survival O O
be O O
prolonged O O
for O O
patients O O
with O O
hormone O O
- O O
resistant O O
prostate O O
cancer O O
? O O

Patients O O
were O O
divided O O
into O O
two O O
group O O
; O O
Control O O
group O O
A O O
in O O
which O O
a O O
hot O O
- O O
water O O
circulating O O
system O O
was O O
used O O
and O O
group O O
B O O
in O O
which O O
a O O
transtracheal O O
heating O O
and O O
humidification O O
system O O
by O O
ANAMED O O
HUMITUBE O O
was O O
used O O
, O O
during O O
gastric O O
cancer O O
operation O O
. O O

The O O
present O O
data O O
also O O
demonstrate O O
that O O
ectopic O O
expression O O
of O O
blr1 S-GENE S-GENE
increased O O
JNK S-GENE S-GENE
/ O O
SAPK S-GENE S-GENE
activity O O
, O O
but O O
JNK/ O B-GENE
SAPK O E-GENE
activation O O
was O O
not O O
needed O O
for O O
accelerated O O
RA O O
- O O
induced O O
differentiation O O
and O O
growth O O
arrest O O
. O O
The O O
effects O O
of O O
the O O
transfected O B-GENE
receptors O E-GENE
were O O
associated O O
with O O
antagonism O O
of O O
activator B-GENE B-GENE
protein I-GENE I-GENE
1 E-GENE E-GENE
( O O
AP-1 S-GENE S-GENE
) O O
activity O O
. O O
Recent O O
studies O O
using O O
isolated O O
rat O O
adipocytes O O
and O O
chemically O O
synthesized O O
PIG O S-GENE
compounds O O
point O O
to O O
IRS1/3 S-GENE B-GENE
tyrosine O I-GENE
phosphorylation O E-GENE
by O O
p59Lyn B-GENE B-GENE
kinase E-GENE E-GENE
as O O
the O O
site O O
of O O
cross O O
- O O
talk O O
, O O
the O O
negative O O
regulation O O
of O O
which O O
by O O
interaction O O
with O O
caveolin S-GENE O
is O O
apparently O O
abrogated O O
by O O
PIG O O
. O O
RESULTS O O
: O O
The O O
parameters O O
SF2 O O
and O O
plating O O
efficiency O O
were O O
stable O O
throughout O O
the O O
4-year O O
test O O
period O O
. O O

Also O O
, O O
small O O
, O O
sense O O
and O O
antisense O O
approximately O O
22 O O
nt O O
RNAs O O
, O O
derived O O
from O O
the O O
satRNA O O
, O O
were O O
associated O O
with O O
the O O
replicating O O
satellite O O
. O O

VE O O
- O O
DEF O O
animals O O
had O O
significantly O O
higher O O
( O O
p O O
< O O
0.05 O O
) O O
levels O O
of O O
myocardial O O
lipid O O
peroxidation O O
and O O
lower O O
( O O
p O O
< O O
0.05 O O
) O O
protein O O
thiols O O
following O O
I O O
- O O
R O O
compared O O
to O O
the O O
CON O O
animals O O
. O O

Grippers O O
with O O
integrated O O
piezoresistive O O
force O O
sensors O O
and O O
with O O
attached O O
strain O O
gauges O O
have O O
been O O
reported O O
. O O

The O O
child O O
left O O
behind O O
. O O

Transition O O
between O O
P- O O
and O O
H O O
- O O
BPPV O O
was O O
found O O
in O O
6 O O
cases O O
. O O

The O O
contrasting O O
effects O O
of O O
dopaminergic O O
stimulation O O
on O O
the O O
motor O O
performance O O
and O O
on O O
some O O
aspects O O
of O O
cognitive O O
processing O O
suggest O O
the O O
existence O O
of O O
complex O O
interactions O O
within O O
pre- O O
and O O
postsynaptic O O
brain B-GENE O
dopamine I-GENE B-GENE
receptors E-GENE E-GENE
, O O
and O O
an O O
intervention O O
of O O
segregated O O
basal O O
ganglia O O
- O O
prefrontal O O
cortex O O
loops O O
in O O
motor O O
and O O
cognitive O O
behaviour O O
. O O
HexA71 S-GENE O
negatively O O
affects O O
RpoS S-GENE S-GENE
, O O
as O O
the O O
levels O O
of O O
this O O
alternative O O
sigma B-GENE B-GENE
factor E-GENE E-GENE
are O O
higher O O
in O O
the O O
HexA- B-GENE B-GENE
mutant E-GENE E-GENE
than O O
in O O
the O O
HexA+ S-GENE O
strain O O
. O O
Multiple O O
copies O O
of O O
rsmB+ B-GENE O
DNA E-GENE O
, O O
on O O
the O O
other O O
hand O O
, O O
stimulate O O
exoenzyme O O
production O O
by O O
relieving O O
the O O
negative O O
effects O O
of O O
a O O
chromosomal O O
copy O O
of O O
hexA+ S-GENE O
. O O
0% O O
) O O
and O O
IL-12 S-GENE O
( O O
42.6% O O
vs. O O
Systematic O O
review O O
of O O
diagnostic O O
tests O O
for O O
vaginal O O
trichomoniasis O O
. O O

CHAP O O
and O O
the O O
Department O O
of O O
Veterans O O
Affairs O O
. O O

More O O
importantly O O
, O O
this O O
fusion O O
converted O O
a O O
less O O
effective O O
vaccine O O
into O O
one O O
with O O
significant O O
potency O O
against O O
established O O
E7-expressing O O
metastatic O O
tumors O O
. O O
We O O
compared O O
previously O O
the O O
methylation O O
status O O
between O O
normal O O
liver O O
and O O
liver O O
tumors O O
in O O
SV40 B-GENE B-GENE
T I-GENE I-GENE
/ I-GENE I-GENE
t I-GENE I-GENE
antigen E-GENE E-GENE
transgenic O O
mice O O
( O O
MT O B-GENE
- O I-GENE
D2 O E-GENE
mice O O
) O O
using O O
Restriction O O
Landmark O O
Genomic O O
Scanning O O
for O O
Methylation O O
( O O
RLGS O S-GENE
- O O
M O O
) O O
and O O
identified O O
several O O
loci O O
/ O O
spots O O
that O O
appeared O O
to O O
be O O
methylated O O
frequently O O
in O O
liver O O
tumors O O
. O O
The O O
Genescan O O
program O O
predicted O O
an O O
open O O
reading O O
frame O O
of O O
a O O
novel O O
, O O
intron O O
- O O
less O O
gene O O
adjacent O O
to O O
the O O
B236 O S-GENE
spot O O
that O O
encodes O O
a O O
putative O O
493-amino O B-GENE
acid O I-GENE
protein O E-GENE
containing O O
the O O
SNAG O B-GENE
repressor O E-GENE
motif O O
in O O
the O O
NH2-terminal O O
region O O
and O O
five O O
C2H2-type O O
zinc O O
finger O O
motifs O O
in O O
the O O
COOH O O
- O O
terminal O O
half O O
. O O

Northern O O
blot O O
analysis O O
revealed O O
that O O
mlt B-GENE B-GENE
1 E-GENE E-GENE
is O O
normally O O
expressed O O
in O O
brain O O
, O O
spleen O O
, O O
stom O O
ach O O
, O O
and O O
liver O O
. O O
Treatment O O
of O O
N18TG-2 O O
cells O O
with O O
a O O
demethylating O O
agent O O
, O O
5-aza O B-GENE
- O I-GENE
deoxycytidine O E-GENE
, O O
resulted O O
in O O
an O O
expression O O
of O O
mlt B-GENE B-GENE
1 E-GENE E-GENE
, O O
indicating O O
that O O
the O O
repression O O
of O O
mlt O B-GENE
1 O E-GENE
is O O
attributable O O
to O O
methylation O O
Thus O O
, O O
mlt O B-GENE
1 O E-GENE
is O O
a O O
novel O O
target O O
gene O O
that O O
is O O
silenced O O
by O O
methylation O O
during O O
liver O O
tumorigenesis O O
initiated O O
by O O
SV40 B-GENE B-GENE
T I-GENE I-GENE
antigen E-GENE E-GENE
. O O
As O O
an O O
oral O O
, O O
nontoxic O O
compound O O
with O O
a O O
mechanism O O
of O O
action O O
distinct O O
from O O
that O O
of O O
ABL B-GENE B-GENE
tyrosine I-GENE I-GENE
kinase E-GENE E-GENE
inhibition O O
, O O
FTI O B-GENE
SCH66336 O E-GENE
shows O O
promise O O
for O O
the O O
treatment O O
of O O
BCR S-GENE S-GENE
/ O O
ABL O S-GENE
- O O
induced O O
leukemia O O
. O O
These O O
results O O
suggested O O
a O O
critical O O
role O O
for O O
tyrosine O O
residue O O
1229 O O
in O O
the O O
regulation O O
of O O
L1 S-GENE B-GENE
endocytosis O E-GENE
. O O
We O O
conclude O O
that O O
RPMS S-GENE S-GENE
acts O O
as O O
a O O
negative O O
regulator O O
of O O
EBNA2 S-GENE S-GENE
and O O
Notch S-GENE O
activity O O
through O O
its O O
interactions O O
with O O
the O O
CBF1-associated B-GENE B-GENE
corepressor I-GENE I-GENE
complex E-GENE E-GENE
. O O
Folate O O
metabolism O O
in O O
the O O
human O B-GENE
malaria O I-GENE
parasite O I-GENE
Plasmodium O I-GENE
falciparum O E-GENE
is O O
an O O
essential O O
activity O O
for O O
cell O O
growth O O
and O O
replication O O
, O O
and O O
the O O
target O O
of O O
an O O
important O O
class O O
of O O
therapeutic O O
agents O O
in O O
widespread O O
use O O
. O O

The O O
BFA O O
System O O
reads O O
a O O
text O O
file O O
with O O
flows O O
, O O
measured O O
with O O
fluorescent O O
microsphere O O
technique O O
, O O
and O O
constructs O O
the O O
lung O O
anatomy O O
with O O
volumetric O O
pixels O O
showing O O
the O O
flows O O
with O O
a O O
color O O
schema O O
. O O

Retinoids O O
participate O O
in O O
the O O
onset O O
of O O
differentiation O O
, O O
apoptosis O O
and O O
the O O
inhibition O O
of O O
growth O O
in O O
a O O
wide O O
variety O O
of O O
normal O O
and O O
cancerous O O
cells O O
. O O

Transactivation O O
of O O
oIFNtau S-GENE B-GENE
enhancer O I-GENE
- O I-GENE
reporter O I-GENE
constructs O E-GENE
was O O
primarily O O
regulated O O
by O O
three O O
regions O O
containing O O
AP-1 B-GENE B-GENE
site E-GENE E-GENE
, O O
GATA B-GENE S-GENE
like I-GENE O
sequence E-GENE O
and O O
site(s O O
) O O
unidentified O O
. O O
These O O
results O O
indicate O O
that O O
evaluation O O
of O O
exposure O O
to O O
S. O O
neurona O O
by O O
WB O O
analysis O O
of O O
serum O O
may O O
be O O
misleading O O
in O O
young O O
horses O O
. O O

Drosophila B-GENE B-GENE
Menin1 I-GENE I-GENE
gene I-GENE I-GENE
transcripts E-GENE E-GENE
use O O
alternative O O
polyadenylation O O
sites O O
resulting O O
in O O
4.3 O O
and O O
5-kb O O
messages O O
. O O
Sequence O O
analysis O O
indicates O O
that O O
RBP21 S-GENE S-GENE
shares O O
homology O O
with O O
other O O
retinoblastoma B-GENE B-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
proteins E-GENE E-GENE
in O O
the O O
pRb B-GENE B-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
motif E-GENE I-GENE
LxCxE O E-GENE
at O O
the O O
C O B-GENE
- O I-GENE
terminal O I-GENE
region O E-GENE
. O O
In O O
addition O O
, O O
the O O
consensus O O
amino O O
acid O O
motif O O
for O O
serine B-GENE B-GENE
threonine I-GENE I-GENE
receptor I-GENE I-GENE
kinases E-GENE E-GENE
was O O
also O O
present O O
. O O
We O O
have O O
also O O
isolated O O
and O O
analyzed O O
the O O
5 O O
' O O
flanking O O
region O O
of O O
the O O
pea O B-GENE
33RNP B-GENE I-GENE
gene E-GENE E-GENE
. O O
OsBBPI S-GENE S-GENE
was O O
found O O
to O O
be O O
rapidly O O
induced O O
in O O
rice O O
seedling O O
leaf O O
in O O
response O O
to O O
cut S-GENE O
, O O
exogenous O O
jasmonic O O
acid O O
( O O
JA O S-GENE
) O O
, O O
and O O
two O O
potent O O
protein B-GENE B-GENE
phosphatase I-GENE I-GENE
2A E-GENE E-GENE
( O O
PP2A S-GENE S-GENE
) O O
inhibitors O O
, O O
cantharidin O O
( O O
CN O S-GENE
) O O
and O O
endothall O O
( O O
EN O O
) O O
, O O
in O O
a O O
light O O
/ O O
dark- O O
, O O
time- O O
and O O
dose O O
- O O
dependent O O
manner O O
; O O
this O O
induction O O
was O O
completely O O
inhibited O O
by O O
cycloheximide O O
( O O
CHX O S-GENE
) O O
, O O
indicating O O
a O O
requirement O O
for O O
de O O
novo O O
protein O O
synthesis O O
in O O
its O O
induction O O
. O O
Copyright O O
2000 O O
John O O
Wiley O O
& O O
Sons O O
, O O
Ltd. O O

The O O
effects O O
of O O
chlordiazepoxide O O
( O O
2.5 O O
- O O
15.0mg O O
/ O O
kg O O
) O O
, O O
a O O
full O O
benzodiazepine B-GENE O
receptor E-GENE O
agonist O O
, O O
and O O
bretazenil O O
( O O
5.0 O O
- O O
30.0mg O O
/ O O
kg O O
) O O
, O O
a O O
partial O O
benzodiazepine O O
receptor O O
agonist O O
, O O
were O O
examined O O
in O O
the O O
murine O O
elevated O O
plus O O
- O O
maze O O
paradigm O O
. O O
However O O
, O O
plasmids O O
carrying O O
the O O
yeast B-GENE O
TyrRS I-GENE B-GENE
gene E-GENE E-GENE
could O O
not O O
be O O
stably O O
maintained O O
in O O
E. O O
coli O O
. O O
In O O
mammalian O O
tissue O O
culture O O
cells O O
, O O
overexpression O O
of O O
any O O
of O O
the O O
four O O
mouse O O
deltex O O
homologs O O
suppressed O O
the O O
transcriptional O O
activity O O
of O O
E47 S-GENE S-GENE
, O O
a O O
basic B-GENE O
helix I-GENE O
- I-GENE O
loop I-GENE O
- I-GENE O
helix I-GENE O
( I-GENE O
bHLH I-GENE S-GENE
) I-GENE O
protein E-GENE O
, O O
in O O
a O O
manner O O
similar O O
to O O
suppression O O
by O O
an O O
activated O O
form O O
of O O
human B-GENE O
Notch1 E-GENE O
or O O
human B-GENE O
DTX1 E-GENE O
. O O
Multiparous O O
women O O
presented O O
higher O O
BMI O O
( O O
P O O
= O O
0.01 O O
) O O
and O O
PBF O O
( O O
P O O
= O O
0.03 O O
) O O
compared O O
with O O
primi- O O
and O O
nulliparous O O
groups O O
. O O

The O O
authors O O
did O O
not O O
detect O O
any O O
significant O O
correlations O O
between O O
parameters O O
of O O
the O O
lipids O O
of O O
bone O O
marrow O O
and O O
leptin S-GENE O
levels O O
in O O
serum O O
and O O
bone O O
marrow O O
. O O
Fluorimetric O O
determination O O
of O O
methylmercury O O
as O O
an O O
ion O O
- O O
association O O
complex O O
with O O
rhodamine O O
B O O
in O O
the O O
presence O O
of O O
iodide O O
. O O

The O O
position O O
of O O
the O O
analyst O O
as O O
expert O O
: O O
yesterday O O
and O O
today O O
. O O

Our O O
results O O
suggest O O
that O O
the O O
central O O
role O O
of O O
the O O
Notch S-GENE B-GENE
- O I-GENE
CBF1/RBP O I-GENE
- O I-GENE
Jkappa O E-GENE
signaling O O
pathway O O
in O O
cell O O
fate O O
decisions O O
renders O O
it O O
susceptible O O
to O O
pathways O O
of O O
viral O O
replication O O
and O O
oncogenic O O
conversion O O
. O O
Using O O
a O O
novel O O
method O O
combining O O
chromatin O O
immunoprecipitation O O
and O O
genomic O O
array O O
hybridization O O
, O O
we O O
have O O
identified O O
a O O
460-kb B-GENE O
CENP I-GENE S-GENE
- I-GENE O
A I-GENE O
- I-GENE O
binding I-GENE O
DNA I-GENE O
domain E-GENE O
of O O
a O O
neocentromere O O
derived O O
from O O
the O O
20p12 O O
region O O
of O O
an O O
invdup O O
( O O
20p O O
) O O
human O O
marker O O
chromosome O O
. O O
We O O
describe O O
a O O
total O O
of O O
39 O O
DEAH B-GENE O
helicases E-GENE O
in O O
these O O
four O O
species O O
. O O
Two O O
cases O O
with O O
marked O O
chronic O O
arm O O
lymphoedema O O
reported O O
major O O
and O O
persistent O O
improvements O O
in O O
arm O O
volume O O
for O O
at O O
least O O
12 O O
months O O
after O O
treatment O O
with O O
HBO2 O O
. O O

The O O
sensitivity O O
of O O
human O O
neuroblastoma O O
cells O O
SK O O
- O O
N O O
- O O
SH O O
to O O
undergo O O
apoptosis O O
induced O O
by O O
thapsigargin O O
was O O
examined O O
. O O

Prophylactic O O
lymph O O
node O O
dissection O O
or O O
radiation O O
therapy O O
to O O
the O O
nodal O O
chain O O
may O O
decrease O O
local O O
recurrence O O
but O O
does O O
not O O
consistently O O
affect O O
overall O O
survival O O
. O O

Currently O O
, O O
the O O
clinical O O
use O O
of O O
5-aminolaevulinic O O
acid O O
( O O
ALA O O
) O O
induced O O
protoporphyrin B-GENE B-GENE
IX E-GENE E-GENE
( O O
PPIX S-GENE S-GENE
) O O
for O O
photodynamic O O
therapy O O
( O O
PDT O O
) O O
is O O
limited O O
by O O
the O O
maximum O O
tolerated O O
oral O O
ALA O O
dose O O
( O O
60 O O
mg O O
/ O O
kg O O
) O O
. O O
We O O
can O O
classify O O
antibiotics O O
into O O
two O O
groups O O
based O O
on O O
initial O O
bactericidal O O
activity O O
against O O
P. O O
aeruginosa O O
; O O
one O O
class O O
is O O
antibiotics O O
having O O
rapid O O
initial O O
killing O O
such O O
as O O
AMK O O
, O O
IPM O O
and O O
PAPM O O
, O O
the O O
other O O
is O O
CAZ O O
, O O
MEPM O O
showing O O
slow O O
initial O O
killing O O
. O O

Managing O O
HIV O O
. O O

In O O
Klinefelter O O
's O O
syndrome O O
( O O
47XXY O O
) O O
, O O
serum O O
testosterone O O
levels O O
are O O
at O O
the O O
lower O O
end O O
of O O
the O O
normal O O
range O O
and O O
dihydrotestosterone O O
levels O O
are O O
low O O
. O O

The O O
histamine B-GENE B-GENE
H1 I-GENE I-GENE
receptor E-GENE E-GENE
antagonists O O
( O O
antihistamines O O
) O O
are O O
an O O
important O O
class O O
of O O
medications O O
used O O
for O O
the O O
relief O O
of O O
common O O
symptoms O O
associated O O
with O O
hyperhistaminic O O
conditions O O
occurring O O
in O O
children O O
and O O
adults O O
. O O
Conclusion O O
: O O
The O O
Lp(a B-GENE O
) E-GENE O
levels O O
in O O
these O O
children O O
were O O
the O O
lower O O
ever O O
reported O O
. O O
A O O
subset O O
of O O
patients O O
( O O
n=30 O O
) O O
underwent O O
multichannel O O
pressure O O
flow O O
studies O O
, O O
which O O
demonstrated O O
that O O
transrectal O O
HIFU O O
reduces O O
bladder O O
outflow O O
obstruction O O
. O O

AIMS O S-GENE
: O O
To O O
establish O O
a O O
baseline O O
and O O
intraindividual O O
fluctuations O O
of O O
the O O
tumour O B-GENE
markers O I-GENE
CEA S-GENE E-GENE
, O O
CA B-GENE S-GENE
50 E-GENE O
and O O
CA B-GENE O
242 E-GENE O
in O O
patients O O
cured O O
from O O
colorectal O O
cancer O O
, O O
and O O
to O O
test O O
the O O
hypothesis O O
that O O
serum O O
concentrations O O
and O O
intraindividual O O
fluctuations O O
do O O
not O O
differ O O
from O O
the O O
concentrations O O
in O O
cancer O O
- O O
free O O
individuals O O
. O O
The O O
homologous O O
active O O
- O O
site O O
framework O O
of O O
these O O
enzymes O O
with O O
distinct O O
structures O O
suggests O O
convergent O O
evolution O O
of O O
a O O
common O O
catalytic O O
mechanism O O
. O O

Cells O O
containing O O
alpha O B-GENE
subunits O E-GENE
that O O
lacked O O
a O O
distal O O
domain O O
( O O
term-3 O O
) O O
or O O
had O O
the O O
alternatively O O
spliced O O
alpha-2 O S-GENE
distal O O
domain O O
showed O O
markedly O O
decreased O O
ability O O
to O O
support O O
tyrosine O O
phosphorylation O O
of O O
Jak-2 S-GENE S-GENE
and O O
its O O
substrates O O
or O O
to O O
up O O
- O O
regulate O O
CD86 S-GENE S-GENE
. O O
We O O
found O O
that O O
RhoA S-GENE S-GENE
can O O
initiate O O
a O O
linear O O
kinase O O
cascade O O
leading O O
to O O
the O O
activation O O
of O O
ERK6 S-GENE S-GENE
( O O
p38 B-GENE B-GENE
gamma E-GENE E-GENE
) O O
, O O
a O O
recently O O
identified O O
member O O
of O O
the O O
p38 B-GENE B-GENE
family E-GENE E-GENE
of O O
MAPKs O S-GENE
. O O
We O O
show O O
that O O
several O O
heme O O
- O O
responsive O O
mechanisms O O
combine O O
to O O
regulate O O
DAN S-GENE S-GENE
/ O O
TIR S-GENE B-GENE
gene O E-GENE
expression O O
. O O
In O O
strains O O
lacking O O
tup11 S-GENE S-GENE
and O O
tup12 S-GENE S-GENE
, O O
the O O
atf1-pcr1 O B-GENE
transcriptional O I-GENE
activator O E-GENE
continues O O
to O O
play O O
a O O
central O O
role O O
in O O
fbp1-lacZ O S-GENE
expression O O
; O O
however O O
, O O
spc1 B-GENE B-GENE
MAPK E-GENE E-GENE
phosphorylation O O
of O O
atf1 O S-GENE
is O O
no O O
longer O O
essential O O
for O O
its O O
activation O O
. O O
In O O
vitro O O
binding O O
studies O O
demonstrate O O
that O O
eIF-5A S-GENE S-GENE
is O O
required O O
for O O
efficient O O
interaction O O
of O O
Rev S-GENE B-GENE
- O I-GENE
NES S-GENE E-GENE
with O O
CRM1/exportin1 O O
and O O
that O O
eIF-5A O S-GENE
interacts O O
with O O
the O O
nucleoporins O O
CAN S-GENE O
/ O O
nup214 S-GENE S-GENE
, O O
nup153 S-GENE O
, O O
nup98 S-GENE O
, O O
and O O
nup62 S-GENE O
. O O
Structural O O
studies O O
have O O
shown O O
that O O
class B-GENE B-GENE
I I-GENE I-GENE
major I-GENE I-GENE
histocompatibility I-GENE I-GENE
complex E-GENE E-GENE
( O O
MHC)-restricted O B-GENE
peptide O I-GENE
- O I-GENE
specific O I-GENE
T B-GENE I-GENE
cell I-GENE I-GENE
receptor I-GENE E-GENE
( I-GENE O
TCR)-alpha I-GENE S-GENE
/ I-GENE O
betas E-GENE O
make O O
multiple O O
contacts O O
with O O
the O O
alpha1 O S-GENE
and O O
alpha2 O O
helices O O
of O O
the O O
MHC O S-GENE
, O O
but O O
it O O
is O O
unclear O O
which O O
or O O
how O O
many O O
of O O
these O O
interactions O O
contribute O O
to O O
functional O O
binding O O
. O O
In O O
Saccharomyces O O
cerevisiae O O
, O O
eIF6 S-GENE S-GENE
is O O
encoded O O
by O O
a O O
single O O
- O O
copy O O
essential O O
gene O O
. O O
Mice O O
homozygous O O
for O O
the O O
dlg S-GENE B-GENE
mutation O E-GENE
exhibit O O
growth O O
retardation O O
in O O
utero O O
, O O
have O O
hypoplasia O O
of O O
the O O
premaxilla O O
and O O
mandible O O
, O O
have O O
a O O
cleft O O
secondary O O
palate O O
, O O
and O O
die O O
perinatally O O
. O O
Moreover O O
, O O
a O O
complex O O
containing O O
PTP B-GENE B-GENE
phi E-GENE E-GENE
, O O
paxillin S-GENE S-GENE
, O O
and O O
a O O
paxillin B-GENE B-GENE
- I-GENE I-GENE
associated I-GENE I-GENE
tyrosine I-GENE I-GENE
kinase E-GENE E-GENE
, O O
Pyk2 S-GENE S-GENE
, O O
can O O
be O O
immunoprecipitated O O
from O O
macrophage O O
lysates O O
, O O
and O O
the O O
catalytic O O
domain O O
of O O
PTP O B-GENE
phi O I-GENE
selectively O I-GENE
binds O I-GENE
paxillin O E-GENE
and O O
Pyk2 O S-GENE
in O O
vitro O O
. O O
A O O
single O O
base O O
change O O
( O O
A8 O B-GENE
G O E-GENE
) O O
in O O
either O O
sequence O O
reduces O O
hnRNP B-GENE B-GENE
A2 E-GENE E-GENE
binding O O
and O O
, O O
in O O
the O O
case O O
of O O
A2RE-2 S-GENE S-GENE
, O O
inhibits O O
RNA O O
transport O O
. O O
Baseline O O
variables O O
associated O O
with O O
CD O O
included O O
a O O
less O O
frequent O O
use O O
of O O
prestroke O O
aspirin O O
and O O
a O O
higher O O
incidence O O
of O O
early O O
CT O O
changes O O
of O O
edema O O
or O O
mass O O
effect O O
or O O
dense O O
middle O O
cerebral O O
artery O O
sign O O
. O O

IL-1beta S-GENE O
was O O
significantly O O
higher O O
in O O
endometrioma O O
than O O
in O O
lesions O O
of O O
other O O
localizations O O
. O O
A O O
complete O O
drug O O
history O O
was O O
compiled O O
, O O
specifying O O
the O O
amount O O
and O O
duration O O
of O O
VGB O O
medication O O
. O O

TaqMan O O
analysis O O
of O O
gene O O
expression O O
following O O
chronic O O
FA O S-GENE
treatment O O
showed O O
neither O O
a O O
decrease O O
in O O
the O O
amount O O
of O O
leptin B-GENE B-GENE
receptor E-GENE E-GENE
( O O
Ob B-GENE B-GENE
- I-GENE I-GENE
R E-GENE E-GENE
) O O
mRNA O O
, O O
nor O O
an O O
increase O O
in O O
the O O
negative O O
regulators O O
of O O
STAT S-GENE B-GENE
signalling O E-GENE
, O O
SOCS3 S-GENE S-GENE
( O O
suppressors B-GENE O
of I-GENE O
cytokine I-GENE O
signalling E-GENE O
) O O
or O O
cytokine B-GENE O
inducible I-GENE O
sequence E-GENE O
( O O
CIS S-GENE O
) O O
. O O
The O O
mutant O B-GENE
receptors O E-GENE
, O O
as O O
well O O
as O O
sBMPR B-GENE B-GENE
- I-GENE I-GENE
IA E-GENE E-GENE
, O O
were O O
expressed O O
as O O
fusion O O
proteins O O
with O O
thioredoxin S-GENE O
in O O
Escherichia O B-GENE
coli O E-GENE
, O O
and O O
purified O O
using O O
reverse O O
phase O O
high O O
performance O O
liquid O O
chromatography O O
( O O
RP O B-GENE
- O I-GENE
HPLC O E-GENE
) O O
after O O
digestion O O
with O O
enterokinase S-GENE O
. O O
The O O
authors O O
undertook O O
a O O
retrospective O O
analysis O O
of O O
pathology O O
with O O
quantification O O
of O O
the O O
percentage O O
of O O
papillary O O
serous O O
component O O
( O O
% O O
PSC O S-GENE
) O O
and O O
p53 S-GENE S-GENE
expression O O
. O O
For O O
this O O
purpose O O
, O O
the O O
immediate O O
and O O
the O O
final O O
( O O
after O O
swelling O O
) O O
fixation O O
strengths O O
of O O
two O O
variations O O
of O O
the O O
swellable O O
bone O O
anchor O O
designs O O
( O O
a O O
smooth O O
anchor O O
and O O
a O O
screw O O
anchor O O
) O O
were O O
measured O O
in O O
two O O
different O O
foams O O
( O O
used O O
to O O
simulate O O
bone O O
) O O
with O O
different O O
densities O O
. O O

Constitutive O O
phosphorylation O O
and O O
nuclear O O
localization O O
of O O
Smad3 S-GENE S-GENE
are O O
correlated O O
with O O
increased O O
collagen B-GENE B-GENE
gene E-GENE I-GENE
transcription O E-GENE
in O O
activated O O
hepatic O O
stellate O O
cells O O
. O O
Cloning O O
and O O
characterization O O
of O O
the O O
murine B-GENE B-GENE
beta(3 I-GENE I-GENE
) I-GENE I-GENE
integrin I-GENE I-GENE
gene E-GENE I-GENE
promoter O E-GENE
: O O
identification O O
of O O
an O O
interleukin-4 B-GENE B-GENE
responsive I-GENE I-GENE
element E-GENE E-GENE
and O O
regulation O O
by O O
STAT-6 S-GENE S-GENE
. O O
CONCLUSIONS O O
: O O
Although O O
the O O
levels O O
of O O
oxLDL B-GENE B-GENE
antibodies E-GENE E-GENE
might O O
be O O
modified O O
in O O
early O O
hypertension O O
, O O
once O O
advanced O O
coronary O O
artery O O
disease O O
has O O
developed O O
the O O
presence O O
of O O
hypertension O O
does O O
not O O
affect O O
anti B-GENE B-GENE
- I-GENE I-GENE
oxLDL E-GENE E-GENE
levels O O
. O O
GafChromic O O
( O O
MD-55 O O
- O O
2 O O
) O O
radiochromic O O
film O O
has O O
become O O
increasingly O O
popular O O
for O O
medical O O
applications O O
and O O
has O O
proven O O
to O O
be O O
useful O O
for O O
brachytherapy O O
dosimetry O O
. O O

RESULTS O O
: O O
Within O O
7 O O
days O O
, O O
all O O
groups O O
re O O
- O O
acquired O O
responding O O
for O O
heroin O O
under O O
CRF O O
at O O
rates O O
similar O O
to O O
their O O
pre O O
- O O
lesion O O
performance O O
. O O

Cis O O
- O O
acting O O
CCAAT O O
elements O O
are O O
frequently O O
found O O
in O O
eukaryotic O O
promoter O O
regions O O
. O O

Twenty O O
- O O
five O O
patients O O
also O O
received O O
PET O O
examinations O O
during O O
the O O
staging O O
procedures O O
. O O

The O O
Gap69C S-GENE O
is O O
a O O
single O O
- O O
copy O O
gene O O
producing O O
a O O
major O O
2.1-kb O O
mRNA O O
throughout O O
development O O
, O O
but O O
its O O
amount O O
is O O
decreased O O
in O O
larvae O O
. O O
Cases O O
of O O
lung O O
cancer O O
with O O
intramedullary O O
metastasis O O
are O O
rare O O
, O O
especially O O
those O O
diagnosed O O
before O O
death O O
. O O

A O O
novel O O
growth O B-GENE
- O I-GENE
related O I-GENE
nuclear O I-GENE
protein O E-GENE
binds O O
and O O
inhibits O O
rat O B-GENE
aldolase B-GENE I-GENE
B I-GENE I-GENE
gene E-GENE I-GENE
promoter O E-GENE
. O O
OBJECTIVE O O
: O O
To O O
investigate O O
the O O
association O O
between O O
complete O O
congenital O O
heart O O
block O O
( O O
CCHB O O
) O O
in O O
the O O
fetus O O
and O O
adult O O
disease O O
. O O

This O O
study O O
examined O O
the O O
role O O
of O O
cholesteryl O B-GENE
ester O I-GENE
transfer O E-GENE
( O O
CET O S-GENE
) O O
, O O
cholesteryl B-GENE B-GENE
ester I-GENE I-GENE
transfer I-GENE I-GENE
protein E-GENE E-GENE
( O O
CETP S-GENE S-GENE
) O O
activity O O
, O O
and O O
phospholipid B-GENE B-GENE
transfer I-GENE I-GENE
protein E-GENE E-GENE
( O O
PLTP S-GENE S-GENE
) O O
activity O O
in O O
the O O
increased O O
prevalence O O
of O O
coronary O O
artery O O
calcification O O
( O O
CAC O O
) O O
in O O
diabetic O O
subjects O O
compared O O
with O O
nondiabetic O O
subjects O O
and O O
in O O
the O O
loss O O
of O O
the O O
sex O O
difference O O
in O O
CAC O O
in O O
diabetes O O
. O O
Two O O
families O O
with O O
concordant O O
inheritance O O
of O O
DNAH9 B-GENE B-GENE
alleles E-GENE E-GENE
in O O
affected O O
individuals O O
were O O
observed O O
. O O
The O O
blood O O
levels O O
of O O
lactate O O
, O O
pyruvate O O
and O O
amino O O
acids O O
were O O
not O O
elevated O O
. O O

Efficacy O O
of O O
first O O
- O O
generation O O
Cavermap O O
to O O
verify O O
location O O
and O O
function O O
of O O
cavernous O O
nerves O O
during O O
radical O O
prostatectomy O O
: O O
a O O
multi O O
- O O
institutional O O
evaluation O O
by O O
experienced O O
surgeons O O
. O O

The O O
( O O
two O O
- O O
motif O O
) O O
domain O O
fold O O
contains O O
a O O
pair O O
of O O
calcium O B-GENE
binding O I-GENE
sites O E-GENE
very O O
similar O O
to O O
those O O
found O O
in O O
a O O
two B-GENE O
- I-GENE O
domain I-GENE O
prokaryotic I-GENE O
betagamma I-GENE B-GENE
- I-GENE I-GENE
crystallin I-GENE I-GENE
fold I-GENE I-GENE
family I-GENE I-GENE
member E-GENE E-GENE
, O O
Protein O B-GENE
S. O I-GENE
Deletional O E-GENE
analyses O O
of O O
VDR S-GENE S-GENE
indicated O O
that O O
GRIP1 S-GENE S-GENE
and O O
RAC3 S-GENE S-GENE
required O O
an O O
intact O O
VDR O O
activation O O
function O O
( O O
AF-2 O S-GENE
) O O
domain O O
for O O
efficient O O
interaction O O
as O O
well O O
as O O
additional O O
but O O
distinct O O
regions O O
of O O
the O O
VDR O O
. O O
Mechanism O O
in O O
the O O
sequential O O
control O O
of O O
cell O O
morphology O O
and O O
S O O
phase O O
entry O O
by O O
epidermal B-GENE B-GENE
growth I-GENE I-GENE
factor E-GENE E-GENE
involves O O
distinct O O
MEK S-GENE S-GENE
/ O O
ERK S-GENE S-GENE
activations O O
. O O
The O O
expression O O
of O O
alpha B-GENE B-GENE
- I-GENE I-GENE
amylase E-GENE E-GENE
can O O
be O O
transactivated O O
by O O
the O O
transcription O B-GENE
factor O I-GENE
GAMyb S-GENE E-GENE
, O O
which O O
is O O
itself O O
induced O O
by O O
GA O O
. O O
3D O O
image O O
- O O
processing O O
permits O O
to O O
analyse O O
ultrasound O O
data O O
interactively O O
in O O
three O O
orthogonal O O
planes O O
( O O
section O O
mode O O
) O O
or O O
in O O
realistic O O
3D O O
views O O
( O O
rendering O O
mode O O
) O O
. O O

Only O O
nine O O
patients O O
were O O
offered O O
surgery O O
( O O
six O O
were O O
resected O O
and O O
three O O
were O O
found O O
inoperable O O
) O O
. O O

Direct O O
superoxide O O
scavenging O O
activity O O
of O O
nonsteroidal O O
anti O O
- O O
inflammatory O O
drugs O O
: O O
determination O O
by O O
electron O O
spin O O
resonance O O
using O O
the O O
spin O O
trap O O
method O O
. O O

BACKGROUND O O
: O O
Dermoscopy O O
is O O
a O O
noninvasive O O
technique O O
that O O
increases O O
the O O
diagnostic O O
accuracy O O
of O O
pigmented O O
skin O O
lesions O O
, O O
particularly O O
improving O O
the O O
diagnosis O O
of O O
patients O O
with O O
cutaneous O O
melanoma O O
in O O
situ O O
( O O
CMIS O O
) O O
and O O
early O O
invasive O O
melanoma O O
. O O

Moreover O O
, O O
PTax S-GENE S-GENE
expressed O O
higher O O
background O O
activities O O
than O O
PTF S-GENE S-GENE
, O O
indicating O O
that O O
the O O
sequence O O
of O O
the O O
synthetic O O
regulatory O O
region O O
can O O
influence O O
background O O
levels O O
. O O
However O O
, O O
the O O
promoter O O
region O O
contains O O
several O O
potential O O
cis O O
- O O
regulatory O O
elements O O
such O O
as O O
Sp1 S-GENE S-GENE
, O O
early B-GENE B-GENE
growth I-GENE I-GENE
response-1 E-GENE E-GENE
, O O
activator B-GENE B-GENE
protein-2 E-GENE E-GENE
, O O
MyoD S-GENE S-GENE
, O O
p300 S-GENE S-GENE
, O O
nuclear B-GENE B-GENE
factor I-GENE I-GENE
- I-GENE I-GENE
kappaB E-GENE E-GENE
, O O
myeloid B-GENE B-GENE
zinc I-GENE I-GENE
finger I-GENE I-GENE
protein-1 E-GENE E-GENE
, O O
caudal B-GENE B-GENE
- I-GENE I-GENE
related I-GENE I-GENE
homeobox I-GENE E-GENE
( I-GENE O
Cdx I-GENE S-GENE
) I-GENE O
gene I-GENE O
A E-GENE O
, O O
and O O
Cdx B-GENE B-GENE
protein-2 I-GENE I-GENE
binding I-GENE I-GENE
sites E-GENE E-GENE
. O O
Thus O O
, O O
the O O
interaction O O
of O O
Tat S-GENE S-GENE
with O O
the O O
components O O
of O O
this O O
rel S-GENE O
/ O O
AP1 S-GENE S-GENE
cooperative O O
complex O O
seems O O
to O O
induce O O
quantitative O O
and O O
qualitative O O
alterations O O
of O O
this O O
complex O O
as O O
activation O O
progresses O O
, O O
resulting O O
in O O
a O O
decrease O O
of O O
IL-2 B-GENE O
gene E-GENE O
transcription O O
. O O
2001 O O
. O O

Adjuvant O O
and O O
neoadjuvant O O
treatment O O
of O O
breast O O
cancer O O
. O O

Unlike O O
other O O
progenitor O O
cells O O
of O O
the O O
brain O O
, O O
SVZa O O
progenitor O O
cells O O
have O O
the O O
capacity O O
to O O
divide O O
even O O
though O O
they O O
express O O
a O O
neuronal O O
phenotype O O
. O O

A O O
minimal O O
ER3 O O
sequence O O
of O O
DNA O O
was O O
further O O
demonstrated O O
to O O
function O O
as O O
a O O
FXR B-GENE B-GENE
HRE E-GENE E-GENE
and O O
was O O
bound O O
in O O
vitro O O
by O O
FXR O B-GENE
- O I-GENE
expressing O I-GENE
yeast O I-GENE
extracts O E-GENE
. O O
OBJECTIVE O O
: O O
To O O
determine O O
the O O
association O O
of O O
depressive O O
symptoms O O
with O O
HIV O O
- O O
related O O
mortality O O
and O O
decline O O
in O O
CD4 S-GENE O
lymphocyte O O
counts O O
among O O
women O O
with O O
HIV O O
. O O
An O O
economic O O
analysis O O
using O O
West O O
of O O
Scotland O O
Coronary O O
Prevention O O
Study O O
( O O
WOSCOPS O O
) O O
findings O O
indicates O O
that O O
statin S-GENE O
treatment O O
would O O
have O O
prevented O O
318 O O
events O O
per O O
10,000 O O
patients O O
in O O
a O O
population O O
similar O O
to O O
that O O
in O O
WOSCOPS O O
( O O
average O O
1.5% O O
annual O O
risk O O
of O O
a O O
cardiovascular O O
event O O
) O O
at O O
a O O
discounted O O
cost O O
per O O
life O O
- O O
year O O
gained O O
of O O
20,375 O O
pounds($31,818 O O
) O O
. O O
Furthermore O O
, O O
the O O
soluble O O
forms O O
of O O
ATF6 S-GENE S-GENE
and O O
the O O
G13 B-GENE B-GENE
gene I-GENE I-GENE
product E-GENE E-GENE
are O O
unable O O
to O O
bind O O
to O O
several O O
point O O
mutants O O
of O O
the O O
cis O O
- O O
acting O O
ER O B-GENE
stress O I-GENE
response O I-GENE
element O E-GENE
in O O
vitro O O
that O O
hardly O O
respond O O
to O O
ER O O
stress O O
in O O
vivo O O
. O O
Sequence O O
analysis O O
revealed O O
significant O O
differences O O
between O O
the O O
5 O O
' O O
region O O
of O O
the O O
beta O B-GENE
subunit O I-GENE
gene O E-GENE
and O O
the O O
corresponding O O
regions O O
of O O
the O O
homologous B-GENE O
GlyR I-GENE B-GENE
alpha I-GENE I-GENE
subunit I-GENE I-GENE
genes E-GENE E-GENE
; O O
it O O
also O O
identified O O
a O O
novel O O
exon O O
( O O
exon O O
0 O O
) O O
that O O
encodes O O
most O O
of O O
the O O
5'-untranslated O O
portion O O
of O O
the O O
GlyR B-GENE B-GENE
beta I-GENE I-GENE
mRNA E-GENE E-GENE
. O O
The O O
present O O
study O O
was O O
initiated O O
to O O
explore O O
the O O
potential O O
of O O
a O O
hybrid O O
biological O O
reactor O O
, O O
combining O O
trickling O O
filter O O
( O O
TF O O
) O O
and O O
activated O O
sludge O O
process O O
( O O
ASP O O
) O O
, O O
to O O
treat O O
wastewater O O
containing O O
trichloroethylene O O
( O O
TCE O O
) O O
at O O
ambient O O
temperature O O
at O O
different O O
hydraulic O O
retention O O
time O O
( O O
HRT O O
) O O
. O O

In O O
DNA O O
strand O O
exchange O O
reactions O O
using O O
oligonucleotides O O
, O O
we O O
found O O
that O O
Rec2 S-GENE O
exhibited O O
a O O
pairing O O
bias O O
that O O
is O O
opposite O O
that O O
of O O
RecA. O O
Anecdotal O O
observations O O
scattered O O
throughout O O
the O O
literature O O
have O O
often O O
provided O O
clues O O
to O O
underlying O O
variations O O
in O O
humans O O
' O O
ability O O
to O O
handle O O
dietary O O
chemicals O O
. O O

Forskolin O O
treatment O O
( O O
10 O O
microM O O
) O O
of O O
the O O
transfected O O
cells O O
for O O
3 O O
- O O
-6 O O
h O O
maximally O O
induced O O
luciferase S-GENE O
threefold O O
. O O
Analysis O O
of O O
ace2Delta O O
cells O O
reveals O O
that O O
Ace2p S-GENE S-GENE
is O O
required O O
for O O
cell O O
separation O O
but O O
not O O
for O O
polarized O O
growth O O
. O O
The O O
results O O
presented O O
here O O
show O O
that O O
AR1 S-GENE S-GENE
of O O
the O O
promoter O B-GENE
- O I-GENE
proximal O I-GENE
CAP B-GENE I-GENE
subunit E-GENE E-GENE
was O O
required O O
for O O
papBA S-GENE S-GENE
transcription O O
even O O
in O O
the O O
absence O O
of O O
the O O
histone B-GENE B-GENE
- I-GENE I-GENE
like I-GENE I-GENE
protein E-GENE I-GENE
H B-GENE E-GENE
- I-GENE O
NS E-GENE O
. O O
A. O O
, O O
Slatkin O O
, O O
D. O O

RESULTS O O
: O O
A O O
significant O O
correlation O O
( O O
p O O
< O O
0.001 O O
) O O
was O O
observed O O
for O O
mean O O
wall O O
thickness O O
and O O
vessel O O
wall O O
area O O
between O O
MRI O O
and O O
histopathology O O
( O O
r O O
= O O
0.87 O O
and O O
r O O
= O O
0.85 O O
, O O
respectively O O
) O O
. O O

Our O O
data O O
indicate O O
that O O
SIP1 S-GENE S-GENE
is O O
required O O
to O O
confine O O
XBra B-GENE B-GENE
gene E-GENE E-GENE
expression O O
to O O
the O O
mesoderm O O
. O O
SIP1 S-GENE S-GENE
( O O
Smad B-GENE B-GENE
interacting I-GENE I-GENE
protein I-GENE I-GENE
1 E-GENE E-GENE
) O O
and O O
deltaEF1 S-GENE S-GENE
( O O
delta B-GENE B-GENE
- I-GENE I-GENE
crystallin I-GENE I-GENE
enhancer I-GENE I-GENE
binding I-GENE I-GENE
factor E-GENE E-GENE
) O O
are O O
structurally O O
similar O O
transcriptional O O
repressors O O
. O O
B B-GENE B-GENE
- I-GENE I-GENE
myb E-GENE E-GENE
is O O
essential O O
for O O
G1/S O O
transition O O
and O O
has O O
been O O
shown O O
to O O
be O O
phosphorylated O O
by O O
the O O
cyclin O B-GENE
A2/cdk2 O I-GENE
complex O E-GENE
. O O
Nucleotide O O
sequence O O
, O O
transcription O O
map O O
, O O
and O O
mutation O O
analysis O O
of O O
the O O
13q14 O O
chromosomal O O
region O O
deleted O O
in O O
B O O
- O O
cell O O
chronic O O
lymphocytic O O
leukemia O O
. O O

Human B-GENE B-GENE
T I-GENE I-GENE
- I-GENE I-GENE
cell I-GENE I-GENE
leukemia I-GENE I-GENE
virus I-GENE I-GENE
type I-GENE I-GENE
I I-GENE E-GENE
( I-GENE O
HTLV I-GENE B-GENE
- I-GENE I-GENE
I I-GENE E-GENE
) I-GENE O
Tax E-GENE O
is O O
a O O
potent O O
transcriptional O O
regulator O O
that O O
can O O
activate O O
or O O
repress O O
specific O O
cellular O O
genes O O
and O O
that O O
has O O
been O O
proposed O O
to O O
contribute O O
to O O
leukemogenesis O O
in O O
adult O O
T O O
- O O
cell O O
leukemia O O
. O O
Requirements O O
for O O
the O O
nuclear O O
- O O
cytoplasmic O O
translocation O O
of O O
infected B-GENE O
- I-GENE O
cell I-GENE O
protein I-GENE O
0 E-GENE O
of O O
herpes O B-GENE
simplex O I-GENE
virus O I-GENE
1 O E-GENE
. O O
The O O
human B-GENE B-GENE
cytomegalovirus I-GENE E-GENE
( I-GENE O
HCMV I-GENE B-GENE
) I-GENE I-GENE
major I-GENE I-GENE
immediate I-GENE I-GENE
- I-GENE I-GENE
early I-GENE I-GENE
protein I-GENE I-GENE
IE2 E-GENE E-GENE
is O O
a O O
nuclear O O
phosphoprotein O O
that O O
is O O
believed O O
to O O
be O O
a O O
key O O
regulator O O
in O O
both O O
lytic O O
and O O
latent O O
infections O O
. O O
OBJECTIVE O O
: O O
To O O
determine O O
whether O O
RSTD O O
predicts O O
coronary O O
anatomy O O
during O O
acute O O
coronary O O
occlusion O O
. O O

The O O
Novacor O O
Left O O
Ventricular O O
Assist O O
System O O
( O O
LVAS O O
) O O
( O O
Novacor O O
Corp O O
, O O
Oakland O O
, O O
CA O O
) O O
was O O
initially O O
console O O
- O O
based O O
and O O
has O O
been O O
available O O
since O O
1993 O O
in O O
a O O
wearable O O
configuration O O
. O O

Atheroma O O
appears O O
as O O
a O O
very O O
low O O
signal O O
intensity O O
area O O
on O O
2-dimensional O O
time O O
- O O
of O O
- O O
flight O O
( O O
TOF O O
) O O
magnetic O O
resonance O O
( O O
MR O O
) O O
images O O
, O O
and O O
its O O
components O O
have O O
various O O
signal O O
intensities O O
on O O
spin O O
- O O
echo O O
( O O
SE O O
) O O
images O O
. O O

Body O O
fat O O
distribution O O
was O O
determined O O
by O O
abdominal O O
computed O O
tomography O O
. O O

The O O
flux O O
rates O O
of O O
p O O
- O O
toluidine O O
decreased O O
as O O
the O O
pH O O
value O O
in O O
the O O
donor O O
solution O O
increased O O
. O O

We O O
have O O
now O O
tested O O
all O O
known O O
mammalian B-GENE B-GENE
Groucho I-GENE I-GENE
family I-GENE E-GENE
members E-GENE O
for O O
their O O
ability O O
to O O
interact O O
specifically O O
with O O
individual O O
Tcf S-GENE B-GENE
/ O I-GENE
Lef S-GENE I-GENE
family O E-GENE
members O O
. O O
We O O
show O O
here O O
that O O
the O O
in O O
vitro O O
transcription O O
extract O O
contains O O
a O O
binding O O
activity O O
that O O
is O O
specific O O
for O O
the O O
initiator O O
element O O
and O O
thus O O
may O O
participate O O
in O O
recruiting O O
RNA B-GENE B-GENE
polymerase I-GENE I-GENE
II E-GENE E-GENE
to O O
the O O
SL O B-GENE
RNA O I-GENE
gene O I-GENE
promoter O E-GENE
. O O
The O O
protein O O
is O O
composed O O
of O O
two O O
major O O
domains O O
separated O O
by O O
a O O
hydrophobic O O
linker O O
region O O
of O O
20 O O
amino O O
acid O O
residues O O
. O O

The O O
438 B-GENE O
bp I-GENE O
EcoRI I-GENE B-GENE
fragment E-GENE E-GENE
, O O
which O O
was O O
detected O O
by O O
Southern O O
hybridization O O
, O O
reveals O O
an O O
open O O
reading O O
frame O O
which O O
encodes O O
a O O
protein O O
of O O
103 O O
amino O O
acids O O
. O O
We O O
performed O O
the O O
present O O
study O O
to O O
clarify O O
the O O
relationship O O
between O O
the O O
DOX O O
binding O O
ability O O
( O O
% O O
DB O O
) O O
and O O
the O O
histologic O O
response O O
, O O
rate O O
of O O
decrease O O
in O O
tumor O O
volume O O
of O O
malignant O O
soft O O
tissue O O
tumors O O
after O O
preoperative O O
chemotherapy O O
and O O
prognosis O O
. O O

To O O
avoid O O
misinterpretations O O
, O O
special O O
reference O O
values O O
should O O
be O O
applied O O
for O O
preadolescents O O
, O O
at O O
least O O
with O O
regard O O
to O O
FVC O O
and O O
FEV1 O O
. O O

Nephrotoxicity O O
after O O
orthotopic O O
liver O O
transplantation O O
in O O
cyclosporin O O
A O O
and O O
FK O O
506-treated O O
patients O O
. O O

Compared O O
with O O
normal O O
control O O
subjects O O
, O O
all O O
74 O O
TOF O O
patients O O
had O O
decreased O O
systolic O O
and O O
diastolic O O
myocardial O O
velocities O O
and O O
a O O
longer O O
isovolumic O O
relaxation O O
time O O
. O O

Acetoin O O
can O O
be O O
reused O O
by O O
the O O
bacteria O O
during O O
stationary O O
phase O O
when O O
other O O
carbon O O
sources O O
have O O
been O O
depleted O O
. O O

Mutational O O
analysis O O
showed O O
that O O
the O O
U O B-GENE
- O I-GENE
box O E-GENE
, O O
like O O
the O O
RING O O
finger O O
in O O
other O O
proteins O O
, O O
forms O O
the O O
physical O O
basis O O
for O O
the O O
interaction O O
with O O
E2 B-GENE B-GENE
enzymes E-GENE E-GENE
. O O
Thus O O
, O O
our O O
studies O O
define O O
Rac S-GENE O
/ O O
Cdc42/Pak O S-GENE
as O O
a O O
module O O
upstream O O
of O O
Raf-1 S-GENE S-GENE
during O O
its O O
activation O O
by O O
microtubule O O
disruption O O
. O O
Nrf2 S-GENE S-GENE
regulates O O
expression O O
of O O
genes O O
encoding O O
enzymes O O
with O O
antioxidant O O
( O O
e.g. O O
heme B-GENE B-GENE
oxygenase-1 E-GENE E-GENE
( O O
HO-1 S-GENE S-GENE
) O O
) O O
or O O
xenobiotic O O
detoxification O O
( O O
e.g. O O
These O O
results O O
indicate O O
that O O
ATF4 S-GENE S-GENE
regulates O O
basal O O
and O O
CdCl(2)-induced O S-GENE
expression O O
of O O
the O O
ho-1 B-GENE B-GENE
gene E-GENE E-GENE
in O O
a O O
cell O O
- O O
specific O O
manner O O
and O O
possibly O O
in O O
a O O
complex O O
with O O
Nrf2 S-GENE S-GENE
. O O
On O O
the O O
other O O
hand O O
, O O
forced O O
overexpression O O
of O O
the O O
wild O O
type O O
, O O
but O O
not O O
the O O
kinase O B-GENE
- O I-GENE
inactivated O I-GENE
mutant O E-GENE
of O O
nm23H1 S-GENE S-GENE
, O O
converted O O
the O O
GDP O S-GENE
- O O
bound O O
forms O O
of O O
Rac1 S-GENE S-GENE
, O O
Cdc42 S-GENE S-GENE
, O O
and O O
RhoA S-GENE S-GENE
to O O
their O O
GTP O S-GENE
- O O
bound O O
forms O O
in O O
vitro O O
by O O
its O O
nucleoside B-GENE B-GENE
diphosphate I-GENE I-GENE
kinase E-GENE E-GENE
activity O O
, O O
but O O
nm23H1 O S-GENE
alone O O
apparently O O
did O O
not O O
produce O O
the O O
GTP O S-GENE
- O O
bound O O
form O O
of O O
these O O
GTPases S-GENE O
in O O
vivo O O
. O O
This O O
effect O O
was O O
observed O O
in O O
the O O
absence O O
of O O
de O O
novo O O
protein O O
synthesis O O
and O O
was O O
independent O O
of O O
histone B-GENE B-GENE
deacetylase E-GENE E-GENE
activity O O
. O O
Deletion O O
of O O
the O O
potential O O
initiator O O
element O O
does O O
not O O
affect O O
repression O O
of O O
the O O
p21 B-GENE B-GENE
promoter E-GENE E-GENE
by O O
c B-GENE B-GENE
- I-GENE I-GENE
Myc E-GENE E-GENE
. O O
Fetal O O
lung O O
volume O O
: O O
estimation O O
at O O
MR O O
imaging O O
- O O
initial O O
results O O
. O O

Of O O
its O O
gene O O
products O O
, O O
E6 S-GENE S-GENE
binds O O
to O O
and O O
inactivates O O
p53 B-GENE B-GENE
tumor I-GENE I-GENE
suppressor I-GENE I-GENE
protein E-GENE E-GENE
by O O
ubiquitin S-GENE B-GENE
/ O I-GENE
proteasome O I-GENE
- O I-GENE
dependent O I-GENE
degradation O E-GENE
. O O
In O O
mouse O O
, O O
Mmip1 S-GENE S-GENE
( O O
Mad B-GENE B-GENE
member I-GENE I-GENE
interacting I-GENE I-GENE
protein I-GENE I-GENE
1 E-GENE E-GENE
) O O
and O O
Smc3 S-GENE S-GENE
share O O
99% O S-GENE
sequence O O
identity O O
and O O
are O O
products O O
of O O
the O O
same O O
gene O O
. O O
An O O
element O O
within O O
the O O
5 O O
' O O
untranslated O O
region O O
of O O
human B-GENE B-GENE
Hsp70 I-GENE I-GENE
mRNA E-GENE E-GENE
which O O
acts O O
as O O
a O O
general O O
enhancer O O
of O O
mRNA O B-GENE
translation O E-GENE
. O O
In O O
SN-48 O S-GENE
neuronal O O
cells O O
that O O
express O O
MR S-GENE O
, O O
GR S-GENE S-GENE
, O O
and O O
5-HT1A B-GENE B-GENE
receptors E-GENE E-GENE
, O O
deletion O O
or O O
inactivation O O
of O O
the O O
nGRE O S-GENE
( O O
negative O O
GRE O S-GENE
) O O
eliminated O O
negative O O
regulation O O
of O O
the O O
rat B-GENE B-GENE
5-HT1A E-GENE E-GENE
or O O
heterologous O O
promoters O O
by O O
corticosteroids O O
, O O
whereas O O
its O O
inclusion O O
conferred O O
corticosteroid O O
- O O
induced O O
inhibition O O
to O O
a O O
heterologous O O
promoter O O
. O O
Corticosteroid O O
- O O
mediated O O
transcriptional O O
inhibition O O
was O O
greater O O
for O O
MR S-GENE O
/ O O
GR S-GENE O
in O O
combination O O
than O O
for O O
MR O O
or O O
GR O O
alone O O
. O O
Whereas O O
Smad2 S-GENE O
was O O
rapidly O O
phosphorylated O O
by O O
TGF B-GENE B-GENE
- I-GENE I-GENE
beta E-GENE E-GENE
and O O
involved O O
in O O
the O O
initial O O
activation O O
of O O
Agc S-GENE S-GENE
expression O O
in O O
confluent O O
cells O O
, O O
Smad2 O S-GENE
activation O O
was O O
not O O
required O O
for O O
maintaining O O
the O O
high O O
level O O
of O O
Agc O S-GENE
expression O O
. O O
Furthermore O O
, O O
this O O
kinase O B-GENE
- O I-GENE
deficient O I-GENE
mutant O E-GENE
inhibited O O
2-MeSADP O B-GENE
- O I-GENE
induced O I-GENE
caspase-3 S-GENE E-GENE
stimulation O O
and O O
the O O
associated O O
decrease O O
in O O
cell O O
number O O
. O O
Reverse B-GENE B-GENE
transcriptase E-GENE I-GENE
- O I-GENE
polymerase O E-GENE
chain O O
reaction O O
assays O O
showed O O
that O O
PKRDeltaE7 S-GENE S-GENE
is O O
expressed O O
in O O
a O O
broad O O
range O O
of O O
human O O
tissues O O
at O O
variable O O
levels O O
. O O
Both O O
pancreatic O O
and O O
intestinal O O
cell O O
lines O O
were O O
found O O
to O O
express O O
a O O
number O O
of O O
POU S-GENE S-GENE
( O O
OCT S-GENE B-GENE
binding O I-GENE
) O I-GENE
homeodomain O I-GENE
proteins O E-GENE
examined O O
by O O
electrophoretic O O
mobility O O
shift O O
assay O O
. O O
SV1 S-GENE S-GENE
has O O
a O O
33-amino O O
acid O O
insert O O
in O O
the O O
S1 O B-GENE
transmembrane O I-GENE
domain O E-GENE
that O O
does O O
not O O
alter O O
S1 O S-GENE
overall O O
hydrophobicity O O
, O O
but O O
makes O O
the O O
S0-S1 O S-GENE
linker O O
longer O O
. O O
Polyclonal O B-GENE
antibodies O E-GENE
against O O
the O O
N O O
- O O
terminal O O
part O O
( O O
amino O O
acids O O
12 O O
- O O
363 O O
) O O
and O O
the O O
C O O
- O O
terminal O O
part O O
( O O
amino O O
acids O O
330 O O
- O O
730 O O
) O O
of O O
rainbow B-GENE B-GENE
trout I-GENE I-GENE
HIF-1alpha I-GENE I-GENE
protein E-GENE E-GENE
recognized O O
rainbow B-GENE O
trout I-GENE O
and I-GENE O
chinook I-GENE B-GENE
salmon I-GENE I-GENE
HIF-1alpha I-GENE I-GENE
protein E-GENE E-GENE
in O O
Western O O
blot O O
analysis O O
. O O
The O O
v B-GENE B-GENE
- I-GENE I-GENE
Src E-GENE I-GENE
SH3 B-GENE I-GENE
domain E-GENE E-GENE
facilitates O O
a O O
cell O O
adhesion O O
- O O
independent O O
association O O
with O O
focal B-GENE B-GENE
adhesion I-GENE I-GENE
kinase E-GENE E-GENE
. O O
A O O
20-base O O
pair O O
oligonucleotide O O
containing O O
this O O
nonamer O O
confers O O
up O O
- O O
regulation O O
by O O
hypoxia O O
and O O
inhibition O O
by O O
unsaturated O O
fatty O O
acids O O
when O O
placed O O
upstream O O
of O O
a O O
heterologous O O
promoter O O
in O O
a O O
lacZ B-GENE B-GENE
reporter I-GENE I-GENE
construct E-GENE E-GENE
. O O
Deletion O O
analyses O O
implicate O O
the O O
N O O
- O O
terminal O O
110 O O
amino O O
acids O O
of O O
Grb14 S-GENE S-GENE
and O O
ankyrin S-GENE O
repeats O O
10 O O
- O O
19 O O
of O O
tankyrase B-GENE B-GENE
2 E-GENE E-GENE
in O O
mediating O O
this O O
interaction O O
. O O
Mutagenesis O O
of O O
SNT1(IRS)CX O S-GENE
identified O O
three O O
classes O O
of O O
effector O O
motifs O O
within O O
SNT O S-GENE
critical O O
for O O
both O O
sustained O O
ERK S-GENE S-GENE
activation O O
and O O
neuronal O O
differentiation O O
: O O
1 O O
) O O
four O O
phosphotyrosine O O
motifs O O
that O O
mediate O O
recruitment O O
of O O
Grb2 S-GENE S-GENE
, O O
2 O S-GENE
) O O
two O O
phosphotyrosine O O
motifs O O
that O O
mediate O O
recruitment O O
of O O
Shp2 S-GENE S-GENE
, O O
and O O
3 O O
) O O
a O O
C O O
- O O
terminal O O
motif O O
that O O
functions O O
by O O
helping O O
to O O
recruit O O
Sos S-GENE O
. O O
Exchanging O S-GENE
the O O
human O B-GENE
propeptide O E-GENE
in O O
this O O
chimera O O
with O O
either O O
the O O
murine B-GENE O
MIC-1 E-GENE S-GENE
or O O
TGF B-GENE B-GENE
- I-GENE I-GENE
beta1 I-GENE I-GENE
propeptide E-GENE E-GENE
resulted O O
in O O
secretion O O
of O O
the O O
unprocessed O O
, O O
monomeric O O
chimera O O
, O O
suggesting O O
a O O
specific O O
interaction O O
between O O
the O O
human B-GENE B-GENE
MIC-1 I-GENE I-GENE
propeptide E-GENE E-GENE
and O O
mature O O
peptide O O
. O O
Radiolabeled O O
biantennary O O
N O O
- O O
glycans O O
synthesized O O
by O O
Pro(-)5Lec20 O O
were O O
proportionately O O
less O O
ricin O O
- O O
bound O O
than O O
similar O O
species O O
from O O
parental O O
CHO O O
cells O O
, O O
and O O
Lec20 O O
cell O O
extracts O O
had O O
a O O
markedly O O
reduced O O
ability O O
to O O
transfer O O
Gal O O
to O O
GlcNAc O O
- O O
terminating O O
acceptors O O
. O O

We O O
found O O
that O O
the O O
SOCS B-GENE S-GENE
box E-GENE O
interacted O O
with O O
Cullin-2 S-GENE S-GENE
and O O
promoted O O
ubiquitination O O
of O O
TEL S-GENE B-GENE
- O I-GENE
JAK2 S-GENE E-GENE
. O O
Neuron B-GENE O
- I-GENE O
specific I-GENE O
Bcl-2 I-GENE S-GENE
homology I-GENE O
3 I-GENE O
domain I-GENE O
- I-GENE O
only I-GENE O
splice I-GENE O
variant E-GENE O
of O O
Bak S-GENE S-GENE
is O O
anti O B-GENE
- O I-GENE
apoptotic O E-GENE
in O O
neurons O O
, O O
but O O
pro O O
- O O
apoptotic O O
in O O
non O O
- O O
neuronal O O
cells O O
. O O
Finally O O
a O O
10-nucleotide O O
region O O
flanking O O
the O O
exon O B-GENE
4 O I-GENE
protein O I-GENE
- O I-GENE
binding O I-GENE
site O E-GENE
is O O
homologous O O
to O O
instability O O
elements O O
within O O
five O O
other O O
transcripts O O
, O O
suggesting O O
that O O
a O O
common O O
coding O O
region O O
determinant O O
may O O
exist O O
. O O

Sequence O O
comparison O O
and O O
binding O O
studies O O
of O O
the O O
18-bp B-GENE B-GENE
MOK2-binding I-GENE I-GENE
sites E-GENE E-GENE
present O O
in O O
intron O O
2 O O
of O O
human O O
, O O
bovine O O
, O O
and O O
mouse B-GENE O
IRBP I-GENE B-GENE
genes E-GENE E-GENE
show O O
that O O
the O O
3'-half O O
sequence O O
is O O
the O O
essential O O
core O O
element O O
for O O
MOK2 O S-GENE
binding O O
. O O
Furthermore O O
, O O
SB203580 O B-GENE
inhibited O I-GENE
LPS O E-GENE
- O O
induced O O
activation O O
of O O
Sp1 S-GENE S-GENE
, O O
as O O
well O O
as O O
the O O
promoter O O
activity O O
in O O
cells O O
transfected O O
with O O
a O O
plasmid O O
containing O O
the O O
Sp1 O B-GENE
consensus O I-GENE
sequence O E-GENE
. O O
We O O
confirmed O O
the O O
interaction O O
between O O
TLS S-GENE S-GENE
and O O
p65 S-GENE S-GENE
by O O
the O O
pull O O
- O O
down O O
assay O O
in O O
vitro O O
and O O
by O O
a O O
coimmunoprecipitation O O
experiment O O
followed O O
by O O
Western O O
blot O O
of O O
the O O
cultured O O
cell O O
in O O
vivo O O
. O O
Analysis O O
of O O
regulatory O O
regions O O
in O O
the O O
promoter O O
of O O
the O O
ctr4(+ B-GENE S-GENE
) I-GENE O
copper I-GENE B-GENE
transporter I-GENE I-GENE
gene E-GENE E-GENE
in O O
fission O O
yeast O O
Schizosaccharomyces O O
pombe O O
reveals O O
the O O
identity O O
of O O
a O O
conserved O O
copper O B-GENE
- O I-GENE
signaling O I-GENE
element O E-GENE
( O O
CuSE O S-GENE
) O O
, O O
which O O
is O O
recognized O O
by O O
the O O
transcription B-GENE B-GENE
factor I-GENE I-GENE
Cuf1 E-GENE E-GENE
. O O
Based O O
on O O
mutational O O
data O O
and O O
possible O O
mRNA O O
structure O O
, O O
we O O
hypothesized O O
about O O
the O O
effect O O
of O O
mRNA O O
structure O O
on O O
translation O O
of O O
the O O
two O O
major O O
C B-GENE B-GENE
/ I-GENE I-GENE
EBPepsilon I-GENE I-GENE
isoforms E-GENE E-GENE
: O O
p32 S-GENE S-GENE
and O O
p30 S-GENE S-GENE
. O O
WRN B-GENE B-GENE
helicase E-GENE E-GENE
resolves O O
alternate O O
DNA O O
structures O O
including O O
tetraplex O O
and O O
triplex O O
DNA O O
, O O
and O O
Holliday O S-GENE
junctions O O
. O O
These O O
data O O
suggest O O
that O O
ADAM B-GENE S-GENE
- I-GENE O
TS12 E-GENE S-GENE
may O O
play O O
roles O O
in O O
pulmonary O O
cells O O
during O O
fetal O O
development O O
or O O
in O O
tumor O O
processes O O
through O O
its O O
proteolytic O O
activity O O
or O O
as O O
a O O
molecule O O
potentially O O
involved O O
in O O
regulation O O
of O O
cell O O
adhesion O O
. O O
Binding O O
of O O
serum B-GENE B-GENE
response I-GENE I-GENE
factor E-GENE E-GENE
to O O
CArG O B-GENE
box O I-GENE
sequences O E-GENE
is O O
necessary O O
but O O
not O O
sufficient O O
to O O
restrict O O
gene O O
expression O O
to O O
arterial O O
smooth O O
muscle O O
cells O O
. O O
Together O O
, O O
these O O
results O O
identify O O
HPK1 S-GENE O
as O O
a O O
new O O
component O O
of O O
TCR S-GENE O
signaling O O
. O O
Biol O O
. O O

The O O
size O O
of O O
the O O
infarct O O
was O O
determined O O
using O O
the O O
creatine B-GENE B-GENE
kinase E-GENE E-GENE
integral O O
method O O
. O O
A O O
new O O
echocardiographic O O
technique O O
is O O
described O O
with O O
a O O
conventional O O
M O O
mode O O
, O O
digitalised O O
2D O O
and O O
tissular O O
Doppler O O
which O O
has O O
a O O
comparable O O
ability O O
to O O
identify O O
the O O
anomalous O O
pathways O O
of O O
electric O O
conduction O O
using O O
a O O
non O O
- O O
invasive O O
method O O
. O O

SELECTION O O
CRITERIA O O
: O O
Randomised O O
controlled O O
trials O O
of O O
cabergoline O O
versus O O
placebo O O
in O O
patients O O
with O O
a O O
clinical O O
diagnosis O O
of O O
idiopathic O O
Parkinson O O
's O O
disease O O
and O O
long O O
- O O
term O O
complications O O
of O O
levodopa O O
therapy O O
. O O

CONCLUSIONS O O
: O O
Using O O
icodextrin O O
- O O
based O O
instead O O
of O O
glucose O O
- O O
based O O
PD O O
fluids O O
can O O
largely O O
reduce O O
the O O
formation O O
of O O
Amadori O B-GENE
albumin S-GENE E-GENE
and O O
AGEs O O
. O O
In O O
contrast O O
, O O
exogenous B-GENE O
PTHrP1 I-GENE S-GENE
- I-GENE O
34 I-GENE O
and I-GENE O
1 I-GENE O
- I-GENE O
86 I-GENE O
peptides E-GENE O
did O O
not O O
significantly O O
affect O O
IL-8 S-GENE O
production O O
; O O
moreover O O
, O O
PTHrP B-GENE B-GENE
- I-GENE I-GENE
neutralizing I-GENE I-GENE
antibodies E-GENE E-GENE
did O O
not O O
inhibit O O
the O O
production O O
of O O
IL-8 O O
by O O
transfected O O
PTHrP. O O
Deterministic O O
effects O O
. O O

Unusual O O
two B-GENE O
- I-GENE O
domain I-GENE B-GENE
arginine I-GENE I-GENE
kinases E-GENE E-GENE
( O O
AKs S-GENE S-GENE
) O O
arose O O
independently O O
at O O
least O O
two O O
times O O
during O O
molecular O O
evolution O O
of O O
phosphagen B-GENE B-GENE
kinases E-GENE E-GENE
: O O
AKs O S-GENE
from O O
the O O
primitive O O
sea O O
anemone O O
Anthopleurura O B-GENE
japonicus O E-GENE
and O O
from O O
the O O
clam O B-GENE
Pseudocardium O E-GENE
sachalinensis O O
. O O
The O O
mouse B-GENE B-GENE
platelet I-GENE I-GENE
- I-GENE I-GENE
derived I-GENE I-GENE
growth I-GENE I-GENE
factor I-GENE E-GENE
( I-GENE O
PDGF I-GENE S-GENE
) I-GENE O
beta I-GENE B-GENE
- I-GENE I-GENE
receptor I-GENE I-GENE
promoter E-GENE E-GENE
contains O O
a O O
CCAAT O O
motif O O
, O O
and O O
NF B-GENE S-GENE
- I-GENE O
Y E-GENE O
plays O O
an O O
essential O O
role O O
in O O
its O O
transcription O O
. O O
Baseline O O
MBF O O
in O O
females O O
was O O
significantly O O
( O O
P<0.001 O O
) O O
higher O O
than O O
in O O
males O O
. O O

No O O
preferential O O
VH S-GENE O
/ O O
VL S-GENE O
- O O
chains O O
correlated O O
with O O
any O O
of O O
the O O
12 O O
different O O
antigen O O
reactivities O O
, O O
even O O
for O O
mAbs O S-GENE
with O O
nearly O O
identical O O
cross O O
- O O
reactivities O O
. O O
Recently O O
, O O
it O O
was O O
shown O O
that O O
purified O O
RAG1/2 B-GENE B-GENE
proteins E-GENE E-GENE
can O O
cleave O O
DNA O O
hairpins O O
in O O
vitro O O
, O O
but O O
the O O
same O O
activity O O
was O O
also O O
described O O
for O O
a O O
protein O O
complex O O
of O O
the O O
DNA O B-GENE
repair O I-GENE
proteins O I-GENE
Nbs1/Mre11/Rad50 O E-GENE
. O O
In O O
addition O O
, O O
we O O
did O O
not O O
detect O O
significant O O
differences O O
in O O
CDR3 B-GENE O
sequences E-GENE O
of O O
endogenous B-GENE O
Ig I-GENE B-GENE
lambdaL E-GENE E-GENE
and O O
kappaL B-GENE B-GENE
chain I-GENE I-GENE
gene I-GENE E-GENE
loci E-GENE O
cloned O O
from O O
peripheral O O
blood O O
lymphocytes O O
of O O
an O O
NBS O S-GENE
patient O O
and O O
of O O
healthy O O
individuals O O
. O O
Phase O O
II O O
study O O
of O O
paclitaxel O O
and O O
oral O O
etoposide O O
in O O
patients O O
with O O
locally O O
advanced O O
or O O
metastatic O O
non O O
- O O
small O O
cell O O
lung O O
cancer O O
. O O

Oral O O
supplementation O O
of O O
L O O
- O O
arginine O O
significantly O O
increased O O
plasma O O
L O O
- O O
citrulline O O
, O O
which O O
indicated O O
enhancement O O
of O O
NO O O
production O O
. O O

This O O
activation O O
was O O
then O O
blocked O O
by O O
CGS O O
12066A. O O

Our O O
results O O
suggest O O
that O O
WASP S-GENE S-GENE
activates O O
transcription O O
following O O
TCR S-GENE S-GENE
stimulation O O
in O O
a O O
manner O O
that O O
is O O
independent O O
of O O
its O O
role O O
in O O
Arp2/3-directed O B-GENE
actin S-GENE I-GENE
polymerization O E-GENE
. O O
Two O O
independent O O
transgenic O O
lines O O
were O O
produced O O
, O O
and O O
both O O
showed O O
expression O O
of O O
the O O
Gus B-GENE B-GENE
gene E-GENE E-GENE
specifically O O
in O O
the O O
endosperm O O
during O O
mid O O
- O O
development O O
( O O
first O O
detected O O
10 O O
- O O
12 O O
d O O
after O O
anthesis O O
) O O
. O O
Here O O
we O O
demonstrate O O
that O O
native B-GENE O
MRCK E-GENE S-GENE
exists O O
in O O
high O O
- O O
molecular O O
- O O
weight O O
complexes O O
. O O
These O O
data O O
define O O
a O O
conserved O O
pathway O O
wherein O O
sequential O O
histone S-GENE O
modifications O O
establish O O
a O O
" O O
histone O O
code O O
" O O
essential O O
for O O
the O O
epigenetic O O
inheritance O O
of O O
heterochromatin O O
assembly O O
. O O
Regression O O
analyses O O
showed O O
that O O
SOREMP O O
dream O O
occurrences O O
were O O
significantly O O
related O O
to O O
the O O
amount O O
of O O
REM O O
sleep O O
, O O
while O O
NREMP O O
dream O O
occurrences O O
were O O
related O O
to O O
arousals O O
from O O
NREM O O
sleep O O
. O O

Instead O O
, O O
TRPS1 S-GENE S-GENE
potently O O
and O O
specifically O O
represses O O
transcriptional O O
activation O O
mediated O O
by O O
other O O
GATA B-GENE B-GENE
factors E-GENE E-GENE
. O O
9.7 O O
( O O
95% O O
CI O O
: O O
9.6 O O
- O O
9.7 O O
) O O
micromol O O
/ O O
L O O
among O O
women O O
( O O
P O O
= O O
0.003 O O
) O O
. O O

Three O O
patients O O
received O O
additional O O
cycles O O
of O O
5-fluorouracil O O
+ O O
/- O O
leucovorin O O
as O O
maintenance O O
chemotherapy O O
. O O
RESULTS O O
: O O
Thirty O O
males O O
and O O
21 O O
females O O
with O O
a O O
median O O
age O O
of O O
55 O O
years O O
( O O
range O O
31 O O
- O O
-73 O O
years O O
) O O
were O O
treated O O
. O O

The O O
Delta6CCI O O
virus O O
was O O
extremely O O
attenuated O O
in O O
replication O O
capacity O O
yet O O
retained O O
infectiousness O O
for O O
CEMx174 O O
and O O
MT4 O O
cells O O
. O O

Secretion O O
of O O
interleukin-8 S-GENE S-GENE
, O O
RANTES S-GENE S-GENE
, O O
macrophage B-GENE B-GENE
inflammatory I-GENE I-GENE
protein I-GENE I-GENE
1alpha E-GENE E-GENE
, O O
and O O
10-kappaDa B-GENE B-GENE
IFN I-GENE I-GENE
- I-GENE I-GENE
gamma I-GENE I-GENE
- I-GENE I-GENE
inducible I-GENE I-GENE
protein E-GENE E-GENE
were O O
increased O O
in O O
differentiating O O
keratinocytes O O
by O O
E6 S-GENE O
. O O
Another O O
mutant O O
, O O
T255A O S-GENE
, O O
lost O O
the O O
ability O O
to O O
bind O O
E4orf6 S-GENE S-GENE
, O O
but O O
unexpectedly O O
, O O
viral O B-GENE
late O I-GENE
- O I-GENE
gene O E-GENE
expression O O
was O O
not O O
affected O O
. O O
Herein O O
PPARgamma S-GENE S-GENE
, O O
liganded O O
by O O
either O O
natural O O
( O O
15d O B-GENE
- O I-GENE
PGJ(2 O E-GENE
) O O
and O O
PGD(2 O S-GENE
) O O
) O O
or O O
synthetic O O
ligands O O
( O O
BRL49653 O S-GENE
and O O
troglitazone O O
) O O
, O O
selectively O O
inhibited O O
expression O O
of O O
the O O
cyclin B-GENE B-GENE
D1 I-GENE I-GENE
gene E-GENE E-GENE
. O O
Here O O
we O O
demonstrate O O
that O O
the O O
Ras S-GENE B-GENE
- O I-GENE
activated O I-GENE
Raf S-GENE I-GENE
- O I-GENE
MEK S-GENE I-GENE
- O I-GENE
extracellular B-GENE I-GENE
signal I-GENE I-GENE
- I-GENE I-GENE
regulated I-GENE I-GENE
kinase E-GENE E-GENE
( O O
ERK S-GENE S-GENE
) O O
signaling O O
pathway O O
can O O
specifically O O
control O O
the O O
expression O O
of O O
individual O O
integrin B-GENE B-GENE
subunits E-GENE E-GENE
in O O
a O O
variety O O
of O O
human O O
and O O
mouse O O
cell O O
lines O O
. O O
PABP S-GENE S-GENE
is O O
a O O
modular O O
protein O O
, O O
with O O
four O O
N O O
- O O
terminal O O
RNA O B-GENE
- O I-GENE
binding O I-GENE
domains O E-GENE
and O O
an O O
extensive O O
C O O
terminus O O
. O O
Children O O
who O O
developed O O
lower O O
respiratory O O
tract O O
infections O O
or O O
PCP O O
had O O
increased O O
rates O O
of O O
decline O O
of O O
CD4 S-GENE O
cell O O
counts O O
during O O
the O O
first O O
6 O O
months O O
of O O
life O O
. O O
The O O
reproductive O O
effects O O
of O O
the O O
administration O O
of O O
4-chloro-2-methylphenoxyacetic O O
acid O O
( O O
MCPA O O
) O O
to O O
rats O O
were O O
evaluated O O
through O O
two O O
generations O O
, O O
from O O
prior O O
to O O
mating O O
, O O
throughout O O
mating O O
, O O
to O O
gestation O O
and O O
lactation O O
. O O

Coexposure O O
to O O
FP O S-GENE
also O O
resulted O O
in O O
a O O
more O O
pronounced O O
and O O
sustained O O
activation O O
of O O
the O O
mitogen B-GENE B-GENE
- I-GENE I-GENE
activated I-GENE I-GENE
protein I-GENE I-GENE
kinase I-GENE I-GENE
kinase E-GENE I-GENE
/ O I-GENE
extracellular B-GENE I-GENE
signal I-GENE I-GENE
- I-GENE I-GENE
regulated I-GENE I-GENE
protein I-GENE I-GENE
kinase E-GENE E-GENE
cascade O O
after O O
PMA O S-GENE
treatment O O
, O O
although O O
disruption O O
of O O
this O O
pathway O O
by O O
the O O
mitogen B-GENE B-GENE
- I-GENE I-GENE
activated I-GENE I-GENE
protein I-GENE I-GENE
kinase I-GENE I-GENE
kinase I-GENE I-GENE
1 E-GENE E-GENE
inhibitor O O
U0126 O S-GENE
did O O
not O O
prevent O O
potentiation O O
of O O
apoptosis O O
. O O
Also O O
, O O
the O O
EWS B-GENE B-GENE
protein E-GENE E-GENE
stimulates O O
transcription O O
mediated O O
by O O
the O O
COOH O B-GENE
- O I-GENE
terminal O I-GENE
transactivation O I-GENE
domain O E-GENE
of O O
the O O
cofactor O B-GENE
CREB B-GENE I-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
protein E-GENE E-GENE
( O O
CBP S-GENE S-GENE
) O O
. O O
In O O
the O O
present O O
study O O
, O O
we O O
have O O
determined O O
the O O
ICBP90 B-GENE B-GENE
gene E-GENE E-GENE
structure O O
by O O
screening O O
of O O
a O O
human O O
placenta O O
genomic O O
library O O
and O O
PCR O O
analysis O O
. O O
Tumor O O
- O O
like O O
accumulation O O
on O O
Tl-201 O O
SPECT O O
in O O
subacute O O
hemorrhagic O O
cerebral O O
infarction O O
. O O

METHODS O O
: O O
126 O O
patients O O
with O O
histologically O O
confirmed O O
MFH O O
were O O
analyzed O O
. O O

It O O
is O O
surprising O O
that O O
dnaE173 O O
, O O
a O O
potent O O
mutator O O
mutation O O
specific O O
for O O
sequence O O
substitution O O
as O O
well O O
as O O
single O O
- O O
base O O
frameshift O O
, O O
did O O
not O O
enhance O O
the O O
frequency O O
of O O
the O O
hot O O
- O O
spot O O
frameshift O O
mutation O O
. O O

Its O O
transcription O O
in O O
vitro O O
by O O
pol B-GENE B-GENE
III E-GENE E-GENE
requires O O
the O O
same O O
factors O O
as O O
the O O
U6 B-GENE B-GENE
gene E-GENE E-GENE
with O O
the O O
major O O
exception O O
that O O
the O O
modified O O
TATA O O
- O O
box O O
of O O
this O O
construct O O
only O O
interacts O O
with O O
a O O
TATA B-GENE B-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
protein E-GENE E-GENE
( O O
TBP S-GENE S-GENE
) O O
mutant O O
( O O
TBP B-GENE B-GENE
- I-GENE I-GENE
DR2 E-GENE E-GENE
) O O
but O O
not O O
with O O
TBP B-GENE B-GENE
wild I-GENE I-GENE
- I-GENE I-GENE
type E-GENE E-GENE
( O O
TBPwt S-GENE S-GENE
) O O
. O O
HSF S-GENE S-GENE
binds O O
DNA O O
as O O
a O O
trimer O O
, O O
and O O
additional O O
trimers O O
can O O
bind O O
DNA O O
co O O
- O O
operatively O O
. O O
We O O
also O O
demonstrate O O
that O O
the O O
spo20(+ B-GENE B-GENE
) I-GENE I-GENE
gene I-GENE I-GENE
product E-GENE E-GENE
is O O
structurally O O
homologous O O
to O O
Saccharomyces B-GENE B-GENE
cerevisiae I-GENE I-GENE
Sec14 E-GENE E-GENE
, O O
the O O
major O B-GENE
phosphatidylinositol O I-GENE
transfer O I-GENE
protein O E-GENE
of O O
budding O O
yeast O O
. O O
There O O
was O O
no O O
evidence O O
of O O
linkage O O
disequilibrium O O
between O O
the O O
polymorphic O O
site O O
in O O
the O O
B O O
cell O O
specific O O
promoter O O
and O O
those O O
in O O
the O O
3 O O
' O O
UTR O O
. O O

Their O O
numbers O O
have O O
regularly O O
increased O O
since O O
the O O
mid-1970s O O
. O O

Specimen O O
mass O O
reduction O O
increased O O
with O O
irradiance O O
from O O
19 O O
to O O
72% O O
of O O
the O O
initial O O
mass O O
for O O
9 O O
- O O
-31 O O
W O O
/ O O
cm(2 O O
) O O
, O O
respectively O O
. O O

In O O
addition O O
, O O
another O O
derivative O O
of O O
pCMVJS21 O S-GENE
( O O
pCMVJS21DeltaGP O O
) O O
in O O
which O O
the O O
gag S-GENE O
, O O
pol S-GENE O
( O O
and O O
orf B-GENE O
- I-GENE O
x E-GENE O
) O O
coding O O
sequences O O
were O O
deleted O O
also O O
gave O O
transformed O O
foci O O
. O O
In O O
conclusion O O
, O O
tube O O
size O O
estimated O O
by O O
Cole O O
's O O
formula O O
tends O O
to O O
be O O
smaller O O
than O O
practically O O
appropriate O O
tube O O
size O O
for O O
pediatric O O
cardiac O O
anesthesia O O
, O O
and O O
therefore O O
we O O
suggest O O
new O O
formula O O
to O O
estimate O O
the O O
tube O O
size O O
. O O

An O O
F222W B-GENE O
: I-GENE O
W21F I-GENE B-GENE
rGST I-GENE I-GENE
A1 I-GENE E-GENE
- I-GENE O
1 I-GENE O
double I-GENE O
mutant E-GENE O
provides O O
a O O
direct O O
fluorescence O O
probe O O
of O O
changes O O
in O O
the O O
environment O O
of O O
the O O
C O B-GENE
- O I-GENE
terminal O I-GENE
residue O E-GENE
. O O
The O O
recessive O O
hos1 S-GENE O
mutation O O
causes O O
enhanced O O
induction O O
of O O
the O O
CBF B-GENE B-GENE
transcription I-GENE I-GENE
factors E-GENE E-GENE
by O O
low O O
temperature O O
as O O
well O O
as O O
of O O
their O O
downstream O O
cold O B-GENE
- O I-GENE
responsive O I-GENE
genes O E-GENE
. O O
Stable O O
transfection O O
of O O
human S-GENE B-GENE
CHOP B-GENE I-GENE
cDNA E-GENE E-GENE
into O O
mammary O O
carcinoma O O
cells O O
demonstrated O O
that O O
CHOP O S-GENE
functioned O O
not O O
as O O
a O O
mediator O O
of O O
hGH S-GENE O
- O O
stimulated O O
mitogenesis O O
but O O
rather O O
enhanced O O
the O O
protection O O
from O O
apoptosis O O
afforded O O
by O O
hGH O O
in O O
a O O
p38 S-GENE B-GENE
MAPK O E-GENE
- O O
dependent O O
manner O O
. O O
In O O
contrast O O
, O O
neither O O
I. O O
argentina O O
nor O O
I. O O
theezans O O
exerted O O
any O O
effect O O
on O O
BF O O
or O O
intestinal O O
propulsion O O
. O O

A O O
comparison O O
of O O
the O O
duplicated O O
Vkappa B-GENE B-GENE
genes E-GENE E-GENE
suggests O O
positive O O
selection O O
on O O
the O O
complementarity O O
- O O
determining O O
regions O O
of O O
the O O
duplicated O O
genes O O
by O O
point O O
mutations O O
. O O
In O O
contrast O O
, O O
the O O
ubiquitous O O
expression O O
of O O
p19(INK4d O S-GENE
) O O
has O O
not O O
been O O
previously O O
described O O
in O O
human O O
or O O
murine O O
B O O
- O O
lineage O O
cells O O
. O O
The O O
results O O
show O O
that O O
cognitive O O
stimulation O O
enhanced O O
performance O O
on O O
the O O
Boston O O
Naming O O
Test O O
and O O
a O O
Word O O
List O O
Recognition O O
Task O O
; O O
physical O O
intervention O O
, O O
however O O
, O O
did O O
not O O
reach O O
statistical O O
significance O O
. O O

Instead O O
, O O
affective O O
flattening O O
was O O
associated O O
with O O
both O O
dopamine B-GENE B-GENE
receptor E-GENE E-GENE
sensitivity O O
and O O
psychomotor O O
slowing O O
. O O
Homo O O
- O O
oligomerisation O O
and O O
nuclear O O
localisation O O
of O O
mouse B-GENE B-GENE
histone I-GENE I-GENE
deacetylase I-GENE I-GENE
1 E-GENE E-GENE
. O O
These O O
data O O
reveal O O
a O O
complex O O
network O O
of O O
interactions O O
between O O
GTPases S-GENE O
in O O
the O O
ARF B-GENE B-GENE
family E-GENE E-GENE
and O O
their O O
effectors O O
and O O
reveal O O
a O O
potential O O
for O O
cross O O
- O O
talk O O
not O O
demonstrated O O
previously O O
. O O
With O O
NEU S-GENE B-GENE
overexpression O E-GENE
, O O
nodal O O
control O O
decreased O O
from O O
72% O O
to O O
34% O O
( O O
p O O
= O O
.008 O O
) O O
. O O
At O O
the O O
time O O
of O O
the O O
blind O O
therapeutic O O
doses O O
, O O
Tg S-GENE O
- O O
off O O
values O O
ranged O O
from O O
8 O O
to O O
608 O O
microg O O
/ O O
l O O
. O O
Effects O O
of O O
a O O
booster O O
dose O O
of O O
tetanus O O
toxoid O O
after O O
different O O
primary O O
courses O O
of O O
vaccination O O
: O O
implications O O
on O O
the O O
use O O
of O O
immune B-GENE B-GENE
globulin E-GENE E-GENE
. O O
Using O O
RACE O O
techniques O O
we O O
have O O
cloned O O
and O O
sequenced O O
one O O
of O O
the O O
hamster O B-GENE
liver O I-GENE
3-hydroxy B-GENE I-GENE
- I-GENE I-GENE
hexobarbital I-GENE I-GENE
dehydrogenases E-GENE E-GENE
which O O
catalyze O O
not O O
only O O
cyclic O O
alcohols O O
but O O
also O O
17beta O O
- O O
hydroxy O O
- O O
steroids O O
and O O
3alpha O B-GENE
- O I-GENE
hydroxysteroids O E-GENE
. O O
A O O
mutation O O
in O O
the O O
C O B-GENE
domain O E-GENE
of O O
Rb S-GENE S-GENE
, O O
L901Q O S-GENE
, O O
has O O
been O O
identified O O
that O O
completely O O
abolishes O O
cdk4/D1 O S-GENE
phosphorylation O O
of O O
the O O
isolated O O
C O B-GENE
domain O E-GENE
. O O
An O O
association O O
was O O
demonstrated O O
between O O
the O O
expression O O
of O O
aberrantly O O
and/or O O
alternatively O O
spliced O O
mdm2 B-GENE B-GENE
mRNAs E-GENE E-GENE
and O O
a O O
lack O O
of O O
progesterone B-GENE B-GENE
receptor E-GENE E-GENE
. O O
Histological O O
examination O O
showed O O
lichenoid O O
changes O O
, O O
acantholytic O O
blister O O
formation O O
and O O
apoptotic O O
keratinocytes O O
. O O

We O O
find O O
that O O
our O O
response O O
function O O
is O O
well O O
approximated O O
by O O
the O O
GSER O O
only O O
within O O
a O O
particular O O
frequency O O
range O O
determined O O
by O O
the O O
material O O
parameters O O
of O O
both O O
the O O
bead O O
and O O
the O O
network O O
. O O

It O O
is O O
shown O O
that O O
, O O
for O O
any O O
periodic O O
input O O
, O O
the O O
map O O
representing O O
the O O
relation O O
between O O
input O O
phases O O
at O O
consecutive O O
discharge O O
times O O
can O O
be O O
restricted O O
to O O
a O O
piecewise O O
continuous O O
, O O
orientation O O
preserving O O
circle O O
map O O
. O O

Nine O O
strains O O
were O O
subtyped O O
as O O
Camp O O
. O O
jejuni O O
subsp O O
. O O
jejuni O O
biotype O O
II O O
and O O
the O O
remaining O O
ones O O
as O O
biotype O O
I. O O

Analysis O O
of O O
mCTR B-GENE B-GENE
mRNAs E-GENE E-GENE
has O O
revealed O O
that O O
the O O
three O O
alternative O O
promoters O O
give O O
rise O O
to O O
at O O
least O O
seven O O
mCTR B-GENE B-GENE
isoforms E-GENE E-GENE
in O O
the O O
5 O O
' O O
region O O
of O O
the O O
gene O O
and O O
generate O O
5'-untranslated O O
regions O O
of O O
very O O
different O O
lengths O O
. O O
We O O
previously O O
showed O O
that O O
this O O
proteolysis O O
1 O O
) O O
can O O
be O O
acutely O O
promoted O O
by O O
the O O
phorbol O B-GENE
ester O I-GENE
phorbol O I-GENE
12-myristate O I-GENE
13-acetate O E-GENE
( O O
PMA O S-GENE
) O O
, O O
2 O O
) O O
requires O O
a O O
metalloprotease S-GENE O
activity O O
, O O
3 O O
) O O
generates O O
both O O
shed O O
GHBP S-GENE S-GENE
and O O
a O O
membrane B-GENE O
- I-GENE O
associated E-GENE O
GHR B-GENE S-GENE
transmembrane I-GENE O
/ I-GENE O
cytoplasmic I-GENE O
domain E-GENE O
remnant O O
, O O
and O O
4 O O
) O O
results O O
in O O
down O O
- O O
regulation O O
of O O
GHR O S-GENE
abundance O O
and O O
GH O B-GENE
signaling O E-GENE
. O O
Effects O O
of O O
3 O O
' O O
terminus O O
modifications O O
on O O
mRNA O O
functional O O
decay O O
during O O
in O O
vitro O O
protein O O
synthesis O O
. O O

A O O
comprehensive O O
neuropsychological O O
battery O O
was O O
administered O O
to O O
48 O O
veterans O O
with O O
Gulf O O
War O O
Illness O O
( O O
GWI O O
) O O
characterized O O
by O O
severe O O
fatigue O O
( O O
GV O O
- O O
F O O
) O O
and O O
39 O O
healthy O O
veterans O O
( O O
GV O O
- O O
H O O
) O O
. O O

Reverse O O
transcription O O
- O O
PCR O O
analysis O O
of O O
mRNA O O
from O O
patients O O
shows O O
that O O
each O O
of O O
these O O
five O O
mutations O O
results O O
in O O
aberrant O O
splicing O O
. O O

RESULTS O O
: O O
Coronary O O
mortality O O
during O O
the O O
median O O
follow O O
- O O
up O O
time O O
of O O
17 O O
months O O
was O O
6-fold O O
higher O O
in O O
the O O
highest O O
tertile O O
for O O
CRP S-GENE S-GENE
and O O
IL-6 S-GENE S-GENE
and O O
3.5-fold O O
higher O O
in O O
the O O
highest O O
tertile O O
for O O
fibrinogen S-GENE S-GENE
and O O
TNF B-GENE B-GENE
- I-GENE I-GENE
alpha E-GENE E-GENE
than O O
in O O
the O O
respective O O
combined O O
lower O O
tertiles O O
. O O
The O O
relationship O O
of O O
the O O
factor B-GENE B-GENE
V I-GENE I-GENE
Leiden I-GENE I-GENE
mutation E-GENE E-GENE
or O O
the O O
deletion O O
- O O
deletion O O
polymorphism O O
of O O
the O O
angiotensin B-GENE B-GENE
converting I-GENE I-GENE
enzyme E-GENE E-GENE
to O O
postoperative O O
thromboembolic O O
events O O
following O O
total O O
joint O O
arthroplasty O O
. O O
These O O
disorders O O
include O O
low O O
- O O
back O O
pain O O
, O O
saddle O O
anesthesia O O
, O O
bilateral O O
sciatica O O
, O O
then O O
motor O O
weakness O O
of O O
the O O
lower O O
extremities O O
or O O
chronic O O
paraplegia O O
and O O
, O O
bladder O O
dysfunction O O
. O O

Sural O O
nerve O O
biopsy O O
showed O O
mild O O
thickening O O
of O O
the O O
perineurium O O
, O O
vascular O O
alterations O O
with O O
inflammatory O O
cell O O
infiltration O O
in O O
the O O
perineurium O O
, O O
and O O
remarkable O O
loss O O
of O O
large O O
and O O
small O O
myelinated O O
fibers O O
. O O

To O O
examine O O
transcriptional O O
regulation O O
of O O
the O O
rat B-GENE B-GENE
eIF4E I-GENE I-GENE
gene E-GENE E-GENE
, O O
2.1 O O
kB O O
of O O
the O O
rat B-GENE B-GENE
eIF4E I-GENE I-GENE
promoter I-GENE E-GENE
region E-GENE O
was O O
cloned O O
and O O
the O O
contribution O O
of O O
specific O O
elements O O
in O O
regulating O O
transcription O O
was O O
determined O O
in O O
primary O O
cultures O O
of O O
rat O O
cardiocytes O O
and O O
in O O
a O O
murine O O
C(2)C(12 O O
) O O
myoblast O O
cell O O
line O O
. O O
When O O
this O O
CCAAT O O
box O O
was O O
inserted O O
into O O
a O O
heterologous O O
promoter O O
construct O O
, O O
OA O O
induction O O
was O O
dependent O O
on O O
an O O
intact O O
CCAAT O O
box O O
. O O

The O O
JHRLSS O O
has O O
been O O
used O O
in O O
prior O O
studies O O
to O O
assess O O
RLS O O
severity O O
, O O
but O O
has O O
not O O
previously O O
been O O
validated O O
in O O
relation O O
to O O
direct O O
measures O O
of O O
the O O
morbidity O O
associated O O
with O O
RLS O O
. O O

In O O
the O O
remaining O O
case O O
, O O
the O O
aneurysm O O
originated O O
from O O
the O O
proximal O O
end O O
of O O
the O O
associated O O
A1 O O
fenestration O O
. O O

GABA(B)R1 B-GENE O
g E-GENE O
was O O
expressed O O
in O O
both O O
brain O O
and O O
peripheral O O
tissues O O
. O O
Raes O O
, O O
P. O O

NF B-GENE B-GENE
- I-GENE I-GENE
kappaB E-GENE E-GENE
pathway O O
activation O O
occurs O O
during O O
transformation O O
induced O O
by O O
a O O
number O O
of O O
classical O O
oncogenes O O
, O O
including O O
Bcr S-GENE S-GENE
/ O O
Abl S-GENE S-GENE
, O O
Ras S-GENE S-GENE
and O O
Rac S-GENE S-GENE
, O O
and O O
is O O
necessary O O
for O O
full O O
transforming O O
potential O O
. O O
We O O
used O O
a O O
rev- O O
and O O
RRE S-GENE B-GENE
- O I-GENE
defective O I-GENE
HIV O I-GENE
type O I-GENE
1 O E-GENE
( O O
HIV-1 O O
) O O
molecular O O
clone O O
in O O
complementation O O
experiments O O
to O O
establish O O
a O O
method O O
for O O
the O O
rapid O O
isolation O O
of O O
posttranscriptional O O
regulatory O O
elements O O
from O O
the O O
mammalian O O
genome O O
by O O
selecting O O
for O O
rescue O O
of O O
virus O O
replication O O
. O O
Copyright O O
2001 O O
Academic O O
Press O O
. O O

A O O
novel O O
myeloid O O
- O O
restricted O O
zebrafish O O
CCAAT B-GENE B-GENE
/ I-GENE I-GENE
enhancer I-GENE I-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
protein E-GENE E-GENE
with O O
a O O
potent O O
transcriptional O O
activation O O
domain O O
. O O
Recently O O
, O O
we O O
discovered O O
that O O
alanine O O
substitutions O O
of O O
the O O
active O O
center O O
cleft O O
residues O O
significantly O O
impair O O
the O O
depurinating O O
and O O
ribosome O O
inhibitory O O
activity O O
of O O
PAP S-GENE S-GENE
. O O
SH2D1A B-GENE B-GENE
protein E-GENE E-GENE
levels O O
are O O
up O O
- O O
regulated O O
by O O
CD40 S-GENE S-GENE
cross O O
- O O
linking O O
and O O
down O O
- O O
regulated O O
by O O
B B-GENE B-GENE
cell I-GENE I-GENE
receptor E-GENE E-GENE
ligation O O
. O O
Cross O O
- O O
linking O O
FcalphaR S-GENE S-GENE
on O O
wt B-GENE O
- I-GENE O
ITAM E-GENE S-GENE
or O O
IIA B-GENE O
- I-GENE O
ITAM E-GENE S-GENE
cells O O
triggered O O
equivalent O O
PI B-GENE B-GENE
3-kinase E-GENE E-GENE
- O O
dependent O O
activation O O
of O O
PKBalpha S-GENE S-GENE
. O O
RPM S-GENE S-GENE
/ O O
RGL3 S-GENE S-GENE
resembled O O
AF-6 S-GENE S-GENE
and O O
Nore1 S-GENE O
in O O
interacting O O
strongly O O
with O O
constitutively O O
active O O
M B-GENE B-GENE
- I-GENE I-GENE
Ras E-GENE E-GENE
and O O
p21 B-GENE B-GENE
Ras E-GENE E-GENE
. O O
A O O
novel O O
potential O O
effector O O
of O O
M B-GENE B-GENE
- I-GENE I-GENE
Ras E-GENE E-GENE
and O O
p21 B-GENE B-GENE
Ras E-GENE E-GENE
negatively O O
regulates O O
p21 O B-GENE
Ras O I-GENE
- O I-GENE
mediated O I-GENE
gene O E-GENE
induction O O
and O O
cell O O
growth O O
. O O
The O O
mice O O
are O O
phenotypically O O
normal O O
and O O
do O O
not O O
develop O O
spontaneous O O
tumors O O
at O O
an O O
early O O
age O O
, O O
in O O
contrast O O
to O O
knock O O
- O O
out O O
( O O
p53(-/- B-GENE O
) E-GENE O
) O O
strains O O
with O O
a O O
defective O O
p53 B-GENE B-GENE
gene E-GENE E-GENE
. O O
Our O O
results O O
suggest O O
that O O
the O O
C O O
- O O
terminal O O
region O O
of O O
Crk S-GENE O
contains O O
negative O O
regulatory O O
elements O O
important O O
for O O
both O O
Abl S-GENE S-GENE
and O O
FAK S-GENE S-GENE
dependent O O
signal O O
pathways O O
, O O
and O O
offers O O
a O O
paradigm O O
for O O
an O O
autoinhibitory O O
region O O
in O O
the O O
SH3 S-GENE B-GENE
linker O I-GENE
/ O I-GENE
C O I-GENE
- O I-GENE
terminal O I-GENE
SH3 O I-GENE
domain O E-GENE
. O O
Cyclins S-GENE S-GENE
are O O
one O O
of O O
the O O
pivotal O O
determinants O O
regulating O O
cell O O
cycle O O
progression O O
. O O
Evidence O O
- O O
based O O
care O O
: O O
a O O
new O O
formula O O
for O O
an O O
old O O
problem O O
? O O

Further O O
, O O
the O O
osteo O O
- O O
retentive O O
ability O O
of O O
the O O
hydroxyapatite O O
in O O
the O O
sockets O O
was O O
seen O O
to O O
be O O
close O O
to O O
significance O O
( O O
after O O
six O O
months O O
width O O
differences O O
, O O
in O O
the O O
canine O O
region O O
: O O
P O O
= O O
0.059 O O
, O O
LHS O O
, O O
and O O
P O O
= O O
0.065 O O
, O O
RHS O O
) O O
. O O

The O O
cleavage O O
site O O
between O O
VPg S-GENE S-GENE
and O O
RNA B-GENE B-GENE
dependent I-GENE I-GENE
RNA I-GENE I-GENE
polymerase E-GENE E-GENE
was O O
predicted O O
to O O
be O O
E445-T446 O O
based O O
on O O
the O O
amino O O
acid O O
sequence O O
analysis O O
of O O
the O O
polyprotein O O
from O O
different O O
sobemoviruses O O
. O O
The O O
% O O
SVend O O
of O O
HCM O O
- O O
I O O
was O O
significantly O O
lower O O
than O O
the O O
respective O O
values O O
of O O
the O O
HCM O O
- O O
II O O
and O O
Control O O
groups O O
. O O

Nearly O O
all O O
isolates O O
of O O
S. O O
intermedius O O
and O O
most O O
isolates O O
of O O
S. O O
constellatus O O
, O O
but O O
only O O
19% O O
of O O
those O O
of O O
S. O O
anginosus O O
, O O
were O O
associated O O
with O O
abscess O O
. O O

DESIGN O O
: O O
Retrospective O O
study O O
. O O

Human O B-GENE
brain O I-GENE
cDNA O E-GENE
library O O
screening O O
and O O
5 O O
' O O
rapid O O
amplification O O
of O O
cDNA O O
ends O O
yielded O O
full B-GENE O
- I-GENE O
length I-GENE O
DENTT I-GENE B-GENE
cDNA E-GENE E-GENE
containing O O
an O O
1899-bp O O
open O O
reading O O
frame O O
encoding O O
a O O
predicted O O
633-amino O B-GENE
- O I-GENE
acid O I-GENE
protein O E-GENE
with O O
four O O
potential O O
nuclear O O
localization O O
signals O O
( O O
NLSs O S-GENE
) O O
and O O
two O O
coiled O O
- O O
coil O O
regions O O
. O O
Transfection O O
of O O
EGFP S-GENE B-GENE
- O I-GENE
tagged O I-GENE
DENTT S-GENE I-GENE
NLS O E-GENE
deletion O O
constructs O O
lacking O O
the O O
bipartite O O
NLS-1 S-GENE S-GENE
were O O
excluded O O
from O O
the O O
nucleolus O O
. O O
These O O
genes O O
encode O O
a O O
tryptophanyl B-GENE B-GENE
tRNA E-GENE E-GENE
, O O
the O O
protein B-GENE O
translocase E-GENE O
component O O
SecE S-GENE S-GENE
, O O
the O O
antiterminator B-GENE B-GENE
protein I-GENE I-GENE
NusG E-GENE E-GENE
, O O
and O O
the O O
ribosomal O B-GENE
proteins O I-GENE
L11 S-GENE E-GENE
and O O
L1 O O
in O O
addition O O
to O O
PkwR S-GENE S-GENE
, O O
a O O
putative O O
regulatory O O
protein O O
of O O
the O O
LacI S-GENE B-GENE
- O I-GENE
GalR S-GENE I-GENE
family O E-GENE
. O O
Rapamycin O S-GENE
( O O
FRAP S-GENE S-GENE
/ O O
mTOR S-GENE B-GENE
inhibitor O E-GENE
) O O
blocked O O
4E B-GENE S-GENE
- I-GENE O
BP1 E-GENE S-GENE
phosphorylation O O
causing O O
a O O
predominance O O
of O O
the O O
alpha O S-GENE
( O O
hypophosphorylated O O
) O O
band O O
. O O
Sixteen O O
out O O
of O O
52 O O
seropositive O O
MS O O
patients O O
( O O
30.8% O O
) O O
showed O O
intrathecal O O
synthesis O O
of O O
C. B-GENE O
pneumoniae I-GENE O
- I-GENE O
specific I-GENE O
IgG E-GENE S-GENE
but O O
only O O
one O O
of O O
43 O O
seropositive O O
controls O O
( O O
2.3% O O
) O O
. O O
Far O O
Western O O
blot O O
analysis O O
suggested O O
that O O
the O O
tandem O O
SH2 B-GENE B-GENE
domains E-GENE E-GENE
of O O
SHP2 S-GENE S-GENE
bind O O
to O O
Gab1 S-GENE S-GENE
in O O
a O O
specific O O
orientation O O
, O O
in O O
which O O
the O O
N B-GENE B-GENE
- I-GENE I-GENE
SH2 I-GENE I-GENE
domain E-GENE E-GENE
binds O O
to O O
phosphotyrosine O O
( O O
Tyr(P))-627 O S-GENE
and O O
the O O
C B-GENE B-GENE
- I-GENE I-GENE
SH2 I-GENE I-GENE
domain E-GENE E-GENE
binds O O
to O O
Tyr(P)-659 O S-GENE
. O O
Molecular O O
cloning O O
, O O
genomic O O
mapping O O
, O O
and O O
expression O O
of O O
two O O
secretor B-GENE B-GENE
blood I-GENE I-GENE
group I-GENE I-GENE
alpha I-GENE E-GENE
( I-GENE O
1,2)fucosyltransferase I-GENE B-GENE
genes E-GENE E-GENE
differentially O O
regulated O O
in O O
mouse O O
uterine O O
epithelium O O
and O O
gastrointestinal O O
tract O O
. O O
The O O
UBA B-GENE B-GENE
domains E-GENE E-GENE
of O O
RAD23 S-GENE S-GENE
and O O
DDI1 S-GENE S-GENE
are O O
required O O
for O O
these O O
interactions O O
. O O
It O O
was O O
found O O
that O O
intrathecal O O
administration O O
( O O
i.t O O
. O O
) O O
of O O
D2 B-GENE B-GENE
receptor E-GENE E-GENE
agonist O O
LY171555 O S-GENE
or O O
D1/D2 B-GENE B-GENE
receptor E-GENE E-GENE
agonist O O
apomorphine O O
increased O O
pain O O
threshold O O
and O O
had O O
a O O
potentiating O O
effect O O
on O O
AA O O
. O O
The O O
R2 O O
between O O
MFI O O
of O O
fresh O O
and O O
frozen O O
muscle O O
was O O
0.94 O O
and O O
0.92 O O
for O O
lamb O O
and O O
pork O O
longissimus O O
, O O
respectively O O
. O O

After O O
all O O
doses O O
of O O
d O O
- O O
amphetamine O O
, O O
responding O O
occurred O O
largely O O
on O O
the O O
saline O O
key O O
under O O
both O O
schedules O O
. O O

Intravenous O O
L O O
- O O
carnitine O O
treatment O O
increased O O
plasma O O
carnitine O O
concentrations O O
, O O
improved O O
patient O O
- O O
assessed O O
fatigue O O
, O O
and O O
may O O
prevent O O
the O O
decline O O
in O O
peak O O
exercise O O
capacity O O
in O O
hemodialysis O O
patients O O
. O O

Elevated O O
expression O O
of O O
full B-GENE O
- I-GENE O
length E-GENE O
UhpB S-GENE O
or O O
of O O
a O O
soluble O O
hybrid O O
protein O O
, O O
GST S-GENE B-GENE
- O I-GENE
Bc S-GENE E-GENE
, O O
which O O
is O O
glutathione B-GENE B-GENE
S I-GENE I-GENE
- I-GENE I-GENE
transferase E-GENE E-GENE
( O O
GST O S-GENE
) O O
fused O O
to O O
the O O
cytoplasmic O O
C O O
- O O
terminal O O
portion O O
of O O
UhpB O S-GENE
, O O
results O O
in O O
complete O O
blockage O O
of O O
uhpT S-GENE O
expression O O
in O O
a O O
uhp(+ B-GENE O
) E-GENE O
strain O O
. O O
This O O
unique O O
location O O
of O O
cavernous O O
malformation O O
is O O
associated O O
with O O
a O O
risk O O
of O O
permanent O O
loss O O
of O O
the O O
vision O O
. O O

Here O O
we O O
show O O
that O O
PKC S-GENE S-GENE
and O O
p44/p42MAPK O S-GENE
signalings O O
are O O
required O O
for O O
the O O
HBx S-GENE S-GENE
- O O
induced O O
Sp1-mediated O B-GENE
IGF B-GENE I-GENE
- I-GENE I-GENE
II E-GENE I-GENE
P4 S-GENE E-GENE
transcriptional O O
activity O O
since O O
( O O
i O O
) O O
PKC O S-GENE
activation O O
by O O
PMA O S-GENE
or O O
PKC O S-GENE
expression O O
vector O O
increases O O
Sp1 O S-GENE
phosphorylation O O
and O O
P4 O S-GENE
activity O O
in O O
HBx O B-GENE
- O I-GENE
transfected O I-GENE
HepG2 O E-GENE
cells O O
; O O
( O O
ii O O
) O O
PKC O S-GENE
inhibition O O
by O O
PKC O B-GENE
inhibitor O I-GENE
Go6976 O E-GENE
reduces O O
Sp1 O S-GENE
phosphorylation O O
, O O
P4 O S-GENE
activity O O
, O O
and O O
IGF B-GENE B-GENE
- I-GENE I-GENE
II I-GENE I-GENE
mRNA E-GENE E-GENE
in O O
HBx O B-GENE
- O I-GENE
transfected O I-GENE
HepG2 O E-GENE
cells O O
; O O
and O O
( O O
iii O O
) O O
the O O
inhibition O O
of O O
MEK S-GENE S-GENE
activation O O
by O O
U0126 O S-GENE
reduces O O
Sp1 O S-GENE
phosphorylation O O
, O O
P4 O S-GENE
activity O O
and O O
IGF O B-GENE
- O I-GENE
II O I-GENE
mRNA O E-GENE
in O O
HBx O S-GENE
- O O
transfected O O
HepG2 O O
cells O O
. O O
Through O O
two O O
novel O O
mechanisms O O
, O O
Arf S-GENE O
inhibits O O
the O O
oncoprotein B-GENE B-GENE
Hdm2 E-GENE E-GENE
, O O
a O O
negative O O
regulator O O
of O O
p53 S-GENE S-GENE
. O O
In O O
the O O
free O O
- O O
swimming O O
rotatory O O
test O O
mice O O
spend O O
most O O
of O O
the O O
time O O
swimming O O
close O O
to O O
the O O
wall O O
of O O
the O O
container O O
attempting O O
to O O
escape O O
from O O
an O O
aversive O O
test O O
situation O O
. O O

Examination O O
of O O
various O O
promoter O O
deletion O O
mutants O O
indicated O O
that O O
SF-1 S-GENE S-GENE
acts O O
through O O
the O O
proximal O B-GENE
promoter O E-GENE
region O O
and O O
upstream O O
promoter O O
sequences O O
. O O
The O O
MSL B-GENE S-GENE
complex E-GENE O
is O O
specifically O O
localized O O
on O O
the O O
male O O
X O O
chromosome O O
to O O
increase O O
its O O
expression O O
approximately O O
2-fold O O
. O O
Prrp S-GENE S-GENE
can O O
also O O
associate O O
with O O
the O O
EVH1 B-GENE B-GENE
domain E-GENE E-GENE
of O O
Mena S-GENE S-GENE
, O O
another O O
microfilament O B-GENE
- O I-GENE
associated O I-GENE
protein O E-GENE
. O O
Srb10 S-GENE O
is O O
a O O
physiological O O
regulator O O
of O O
Gcn4 S-GENE S-GENE
stability O O
because O O
both O O
phosphorylation O O
and O O
turnover O O
of O O
Gcn4 O S-GENE
are O O
diminished O O
in O O
srb10 B-GENE B-GENE
mutants E-GENE E-GENE
. O O
Consistent O O
effects O O
on O O
pVHL S-GENE S-GENE
function O O
were O O
observed O O
for O O
all O O
mutations O O
within O O
each O O
subclass O O
. O O
A O O
new O O
intron O O
of O O
476 O O
base O O
pairs O O
was O O
found O O
in O O
the O O
middle O O
of O O
the O O
5'-untranslated O O
leader O O
sequence O O
and O O
was O O
shown O O
to O O
robustly O O
enhance O O
the O O
promoter O O
activity O O
. O O

Based O O
on O O
this O O
analysis O O
, O O
we O O
propose O O
that O O
the O O
interactions O O
of O O
Sos S-GENE O
with O O
the O O
switch O O
1 O O
and O O
switch O O
2 O O
regions O O
of O O
Ras S-GENE S-GENE
have O O
distinct O O
functional O O
consequences O O
: O O
the O O
interaction O O
with O O
switch O O
2 O O
mediates O O
the O O
anchoring O O
of O O
Ras O S-GENE
to O O
Sos O O
, O O
whereas O O
the O O
interaction O O
with O O
switch O O
1 O O
leads O O
to O O
disruption O O
of O O
the O O
nucleotide O O
- O O
binding O O
site O O
and O O
GDP O O
dissociation O O
. O O
A O O
log O O
- O O
linear O O
dose O O
- O O
response O O
was O O
obtained O O
for O O
the O O
average O O
increase O O
in O O
FEV1 O O
up O O
to O O
6 O O
h O O
( O O
AUC0 O O
- O O
6 O O
h O O
) O O
and O O
peak O O
FEV1 O O
across O O
the O O
dose O O
range O O
administered O O
by O O
Respimat O O
. O O

Bandshift O O
experiments O O
demonstrate O O
that O O
BmHR3A S-GENE S-GENE
binds O O
specifically O O
to O O
RORE S-GENE S-GENE
( O O
Retinoic O B-GENE
acid O I-GENE
- O I-GENE
related O I-GENE
Orphan O I-GENE
receptor O I-GENE
Response O I-GENE
Element)-like O I-GENE
sequences O E-GENE
in O O
the O O
promoters O O
of O O
both O O
genes O O
, O O
thus O O
suggesting O O
a O O
direct O O
role O O
for O O
BmHR3A O S-GENE
in O O
regulating O O
the O O
expression O O
of O O
BmGATAbeta S-GENE O
and O O
ESP B-GENE B-GENE
genes E-GENE E-GENE
during O O
vitellogenesis O O
. O O
This O O
was O O
most O O
pronounced O O
during O O
the O O
initial O O
phase O O
of O O
Erk S-GENE O
activation O O
. O O
The O O
iterative O O
method O O
proposed O O
by O O
Bengtsson O O
[ O O
Appl O O
. O O

Here O O
, O O
we O O
identify O O
Rsc3 S-GENE S-GENE
and O O
Rsc30 S-GENE S-GENE
as O O
novel O O
components O O
of O O
the O O
essential O O
yeast B-GENE O
remodeler I-GENE O
RSC I-GENE S-GENE
complex E-GENE O
. O O
The O O
COD O S-GENE
and O O
color O O
removals O O
were O O
both O O
more O O
than O O
90% O O
when O O
FeCl3 O O
was O O
used O O
as O O
the O O
coagulation O O
( O O
dosages O O
of O O
two O O
- O O
step O O
coagulation O O
were O O
0.031 O O
and O O
0.012 O O
mol O O
/ O O
L O O
respectively O O
) O O
after O O
a O O
ferrous O O
hydrogen O O
peroxide O O
oxidation O O
pretreatment O O
at O O
a O O
H2O2 O O
dosage O O
of O O
0.06 O O
mol O O
/ O O
L. O O

Although O O
there O O
was O O
a O O
high O O
correlation O O
between O O
sap O O
flux O O
densities O O
registered O O
by O O
the O O
old O O
and O O
new O O
sensors O O
, O O
significant O O
differences O O
in O O
sap O O
flux O O
densities O O
between O O
the O O
duplicated O O
sensors O O
were O O
detected O O
. O O

Three O O
of O O
the O O
proteins O O
involved O O
in O O
checkpoint O O
signaling O O
, O O
Rad1 S-GENE S-GENE
, O O
Hus1 S-GENE S-GENE
, O O
and O O
Rad9 S-GENE S-GENE
, O O
have O O
been O O
shown O O
to O O
interact O O
by O O
immunoprecipitation O O
and O O
yeast O O
two O O
- O O
hybrid O O
studies O O
. O O
Based O O
on O O
the O O
hypothesis O O
that O O
evolutionarily O O
conserved O O
regions O O
are O O
functionally O O
important O O
and O O
likely O O
to O O
interact O O
with O O
coactivators O O
, O O
we O O
compared O O
the O O
amino O O
acid O O
sequence O O
of O O
C B-GENE O
/ I-GENE O
EBPalpha E-GENE S-GENE
from O O
different O O
species O O
( O O
frog O O
to O O
human O O
) O O
and O O
identified O O
four O O
highly O O
conserved O O
regions O O
( O O
CR1-CR4 O S-GENE
) O O
within O O
the O O
transactivation O O
domain O O
. O O
Tolerance O O
to O O
ADAL-2 O O
was O O
similar O O
to O O
that O O
of O O
Vicryl O O
suture O O
and O O
tolerance O O
to O O
ADAL-2 O O
was O O
superior O O
to O O
that O O
to O O
Tisuacryl O O
. O O

Of O O
the O O
patients O O
in O O
each O O
regimen O O
who O O
reached O O
study O O
end O O
points O O
, O O
17 O O
of O O
29 O O
( O O
59% O O
) O O
were O O
in O O
regimen O O
A O O
, O O
11 O O
of O O
20 O O
( O O
55% O O
) O O
were O O
in O O
regimen O O
B O O
, O O
and O O
28 O O
of O O
43 O O
( O O
65% O O
) O O
were O O
in O O
regimen O O
C O O
met O O
the O O
treatment O O
success O O
criterion O O
. O O

Early O O
indicators O O
of O O
the O O
effect O O
of O O
a O O
breast O O
cancer O O
screening O O
program O O
for O O
low O O
- O O
income O O
women O O
. O O

SAMPLE O O
POPULATION O O
: O O
MCB O O
from O O
7 O O
racing O O
Greyhounds O O
euthanatized O O
for O O
reasons O O
unrelated O O
to O O
MCB O O
abnormalities O O
. O O

CONCLUSIONS O O
AND O O
CLINICAL O O
RELEVANCE O O
: O O
Increased O O
cortical O O
thickness O O
and O O
geometric O O
properties O O
of O O
left O O
MCB O B-GENE
- O I-GENE
IV O E-GENE
and O O
-V O O
of O O
Greyhounds O O
, O O
together O O
with O O
altered O O
turnover O O
and O O
orientation O O
of O O
osteons O O
in O O
the O O
dorsal O O
quadrants O O
of O O
left O O
MCB O O
, O O
are O O
site O O
- O O
specific O O
adaptive O O
responses O O
associated O O
with O O
asymmetric O O
cyclic O O
loading O O
as O O
a O O
result O O
of O O
racing O O
on O O
circular O O
tracks O O
. O O

Linear O O
eight- O O
or O O
nine O O
- O O
residue O O
D O O
- O O
peptides O O
derived O O
from O O
the O O
pocket O O
- O O
binding O O
domain O O
of O O
the O O
cyclic O O
molecules O O
also O O
bind O O
specifically O O
. O O

METHODS O O
AND O O
RESULTS O O
: O O
Palmaz O O
- O O
Schatz O O
stents O O
were O O
dip O O
- O O
coated O O
with O O
paclitaxel O O
( O O
0 O O
, O O
0.2 O O
, O O
15 O O
, O O
or O O
187 O O
microgram O O
/ O O
stent O O
) O O
by O O
immersion O O
in O O
ethanolic O O
paclitaxel O O
and O O
evaporation O O
of O O
the O O
solvent O O
. O O

Percentages O O
of O O
recovery O O
for O O
overload O O
and O O
dilution O O
tests O O
were O O
between O O
87 O O
and O O
120% O O
. O O

One O O
of O O
the O O
conserved O O
RNA O O
subdomains O O
, O O
designated O O
P3 S-GENE O
, O O
has O O
previously O O
been O O
shown O O
to O O
be O O
required O O
for O O
nucleolar O O
localization O O
. O O
In O O
Cd O O
- O O
spiked O O
OECD O O
soil O O
, O O
internal O O
Cd O O
levels O O
were O O
linearly O O
related O O
to O O
external O O
Cd O O
concentrations O O
, O O
whereas O O
the O O
springtails O O
maintained O O
fixed O O
internal O O
levels O O
of O O
Cu O O
and O O
Zn O O
regardless O O
of O O
spiked O O
concentrations O O
. O O

Nutritional O O
status O O
in O O
adults O O
on O O
an O O
alternative O O
or O O
traditional O O
diet O O
] O O
BACKGROUND O O
: O O
Plant O O
food O O
lacks O O
vitamin O O
B12 O O
, O O
vitamin O O
D O O
and O O
higher O O
n-3 O O
polyunsaturated O O
fatty O O
acids O O
. O O

It O O
is O O
useful O O
as O O
an O O
adjunct O O
to O O
mammography O O
in O O
those O O
patients O O
with O O
radiographically O O
dense O O
breasts O O
for O O
the O O
characterization O O
of O O
palpable O O
masses O O
. O O

Measurements O O
were O O
obtained O O
: O O
( O O
i O O
) O O
just O O
after O O
the O O
traumatic O O
exposure O O
( O O
D0 O O
) O O
; O O
( O O
ii O O
) O O
3 O O
days O O
after O O
this O O
first O O
measurement O O
( O O
D3 O O
) O O
; O O
and O O
( O O
iii O O
) O O
30 O O
days O O
after O O
( O O
D30 O O
) O O
. O O

Here O O
we O O
present O O
evidence O O
that O O
the O O
distal O O
half O O
( O O
Stem O O
2 O O
) O O
of O O
the O O
conserved O O
base O O
- O O
paired O O
stem O O
structure O O
found O O
in O O
all O O
hY B-GENE B-GENE
RNAs E-GENE E-GENE
also O O
plays O O
a O O
critical O O
role O O
in O O
the O O
export O O
process O O
. O O
Changes O O
of O O
the O O
DB O O
sequence O O
without O O
affecting O O
the O O
postulated O O
stem O O
structure O O
led O O
to O O
drastic O O
losses O O
of O O
translation O O
efficiency O O
. O O

It O O
has O O
been O O
suggested O O
that O O
members O O
of O O
this O O
protein O O
family O O
exhibit O O
both O O
prolyl B-GENE B-GENE
isomerase E-GENE E-GENE
and O O
chaperone O O
activity O O
. O O
Inhibition O O
of O O
the O O
Raf-1 B-GENE S-GENE
target E-GENE O
ERK B-GENE B-GENE
kinase E-GENE E-GENE
( O O
MEK S-GENE S-GENE
) O O
either O O
attenuated O O
or O O
abolished O O
Rp O B-GENE
- O I-GENE
cAMPS- O E-GENE
and O O
PKI S-GENE S-GENE
- O O
induced O O
ERK O S-GENE
activation O O
, O O
caldesmon S-GENE B-GENE
phosphorylation O E-GENE
, O O
and O O
stress O O
fiber O O
formation O O
. O O
PACAP B-GENE B-GENE
mRNA E-GENE E-GENE
was O O
widely O O
expressed O O
in O O
most O O
human O O
tissues O O
; O O
in O O
transfected O O
cells O O
, O O
PACAP O S-GENE
was O O
diffusely O O
expressed O O
in O O
the O O
cytoplasm O O
. O O
Here O O
we O O
provide O O
the O O
first O O
evidence O O
for O O
the O O
involvement O O
of O O
GCN1-GCN2 O O
interaction O O
in O O
activation O O
of O O
GCN2 O O
per O O
se O O
. O O
The O O
radial O O
forearm O O
flap O O
is O O
used O O
most O O
commonly O O
, O O
however O O
the O O
lateral O O
arm O O
flap O O
may O O
be O O
the O O
flap O O
of O O
choice O O
in O O
certain O O
situations O O
. O O

By O O
comparison O O
, O O
in O O
nontumorigenic O O
Ad5 O O
cells O O
, O O
class O B-GENE
I O E-GENE
expression O O
is O O
high O O
due O O
to O O
negligible O O
binding O O
of O O
COUP B-GENE B-GENE
- I-GENE I-GENE
TF E-GENE E-GENE
and O O
strong O O
binding O O
of O O
NF O B-GENE
- O I-GENE
kappaB. O E-GENE
As O O
an O O
application O O
of O O
reverse O O
genetics O O
, O O
we O O
introduced O O
one O O
nucleotide O O
change O O
( O O
UCU O S-GENE
to O O
ACU O S-GENE
) O O
to O O
immediate O O
downstream O O
of O O
the O O
RNA O B-GENE
- O I-GENE
editing O I-GENE
site O E-GENE
of O O
the O O
V B-GENE B-GENE
gene E-GENE E-GENE
in O O
the O O
full O O
- O O
length O O
hPIV2 O B-GENE
cDNA O E-GENE
and O O
were O O
able O O
to O O
obtain O O
infectious O O
viruses O O
[ O O
rPIV2V(- O O
) O O
] O O
from O O
the O O
cDNA O O
. O O
The O O
frameshift O O
initiated O O
by O O
ADEx2 O S-GENE
is O O
believed O O
to O O
alter O O
the O O
regular O O
coding O O
sequence O O
, O O
acting O O
as O O
a O O
loss O O
- O O
of O O
- O O
function O O
ASIP B-GENE B-GENE
mutation E-GENE E-GENE
. O O
In O O
regards O O
to O O
the O O
latter O O
activity O O
, O O
it O O
has O O
been O O
shown O O
that O O
S3 S-GENE O
contains O O
vigorous O O
N B-GENE B-GENE
- I-GENE I-GENE
glycosylase E-GENE E-GENE
activity O O
for O O
the O O
removal O O
of O O
8-oxoguanine O O
residues O O
in O O
DNA O O
that O O
leaves O O
baseless O O
sites O O
in O O
their O O
places O O
. O O
Here O O
we O O
report O O
the O O
isolation O O
and O O
characterization O O
of O O
the O O
forkhead B-GENE O
homologue I-GENE O
in I-GENE O
rhabdomyosarcoma E-GENE O
( O O
FKHR S-GENE S-GENE
) O O
, O O
a O O
recently O O
described O O
member O O
of O O
the O O
hepatocyte O B-GENE
nuclear O I-GENE
factor O I-GENE
3/forkhead O I-GENE
homeotic B-GENE I-GENE
gene I-GENE I-GENE
family E-GENE E-GENE
, O O
as O O
a O O
nuclear B-GENE B-GENE
hormone I-GENE I-GENE
receptor E-GENE E-GENE
( O O
NR S-GENE B-GENE
) O I-GENE
intermediary O I-GENE
protein O E-GENE
. O O
The O O
improved O O
CSF O O
outflow O O
conductance O O
may O O
increase O O
the O O
intracranial O O
compliance O O
and O O
thereby O O
dampen O O
a O O
pathological O O
ICP O O
waveform O O
. O O

A O O
new O O
species O O
of O O
Euspondylus O O
is O O
described O O
based O O
on O O
a O O
female O O
( O O
taken O O
within O O
a O O
bromeliad O O
) O O
from O O
Cerro O O
El O O
Humo O O
, O O
Sucre O O
, O O
northeastern O O
Venezuela O O
. O O

The O O
cyclins S-GENE S-GENE
bind O O
to O O
and O O
activate O O
the O O
CDK S-GENE S-GENE
, O O
which O O
leads O O
to O O
phosphorylation O O
( O O
and O O
then O O
inhibition O O
) O O
of O O
the O O
tumor O B-GENE
suppressor O I-GENE
protein O E-GENE
, O O
pRb S-GENE S-GENE
. O O
pRb O S-GENE
controls O O
commitment O O
to O O
progress O O
from O O
the O O
G1 O O
to O O
S O O
phase O O
, O O
at O O
least O O
in O O
part O O
by O O
repressing O O
the O O
activity O O
of O O
the O O
E2F B-GENE B-GENE
transcription I-GENE I-GENE
factors E-GENE E-GENE
known O O
to O O
promote O O
cell O O
proliferation O O
. O O
Additional O O
education O O
and O O
research O O
is O O
needed O O
to O O
provide O O
further O O
direction O O
for O O
intervention O O
and O O
incorporation O O
into O O
practice O O
. O O

Proliferative O O
vasculopathy O O
and O O
cutaneous O O
hemorrhages O O
in O O
porcine O O
neonates O O
infected O O
with O O
the O O
porcine O O
reproductive O O
and O O
respiratory O O
syndrome O O
virus O O
. O O

The O O
difference O O
of O O
hardness O O
over O O
time O O
of O O
composite O O
specimens O O
was O O
measured O O
using O O
Knoop O O
hardness O O
measurements O O
taken O O
at O O
the O O
top O O
and O O
bottom O O
surfaces O O
of O O
resin O O
specimens O O
made O O
in O O
a O O
Teflon O O
mold O O
the O O
same O O
dimensions O O
as O O
the O O
cavity O O
prepared O O
in O O
dentin O O
. O O

An O O
18-kb O O
genomic O O
clone O O
including O O
sequences O O
encoding O O
for O O
the O O
two O O
GHS B-GENE B-GENE
- I-GENE I-GENE
R I-GENE I-GENE
variants E-GENE E-GENE
was O O
isolated O O
. O O
Saccharomyces O O
cerevisiae O O
activates O O
a O O
regulatory O O
network O O
called O O
" O O
general O O
control O O
" O O
that O O
provides O O
the O O
cell O O
with O O
sufficient O O
amounts O O
of O O
protein O O
precursors O O
during O O
amino O O
acid O O
starvation O O
. O O

In O O
Ka13 O S-GENE
cells O O
, O O
CoCl(2 O O
) O O
stimulated O O
expression O O
of O O
a O O
luciferase B-GENE B-GENE
reporter I-GENE I-GENE
gene E-GENE E-GENE
under O O
the O O
control O O
of O O
a O O
15-kilobase B-GENE O
pair I-GENE O
mouse I-GENE B-GENE
ho-1 I-GENE I-GENE
promoter E-GENE E-GENE
( O O
pHO15luc S-GENE S-GENE
) O O
. O O
Mutation O O
analyses O O
identified O O
the O O
cobalt O O
- O O
responsive O O
sequences O O
as O O
the O O
stress O O
- O O
response O O
elements O O
( O O
StREs O O
) O O
. O O

Members O O
of O O
the O O
AP-1 B-GENE B-GENE
superfamily I-GENE E-GENE
of E-GENE O
basic B-GENE B-GENE
- I-GENE I-GENE
leucine I-GENE I-GENE
zipper I-GENE I-GENE
factors E-GENE E-GENE
bind O O
to O O
the O O
StRE O S-GENE
. O O
Descriptions O O
of O O
this O O
locus O O
would O O
allow O O
comparison O O
with O O
functionally O O
relevant O O
molecular O O
genetic O O
features O O
of O O
other O O
species O O
' O O
homologous O O
loci O O
including O O
the O O
single O O
- O O
copy O O
equid O O
LH S-GENE B-GENE
/ O I-GENE
CGbeta S-GENE I-GENE
gene O E-GENE
and O O
the O O
primate O O
LHbeta S-GENE B-GENE
- O I-GENE
CGbeta O I-GENE
gene O I-GENE
cluster O I-GENE
locus O E-GENE
. O O
Like O O
the O O
consensus B-GENE O
mammalian I-GENE O
LHbeta I-GENE B-GENE
gene E-GENE E-GENE
, O O
the O O
5'-flanking O O
region O O
of O O
the O O
gpLH S-GENE B-GENE
/ O I-GENE
CGbeta S-GENE I-GENE
gene O E-GENE
contains O O
a O O
single O O
TATA O O
sequence O O
37 O O
bp O O
upstream O O
of O O
the O O
translation O O
start O O
codon O O
. O O
This O O
shows O O
that O O
in O O
situations O O
of O O
separated O O
breaks O O
, O O
NHEJ O O
deficiency O O
leads O O
to O O
genomic O O
rearrangements O O
, O O
in O O
agreement O O
with O O
chromosomal O O
studies O O
. O O

Expression O O
of O O
human B-GENE O
RACK1 E-GENE S-GENE
efficiently O O
relieves O O
E1A S-GENE S-GENE
- O O
mediated O O
growth O O
inhibition O O
in O O
HF7c O S-GENE
and O O
protects O O
human O O
tumor O O
cells O O
from O O
E1A O S-GENE
- O O
induced O O
apoptosis O O
. O O
Foxp1 S-GENE S-GENE
and O O
Foxp2 S-GENE S-GENE
are O O
expressed O O
at O O
high O O
levels O O
in O O
the O O
lung O O
as O O
early O O
as O O
E12.5 O O
of O O
mouse O O
development O O
with O O
Foxp2 O S-GENE
expression O O
restricted O O
to O O
the O O
airway O O
epithelium O O
. O O
Molecular O O
analysis O O
of O O
the O O
pRA2 O S-GENE
partitioning O O
region O O
: O O
ParB S-GENE B-GENE
autoregulates O I-GENE
parAB S-GENE I-GENE
transcription O E-GENE
and O O
forms O O
a O O
nucleoprotein O O
complex O O
with O O
the O O
plasmid O O
partition O O
site O O
, O O
parS. O B-GENE
Immunological O E-GENE
and O O
biochemical O O
characterization O O
of O O
streptococcal B-GENE B-GENE
pyrogenic I-GENE I-GENE
exotoxins I-GENE I-GENE
I I-GENE E-GENE
and I-GENE O
J E-GENE O
( O O
SPE B-GENE B-GENE
- I-GENE I-GENE
I E-GENE E-GENE
and O O
SPE B-GENE S-GENE
- I-GENE O
J E-GENE O
) O O
from O O
Streptococcus O O
pyogenes O O
. O O
Several O O
dozen O O
HIF-1 B-GENE S-GENE
targets E-GENE O
are O O
known O O
, O O
including O O
the O O
gene O B-GENE
encoding O I-GENE
vascular B-GENE I-GENE
endothelial I-GENE I-GENE
growth I-GENE I-GENE
factor E-GENE E-GENE
( O O
VEGF S-GENE S-GENE
) O O
. O O
We O O
previously O O
reported O O
that O O
Tax S-GENE O
induced O O
cell O O
cycle O O
progression O O
from O O
G0/G1 O O
phase O O
to O O
S O O
and O O
G2/M O O
phases O O
in O O
human O O
T O O
- O O
cell O O
line O O
Kit O O
225 O O
cells O O
. O O
Most O O
yeast B-GENE O
peroxisomal I-GENE O
matrix I-GENE O
proteins E-GENE O
contain O O
a O O
type O O
1C O S-GENE
- O O
terminal O O
peroxisomal O O
targeting O O
signal O O
( O O
PTS1 O S-GENE
) O O
consisting O O
of O O
the O O
tripeptide O O
SKL O S-GENE
or O O
a O O
conservative O O
variant O O
thereof O O
. O O
Here O O
, O O
the O O
PEX5-TPR O B-GENE
domains O E-GENE
from O O
human O O
, O O
tobacco O O
, O O
and O O
nematode O O
were O O
inserted O O
into O O
a O O
TPR O O
- O O
less O O
yeast O O
Pex5p S-GENE O
construct O O
to O O
generate O O
Pex5p O O
chimaeras O O
. O O
HIV-1 O O
and O O
hepatitis O O
B O O
virus O O
infections O O
in O O
adolescents O O
lodged O O
in O O
security O O
institutes O O
of O O
Buenos O O
Aires O O
. O O

Immunofixation O O
experiments O O
of O O
C4A S-GENE S-GENE
and O O
C4B S-GENE S-GENE
demonstrate O O
> O O
41 O O
allotypes O O
in O O
the O O
two O O
classes O O
of O O
proteins O O
. O O
However O O
, O O
C4B B-GENE B-GENE
proteins E-GENE I-GENE
encoded O E-GENE
by O O
monomodular O O
short O O
genes O O
may O O
have O O
relatively O O
higher O O
concentrations O O
than O O
those O O
from O O
long B-GENE O
C4A I-GENE B-GENE
genes E-GENE E-GENE
. O O
In O O
the O O
course O O
of O O
screening O O
for O O
transcription O O
factors O O
which O O
interact O O
with O O
the O O
human B-GENE B-GENE
myeloperoxidase E-GENE E-GENE
( O O
MPO S-GENE S-GENE
) O O
promoter O O
we O O
, O O
for O O
the O O
first O O
time O O
, O O
identified O O
and O O
cloned O O
the O O
cDNA O O
and O O
genomic O O
DNA O O
for O O
human B-GENE O
HBP1 E-GENE S-GENE
( O O
HMG B-GENE B-GENE
- I-GENE I-GENE
Box I-GENE I-GENE
containing I-GENE I-GENE
protein I-GENE I-GENE
1 E-GENE E-GENE
) O O
, O O
a O O
member O O
of O O
the O O
high B-GENE O
mobility I-GENE O
group I-GENE O
of I-GENE O
non I-GENE B-GENE
- I-GENE I-GENE
histone I-GENE I-GENE
chromosomal I-GENE I-GENE
proteins E-GENE E-GENE
. O O
The O O
human O B-GENE
protein O E-GENE
sequence O O
exhibits O O
a O O
putative O O
DNA O O
- O O
binding O O
domain O O
similar O O
to O O
that O O
seen O O
in O O
rat B-GENE O
HBP1 E-GENE S-GENE
and O O
shows O O
homology O O
with O O
the O O
activation O O
and O O
repressor O O
domains O O
previously O O
demonstrated O O
in O O
the O O
rat O B-GENE
protein O E-GENE
. O O
Promoter O O
transcriptional O O
activity O O
was O O
determined O O
for O O
a O O
wide O O
5 O O
' O O
portion O O
of O O
the O O
human O B-GENE
annexin B-GENE I-GENE
A5 I-GENE I-GENE
gene E-GENE E-GENE
, O O
from O O
bp O O
-1275 O O
to O O
+ O O
79 O O
relative O O
to O O
the O O
most O O
5 O O
' O O
of O O
several O O
discrete O O
transcription O O
start O O
points O O
. O O
In O O
contrast O O
the O O
human O O
and O O
mouse B-GENE B-GENE
BCNT I-GENE I-GENE
proteins E-GENE E-GENE
contain O O
one O O
repeat O O
unit O O
and O O
lack O O
the O O
RTE-1-derived O O
portion O O
. O O
Molecular O O
identification O O
of O O
smg-4 S-GENE O
, O O
required O O
for O O
mRNA O O
surveillance O O
in O O
C. O O
elegans O O
. O O
Two O O
remotely O O
situated O O
exons O O
within O O
the O O
complement B-GENE B-GENE
C3 E-GENE I-GENE
gene O I-GENE
locus O E-GENE
encode O O
an O O
alternate O O
5 O O
' O O
end O O
and O O
proximal O O
ORF O O
under O O
the O O
control O O
of O O
a O O
bidirectional O O
promoter O O
. O O
CONCLUSIONS O O
: O O
Adding O O
MMF O O
, O O
a O O
potent O O
topical O O
corticosteroid O O
, O O
to O O
an O O
emollient O O
cream O O
is O O
statistically O O
significantly O O
more O O
effective O O
than O O
emollient O O
cream O O
alone O O
in O O
reducing O O
acute O O
radiation O O
dermatitis O O
. O O

Recent O O
advances O O
have O O
shown O O
that O O
volatile O O
sulfur O O
is O O
a O O
result O O
of O O
ecological O O
interactions O O
and O O
transformation O O
processes O O
through O O
planktonic O O
food O O
webs O O
. O O

The O O
first O O
hypothesis O O
was O O
supported O O
in O O
the O O
sense O O
that O O
stimulus O O
differences O O
might O O
affect O O
behaviour O O
even O O
without O O
their O O
successful O O
attentive O O
processing O O
in O O
normal O O
participants O O
. O O

There O O
was O O
an O O
increase O O
in O O
protein O O
binding O O
onto O O
this O O
element O O
only O O
after O O
peptide O O
treatment O O
. O O

CSR O S-GENE
is O O
directed O O
to O O
specific O O
heavy O B-GENE
chain O I-GENE
isotypes O E-GENE
by O O
cytokines O O
and O O
B O O
cell O O
activators O O
that O O
induce O O
transcription O O
from O O
the O O
unrearranged O O
, O O
or O O
germline O O
( O O
GL O S-GENE
) O O
, O O
C(H B-GENE S-GENE
) I-GENE O
region I-GENE O
genes E-GENE O
. O O
In O O
this O O
manuscript O O
we O O
demonstrate O O
that O O
two O O
tandem B-GENE O
Ets I-GENE B-GENE
sites E-GENE E-GENE
in O O
the O O
mouse S-GENE B-GENE
GL B-GENE I-GENE
alpha I-GENE I-GENE
promoter E-GENE E-GENE
bind O O
the O O
transcription B-GENE B-GENE
factors I-GENE I-GENE
Elf-1 E-GENE E-GENE
and O O
PU.1 S-GENE S-GENE
, O O
and O O
that O O
the O O
3 O O
' O O
site O O
is O O
essential O O
for O O
expression O O
of O O
a O O
luciferase B-GENE B-GENE
reporter I-GENE I-GENE
gene E-GENE E-GENE
driven O O
by O O
the O O
GL O O
alpha O O
promoter O O
. O O
Cell O O
. O O

The O O
mean O O
serum O O
creatinine O O
level O O
did O O
not O O
change O O
during O O
the O O
first O O
6 O O
months O O
after O O
withdrawal O O
of O O
MMF O O
. O O

The O O
proportion O O
of O O
the O O
biopsies O O
found O O
to O O
be O O
seropositive O O
for O O
HBs B-GENE B-GENE
antigen E-GENE E-GENE
was O O
27.9% O O
, O O
and O O
these O O
showed O O
either O O
MGN O O
or O O
MPGN O O
pattern O O
. O O
They O O
correspond O O
to O O
nucleotides O O
equivalent O O
to O O
base O O
- O O
pair O O
C1-G72 O O
and O O
discriminator O O
base O O
A73 O O
in O O
the O O
amino O O
acid O O
- O O
acceptor O O
branch O O
of O O
the O O
molecule O O
. O O

This O O
domain O O
without O O
the O O
canonical O O
anticodon O O
loop O O
or O O
the O O
tyrosine O O
anticodon O O
acts O O
as O O
an O O
anchor O O
for O O
TyrRS S-GENE S-GENE
interaction O O
leading O O
to O O
a O O
better O O
efficiency O O
of O O
tyrosylation O O
. O O
During O O
most O O
of O O
the O O
cell O O
cycle O O
, O O
separase S-GENE S-GENE
is O O
kept O O
inactive O O
by O O
binding O O
to O O
an O O
inhibitory O O
protein O O
called O O
securin S-GENE S-GENE
. O O
Mechanical O O
ventilation O O
in O O
control O O
lungs O O
produced O O
a O O
47% O O
decrease O O
in O O
chord O O
compliance O O
, O O
an O O
increase O O
in O O
lung O O
lavage O O
levels O O
of O O
tumor B-GENE B-GENE
necrosis I-GENE I-GENE
factor I-GENE E-GENE
( I-GENE O
TNF)-alpha E-GENE O
( O O
722 O O
+ O O
/- O O
306 O O
pg O O
/ O O
ml O O
) O O
, O O
interleukin B-GENE O
( I-GENE O
IL)-1beta E-GENE O
( O O
902 O O
+ O O
/- O O
322 O O
pg O O
/ O O
ml O O
) O O
, O O
and O O
macrophage B-GENE B-GENE
inflammatory I-GENE I-GENE
protein-2 E-GENE E-GENE
( O O
MIP-2 S-GENE S-GENE
) O O
( O O
363 O O
+ O O
/- O O
104 O O
pg O O
/ O O
ml O O
) O O
as O O
compared O O
with O O
low O O
levels O O
of O O
cytokines O O
detected O O
in O O
preventilation O O
data O O
, O O
and O O
no O O
change O O
in O O
percentage O O
of O O
surfactant O O
large O O
aggregates O O
( O O
LA O O
) O O
. O O
Maternal O O
p O O
, O O
p'DDE O O
and O O
beta O O
- O O
HCH O O
levels O O
were O O
also O O
associated O O
with O O
newborn O O
levels O O
, O O
but O O
levels O O
of O O
PCBs O O
were O O
not O O
. O O

Multiple O O
regression O O
analysis O O
performed O O
between O O
these O O
long O O
- O O
term O O
abiotic O O
factors O O
and O O
nymphal O O
abundance O O
in O O
positive O O
sites O O
showed O O
high O O
relationship O O
( O O
R2 O O
coefficients O O
) O O
for O O
every O O
habitat O O
category O O
and O O
explained O O
> O O
50% O O
of O O
the O O
variation O O
in O O
tick O O
abundance O O
. O O

In O O
summary O O
, O O
we O O
conclude O O
that O O
the O O
adenoviral O B-GENE
oncoprotein O I-GENE
E1A S-GENE E-GENE
activates O O
transcription O O
from O O
the O O
endogenous O O
AP-2alpha B-GENE B-GENE
gene E-GENE E-GENE
, O O
an O O
effect O O
that O O
involves O O
transcriptional O O
derepression O O
of O O
the O O
AP-2alpha B-GENE B-GENE
promoter E-GENE E-GENE
by O O
interaction O O
of O O
E1A O S-GENE
with O O
the O O
AP-2rep S-GENE B-GENE
corepressor O I-GENE
CtBP1 S-GENE E-GENE
. O O
Additional O O
factors O O
such O O
as O O
advanced O O
age O O
, O O
concomitant O O
use O O
of O O
corticosteroids O O
or O O
anticoagulants O O
, O O
prior O O
ulcer O O
complications O O
and O O
co O O
- O O
morbid O O
diseases O O
may O O
further O O
increase O O
the O O
risk O O
of O O
bleeding O O
. O O

SERS O O
spectra O O
were O O
obtained O O
by O O
vacuum O O
evaporation O O
and O O
casting O O
of O O
p O O
- O O
NTP O O
onto O O
silver O O
island O O
films O O
, O O
and O O
also O O
from O O
colloidal O O
silver O O
solutions O O
. O O

Copyright O O
2001 O O
Academic O O
Press O O
. O O

The O O
core O B-GENE
promoter O E-GENE
of O O
human B-GENE B-GENE
thioredoxin I-GENE I-GENE
reductase I-GENE I-GENE
1 E-GENE E-GENE
: O O
cloning O O
, O O
transcriptional O O
activity O O
, O O
and O O
Oct-1 S-GENE O
, O O
Sp1 S-GENE S-GENE
, O O
and O O
Sp3 S-GENE B-GENE
binding O I-GENE
reveal O I-GENE
a O I-GENE
housekeeping O I-GENE
- O I-GENE
type O I-GENE
promoter O E-GENE
for O O
the O O
AU O B-GENE
- O I-GENE
rich O I-GENE
element O I-GENE
- O I-GENE
regulated O I-GENE
gene O E-GENE
. O O
Here O O
we O O
show O O
that O O
phosphorylation O O
- O O
induced O O
loss O O
of O O
the O O
protein O B-GENE
kinase O E-GENE
activity O O
of O O
DNA B-GENE B-GENE
- I-GENE I-GENE
PK E-GENE E-GENE
is O O
restored O O
by O O
the O O
addition O O
of O O
the O O
purified O O
catalytic O O
subunit O O
of O O
either O O
protein B-GENE B-GENE
phosphatase I-GENE I-GENE
1 E-GENE I-GENE
or O I-GENE
protein B-GENE I-GENE
phosphatase I-GENE I-GENE
2A E-GENE E-GENE
( O O
PP2A S-GENE S-GENE
) O O
and O O
that O O
this O O
reactivation O O
is O O
blocked O O
by O O
the O O
potent O O
protein O B-GENE
phosphatase O I-GENE
inhibitor O E-GENE
, O O
microcystin O O
. O O
The O O
first O O
exon O O
( O O
exon O O
1A O O
) O O
that O O
corresponded O O
to O O
the O O
5'-untranslated O O
region O O
of O O
the O O
GHR B-GENE B-GENE
1A I-GENE I-GENE
mRNA E-GENE E-GENE
was O O
15,250 O O
bp O O
upstream O O
from O O
exon O O
2 O O
in O O
the O O
GHR B-GENE B-GENE
gene E-GENE E-GENE
. O O
These O O
corrections O O
do O O
not O O
involve O O
sequences O O
predicted O O
to O O
function O O
as O O
transcription O O
factor O O
binding O O
sites O O
. O O

FLP S-GENE S-GENE
and O O
Cre B-GENE O
recombinase E-GENE O
function O O
in O O
Xenopus O O
embryos O O
. O O
A O O
method O O
of O O
three O O
- O O
station O O
three O O
- O O
dimensional O O
magnetic O O
resonance O O
( O O
MR O O
) O O
angiography O O
of O O
the O O
lower O O
extremities O O
with O O
segmented O O
volume O O
acquisition O O
is O O
presented O O
. O O

A O O
single O O
nucleotide O O
polymorphism O O
( O O
SNP O S-GENE
) O O
in O O
exon O O
2 O O
, O O
which O O
is O O
tightly O O
liked O O
to O O
another O O
SNP O S-GENE
( O O
GTG83/ATG83 O O
) O O
, O O
creates O O
an O O
additional O O
alternative O O
in O O
- O O
frame O O
AUG O O
in O O
B B-GENE B-GENE
- I-GENE I-GENE
type I-GENE I-GENE
MTH1 I-GENE I-GENE
mRNAs E-GENE E-GENE
yielding O O
the O O
fourth O O
MTH1 B-GENE B-GENE
polypeptide E-GENE E-GENE
, O O
p26 S-GENE O
that O O
possesses O O
an O O
additional O O
mitochondrial O O
targeting O O
signal O O
. O O
Our O O
previous O O
studies O O
have O O
shown O O
that O O
SHP-1 S-GENE S-GENE
, O O
a O O
SH2 B-GENE B-GENE
domain I-GENE I-GENE
- I-GENE I-GENE
containing I-GENE I-GENE
protein I-GENE I-GENE
- I-GENE I-GENE
tyrosine I-GENE I-GENE
phosphatase E-GENE E-GENE
, O O
is O O
expressed O O
not O O
only O O
in O O
cells O O
of O O
hematopoietic O O
lineages O O
, O O
but O O
also O O
in O O
many O O
non O O
- O O
hematopoietic O O
cells O O
under O O
the O O
control O O
of O O
an O O
alternative O O
tissue O B-GENE
- O I-GENE
specific O I-GENE
promoter O E-GENE
, O O
P1 O S-GENE
. O O
Unexpectedly O O
, O O
Arg1-expressing O O
COS1 O S-GENE
cells O O
showed O O
no O O
significant O O
proteinase O O
activity O O
to O O
various O O
synthesized O O
substrates O O
under O O
neutral O O
or O O
acidic O O
conditions O O
in O O
this O O
study O O
. O O
ORF1 O O
( O O
1029 O O
bp O O
; O O
EMBL O O
databank O O
, O O
Accession O O
No O O
. O O

In O O
the O O
meantime O O
, O O
one O O
has O O
succeeded O O
to O O
establish O O
the O O
deammonification O O
processes O O
in O O
a O O
continuous O O
flow O O
moving O O
- O O
bed O O
pilot O O
plant O O
. O O

The O O
purpose O O
of O O
this O O
study O O
was O O
to O O
evaluate O O
simplified O O
methods O O
for O O
estimation O O
of O O
Technetium O O
Tc O O
99 O O
m O O
( O O
99mTc)-pentetate O O
and O O
orthoiodohippurate O O
I O O
131 O O
( O O
131I O O
- O O
OIH O O
) O O
plasma O O
clearance O O
in O O
dogs O O
and O O
cats O O
with O O
1 O O
and O O
2 O O
blood O O
samples O O
. O O

A O O
patient O O
is O O
described O O
with O O
skin O O
lesions O O
resembling O O
Kaposi O O
's O O
sarcoma O O
( O O
KS O O
) O O
. O O

Interventions O O
aimed O O
at O O
these O O
specific O O
mediators O O
and O O
processes O O
may O O
be O O
successful O O
in O O
reducing O O
the O O
very O O
significant O O
human O O
and O O
economic O O
costs O O
of O O
vascular O O
access O O
dysfunction O O
. O O

In O O
addition O O
, O O
stonin B-GENE O
2 E-GENE O
binds O O
to O O
the O O
C2B O B-GENE
domains O E-GENE
of O O
synaptotagmins B-GENE B-GENE
I I-GENE E-GENE
and I-GENE O
II E-GENE S-GENE
. O O
This O O
partial O O
transection O O
could O O
permit O O
vasopressin S-GENE O
to O O
be O O
secreted O O
in O O
response O O
to O O
a O O
larger O O
rise O O
in O O
plasma O O
sodium O O
concentration O O
. O O
In O O
conclusion O O
, O O
USPIO O O
- O O
enhanced O O
MRI O O
data O O
were O O
capable O O
to O O
characterize O O
tumor O O
microvessel O O
properties O O
in O O
this O O
breast O O
cancer O O
model O O
: O O
microvascular O O
permeability O O
( O O
determined O O
using O O
USPIO O O
) O O
correlated O O
significantly O O
with O O
tumor O O
grade O O
. O O

The O O
images O O
showed O O
rapid O O
, O O
predominantly O O
urinary O O
excretion O O
of O O
99mTc O O
ciprofloxacin O O
, O O
with O O
low O O
to O O
absent O O
brain O O
, O O
lung O O
and O O
bone O O
marrow O O
uptake O O
and O O
low O O
liver O O
uptake O O
and O O
excretion O O
. O O

To O O
this O O
end O O
, O O
an O O
expression O O
cassette O O
consisting O O
of O O
the O O
gene O O
for O O
a O O
green B-GENE O
fluorescent I-GENE O
protein E-GENE O
( O O
GFP S-GENE S-GENE
) O O
flanked O O
at O O
its O O
3 O O
' O O
end O O
by O O
EAV O B-GENE
- O I-GENE
specific O I-GENE
transcription O I-GENE
- O I-GENE
regulating O I-GENE
sequences O E-GENE
was O O
constructed O O
. O O
However O O
, O O
the O O
N63S O B-GENE
mutation O E-GENE
in O O
the O O
wild B-GENE B-GENE
- I-GENE I-GENE
type I-GENE I-GENE
VP5 E-GENE E-GENE
background O O
increased O O
the O O
interaction O O
, O O
as O O
judged O O
by O O
the O O
beta B-GENE B-GENE
- I-GENE I-GENE
galactosidase E-GENE E-GENE
activity O O
, O O
by O O
a O O
factor O O
of O O
9 O O
relative O O
to O O
when O O
the O O
PR7 O B-GENE
mutation O E-GENE
was O O
present O O
. O O
In O O
addition O O
, O O
severe O O
vision O O
loss O O
can O O
be O O
seen O O
with O O
interferon B-GENE B-GENE
alfa-2b E-GENE E-GENE
- O O
associated O O
retinopathy O O
. O O
The O O
mechanism O O
of O O
the O O
induction O O
of O O
3beta B-GENE B-GENE
- I-GENE I-GENE
HSD I-GENE I-GENE
type I-GENE I-GENE
1 I-GENE I-GENE
gene E-GENE E-GENE
expression O O
was O O
further O O
characterized O O
in O O
ZR-75 O B-GENE
- O I-GENE
1 O I-GENE
human O E-GENE
breast O O
cancer O O
cells O O
. O O
An O O
integrated O O
RTC O O
algorithm O O
for O O
the O O
urban O O
wastewater O O
system O O
is O O
formulated O O
, O O
the O O
parameters O O
of O O
which O O
are O O
optimized O O
using O O
various O O
global O O
optimization O O
routines O O
. O O

SKP1-SnRK O B-GENE
protein O I-GENE
kinase O E-GENE
interactions O O
mediate O O
proteasomal O O
binding O O
of O O
a O O
plant O O
SCF B-GENE B-GENE
ubiquitin I-GENE I-GENE
ligase E-GENE E-GENE
. O O
PATIENTS O O
AND O O
METHODS O O
: O O
Between O O
June O O
1991 O O
and O O
December O O
1996 O O
, O O
we O O
administered O O
the O O
nucleoside O O
analog O O
2-chlorodeoxyadenosine O O
( O O
2-CDA O O
) O O
to O O
73 O O
children O O
with O O
primary O O
AML O O
and O O
20 O O
children O O
with O O
secondary O O
AML O O
or O O
myelodysplastic O O
syndrome O O
( O O
MDS O O
) O O
. O O

The O O
severity O O
of O O
pathologic O O
changes O O
increased O O
with O O
the O O
magnitude O O
of O O
percussion O O
. O O

Experimental O O
study O O
of O O
ta O O
chengchi O O
tang O O
decoction O O
for O O
relieving O O
lung O O
injury O O
during O O
acute O O
necrotizing O O
pancreatitis O O
] O O
The O O
objectives O O
of O O
the O O
study O O
were O O
to O O
investigate O O
the O O
changes O O
of O O
leukocyte O O
adhesiveness O O
and O O
tumor B-GENE B-GENE
necrosis I-GENE I-GENE
factor E-GENE E-GENE
( O O
TNF S-GENE S-GENE
) O O
in O O
the O O
early O O
stage O O
of O O
acute O O
necrotizing O O
pancreatitis O O
( O O
ANP O O
) O O
, O O
to O O
go O O
further O O
into O O
the O O
relation O O
of O O
those O O
changes O O
to O O
lung O O
injury O O
of O O
ANP O O
, O O
and O O
to O O
evaluate O O
the O O
prohibitive O O
effect O O
of O O
ta O O
chengchi O O
tang O O
Decoction O O
on O O
leukocyte O O
adhesion O O
and O O
TNF O S-GENE
secretion O O
. O O
A O O
variety O O
of O O
receptor O O
- O O
mediated O O
signaling O O
pathways O O
are O O
controlled O O
by O O
both O O
positive O O
and O O
negative O O
extracellular O O
regulators O O
. O O

TT O S-GENE
cells O O
, O O
a O O
human O O
MTC O O
cell O O
line O O
expressing O O
MEN B-GENE O
2A I-GENE O
type I-GENE O
RET E-GENE S-GENE
, O O
display O O
transcriptionally O O
active O O
RelA(p65 B-GENE S-GENE
) E-GENE O
in O O
the O O
nucleus O O
. O O
Inhibition O O
of O O
constitutive O O
NF B-GENE B-GENE
- I-GENE I-GENE
kappaB E-GENE E-GENE
activity O O
results O O
in O O
cell O O
death O O
of O O
TT O S-GENE
cells O O
and O O
blocks O O
focus O O
formation O O
induced O O
by O O
oncogenic O O
forms O O
of O O
RET S-GENE S-GENE
in O O
NIH O B-GENE
3T3 O E-GENE
cells O O
. O O
Reciprocally O O
, O O
HMGI B-GENE B-GENE
- I-GENE I-GENE
C E-GENE E-GENE
expression O O
also O O
coordinately O O
enhances O O
PIAS3-mediated O S-GENE
repression O O
of O O
STAT3-dependent O B-GENE
transactivation O E-GENE
. O O
A O O
central O O
finding O O
is O O
the O O
identification O O
of O O
a O O
GC O O
- O O
rich O O
sequence O O
in O O
the O O
-99/-91 O O
Cp S-GENE O
region O O
that O O
is O O
essential O O
for O O
oriPI O B-GENE
- O I-GENE
EBNA1-independent O E-GENE
as O O
well O O
as O O
oriPI O B-GENE
- O I-GENE
EBNA1-dependent O E-GENE
activity O O
of O O
the O O
promoter O O
. O O
Additional O O
deletion O O
mutations O O
revealed O O
a O O
new O O
, O O
67-amino O O
- O O
acid O O
functional O O
domain O O
within O O
the O O
proline O O
- O O
rich O O
region O O
of O O
SLP-76 S-GENE S-GENE
, O O
which O O
we O O
have O O
termed O O
the O O
P-1 O B-GENE
domain O E-GENE
. O O
Finally O O
, O O
profiling O O
of O O
a O O
gcn4Delta B-GENE B-GENE
mutant E-GENE E-GENE
uncovered O O
an O O
alternative O O
induction O O
pathway O O
operating O O
at O O
many O O
Gcn4p B-GENE B-GENE
target I-GENE I-GENE
genes E-GENE E-GENE
in O O
histidine O O
- O O
starved O O
cells O O
. O O
Evidence O O
from O O
a O O
Northern O O
hybridization O O
indicated O O
that O O
jadM S-GENE O
expression O O
is O O
correlated O O
with O O
jadomycin B-GENE O
B E-GENE O
synthesis O O
. O O
Right O O
LHR O O
( O O
R O O
- O O
LHR O O
) O O
provided O O
the O O
best O O
interobserver O O
and O O
intraobserver O O
reproducibility O O
. O O

CONCLUSIONS O O
: O O
The O O
methodology O O
of O O
LHR O O
measurement O O
significantly O O
influences O O
the O O
clinical O O
contribution O O
of O O
Tl-201 O O
lung O O
uptake O O
evaluation O O
. O O

Mutation O O
of O O
the O O
NF B-GENE B-GENE
- I-GENE I-GENE
kappaB I-GENE I-GENE
site E-GENE E-GENE
in O O
the O O
Mdr1b B-GENE B-GENE
promoter E-GENE E-GENE
prevents O O
its O O
induction O O
by O O
TNF B-GENE B-GENE
- I-GENE I-GENE
alpha E-GENE E-GENE
. O O
To O O
determine O O
the O O
genomic O O
complexity O O
of O O
the O O
deleted O O
region O O
shared O O
among O O
tumors O O
, O O
we O O
assembled O O
a O O
physical O O
map O O
of O O
the O O
I O O
Mbp O O
SRO O O
consisting O O
predominantly O O
of O O
bacteriophage O O
P1-derived O O
artificial O O
chromosome O O
( O O
PAC O O
) O O
clones O O
. O O

Online O O
teaching O O
: O O
design O O
and O O
techniques O O
. O O

The O O
application O O
of O O
the O O
biotechnology O O
at O O
the O O
plants O O
for O O
treatment O O
of O O
the O O
surface O O
storm O O
waters O O
from O O
the O O
industrial O O
zone O O
Telychka O O
of O O
the O O
city O O
of O O
Kyiv O O
has O O
allowed O O
the O O
content O O
of O O
petroleum O O
in O O
water O O
dropped O O
to O O
the O O
Dnieper O O
to O O
be O O
constantly O O
reduced O O
50 O O
- O O
100 O O
times O O
. O O

Data O O
were O O
obtained O O
from O O
2 O O
undergraduate O O
student O O
samples O O
, O O
a O O
self O O
- O O
report O O
group O O
( O O
n O O
= O O
132 O O
) O O
who O O
provided O O
NEO O O
- O O
PI O O
- O O
R O O
self O O
- O O
ratings O O
on O O
2 O O
occasions O O
separated O O
by O O
a O O
7- O O
to O O
14-day O O
interval O O
and O O
an O O
informant O O
group O O
( O O
n O O
= O O
109 O O
) O O
who O O
provided O O
ratings O O
of O O
well O O
- O O
known O O
friends O O
or O O
relatives O O
on O O
2 O O
occasions O O
separated O O
by O O
a O O
6 O O
month O O
interval O O
. O O

Northern O O
blot O O
analysis O O
of O O
RNAs O O
from O O
a O O
number O O
of O O
mouse O O
tissues O O
reveals O O
that O O
Atp6i S-GENE S-GENE
is O O
expressed O O
predominantly O O
in O O
osteoclasts O O
, O O
and O O
this O O
predominant O O
expression O O
was O O
confirmed O O
by O O
reverse O B-GENE
- O I-GENE
transcription O I-GENE
polymerase O I-GENE
chain O I-GENE
reaction O E-GENE
( O O
RT O B-GENE
- O I-GENE
PCR O E-GENE
) O O
assay O O
and O O
immunohistochemical O O
analysis O O
. O O
Indeed O O
, O O
mutation O O
of O O
two O O
of O O
these O O
motifs O O
, O O
known O O
to O O
be O O
important O O
to O O
regulation O O
of O O
sid1 S-GENE O
, O O
altered O O
the O O
differential O O
regulation O O
of O O
sid2 S-GENE O
by O O
iron O O
. O O
The O O
described O O
results O O
show O O
that O O
DTD O S-GENE
is O O
fast O O
, O O
simple O O
, O O
and O O
easy O O
to O O
automate O O
; O O
requires O O
only O O
a O O
small O O
amount O O
of O O
sample O O
( O O
approximately O O
50 O O
mg O O
) O O
; O O
and O O
affords O O
quantitative O O
information O O
about O O
the O O
main O O
groups O O
of O O
compounds O O
present O O
in O O
cheeses O O
. O O

Guidelines O O
for O O
performing O O
a O O
routine O O
spiral O O
assay O O
are O O
presented O O
, O O
and O O
alternative O O
test O O
methods O O
intended O O
to O O
overcome O O
a O O
variety O O
of O O
technical O O
difficulties O O
( O O
such O O
as O O
restricted O O
sample O O
availability O O
, O O
sample O O
viscosity O O
or O O
volatility O O
, O O
etc O O
. O O
) O O
are O O
recommended O O
. O O

In O O
conclusion O O
, O O
obesity O O
, O O
alcohol O O
intake O O
, O O
and O O
multimetabolic O O
disorders O O
were O O
determined O O
to O O
be O O
independent O O
predictors O O
for O O
the O O
development O O
of O O
hyperuricemia O O
. O O

Fans O O
in O O
tunnels O O
and O O
open O O
windows O O
at O O
aboveground O O
locations O O
appeared O O
to O O
greatly O O
reduce O O
the O O
likelihood O O
of O O
high O O
PH3 O O
concentrations O O
in O O
enclosed O O
areas O O
. O O

Autoregulation O O
enables O O
different O O
pathways O O
to O O
control O O
CCAAT B-GENE B-GENE
/ I-GENE I-GENE
enhancer I-GENE I-GENE
binding I-GENE I-GENE
protein I-GENE I-GENE
beta E-GENE E-GENE
( O O
C B-GENE B-GENE
/ I-GENE I-GENE
EBP I-GENE I-GENE
beta E-GENE E-GENE
) O O
transcription O O
. O O
The O O
first O O
case O O
of O O
HCV O O
seroconversion O O
in O O
Portugal O O
after O O
the O O
introduction O O
of O O
HCV O O
NAT O O
screening O O
. O O

As O O
a O O
reflection O O
of O O
uncertainties O O
in O O
the O O
estimates O O
for O O
individual O O
sources O O
, O O
the O O
90th O O
percentiles O O
of O O
PCDD O O
/ O O
F O O
releases O O
for O O
1999 O O
ranged O O
up O O
to O O
4.1 O O
g O O
I O O
- O O
TEQ O O
/ O O
y O O
. O O

Gabapentin O O
for O O
opiod O O
- O O
related O O
myoclonus O O
in O O
cancer O O
patients O O
. O O

CONCLUSIONS O O
: O O
Our O O
meta O O
- O O
analysis O O
of O O
randomized O O
controlled O O
trials O O
of O O
HRT O O
noted O O
a O O
statistically O O
significant O O
reduction O O
in O O
nonvertebral O O
fractures O O
. O O

Newcastle B-GENE O
disease I-GENE O
antibody E-GENE O
titre O O
is O O
dependent O O
on O O
serum O O
calcium O O
concentration O O
. O O
A O O
total O O
of O O
25 O O
patients O O
with O O
malignant O O
brain O O
tumours O O
were O O
investigated O O
. O O

Net O O
lift O O
and O O
combined O O
drag O O
from O O
all O O
8 O O
bearings O O
of O O
the O O
4-bladed O O
impeller O O
are O O
compared O O
with O O
predictions O O
based O O
on O O
2-D O O
theory O O
. O O

Our O O
results O O
indicate O O
that O O
Gab1 S-GENE S-GENE
is O O
involved O O
in O O
the O O
control O O
of O O
egr-1 S-GENE O
expression O O
regulated O O
by O O
insulin S-GENE S-GENE
. O O
The O O
observed O O
triplexes O O
depend O O
on O O
the O O
length O O
of O O
the O O
repeat O O
. O O

The O O
co O O
- O O
existence O O
of O O
TE B-GENE S-GENE
domains E-GENE O
within O O
modular O O
PKSs S-GENE S-GENE
along O O
with O O
physically O O
separated O O
, O O
monofunctional O O
TEs S-GENE S-GENE
( O O
TE B-GENE B-GENE
IIs E-GENE E-GENE
) O O
has O O
been O O
reported O O
for O O
a O O
number O O
of O O
modular O O
polyketide O O
and O O
non B-GENE O
- I-GENE O
ribosomal I-GENE B-GENE
peptide I-GENE I-GENE
synthases E-GENE E-GENE
( O O
NRPS S-GENE S-GENE
) O O
. O O
To O O
gain O O
an O O
understanding O O
of O O
the O O
mGSTM2 S-GENE O
regulation O O
, O O
we O O
have O O
also O O
cloned O O
and O O
analyzed O O
its O O
promoter O O
region O O
. O O
10.0 O O
+ O O
/- O O
2.0 O O
pmol/24 O O
h O O
, O O
P O O
< O O
0.01 O O
) O O
and O O
remained O O
elevated O O
. O O

SELECTION O O
CRITERIA O O
: O O
All O O
randomised O O
controlled O O
trials O O
comparing O O
IUSs O O
with O O
other O O
forms O O
of O O
reversible O O
contraceptives O O
and O O
reporting O O
on O O
pre O O
- O O
determined O O
outcomes O O
in O O
women O O
of O O
reproductive O O
years O O
. O O

OBJECTIVES O O
: O O
The O O
objective O O
of O O
this O O
review O O
was O O
to O O
compare O O
the O O
effectiveness O O
, O O
safety O O
and O O
acceptability O O
of O O
the O O
diaphragm O O
with O O
and O O
without O O
spermicide O O
. O O

To O O
test O O
the O O
hypothesis O O
that O O
these O O
elements O O
are O O
required O O
for O O
promoter O O
activity O O
, O O
we O O
compared O O
the O O
reporter O O
expression O O
activity O O
of O O
segments O O
containing O O
mutations O O
of O O
these O O
elements O O
with O O
activity O O
of O O
the O O
parent B-GENE O
Hlx I-GENE B-GENE
promoter I-GENE E-GENE
sequence E-GENE O
. O O
In O O
all O O
of O O
these O O
cases O O
, O O
expression O O
of O O
the O O
implicated O O
genes O O
was O O
absent O O
. O O

CONCLUSIONS O O
: O O
Ketamine O O
- O O
induced O O
dissociative O O
anesthesia O O
produces O O
persistently O O
elevated O O
BIS O O
index O O
which O O
is O O
different O O
from O O
thiamylal O O
and O O
those O O
reported O O
with O O
other O O
conventional O O
anesthetic O O
agents O O
. O O

Our O O
results O O
are O O
reassuring O O
and O O
we O O
therefore O O
advise O O
that O O
in O O
patients O O
undergoing O O
free O O
jejunum O O
flap O O
reconstruction O O
of O O
the O O
hypopharyngo O O
- O O
esophageal O O
tract O O
voice O O
restoration O O
should O O
be O O
attempted O O
by O O
placing O O
a O O
voice O O
prosthesis O O
through O O
a O O
secondary O O
tracheo O O
- O O
esophageal O O
puncture O O
and O O
providing O O
intensive O O
speech O O
training O O
. O O

Hypercalcemia O O
associated O O
with O O
elevated O O
serum B-GENE B-GENE
PTH E-GENE E-GENE
concentration O O
indicating O O
primary O O
hyperparathyroidism O O
was O O
found O O
in O O
7 O O
BC O O
patients O O
( O O
7% O O
) O O
and O O
in O O
none O O
of O O
healthy O O
women O O
or O O
patients O O
with O O
thyroid O O
cancer O O
. O O
Positive O O
and O O
significant O O
correlations O O
were O O
found O O
between O O
the O O
weeks O O
of O O
pregnancy O O
and O O
Se O O
levels O O
in O O
kidney O O
( O O
r=0.433 O O
, O O
P=0.023 O O
) O O
and O O
heart O O
( O O
r=0.313 O O
, O O
P=0.030 O O
) O O
. O O

This O O
study O O
suggests O O
that O O
PSP O O
is O O
more O O
common O O
than O O
previously O O
considered O O
, O O
is O O
commonly O O
misdiagnosed O O
and O O
that O O
the O O
majority O O
of O O
cases O O
are O O
not O O
initially O O
referred O O
to O O
neurologists O O
. O O

In O O
Saccharomyces O O
cerevisiae O O
, O O
entry O O
into O O
mitosis O O
requires O O
activation O O
of O O
the O O
cyclin B-GENE B-GENE
- I-GENE I-GENE
dependent I-GENE I-GENE
kinase E-GENE I-GENE
Cdc28 S-GENE E-GENE
in O O
its O O
cyclin B-GENE B-GENE
B E-GENE E-GENE
( O O
Clb)-associated O S-GENE
form O O
. O O
We O O
investigated O O
the O O
production O O
of O O
hyaluronan O S-GENE
( O O
HA O S-GENE
) O O
and O O
its O O
effect O O
on O O
cell O O
motility O O
in O O
cells O O
expressing O O
the O O
v B-GENE B-GENE
- I-GENE I-GENE
src I-GENE I-GENE
mutants E-GENE E-GENE
. O O
Our O O
results O O
indicate O O
that O O
D(4 O S-GENE
) O O
and O O
D(2L O S-GENE
) O O
receptors O O
activate O O
the O O
ERK B-GENE B-GENE
kinase E-GENE E-GENE
cascade O O
by O O
first O O
mobilizing O O
signaling O O
by O O
the O O
PDGF B-GENE B-GENE
receptor E-GENE E-GENE
, O O
followed O O
by O O
the O O
subsequent O O
activation O O
of O O
ERK1/2 S-GENE S-GENE
by O O
pathways O O
associated O O
with O O
this O O
receptor B-GENE B-GENE
tyrosine I-GENE I-GENE
kinase E-GENE E-GENE
. O O
Karger O O
AG O O
, O O
Basel O O

We O O
used O O
stored O O
plasma O O
samples O O
from O O
409 O O
patients O O
in O O
the O O
National O O
Institute O O
of O O
Neurological O O
Diseases O O
and O O
Stroke O O
( O O
NINDS O O
) O O
tissue B-GENE O
plasminogen I-GENE B-GENE
activator E-GENE E-GENE
( O O
t B-GENE B-GENE
- I-GENE I-GENE
PA E-GENE E-GENE
) O O
Stroke O O
Trial O O
to O O
examine O O
the O O
relationship O O
between O O
an O O
apolipoprotein B-GENE O
( I-GENE O
Apo I-GENE S-GENE
) I-GENE O
E2 E-GENE O
or O O
an O O
Apo B-GENE B-GENE
E4 E-GENE I-GENE
phenotype O E-GENE
and O O
a O O
favorable O O
outcome O O
3 O O
months O O
after O O
stroke O O
, O O
the O O
risk O O
of O O
intracerebral O O
hemorrhage O O
, O O
and O O
the O O
response O O
to O O
intravenous O O
t O O
- O O
PA O O
therapy O O
. O O
NIRS O O
was O O
used O O
for O O
the O O
quantitative O O
measurement O O
of O O
muscle O O
O(2 O O
) O O
consumption O O
( O O
mV.O(2 O O
) O O
) O O
and O O
forearm O O
blood O O
flow O O
( O O
FBF O O
) O O
in O O
78 O O
healthy O O
subjects O O
. O O

No O O
dominant O O
clinical O O
factor O O
of O O
risk O O
was O O
found O O
, O O
but O O
multiple O O
regression O O
analysis O O
identified O O
age O O
, O O
body O O
surface O O
area O O
, O O
valve O O
size O O
, O O
shop O O
order O O
fracture O O
rate O O
, O O
and O O
manufacturing O O
period O O
as O O
risk O O
factors O O
for O O
OSF O O
. O O

In O O
this O O
report O O
this O O
technique O O
was O O
applied O O
to O O
human O O
breast O O
carcinoma O O
MDA O B-GENE
- O I-GENE
MB231 O E-GENE
cells O O
overexpressing O O
human B-GENE O
MPG E-GENE S-GENE
in O O
order O O
to O O
assess O O
whether O O
up O O
- O O
regulation O O
of O O
the O O
initial O O
step O O
in O O
BER O S-GENE
alters O O
the O O
activity O O
of O O
selected O O
other O O
BER O S-GENE
( O O
hOGG1 S-GENE S-GENE
and O O
APE S-GENE B-GENE
/ O I-GENE
ref-1 S-GENE E-GENE
) O O
or O O
direct O O
reversal O O
( O O
MGMT S-GENE S-GENE
) O O
repair O O
activities O O
. O O
The O O
selective O O
alteration O O
of O O
the O O
genome O O
using O O
Cre B-GENE O
recombinase E-GENE O
to O O
target O O
the O O
rearrangement O O
of O O
genes O O
flanked O O
by O O
LOX B-GENE S-GENE
recognition I-GENE O
sequences E-GENE O
has O O
required O O
the O O
use O O
of O O
two O O
separate O O
genetic O O
constructs O O
in O O
trans O O
, O O
one O O
containing O O
cre O O
and O O
the O O
other O O
containing O O
the O O
gene O O
of O O
interest O O
flanked O O
by O O
LOX B-GENE B-GENE
sites E-GENE E-GENE
. O O
Colorectal O O
cancer O O
was O O
shown O O
to O O
disproportionately O O
overburden O O
Ashkenazi O O
Jews O O
, O O
who O O
may O O
also O O
be O O
at O O
increased O O
risk O O
for O O
ovarian O O
, O O
pancreatic O O
and O O
stomach O O
cancer O O
, O O
and O O
non O O
- O O
Hodgkin O O
's O O
lymphoma O O
. O O

Influence O O
of O O
compression O O
therapy O O
on O O
symptoms O O
following O O
soft O O
tissue O O
injury O O
from O O
maximal O O
eccentric O O
exercise O O
. O O

Keratoconjunctivitis O O
sicca O O
appears O O
to O O
be O O
a O O
common O O
ocular O O
complication O O
and O O
all O O
children O O
with O O
JRA O O
should O O
be O O
screened O O
for O O
it O O
with O O
a O O
comprehensive O O
battery O O
of O O
tests O O
. O O

STAT5A S-GENE O
mutations O O
in O O
the O O
Src B-GENE B-GENE
homology I-GENE I-GENE
2 E-GENE E-GENE
( O O
SH2 S-GENE S-GENE
) O O
and O O
SH3 B-GENE S-GENE
domains E-GENE O
did O O
not O O
alter O O
the O O
BTK S-GENE B-GENE
- O I-GENE
mediated O I-GENE
tyrosine O I-GENE
phosphorylation O E-GENE
. O O
In O O
conclusion O O
, O O
primary O O
chemotherapy O O
based O O
on O O
high O O
dose O O
MTX O O
and O O
ara O O
- O O
C O O
is O O
highly O O
efficient O O
in O O
PCNSL O O
. O O

RANTES S-GENE S-GENE
( O O
regulated B-GENE O
upon I-GENE O
activation I-GENE O
, I-GENE O
normally I-GENE O
T I-GENE O
- I-GENE O
cell I-GENE O
expressed I-GENE O
and I-GENE O
presumably I-GENE O
secreted E-GENE O
) O O
is O O
a O O
CC O O
chemokine O O
which O O
recruits O O
and O O
activates O O
monocytes O O
, O O
lymphocytes O O
, O O
and O O
eosinophils O O
, O O
all O O
cell O O
types O O
present O O
in O O
the O O
lung O O
inflammatory O O
infiltrate O O
induced O O
by O O
RSV O O
infection O O
. O O
Reovirus O O
mRNAs O O
are O O
efficiently O O
translated O O
within O O
host O O
cells O O
despite O O
the O O
absence O O
of O O
3 O O
' O O
polyadenylated O O
tails O O
. O O

Analyses O O
revealed O O
that O O
scale O O
matters O O
above O O
and O O
beyond O O
the O O
effect O O
of O O
quadrat O O
area O O
. O O

Myasthenia O O
gravis O O
is O O
an O O
autoimmune O O
disease O O
resulting O O
from O O
the O O
production O O
of O O
antibodies O O
against O O
the O O
ACh B-GENE O
receptors E-GENE O
of O O
the O O
neuromuscular O O
synapse O O
. O O
Copyright O O
2001 O O
Academic O O
Press O O
. O O

Using O O
the O O
postural O O
and O O
force O O
data O O
as O O
input O O
to O O
a O O
3-D O O
biomechanical O O
model O O
, O O
the O O
lumbosacral O O
spinal O O
compression O O
was O O
calculated O O
. O O

Angina O O
( O O
Q O O
) O O
persistence O O
showed O O
marked O O
associations O O
with O O
previous O O
myocardial O O
infarction O O
, O O
diagnosed O O
angina O O
, O O
electrocardiogram O O
ischemia O O
, O O
and O O
subsequent O O
major O O
ischemic O O
heart O O
disease O O
events O O
from O O
Q5 O O
onward O O
. O O

In O O
the O O
past O O
decade O O
, O O
there O O
have O O
been O O
enormous O O
advances O O
in O O
the O O
use O O
of O O
Bayesian O O
methodology O O
for O O
analysis O O
of O O
epidemiologic O O
data O O
, O O
and O O
there O O
are O O
now O O
many O O
practical O O
advantages O O
to O O
the O O
Bayesian O O
approach O O
. O O

To O O
assess O O
more O O
specific O O
PKA S-GENE O
- O O
dependent O O
mediation O O
of O O
LH B-GENE S-GENE
's E-GENE O
contribution O O
to O O
combined O O
hormonal O O
drive O O
, O O
the O O
LDL B-GENE B-GENE
receptor I-GENE E-GENE
( I-GENE O
-1076 I-GENE O
to I-GENE O
+ I-GENE O
11 I-GENE O
bp I-GENE O
) I-GENE O
reporter E-GENE O
plasmid O O
was O O
cotransfected O O
with O O
a O O
full B-GENE O
- I-GENE O
sequence I-GENE O
rabbit I-GENE B-GENE
muscle I-GENE I-GENE
protein I-GENE I-GENE
kinase I-GENE I-GENE
inhibitor E-GENE E-GENE
( O O
PKI S-GENE S-GENE
) O O
minigene O O
driven O O
constitutively O O
by O O
a O O
Rous B-GENE B-GENE
sarcoma I-GENE I-GENE
virus I-GENE I-GENE
promoter E-GENE E-GENE
. O O
To O O
investigate O O
the O O
convergent O O
role O O
of O O
the O O
insulin S-GENE S-GENE
/ O O
IGF B-GENE B-GENE
- I-GENE I-GENE
I E-GENE E-GENE
effector O O
pathway O O
mediating O O
bihormonal O O
stimulation O O
of O O
LDL B-GENE B-GENE
receptor I-GENE I-GENE
promoter E-GENE E-GENE
expression O O
, O O
transfected O O
granulosa O O
- O O
luteal O O
cells O O
were O O
pretreated O O
for O O
30 O O
min O O
with O O
two O O
specific O O
inhibitors O O
of O O
phophatidylinositol B-GENE B-GENE
3-kinase E-GENE E-GENE
, O O
wortmannin O O
( O O
100 O O
nM O O
) O O
and O O
LY O B-GENE
294002 O E-GENE
( O O
10 O O
microM O O
) O O
, O O
or O O
of O O
mitogen B-GENE B-GENE
- I-GENE I-GENE
activated I-GENE I-GENE
protein I-GENE I-GENE
kinase I-GENE I-GENE
kinase E-GENE E-GENE
, O O
PD O B-GENE
98059 O E-GENE
( O O
50 O O
microM O O
) O O
, O O
U0126 O S-GENE
( O O
10 O O
microM O O
) O O
, O O
or O O
the O O
latter O O
's O O
inactive O O
derivative O O
, O O
U0124 O S-GENE
( O O
10 O O
microM O O
) O O
. O O
Concerted O O
transcriptional O O
activation O O
of O O
the O O
low B-GENE O
density I-GENE O
lipoprotein I-GENE B-GENE
receptor I-GENE I-GENE
gene E-GENE E-GENE
by O O
insulin S-GENE S-GENE
and O O
luteinizing B-GENE B-GENE
hormone E-GENE E-GENE
in O O
cultured O O
porcine O O
granulosa O O
- O O
luteal O O
cells O O
: O O
possible O O
convergence O O
of O O
protein B-GENE B-GENE
kinase I-GENE E-GENE
a E-GENE O
, O O
phosphatidylinositol B-GENE B-GENE
3-kinase E-GENE E-GENE
, O O
and O O
mitogen B-GENE B-GENE
- I-GENE I-GENE
activated I-GENE I-GENE
protein I-GENE I-GENE
kinase E-GENE E-GENE
signaling O O
pathways O O
. O O
These O O
studies O O
demonstrate O O
that O O
site O O
- O O
specific O O
recognition O O
of O O
the O O
bxd B-GENE B-GENE
PRE E-GENE E-GENE
by O O
d(GA)(n O S-GENE
) O O
repeat O O
binding O O
activities O O
mediates O O
PcG S-GENE B-GENE
- O I-GENE
dependent O I-GENE
silencing O E-GENE
. O O
Our O O
findings O O
further O O
our O O
understanding O O
of O O
how O O
ZBP-89 S-GENE S-GENE
modulates O O
cell O O
proliferation O O
and O O
reveals O O
a O O
novel O O
mechanism O O
by O O
which O O
the O O
p53 B-GENE B-GENE
protein E-GENE E-GENE
is O O
stabilized O O
. O O
A O O
computerized O O
method O O
of O O
determining O O
the O O
focal O O
point O O
of O O
electrical O O
activity O O
in O O
the O O
pallidum O O
of O O
parkinsonian O O
patients O O
was O O
developed O O
using O O
on O O
- O O
line O O
quantitative O O
physiological O O
data O O
analysis O O
. O O

Five O O
modalities O O
of O O
nonpharmacologic O O
approaches O O
are O O
recommended O O
at O O
present O O
for O O
lifestyle O O
modification O O
and O O
control O O
of O O
arterial O O
blood O O
pressure O O
elevation O O
: O O
1 O O
) O O
weight O O
reduction O O
to O O
ideal O O
body O O
weight O O
, O O
since O O
it O O
reduces O O
risk O O
of O O
hypertension O O
as O O
well O O
as O O
overall O O
cardiovascular O O
morbidity O O
and O O
mortality O O
; O O
2 O O
) O O
dietary O O
sodium O O
restriction O O
to O O
less O O
than O O
2 O O
g O O
a O O
day O O
, O O
without O O
assurance O O
that O O
it O O
will O O
normalize O O
arterial O O
pressure O O
although O O
it O O
may O O
help O O
reduce O O
dosage O O
and O O
numbers O O
of O O
prescribed O O
antihypertensive O O
drugs O O
; O O
3 O O
) O O
moderation O O
of O O
alcohol O O
consumption O O
to O O
less O O
than O O
1 O O
ounce O O
a O O
day O O
; O O
4 O O
) O O
a O O
regular O O
isotonic O O
exercise O O
program O O
; O O
and O O
5 O O
) O O
cessation O O
of O O
tobacco O O
consumption O O
. O O

Isolated O O
Systolic O O
Hypertension O O
: O O
An O O
Update O O
. O O

Ga-67 O O
and O O
Tl-201 O O
scintigraphy O O
in O O
extramedullary O O
plasmacytoma O O
: O O
a O O
case O O
report O O
. O O

Arterial O O
blood O O
gas O O
tensions O O
were O O
similar O O
across O O
all O O
ventilation O O
modes O O
. O O

As O O
expected O O
, O O
homologous B-GENE O
loxP I-GENE S-GENE
sequences E-GENE O
efficiently O O
underwent O O
Cre S-GENE O
- O O
mediated O O
recombination O O
. O O
The O O
N O O
- O O
terminal O O
portion O O
of O O
Notch(IC B-GENE S-GENE
) E-GENE O
inhibited O O
p50 S-GENE B-GENE
DNA O I-GENE
binding O E-GENE
and O O
interacted O O
specifically O O
with O O
p50 B-GENE B-GENE
subunit E-GENE E-GENE
, O O
not O O
p65 S-GENE S-GENE
of O O
NF O B-GENE
- O I-GENE
kappaB. O E-GENE
Conformational O O
changes O O
of O O
the O O
ferric B-GENE B-GENE
uptake I-GENE I-GENE
regulation I-GENE I-GENE
protein E-GENE E-GENE
upon O O
metal O O
activation O O
and O O
DNA O O
binding O O
; O O
first O O
evidence O O
of O O
structural O O
homologies O O
with O O
the O O
diphtheria B-GENE B-GENE
toxin I-GENE I-GENE
repressor E-GENE E-GENE
. O O
As O O
a O O
complement O O
to O O
genome O O
- O O
wide O O
mapping O O
and O O
sequencing O O
efforts O O
, O O
it O O
is O O
often O O
important O O
to O O
generate O O
detailed O O
maps O O
and O O
sequence O O
data O O
for O O
specific O O
regions O O
of O O
interest O O
. O O

Granulocyte B-GENE B-GENE
colony I-GENE I-GENE
- I-GENE I-GENE
stimulating I-GENE I-GENE
factor E-GENE E-GENE
( O O
G B-GENE B-GENE
- I-GENE I-GENE
CSF E-GENE E-GENE
) O O
administration O O
in O O
vivo O O
has O O
been O O
shown O O
to O O
improve O O
the O O
defence O O
mechanisms O O
against O O
infection O O
by O O
different O O
microbes O O
. O O
Among O O
individuals O O
, O O
however O O
, O O
changes O O
were O O
strongly O O
correlated O O
with O O
ACR O O
levels O O
at O O
baseline O O
. O O

Thus O O
, O O
the O O
screen O O
for O O
toxic O O
p53 B-GENE B-GENE
mutants E-GENE E-GENE
in O O
yeast O O
can O O
identify O O
novel O O
p53 O B-GENE
variants O E-GENE
that O O
may O O
be O O
useful O O
in O O
dissecting O O
p53 O S-GENE
regulated O O
cellular O O
responses O O
and O O
in O O
developing O O
p53-based O O
cancer O O
therapies O O
. O O
This O O
is O O
necessary O O
if O O
psychiatric O O
diagnoses O O
are O O
ultimately O O
going O O
to O O
be O O
refined O O
and O O
validated O O
against O O
biological O O
criteria O O
. O O

Since O O
the O O
latter O O
is O O
very O O
small O O
for O O
physiological O O
flows O O
, O O
the O O
result O O
is O O
that O O
alpha O O
< O O
1 O O
even O O
at O O
relatively O O
high O O
values O O
of O O
the O O
Reynolds O O
number O O
( O O
i.e. O O
, O O
for O O
non O O
- O O
negligible O O
inertia O O
) O O
and O O
we O O
validate O O
our O O
perturbation O O
theory O O
results O O
by O O
comparison O O
with O O
a O O
numerical O O
integration O O
of O O
the O O
full O O
model O O
. O O

Cells O O
lacking O O
p116 S-GENE O
exhibit O O
a O O
striking O O
defect O O
in O O
the O O
formation O O
of O O
these O O
macropinocytic O O
structures O O
, O O
a O O
concomitant O O
reduction O O
in O O
the O O
rate O O
of O O
fluid O O
phase O O
pinocytosis O O
, O O
a O O
significant O O
decrease O O
in O O
the O O
efficiency O O
of O O
chemotactic O O
aggregation O O
, O O
and O O
a O O
decrease O O
in O O
cellular O O
F B-GENE O
- I-GENE O
actin E-GENE O
content O O
. O O
The O O
validity O O
of O O
the O O
FPS O O
- O O
R O O
was O O
further O O
supported O O
by O O
strong O O
positive O O
correlations O O
with O O
the O O
VAS O O
( O O
r=0.92 O O
, O O
N=45 O O
) O O
and O O
the O O
CAS O O
( O O
r=0.84 O O
, O O
N=45 O O
) O O
in O O
this O O
clinical O O
sample O O
. O O

The O O
susceptibility O O
of O O
Aspergillus O O
fumigatus O O
to O O
mulundocandin O O
, O O
an O O
echinocandin O O
- O O
like O O
compound O O
, O O
and O O
other O O
antifungal O O
agents O O
was O O
assessed O O
by O O
the O O
National O O
Committee O O
for O O
Clinical O O
Laboratory O O
Standards O O
( O O
NCCLS O O
) O O
M38-P O O
method O O
, O O
a O O
2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenyl O O
- O O
amino)carbonyl]-2H O O
- O O
tetrazolium O O
hydroxide O O
( O O
XTT)-based O O
colorimetric O O
assay O O
, O O
and O O
determination O O
of O O
morphologic O O
alterations O O
by O O
microscopy O O
. O O

The O O
Van O O
der O O
Hoeve O O
's O O
syndrome O O
lesions O O
as O O
poorly O O
mineralized O O
, O O
with O O
low O O
calcium O O
salt O O
and O O
apparent O O
increase O O
of O O
phosphates O O
. O O

A O O
5-month O O
- O O
old O O
infant O O
with O O
persistent O O
congenital O O
stridor O O
and O O
acute O O
respiratory O O
distress O O
is O O
presented O O
. O O

DESIGN O O
: O O
A O O
retrospective O O
chart O O
review O O
of O O
9,322 O O
patients O O
undergoing O O
surgical O O
procedures O O
in O O
the O O
period O O
January O O
1993 O O
to O O
December O O
1998 O O
. O O

Pulmonary O O
vein O O
varix O O
in O O
association O O
with O O
bilateral O O
pulmonary O O
vein O O
stenosis O O
. O O

Biochemical O O
experiments O O
have O O
shown O O
that O O
CopG S-GENE S-GENE
co O O
- O O
operatively O O
associates O O
to O O
its O O
target O O
DNA O O
at O O
low O O
protein O O
: O O
DNA O O
ratios O O
, O O
completely O O
protecting O O
four O O
helical O O
turns O O
on O O
the O O
same O O
face O O
of O O
the O O
double O O
helix O O
in O O
both O O
directions O O
from O O
the O O
inverted O O
repeat O O
that O O
constitutes O O
the O O
CopG O S-GENE
primary O O
target O O
. O O
We O O
demonstrated O O
that O O
, O O
under O O
serum O B-GENE
- O I-GENE
starved O E-GENE
conditions O O
, O O
KMS-11 O S-GENE
and O O
OPM-2 O S-GENE
cells O O
express O O
appreciable O O
levels O O
of O O
phosphorylated O O
FGFR3 B-GENE B-GENE
mutants E-GENE E-GENE
indicating O O
a O O
constitutive O O
activation O O
of O O
the O O
Y373C B-GENE S-GENE
and I-GENE O
K650E I-GENE B-GENE
receptors E-GENE E-GENE
; O O
the O O
addition O O
of O O
the O O
aFGF B-GENE S-GENE
ligand E-GENE O
further O O
increased O O
the O O
level O O
of O O
receptor O B-GENE
phosphorylation O E-GENE
. O O
[ O O
figure O O
: O O
see O O
text O O
] O O
The O O
Stille O O
coupling O O
reaction O O
has O O
been O O
performed O O
in O O
1-butyl-3-methylimidazolium O O
tetrafluoroborate O O
( O O
BMIM O O
BF4 O O
) O O
, O O
a O O
room O O
- O O
temperature O O
ionic O O
liquid O O
( O O
RTIL O O
) O O
. O O

Special O O
issues O O
devoted O O
to O O
the O O
biosynthesis O O
of O O
woody O O
plant O O
biopolymers O O
and O O
related O O
substances O O
. O O

Interactions O O
between O O
the O O
checkpoint O B-GENE
abrogator O I-GENE
UCN-01 O E-GENE
and O O
several O O
pharmacological O O
inhibitors O O
of O O
the O O
mitogen B-GENE B-GENE
- I-GENE I-GENE
activated I-GENE I-GENE
protein I-GENE I-GENE
kinase I-GENE E-GENE
( E-GENE O
MAPK B-GENE S-GENE
) I-GENE O
kinase E-GENE S-GENE
( O O
MEK)/MAPK O S-GENE
pathway O O
have O O
been O O
examined O O
in O O
a O O
variety O O
of O O
human O O
leukemia O O
cell O O
lines O O
. O O
Low O O
affinity O O
binding O O
of O O
Rab6A B-GENE B-GENE
- I-GENE I-GENE
GTP E-GENE E-GENE
was O O
also O O
observed O O
( O O
K(d O S-GENE
) O O
= O O
16 O O
microm O O
) O O
, O O
whereas O O
Rab1B B-GENE O
, I-GENE O
-5 I-GENE O
, I-GENE O
-7 I-GENE O
, I-GENE O
-8 I-GENE O
, I-GENE O
or I-GENE O
-11A E-GENE O
did O O
not O O
bind O O
. O O
The O O
students O O
who O O
had O O
abnormal O O
urine O O
screening O O
results O O
at O O
the O O
first O O
time O O
received O O
a O O
second O O
urine O O
analysis O O
10 O O
to O O
15 O O
days O O
later O O
to O O
confirm O O
the O O
abnormal O O
urine O O
analysis O O
. O O

PURPOSE O O
: O O
The O O
objective O O
of O O
this O O
study O O
was O O
to O O
assess O O
first O O
embryo O O
cleavage O O
( O O
FEC O O
) O O
25 O O
- O O
27 O O
h O O
after O O
intracytoplasmic O O
sperm O O
injection O O
( O O
ICSI O O
) O O
as O O
a O O
parameter O O
for O O
the O O
embryo O O
selection O O
process O O
. O O

Regulation O O
of O O
laminin B-GENE B-GENE
beta2 I-GENE I-GENE
chain I-GENE I-GENE
gene E-GENE E-GENE
expression O O
in O O
human O O
cancer O O
cell O O
lines O O
. O O
Northern O O
and O O
Western O O
blot O O
analyses O O
demonstrated O O
that O O
Graf2 S-GENE S-GENE
is O O
expressed O O
in O O
several O O
tissues O O
, O O
with O O
the O O
highest O O
expression O O
in O O
skeletal O O
muscle O O
. O O
However O O
, O O
when O O
directed O O
to O O
the O O
nucleosome O O
by O O
fusion O O
to O O
core S-GENE B-GENE
histone B-GENE I-GENE
H2A E-GENE E-GENE
or O O
H2B S-GENE S-GENE
, O O
the O O
non O O
- O O
histone O O
tail O O
forms O O
an O O
MCB O S-GENE
that O O
appears O O
identical O O
to O O
that O O
of O O
the O O
endogenous O B-GENE
protein O E-GENE
. O O
These O O
data O O
suggest O O
that O O
proper O O
direct O O
binding O O
of O O
Nhp2p S-GENE S-GENE
to O O
H B-GENE O
/ I-GENE O
ACA I-GENE B-GENE
snoRNAs E-GENE E-GENE
is O O
required O O
for O O
the O O
assembly O O
of O O
H B-GENE O
/ I-GENE O
ACA I-GENE B-GENE
snoRNPs E-GENE E-GENE
and O O
hence O O
for O O
the O O
stability O O
of O O
some O O
of O O
their O O
components O O
. O O
Telomerase S-GENE O
is O O
a O O
ribonucleoprotein O O
complex O O
that O O
synthesizes O O
telomeric O O
DNA O O
onto O O
chromosomes O O
using O O
its O O
RNA O O
component O O
as O O
template O O
. O O
SIT S-GENE S-GENE
( O O
SHP2-interacting B-GENE B-GENE
transmembrane I-GENE I-GENE
adaptor I-GENE I-GENE
protein E-GENE E-GENE
) O O
is O O
a O O
recently O O
identified O O
transmembrane O B-GENE
adaptor O I-GENE
protein O E-GENE
, O O
which O O
is O O
expressed O O
in O O
lymphocytes O O
. O O
In O O
35 O O
of O O
those O O
patients O O
DD O O
was O O
measured O O
also O O
with O O
microlatex O O
tests O O
-- O O
Tinaquant O O
and O O
BC O O
d O O
- O O
dimer O O
. O O

Cytosolic B-GENE B-GENE
acetyl I-GENE I-GENE
- I-GENE I-GENE
CoA I-GENE I-GENE
synthetase E-GENE E-GENE
( O O
AceCS1 S-GENE S-GENE
) O O
activates O O
acetate O O
to O O
supply O O
the O O
cells O O
with O O
acetyl O B-GENE
- O I-GENE
CoA O E-GENE
for O O
lipid O O
synthesis O O
. O O
Ileal O O
digestibilities O O
of O O
DM O O
, O O
OM O O
, O O
CP O O
, O O
total O O
dietary O O
fiber O O
( O O
TDF O O
) O O
, O O
fat O O
and O O
gross O O
energy O O
( O O
GE O O
) O O
were O O
lower O O
( O O
P O O
< O O
0.05 O O
) O O
for O O
dogs O O
fed O O
diets O O
containing O O
supplemental O O
fiber O O
compared O O
with O O
dogs O O
fed O O
the O O
control O O
diet O O
. O O

Together O O
these O O
data O O
imply O O
that O O
the O O
HFV B-GENE S-GENE
R I-GENE O
region E-GENE O
acts O O
in O O
the O O
nucleus O O
to O O
modify O O
the O O
cytoplasmic O O
fate O O
of O O
target O O
HFV O B-GENE
mRNA O E-GENE
. O O
These O O
TxRE S-GENE S-GENE
contain O O
cyclic O B-GENE
AMP O I-GENE
- O I-GENE
responsive O I-GENE
elements O E-GENE
( O O
CRE O O
) O O
, O O
but O O
, O O
remarkably O O
, O O
the O O
" O O
TGACGTCA O S-GENE
" O O
consensus O O
is O O
never O O
strictly O O
conserved O O
in O O
any O O
viral O O
strain O O
( O O
e.g.,AGACGTCA O O
, O O
TGACGGCA O S-GENE
, O O
TGACCTCA O S-GENE
) O O
. O O
And O O
, O O
most O O
importantly O O
, O O
reconstitution O O
of O O
a O O
consensus O O
CRE O O
, O O
within O O
the O O
21-bp O O
enhancers O O
increases O O
binding O O
of O O
CREB S-GENE B-GENE
/ O I-GENE
ATF S-GENE I-GENE
proteins O E-GENE
but O O
abrogates O O
basal O O
repression O O
of O O
LTR O B-GENE
- O I-GENE
directed O I-GENE
transcription O E-GENE
in O O
vitro O O
. O O
Site O O
- O O
directed O O
mutagenesis O O
of O O
CAR S-GENE O
revealed O O
that O O
CAR O O
residues O O
Leu73 O S-GENE
and O O
Lys121 O S-GENE
and/or O O
Lys123 O S-GENE
are O O
critical O O
contact O O
residues O O
, O O
with O O
Tyr80 O O
and O O
Tyr83 O O
being O O
peripherally O O
involved O O
in O O
the O O
binding O O
interaction O O
with O O
the O O
Ad5 B-GENE O
, I-GENE O
Ad9 I-GENE O
, I-GENE O
Ad12 I-GENE S-GENE
, I-GENE O
and I-GENE O
Ad41L I-GENE O
fiber I-GENE O
knobs E-GENE O
. O O
This O O
subfamily O O
of O O
genes O O
all O O
have O O
a O O
single O O
ATP O O
- O O
binding O O
domain O O
at O O
the O O
N O O
- O O
terminus O O
and O O
a O O
single O O
C O O
- O O
terminal O O
set O O
of O O
transmembrane O O
segments O O
. O O

Tolerance O O
in O O
renal O O
transplantation O O
after O O
allogeneic O O
bone O O
marrow O O
transplantation-6-year O O
follow O O
- O O
up O O
. O O

The O O
promoter O O
activity O O
of O O
the O O
proximal O O
region O O
was O O
found O O
to O O
be O O
restricted O O
to O O
a O O
subset O O
of O O
prestalk O O
cells O O
. O O

Substitution O O
of O O
serine O O
residues O O
at O O
the O O
C O O
- O O
terminus O O
indicated O O
that O O
loss O O
of O O
phosphorylation O O
sites O O
did O O
not O O
appear O O
to O O
have O O
any O O
effect O O
on O O
transcription O O
and O O
replication O O
. O O

Thus O O
, O O
replication O O
fork O O
movement O O
near O O
HML S-GENE S-GENE
pauses O O
at O O
a O O
silent O O
origin O O
which O O
is O O
competent O O
for O O
replication O O
initiation O O
but O O
kept O O
silent O O
through O O
Orc2p S-GENE S-GENE
, O O
a O O
component O O
of O O
the O O
replication O O
initiator O O
. O O
These O O
findings O O
suggest O O
that O O
the O O
adapter O O
Gab1 S-GENE S-GENE
may O O
redirect O O
c B-GENE O
- I-GENE O
Met E-GENE O
signaling O O
through O O
PI3 B-GENE B-GENE
K E-GENE E-GENE
away O O
from O O
a O O
c B-GENE B-GENE
- I-GENE I-GENE
Akt E-GENE E-GENE
/ O O
Pak1 S-GENE S-GENE
cell O O
survival O O
pathway O O
. O O
We O O
have O O
cloned O O
a O O
novel O O
mouse O B-GENE
protein O E-GENE
, O O
TAF(II)140 S-GENE S-GENE
, O O
containing O O
an O O
HFD S-GENE S-GENE
and O O
a O O
plant B-GENE O
homeodomain E-GENE O
( O O
PHD S-GENE S-GENE
) O O
finger O O
, O O
which O O
we O O
demonstrated O O
by O O
immunoprecipitation O O
to O O
be O O
a O O
mammalian B-GENE O
TFIID I-GENE S-GENE
component E-GENE O
. O O
The O O
other O O
inhibitor O O
was O O
a O O
single O O
TAR S-GENE O
decoy O O
, O O
driven O O
by O O
the O O
U6 B-GENE B-GENE
small I-GENE I-GENE
nuclear I-GENE I-GENE
RNA I-GENE I-GENE
promoter E-GENE E-GENE
( O O
U6-P S-GENE O
) O O
. O O
In O O
contrast O O
to O O
MPc3 S-GENE O
, O O
data O O
indicate O O
that O O
the O O
Pc B-GENE O
protein E-GENE O
M33 S-GENE O
does O O
not O O
interact O O
with O O
AF9 S-GENE O
. O O
Foreigners O O
return O O
. O O

Long O O
- O O
term O O
results O O
with O O
MACOP O O
- O O
B O O
and O O
radiation O O
therapy O O
for O O
aggressive O O
lymphomas O O
] O O
BACKGROUND O O
: O O
Long O O
- O O
term O O
results O O
are O O
needed O O
to O O
evaluate O O
chemotherapy O O
regimens O O
and O O
prognostic O O
factors O O
in O O
non O O
- O O
Hodgkin O O
's O O
lymphomas O O
( O O
NHL O O
) O O
. O O

At O O
20 O O
days O O
( O O
D O O
) O O
and O O
at O O
3 O O
months O O
post O O
- O O
TBI O O
, O O
irradiated O O
rats O O
had O O
a O O
significantly O O
lower O O
percentage O O
of O O
avoidance O O
than O O
controls O O
but O O
no O O
statistical O O
difference O O
was O O
found O O
at O O
5 O O
months O O
post O O
- O O
TBI O O
. O O
b/ O O
Two O O
- O O
way O O
avoidance O O
test O O
: O O
this O O
test O O
was O O
performed O O
only O O
after O O
TBI O O
. O O

At O O
the O O
end O O
of O O
each O O
day O O
of O O
migration O O
the O O
pulmonary O O
hemolymph O O
PO2 O O
decreased O O
by O O
1 O O
- O O
2.5 O O
kPa O O
, O O
but O O
the O O
hemocyanin O O
remained O O
saturated O O
with O O
O2 O O
and O O
the O O
venous O O
reserve O O
was O O
largely O O
unchanged O O
( O O
O2 O O
> O O
0.4 O O
mmol O O
x O O
l(-1 O O
) O O
) O O
. O O

DESIGN O O
: O O
Prospective O O
cohort O O
study O O
with O O
a O O
20 O O
y O O
follow O O
- O O
up O O
period O O
, O O
the O O
First O O
National O O
Health O O
and O O
Examination O O
Survey O O
( O O
NHANES O O
1 O O
) O O
Epidemiologic O O
Follow O O
- O O
up O O
Study O O
( O O
NHEFS O O
) O O
. O O

Mean O O
Hg O O
concentrations O O
in O O
the O O
livers O O
of O O
mice O O
at O O
some O O
sites O O
in O O
Isle O O
Royale O O
are O O
not O O
significantly O O
lower O O
( O O
P O O
= O O
0.62 O O
) O O
than O O
Hg O O
concentrations O O
considered O O
by O O
some O O
government O O
agencies O O
to O O
be O O
unhealthy O O
for O O
human O O
consumption O O
. O O

There O O
are O O
many O O
different O O
proposals O O
for O O
the O O
statistical O O
analysis O O
of O O
data O O
to O O
determine O O
early O O
onset O O
of O O
action O O
. O O

The O O
assay O O
herein O O
described O O
allows O O
the O O
comparison O O
of O O
relative O O
FGFR S-GENE S-GENE
expression O O
levels O O
, O O
both O O
within O O
a O O
single O O
RNA O O
pool O O
and O O
among O O
multiple O O
RNA O O
pool O O
samples O O
. O O
The O O
amount O O
of O O
drained O O
effusion O O
was O O
measured O O
, O O
and O O
fluid O O
was O O
sent O O
for O O
diagnostic O O
assessment O O
. O O

The O O
system O O
, O O
designed O O
to O O
exploit O O
the O O
relatively O O
constant O O
small O O
intestine O O
transit O O
time O O
, O O
consists O O
of O O
a O O
drug O O
- O O
containing O O
core O O
coated O O
with O O
a O O
polymeric O O
matrix O O
formed O O
by O O
a O O
channeling O O
agent O O
( O O
NaCl O O
, O O
mannitol O O
, O O
and O O
Emdex O O
) O O
and O O
an O O
inert O O
polymer O O
( O O
Eudragit O O
RS100 O O
) O O
. O O

STUDY O O
OBJECTIVE O O
: O O
This O O
study O O
assessed O O
several O O
methodological O O
aspects O O
related O O
to O O
the O O
quality O O
of O O
published O O
controlled O O
clinical O O
trials O O
( O O
CCTs O O
) O O
in O O
relation O O
to O O
the O O
participation O O
of O O
an O O
epidemiologist O O
/ O O
biostatistician O O
( O O
E O O
/ O O
B O O
) O O
. O O

The O O
median O O
preoperative O O
best O O
- O O
corrected O O
visual O O
acuity O O
of O O
0.08 O O
( O O
range O O
hand O O
motions/0.003 O O
to O O
0.4 O O
) O O
, O O
improved O O
by O O
5 O O
lines O O
to O O
a O O
median O O
final O O
postoperative O O
best O O
- O O
corrected O O
visual O O
acuity O O
of O O
0.25 O O
( O O
range O O
0.025 O O
- O O
0.5 O O
) O O
( O O
P O O
= O O
0.001 O O
) O O
. O O

A O O
rare O O
case O O
of O O
primary O O
group O O
A O O
streptococcal O O
peritonitis O O
. O O

Gimpl O O
, O O
F. O O

The O O
present O O
chemotherapy O O
of O O
AE O O
is O O
based O O
on O O
the O O
administration O O
of O O
benzimidazole O O
carbamate O O
derivatives O O
, O O
such O O
as O O
mebendazole O O
and O O
albendazole O O
. O O

Topological O O
and O O
mutational O O
analysis O O
of O O
Saccharomyces B-GENE B-GENE
cerevisiae I-GENE I-GENE
Ste14p E-GENE E-GENE
, O O
founding O O
member O O
of O O
the O O
isoprenylcysteine B-GENE B-GENE
carboxyl I-GENE I-GENE
methyltransferase I-GENE I-GENE
family E-GENE E-GENE
. O O
Hormonal O O
regulation O O
of O O
multiple O O
promoters O O
of O O
the O O
rat B-GENE B-GENE
mitochondrial I-GENE I-GENE
glycerol-3-phosphate I-GENE I-GENE
dehydrogenase I-GENE I-GENE
gene E-GENE E-GENE
: O O
identification O O
of O O
a O O
complex O O
hormone O B-GENE
- O I-GENE
response O I-GENE
element O E-GENE
in O O
the O O
ubiquitous O O
promoter O O
B. O O
BACKGROUND O O
/ O O
AIMS O S-GENE
: O O
Hepatitis O O
C O O
and O O
nonalcoholic O O
fatty O O
liver O O
disease O O
( O O
NAFL O O
) O O
are O O
the O O
two O O
most O O
common O O
forms O O
of O O
liver O O
disease O O
in O O
the O O
United O O
States O O
. O O

Statistical O O
Analysis O O
included O O
ANOVA O O
, O O
the O O
Pearson O B-GENE
Product O E-GENE
Moment O O
Correlation O O
Coefficient O O
, O O
Principal O O
Components O O
Analysis O O
and O O
Discriminant O O
Function O O
Analysis O O
and O O
the O O
calculation O O
of O O
Cronbach O O
's O O
alpha O O
( O O
alpha O O
) O O
RESULTS O O
: O O
Both O O
Sensitivity O O
and O O
specificity O O
exceed O O
90.00 O O
at O O
23/24 O O
, O O
Chronbach O O
's O O
alpha O O
for O O
the O O
total O O
scale O O
was O O
equal O O
to O O
0.95 O O
. O O

The O O
telomerase B-GENE B-GENE
RNA I-GENE I-GENE
- I-GENE I-GENE
protein I-GENE I-GENE
complex E-GENE E-GENE
responsible O O
for O O
maintenance O O
of O O
telomeric O O
DNA O O
at O O
chromosome O O
ends O O
, O O
is O O
usually O O
inactive O O
in O O
most O O
primary O O
somatic O O
human O O
cells O O
, O O
but O O
is O O
specifically O O
activated O O
with O O
in O O
vitro O O
immortalization O O
and O O
during O O
tumorigenesis O O
. O O
The O O
titer O O
of O O
TSH B-GENE B-GENE
binding I-GENE I-GENE
inhibitor I-GENE I-GENE
immunoglobulin E-GENE E-GENE
( O O
TBII S-GENE S-GENE
) O O
, O O
which O O
had O O
been O O
8.6% O O
at O O
initial O O
presentation O O
, O O
rose O O
to O O
14.9% O O
in O O
2 O O
weeks O O
. O O
Our O O
results O O
show O O
that O O
CVN S-GENE O
specifically O O
recognizes O O
with O O
nanomolar O O
affinity O O
Man(9)GlcNAc(2 O S-GENE
) O O
and O O
the O O
D1D3 O S-GENE
isomer O O
of O O
Man(8)GlcNAc(2 O S-GENE
) O O
. O O
Here O O
we O O
show O O
that O O
independent O O
of O O
uncertainties O O
in O O
the O O
models O O
, O O
terrestrial O O
planets O O
with O O
dense O O
atmosphere O O
like O O
Venus O O
can O O
evolve O O
into O O
one O O
of O O
only O O
four O O
possible O O
rotation O O
states O O
. O O

Enantiomer O O
separation O O
of O O
venlafaxine O O
and O O
O O O
- O O
desmethylvenlafaxine O O
in O O
human O O
plasma O O
. O O

TE-671 O O
cells O O
that O O
were O O
transfected O O
with O O
cAMP O B-GENE
response O I-GENE
element O I-GENE
mutant O E-GENE
constructs O O
demonstrated O O
a O O
diminished O O
basal O O
activity O O
of O O
the O O
GnRH B-GENE B-GENE
- I-GENE I-GENE
II I-GENE I-GENE
promoter E-GENE E-GENE
. O O
They O O
consist O O
of O O
at O O
least O O
two O O
separable O O
components O O
, O O
one O O
heat O O
stable O O
and O O
the O O
other O O
heat O O
labile O O
. O O

Altogether O O
, O O
we O O
confirm O O
that O O
all O O
genes O O
of O O
the O O
Rad52 S-GENE S-GENE
recombinational O O
repair O O
pathway O O
are O O
required O O
for O O
the O O
survival O O
of O O
rad27 B-GENE O
Delta E-GENE O
strains O O
at O O
both O O
permissive O O
( O O
23 O O
degrees O O
C O O
) O O
and O O
semipermissive O O
( O O
30 O O
degrees O O
C O O
) O O
temperatures O O
for O O
growth O O
. O O
In O O
the O O
last O O
case O O
, O O
both O O
hydroxychloroquine O O
, O O
carbamazepine O O
and O O
fluvoxamine O O
had O O
a O O
common O O
imputability O O
which O O
was O O
plausible O O
. O O

We O O
investigate O O
the O O
reaction O O
kinetics O O
of O O
small O O
spherical O O
particles O O
with O O
inertia O O
, O O
obeying O O
coalescence O O
type O O
of O O
reaction O O
, O O
B+B-->B O O
, O O
and O O
being O O
advected O O
by O O
hydrodynamical O O
flows O O
with O O
time O O
- O O
periodic O O
forcing O O
. O O

The O O
role O O
of O O
the O O
Vp1 B-GENE B-GENE
DBD E-GENE E-GENE
during O O
infection O O
was O O
investigated O O
by O O
taking O O
advantage O O
of O O
NLS O B-GENE
phenotypic O I-GENE
complementation O E-GENE
( O O
N. O O
2 O O
were O O
nonviable O O
, O O
and O O
the O O
mutant B-GENE B-GENE
Vp1s E-GENE E-GENE
unexpectedly O O
failed O O
to O O
localize O O
to O O
the O O
nucleus O O
though O O
Vp2 S-GENE O
and O O
Vp3 S-GENE O
did O O
, O O
suggesting O O
that O O
the O O
mutated B-GENE O
NLS1 E-GENE S-GENE
acted O O
as O O
a O O
dominant O O
signal O O
for O O
the O O
cytoplasmic O O
localization O O
of O O
Vp1 O O
. O O
Zhu O O
, O O
V. O O

Fasting O O
gastrin S-GENE S-GENE
levels O O
( O O
normal O O
range O O
: O O
25 O O
- O O
110 O O
mU O O
/ O O
L O O
) O O
varied O O
from O O
48.78 O O
mU O O
/ O O
L-168.20 O O
( O O
mean O O
: O O
85.23 O O
mU O O
/ O O
L O O
) O O
. O O
Here O O
, O O
we O O
show O O
that O O
the O O
phorbol O O
ester O O
PMA O O
decreases O O
both O O
basal O O
and O O
dexamethasone O O
/ O O
cAMP O O
- O O
induced O O
expression O O
of O O
a O O
luciferase B-GENE B-GENE
gene E-GENE E-GENE
under O O
the O O
control O O
of O O
the O O
G6Pase B-GENE B-GENE
promoter E-GENE E-GENE
in O O
transiently O O
transfected O O
H4IIE O S-GENE
hepatoma O O
cells O O
. O O
Through O O
deletion O O
mutagenesis O O
, O O
we O O
identify O O
amino O O
acids O O
2003 O O
to O O
2212 O O
of O O
CBP S-GENE O
, O O
which O O
we O O
call O O
carboxy O O
- O O
terminal O O
region O O
2 O O
( O O
CR2 O S-GENE
) O O
, O O
as O O
the O O
minimal O O
region O O
for O O
Tax S-GENE O
interaction O O
. O O
Such O O
knowledge O O
could O O
advance O O
diagnosis O O
and O O
treatment O O
of O O
the O O
patient O O
and O O
counseling O O
of O O
the O O
affected O O
family O O
. O O

BACKGROUND O O
: O O
There O O
is O O
increasing O O
interest O O
on O O
the O O
part O O
of O O
investigators O O
and O O
the O O
public O O
at O O
large O O
in O O
finding O O
ways O O
to O O
study O O
and O O
improve O O
treatments O O
for O O
the O O
seriously O O
mentally O O
ill O O
without O O
exposing O O
such O O
individuals O O
to O O
unnecessary O O
risks O O
. O O

In O O
the O O
next O O
week O O
, O O
the O O
beta O O
- O O
adrenergic O O
antagonist O O
atenolol O O
was O O
added O O
at O O
an O O
initial O O
dose O O
of O O
25 O O
mg O O
/ O O
day O O
and O O
titrated O O
to O O
50 O O
mg O O
/ O O
day O O
within O O
1 O O
week O O
. O O

Lack O O
of O O
association O O
between O O
Kawasaki O O
syndrome O O
and O O
infection O O
with O O
Rickettsia O O
conorii O O
, O O
Rickettsia O O
typhi O O
, O O
Coxiella O O
burnetii O O
or O O
Ehrlichia O O
phagocytophila O O
group O O
. O O

The O O
presence O O
of O O
AS O O
- O O
oligo O O
had O O
no O O
further O O
effect O O
on O O
the O O
FSH S-GENE S-GENE
- O O
mediated O O
activation O O
of O O
the O O
EB*-mTf O B-GENE
- O I-GENE
CAT S-GENE E-GENE
construct O O
but O O
reduced O O
cAMP O O
- O O
mediated O O
activation O O
. O O
This O O
is O O
a O O
challenging O O
task O O
insofar O O
as O O
direct O O
measures O O
of O O
ISF O O
glucose O O
are O O
not O O
readily O O
available O O
. O O

We O O
report O O
the O O
results O O
of O O
a O O
detailed O O
policy O O
analysis O O
comparing O O
2 O O
CJD O O
- O O
related O O
decisions O O
: O O
a O O
1995 O O
recall O O
of O O
blood O O
from O O
a O O
donor O O
with O O
classic O O
CJD O O
and O O
the O O
1999 O O
decision O O
to O O
defer O O
donations O O
from O O
individuals O O
with O O
a O O
6-month O O
travel O O
history O O
to O O
the O O
UK O O
between O O
1980 O O
and O O
1996 O O
due O O
to O O
concerns O O
related O O
to O O
variant O O
CJD O O
. O O

The O O
novel O O
approach O O
to O O
insulin S-GENE S-GENE
administration O O
known O O
as O O
chronic O O
intermittent O O
intravenous O O
insulin O S-GENE
therapy O O
( O O
CIIIT O S-GENE
) O O
delivers O O
insulin O S-GENE
in O O
a O O
pulsatile O O
fashion O O
and O O
achieves O O
physiological O O
insulin O S-GENE
concentration O O
in O O
the O O
portal O O
vein O O
. O O
At O O
visit O O
5 O O
, O O
the O O
isokinetic O O
test O O
showed O O
impaired O O
muscle O O
function O O
recovery O O
from O O
23% O O
to O O
32% O O
, O O
while O O
the O O
manual O O
test O O
showed O O
almost O O
full O O
recovery O O
. O O

We O O
developed O O
a O O
system O O
for O O
domain O O
shuffling O O
to O O
establish O O
the O O
function O O
of O O
C1 S-GENE B-GENE
domains O I-GENE
from O I-GENE
human B-GENE I-GENE
Raf I-GENE I-GENE
kinase E-GENE E-GENE
and O O
rat B-GENE B-GENE
PKC I-GENE I-GENE
eta E-GENE E-GENE
in O O
yeast O O
. O O
We O O
interpret O O
these O O
data O O
as O O
further O O
evidence O O
that O O
interaction O O
with O O
a O O
small B-GENE O
GTPase E-GENE O
is O O
the O O
main O O
regulatory O O
function O O
of O O
the O O
C1 S-GENE B-GENE
domain O E-GENE
in O O
yeast O O
. O O
Breast O O
cancer O O
risk O O
assessment O O
: O O
Who O O
holds O O
the O O
magic O O
crystal O O
ball O O
? O O

Patients O O
with O O
type O O
III O B-GENE
SOD O E-GENE
may O O
have O O
visceral O O
hyperalgesia O O
; O O
a O O
trial O O
of O O
antidepressants O O
or O O
a O O
therapeutic O O
trial O O
with O O
botulinum B-GENE B-GENE
toxin E-GENE E-GENE
injection O O
into O O
the O O
ampulla O O
should O O
be O O
considered O O
prior O O
to O O
more O O
invasive O O
endoscopic O O
therapy O O
. O O
The O O
activity O O
of O O
Rac1 S-GENE S-GENE
leads O O
to O O
STAT3 S-GENE S-GENE
translocation O O
to O O
the O O
nucleus O O
coincident O O
with O O
STAT3-dependent O B-GENE
gene O E-GENE
expression O O
. O O
RESULTS O O
: O O
There O O
is O O
a O O
considerable O O
amount O O
of O O
variation O O
between O O
the O O
results O O
of O O
TRA1 O O
and O O
TRA2 O O
and O O
between O O
the O O
results O O
of O O
both O O
TRA O O
's O O
and O O
the O O
door O O
- O O
to O O
- O O
door O O
survey O O
. O O

In O O
addition O O
, O O
these O O
patients O O
show O O
both O O
quantitative O O
and O O
qualitative O O
differences O O
in O O
their O O
infectious O O
microbiological O O
spectrum O O
, O O
mainly O O
in O O
clean O O
- O O
contaminated O O
, O O
contaminated O O
and O O
dirty O O
surgical O O
procedures O O
. O O

CONCLUSION O O
: O O
Extrusion O O
cooking O O
is O O
effective O O
for O O
the O O
inactivation O O
of O O
DON O O
but O O
is O O
of O O
limited O O
value O O
for O O
AFB1 S-GENE S-GENE
, O O
even O O
if O O
metabisulphite O O
is O O
added O O
. O O
The O O
differences O O
in O O
the O O
CPIgG S-GENE O
, O O
CRP S-GENE S-GENE
, O O
and O O
fibrinogen S-GENE S-GENE
levels O O
in O O
patients O O
who O O
were O O
diagnosed O O
with O O
ACS O O
versus O O
those O O
who O O
were O O
not O O
( O O
non O O
- O O
ACS O O
) O O
were O O
evaluated O O
. O O
NaeI S-GENE O
, O O
a O O
novel O O
DNA B-GENE O
endonuclease E-GENE O
, O O
shows O O
topoisomerase S-GENE O
and O O
recombinase S-GENE O
activities O O
when O O
a O O
Lys O O
residue O O
is O O
substituted O O
for O O
Leu O O
43 O O
. O O
Mss4 S-GENE S-GENE
also O O
acts O O
as O O
a O O
relatively O O
inefficient O O
guanine B-GENE B-GENE
nucleotide I-GENE I-GENE
exchange I-GENE I-GENE
factor E-GENE E-GENE
( O O
GEF S-GENE O
) O O
. O O
The O O
decrements O O
in O O
cerebrovascular O O
resistance O O
induced O O
by O O
hexamethonium O O
, O O
in O O
mm O O
Hg O O
ml(-1).min(-1 O O
) O O
, O O
were O O
: O O
under O O
control O O
. O O

The O O
desirability O O
function O O
is O O
based O O
on O O
the O O
search O O
for O O
a O O
global O O
optimum O O
[ O O
D O O
= O O
f O O
( O O
Y1 O O
, O O
Y2 O O
, O O
... O O
, O O
Yn O O
) O O
] O O
by O O
the O O
transformation O O
of O O
the O O
measured O O
property O O
to O O
a O O
dimensionless O O
scale O O
for O O
each O O
criterion O O
. O O

She O O
has O O
since O O
developed O O
a O O
positive O O
anti B-GENE B-GENE
- I-GENE I-GENE
cardiolipin I-GENE I-GENE
antibody E-GENE E-GENE
but O O
does O O
not O O
meet O O
diagnostic O O
criteria O O
for O O
systemic O O
lupus O O
erythematosis O O
. O O
CONCLUSION O O
: O O
The O O
presence O O
of O O
known O O
autoimmune O O
disease O O
in O O
a O O
woman O O
with O O
POF O O
should O O
not O O
dissuade O O
the O O
clinician O O
from O O
evaluating O O
for O O
a O O
potential O O
genetic O O
cause O O
. O O
RESULTS O O
: O O
In O O
vivo O O
, O O
there O O
was O O
a O O
wide O O
distribution O O
with O O
the O O
coefficient O O
of O O
variation O O
( O O
SD O O
/ O O
mean O O
x O O
100% O O
) O O
for O O
different O O
valve O O
sizes O O
ranging O O
from O O
21% O O
to O O
39% O O
in O O
the O O
St O O
Jude O O
Medical O O
valve O O
and O O
from O O
25% O O
to O O
33% O O
in O O
the O O
Omnicarbon O O
valve O O
. O O

Even O O
if O O
the O O
electrocardiographic O O
signs O O
are O O
subdued O O
, O O
the O O
underlying O O
blockade O O
of O O
I(Kr O O
) O O
current O O
may O O
precipitate O O
the O O
occurrence O O
of O O
arrhythmia O O
. O O

Effects O O
of O O
aerosol O O
- O O
vapor O O
JP-8 O O
jet O O
fuel O O
on O O
the O O
functional O O
observational O O
battery O O
, O O
and O O
learning O O
and O O
memory O O
in O O
the O O
rat O O
. O O

The O O
production O O
of O O
ceramide O O
is O O
emerging O O
as O O
a O O
fixture O O
of O O
programmed O O
cell O O
death O O
. O O

We O O
randomly O O
assigned O O
1,219 O O
subjects O O
to O O
receive O O
either O O
the O O
standard O O
three O O
- O O
times O O
- O O
weekly O O
( O O
TIW O O
) O O
interferon B-GENE O
alfa-2b E-GENE O
dose O O
( O O
3 O O
MIU O O
) O O
or O O
the O O
once O O
- O O
weekly O O
( O O
QW O O
) O O
peginterferon B-GENE O
alfa-2b E-GENE O
( O O
0.5 O O
, O O
1.0 O O
, O O
or O O
1.5 O O
microg O O
/ O O
kg O O
) O O
. O O
At O O
cross O O
purposes O O
. O O

CONCLUSION O O
: O O
There O O
are O O
no O O
differences O O
in O O
the O O
measurement O O
data O O
derived O O
from O O
this O O
method O O
and O O
actual O O
measurement O O
data O O
from O O
an O O
object O O
created O O
by O O
the O O
computer O O
- O O
aided O O
dental O O
design O O
program O O
. O O

Among O O
the O O
transcription O O
factors O O
known O O
to O O
interact O O
with O O
Groucho B-GENE B-GENE
- I-GENE I-GENE
related I-GENE I-GENE
protein E-GENE E-GENE
, O O
only O O
RUNX1 S-GENE S-GENE
was O O
appreciably O O
downregulated O O
by O O
E2A S-GENE B-GENE
- O I-GENE
HLF S-GENE E-GENE
. O O
Many O O
factors O O
do O O
influence O O
the O O
educational O O
outcome O O
in O O
students O O
and O O
large O O
statistical O O
power O O
( O O
such O O
as O O
meta O O
analysis O O
) O O
should O O
be O O
helpful O O
to O O
eliminate O O
many O O
sources O O
of O O
error O O
. O O

The O O
combination O O
of O O
ifosfamide O O
, O O
epirubicin O O
and O O
etoposide O O
( O O
IEV O O
) O O
is O O
an O O
effective O O
salvage O O
regimen O O
for O O
lymphoproliferative O O
disease O O
. O O

A O O
prospective O O
trial O O
was O O
undertaken O O
to O O
determine O O
( O O
1 O O
) O O
clinical O O
characteristics O O
of O O
patients O O
with O O
chest O O
pain O O
; O O
( O O
2 O O
) O O
value O O
of O O
cardiac O O
markers O O
troponin B-GENE B-GENE
T E-GENE E-GENE
, O O
myoglobin S-GENE S-GENE
and O O
CK S-GENE B-GENE
- O I-GENE
MB S-GENE E-GENE
mass O O
in O O
differentiating O O
cardiac O O
and O O
noncardiac O O
chest O O
pain O O
; O O
( O O
3 O O
) O O
the O O
proportion O O
of O O
patients O O
with O O
ACS O O
in O O
whom O O
these O O
markers O O
provided O O
helpful O O
additional O O
information O O
on O O
admission O O
and O O
afterwards O O
. O O
Cardiac O O
markers O O
troponin B-GENE B-GENE
T E-GENE E-GENE
, O O
CK S-GENE B-GENE
- O I-GENE
MB S-GENE E-GENE
mass O O
and O O
myoglobin S-GENE S-GENE
were O O
helpful O O
in O O
the O O
differential O O
diagnosis O O
of O O
chest O O
pain O O
, O O
even O O
when O O
the O O
ECG O O
was O O
unremarkable O O
or O O
nonspecific O O
. O O
At O O
termination O O
( O O
gd O O
20 O O
) O O
, O O
confirmed O O
- O O
pregnant O O
females O O
( O O
21 O O
to O O
25 O O
per O O
group O O
) O O
were O O
evaluated O O
for O O
clinical O O
status O O
and O O
gestational O O
outcome O O
; O O
live O O
fetuses O O
were O O
examined O O
for O O
external O O
, O O
visceral O O
, O O
and O O
skeletal O O
malformations O O
. O O

One O O
maternal O O
death O O
, O O
reduced O O
body O O
weight O O
, O O
and O O
reduced O O
weight O O
gain O O
were O O
noted O O
at O O
the O O
high O O
dose O O
; O O
confirmed O O
pregnancy O O
rates O O
were O O
84 O O
to O O
100% O O
for O O
each O O
group O O
. O O

In O O
the O O
further O O
development O O
of O O
bladder O O
neck O O
suspension O O
according O O
to O O
Stamey O O
- O O
Pereyra O O
, O O
the O O
use O O
of O O
miniature O O
bone O O
anchors O O
received O O
considerable O O
support O O
. O O

Our O O
results O O
demonstrated O O
that O O
50% O O
of O O
the O O
hepatic O O
artery O O
- O O
alone O O
ALT O O
graft O O
showed O O
almost O O
normal O O
structure O O
histologically O O
at O O
1 O O
month O O
after O O
grafting O O
, O O
with O O
bile O O
secretion O O
preserved O O
. O O

Simulating O O
the O O
impact O O
during O O
human O O
jumping O O
by O O
means O O
of O O
a O O
4-degrees O O
- O O
of O O
- O O
freedom O O
model O O
with O O
time O O
- O O
dependent O O
properties O O
. O O

A O O
1-base O O
pair O O
mismatch O O
within O O
the O O
corresponding O O
region O O
of O O
the O O
CYP3A4 B-GENE B-GENE
gene E-GENE E-GENE
was O O
sufficient O O
for O O
a O O
differential O O
enhancer O O
activity O O
. O O
The O O
authors O O
made O O
an O O
analysis O O
of O O
social O O
- O O
economical O O
conditions O O
limiting O O
the O O
possibilities O O
of O O
rendering O O
cardiosurgical O O
care O O
to O O
children O O
. O O

METHODS O O
: O O
93 O O
female O O
and O O
43 O O
male O O
patients O O
undergoing O O
thyroid O O
surgery O O
were O O
stratified O O
according O O
to O O
gender O O
and O O
then O O
randomised O O
to O O
receive O O
double O O
- O O
blind O O
one O O
of O O
four O O
antiemetic O O
regimes O O
: O O
50 O O
mg O O
dolasetron O O
given O O
orally O O
45 O O
minutes O O
prior O O
to O O
induction O O
of O O
anaesthesia O O
( O O
group O O
I O O
) O O
, O O
12.5 O O
mg O O
dolasetron O O
given O O
intravenously O O
during O O
induction O O
of O O
anaesthesia O O
( O O
group O O
II O O
) O O
, O O
1.25 O O
mg O O
DHB S-GENE O
given O O
intravenously O O
during O O
induction O O
of O O
anaesthesia O O
( O O
group O O
III O O
) O O
or O O
placebo O O
( O O
group O O
IV O O
) O O
. O O
This O O
slow O O
progression O O
through O O
the O O
early O O
G1-phase O O
resulted O O
in O O
decreased O O
phosphorylation O O
of O O
the O O
RB B-GENE B-GENE
protein E-GENE E-GENE
and O O
subsequent O O
delay O O
into O O
the O O
S O O
phase O O
transition O O
. O O
In O O
mammals O O
, O O
the O O
transcriptional O O
repressors O O
in O O
the O O
Wnt S-GENE S-GENE
pathway O O
are O O
not O O
well O O
defined O O
. O O
The O O
human B-GENE B-GENE
ABCG1 I-GENE I-GENE
gene E-GENE E-GENE
encodes O O
a O O
member O O
of O O
the O O
ATP B-GENE B-GENE
- I-GENE I-GENE
binding I-GENE I-GENE
cassette E-GENE E-GENE
( O O
ABC O S-GENE
) O O
superfamily O O
of O O
transporter B-GENE B-GENE
proteins E-GENE E-GENE
and O O
is O O
highly O O
induced O O
when O O
macrophages O O
are O O
incubated O O
with O O
oxysterols O O
. O O
Despite O O
abundant O O
expression O O
of O O
NtmybAS B-GENE B-GENE
transcripts E-GENE E-GENE
in O O
mature O O
pollen O O
, O O
gPAL1 B-GENE B-GENE
transcripts E-GENE E-GENE
were O O
not O O
detectable O O
in O O
pollen O O
. O O
C B-GENE B-GENE
/ I-GENE I-GENE
EBPbeta I-GENE I-GENE
LIP E-GENE E-GENE
overexpressing O O
HC11 O S-GENE
cells O O
did O O
not O O
express O O
beta B-GENE B-GENE
- I-GENE I-GENE
casein I-GENE I-GENE
mRNA E-GENE E-GENE
( O O
mammary O O
epithelial O O
cell O O
differentiation O O
marker O O
) O O
in O O
response O O
to O O
lactogenic O B-GENE
hormones O E-GENE
. O O
Identical O O
effects O O
were O O
obtained O O
when O O
inhibitors O O
and O O
dominant O O
negative O O
mutants O O
were O O
tested O O
on O O
the O O
-29 O O
to O O
+ O O
139 O O
bp O O
region O O
of O O
the O O
cyclin B-GENE B-GENE
D1 I-GENE I-GENE
promoter E-GENE E-GENE
. O O
These O O
findings O O
suggest O O
a O O
novel O O
ankyrin S-GENE O
- O O
independent O O
role O O
for O O
LAD-1 S-GENE S-GENE
related O O
to O O
FGFR S-GENE S-GENE
signaling O O
. O O
Moreover O O
, O O
elderly O O
men O O
with O O
bioavailable O O
estradiol O O
levels O O
below O O
the O O
median O O
[ O O
40 O O
pmol O O
/ O O
liter O O
( O O
11 O O
pg O O
/ O O
ml O O
) O O
] O O
had O O
significantly O O
higher O O
rates O O
of O O
bone O O
loss O O
and O O
levels O O
of O O
bone O O
resorption O O
markers O O
than O O
men O O
with O O
bioavailable O O
estradiol O O
levels O O
above O O
40 O O
pmol O O
/ O O
liter O O
. O O

Competition O O
electrophoretic O O
mobility O O
shift O O
and O O
immunoshift O O
assays O O
confirmed O O
that O O
NF1 B-GENE B-GENE
factors E-GENE E-GENE
present O O
in O O
nuclear O O
extracts O O
of O O
HeLa O O
and O O
CV-1 O S-GENE
cells O O
bind O O
to O O
the O O
BKV B-GENE B-GENE
- I-GENE I-GENE
MLP E-GENE E-GENE
. O O
This O O
study O O
demonstrates O O
that O O
inducible O O
expression O O
in O O
response O O
to O O
either O O
PMA O O
or O O
TPO S-GENE S-GENE
is O O
mediated O O
through O O
the O O
Ets B-GENE B-GENE
site E-GENE E-GENE
in O O
the O O
proximal O B-GENE
promoter O E-GENE
of O O
GPIX S-GENE S-GENE
and O O
is O O
dependent O O
upon O O
the O O
upstream O O
activation O O
of O O
MAPK S-GENE B-GENE
/ O I-GENE
extracellular B-GENE I-GENE
signal I-GENE I-GENE
- I-GENE I-GENE
regulated I-GENE I-GENE
kinase E-GENE E-GENE
. O O
RESULTS O O
: O O
The O O
analyzed O O
fragment O O
has O O
significant O O
activity O O
in O O
EpCAM S-GENE S-GENE
positive O O
cells O O
, O O
and O O
it O O
is O O
regulated O O
negatively O O
by O O
tumor B-GENE B-GENE
necrosis I-GENE I-GENE
factor I-GENE I-GENE
alpha E-GENE E-GENE
( O O
TNFalpha S-GENE S-GENE
) O O
. O O
On O O
Cox O O
proportional O O
hazards O O
regression O O
adenocarcinoma O O
( O O
P=0.006 O O
) O O
, O O
the O O
development O O
of O O
BPF O O
( O O
P=0.003 O O
) O O
, O O
older O O
age O O
( O O
P=0.03 O O
) O O
and O O
higher O O
pathological O O
stage O O
( O O
P=0.02 O O
) O O
were O O
independent O O
adverse O O
predictors O O
of O O
survival O O
. O O

Phosphatidylinositol B-GENE B-GENE
3-kinase E-GENE E-GENE
potentiates O O
, O O
but O O
does O O
not O O
trigger O O
, O O
T O O
cell O O
proliferation O O
mediated O O
by O O
the O O
IL-2 B-GENE B-GENE
receptor E-GENE E-GENE
. O O
In O O
the O O
stable O O
transfectants O O
( O O
BM3 O S-GENE
cells O O
) O O
expressing O O
a O O
mutant B-GENE B-GENE
bacterial I-GENE I-GENE
P450 I-GENE I-GENE
AA I-GENE I-GENE
epoxygenase E-GENE E-GENE
, O O
F87V O B-GENE
BM3 O E-GENE
, O O
which O O
was O O
genetically O O
engineered O O
to O O
metabolize O O
arachidonic O O
acid O O
only O O
to O O
14,15-EET O S-GENE
, O O
AA O O
did O O
not O O
induce O O
apoptosis O O
and O O
protected O O
against O O
agonist O O
- O O
induced O O
apoptosis O O
. O O
The O O
loop O O
domain O O
of O O
heat B-GENE B-GENE
shock I-GENE I-GENE
transcription I-GENE I-GENE
factor I-GENE I-GENE
1 E-GENE E-GENE
dictates O O
DNA O O
- O O
binding O O
specificity O O
and O O
responses O O
to O O
heat O O
stress O O
. O O
EXAFS O S-GENE
measurements O O
around O O
the O O
Ge O O
- O O
K O O
edge O O
have O O
been O O
carried O O
out O O
for O O
liquid O O
Ge O O
- O O
Si O O
alloys O O
for O O
the O O
first O O
time O O
to O O
investigate O O
the O O
local O O
structure O O
around O O
a O O
Ge O O
atom O O
. O O

Progressive O O
study O O
and O O
robustness O O
test O O
of O O
QSAR O O
model O O
based O O
on O O
quantum O O
chemical O O
parameters O O
for O O
predicting O O
BCF O O
of O O
selected O O
polychlorinated O O
organic O O
compounds O O
( O O
PCOCs O O
) O O
. O O

Of O O
the O O
six O O
cases O O
of O O
malignant O O
polyposis O O
, O O
none O O
were O O
identified O O
using O O
CT O O
, O O
and O O
only O O
two O O
were O O
diagnosed O O
by O O
small O O
bowel O O
follow O O
- O O
through O O
. O O

Using O O
the O O
two O O
- O O
hybrid O O
system O O
, O O
we O O
show O O
that O O
nonprenylated O O
Rac1 S-GENE S-GENE
interacts O O
very O O
weakly O O
with O O
Rho B-GENE B-GENE
- I-GENE I-GENE
GDI E-GENE E-GENE
, O O
pointing O O
to O O
the O O
predominant O O
role O O
of O O
protein O B-GENE
- O I-GENE
isoprene O I-GENE
interaction O E-GENE
in O O
complex O O
formation O O
. O O
Although O O
metabolized O O
by O O
the O O
cytochrome B-GENE B-GENE
P-450 E-GENE E-GENE
( O O
CYP S-GENE S-GENE
) O O
system O O
, O O
venlafaxine O O
inhibits O O
CYP B-GENE B-GENE
2D6 I-GENE E-GENE
and I-GENE O
3A4 E-GENE S-GENE
to O O
a O O
far O O
lesser O O
extent O O
than O O
do O O
the O O
SSRIs O S-GENE
. O O
Analysis O O
of O O
the O O
promoter O O
sequence O O
revealed O O
the O O
presence O O
of O O
a O O
major O O
transcriptional O O
start O O
site O O
, O O
a O O
canonical O O
TATA O O
box O O
and O O
putative O O
cis O O
regulatory O O
elements O O
for O O
pituitary O O
specific O O
expression O O
as O O
well O O
as O O
an O O
E O O
- O O
responsive O O
element O O
. O O

Novel O O
intronic O O
promoter O O
in O O
the O O
rat B-GENE B-GENE
ER I-GENE I-GENE
alpha I-GENE I-GENE
gene E-GENE E-GENE
responsible O O
for O O
the O O
transient O O
transcription O O
of O O
a O O
variant O B-GENE
receptor O E-GENE
. O O
Pitx2 S-GENE S-GENE
rescues O O
the O O
GABAergic O S-GENE
differentiation O O
defect O O
and O O
partially O O
rescues O O
the O O
axon O O
guidance O O
and O O
behavioral O O
phenotypes O O
of O O
unc-30 B-GENE B-GENE
mutants E-GENE E-GENE
, O O
indicating O O
a O O
high O O
degree O O
of O O
functional O O
conservation O O
between O O
these O O
evolutionarily O O
related O O
genes O O
. O O
The O O
patterns O O
of O O
early O B-GENE
mRNA O E-GENE
and O O
protein O O
expression O O
in O O
these O O
seven O O
mutants O O
were O O
examined O O
, O O
and O O
it O O
was O O
found O O
that O O
mutation O O
of O O
the O O
T'(135 B-GENE S-GENE
) E-GENE O
acceptor O O
site O O
resulted O O
in O O
the O O
utilization O O
of O O
cryptic O O
splice O O
sites O O
and O O
the O O
generation O O
of O O
new O O
T O O
' O O
species O O
. O O
Sixty O O
- O O
one O O
cases O O
of O O
cholera O O
, O O
all O O
caused O O
by O O
V. O O
cholerae O O
O1 O O
, O O
were O O
reported O O
. O O

Subsequently O O
, O O
these O O
coordinates O O
must O O
be O O
interpreted O O
to O O
define O O
particular O O
tissues O O
and O O
organs O O
. O O

Testing O O
was O O
associated O O
with O O
a O O
history O O
of O O
nonsexual O O
risk O O
behavior O O
, O O
increased O O
knowledge O O
of O O
the O O
hepatitis O O
C O O
virus O O
, O O
and O O
healthcare O O
provider O O
communication O O
. O O

Low O O
- O O
selenium O O
diet O O
has O O
a O O
human O O
unfavourable O O
impact O O
. O O

Thus O O
, O O
BALB O O
/ O O
c O O
mice O O
appear O O
to O O
be O O
the O O
most O O
appropriate O O
strain O O
of O O
mice O O
to O O
perform O O
studies O O
on O O
the O O
possible O O
connection O O
between O O
infection O O
with O O
T. O O
canis O O
and O O
allergic O O
asthma O O
. O O

We O O
have O O
previously O O
shown O O
that O O
the O O
adenoviral B-GENE B-GENE
12S I-GENE I-GENE
E1A I-GENE I-GENE
protein E-GENE E-GENE
modulates O O
the O O
phosphorylation O O
status O O
of O O
p130 S-GENE S-GENE
and O O
p107 S-GENE S-GENE
without O O
apparent O O
changes O O
in O O
the O O
cell O O
cycle O O
dependent O O
phosphorylation O O
of O O
the O O
retinoblastoma B-GENE B-GENE
protein E-GENE E-GENE
. O O
The O O
prevalence O O
of O O
tobacco O O
dependence O O
diagnosed O O
according O O
to O O
the O O
ICD-10 O O
criteria O O
was O O
higher O O
in O O
alcohol O O
- O O
dependent O O
individuals O O
( O O
58.1% O O
) O O
than O O
in O O
nondrinkers O O
or O O
social O O
drinkers O O
( O O
12.8% O O
) O O
. O O

Diffuse O O
myalgias O O
were O O
more O O
frequent O O
in O O
patients O O
with O O
than O O
without O O
an O O
MMF O O
lesion O O
at O O
deltoid O O
muscle O O
biopsy O O
( O O
P O O
< O O
0.0001 O O
) O O
. O O

Furthermore O O
, O O
hormonal O O
regulation O O
of O O
G(1 O S-GENE
) O O
gene O O
transcription O O
can O O
occur O O
even O O
without O O
additional O O
activation O O
of O O
the O O
Mek S-GENE B-GENE
- O I-GENE
Erk1/2 S-GENE E-GENE
pathway O O
by O O
estrogen B-GENE B-GENE
receptors E-GENE E-GENE
. O O
Therefore O O
, O O
to O O
understand O O
how O O
ErbB1/ErbB2 O S-GENE
signaling O O
contributes O O
to O O
this O O
process O O
, O O
we O O
used O O
the O O
ErbB B-GENE B-GENE
kinase E-GENE I-GENE
inhibitor O I-GENE
AG1478 O E-GENE
in O O
ErbB2-dependent O B-GENE
BT-474 O E-GENE
and O O
SKBR-3 O S-GENE
human O O
breast O O
cancer O O
cells O O
. O O
This O O
plus O O
the O O
reduced O O
phosphorylation O O
of O O
p27 S-GENE S-GENE
by O O
MAPK S-GENE S-GENE
enhanced O O
the O O
stability O O
of O O
p27 O S-GENE
that O O
associated O O
with O O
nuclear B-GENE O
Cdk2 E-GENE S-GENE
at O O
high O O
stoichiometry O O
and O O
inhibited O O
its O O
kinase O O
activity O O
. O O
ICA O O
in O O
the O O
reference O O
solution O O
was O O
characterised O O
by O O
LC O O
and O O
time O O
- O O
of O O
- O O
flight O O
( O O
TOF O O
) O O
MS O O
and O O
quantified O O
by O O
LC O O
chemiluminescent O O
nitrogen O O
detection O O
( O O
LC O O
- O O
CLND O O
) O O
. O O

Forced O O
expression O O
of O O
BZAP45 S-GENE B-GENE
strongly O I-GENE
stimulates O I-GENE
H4 B-GENE I-GENE
promoter E-GENE E-GENE
( O O
nt O O
-215 O O
to O O
-1)/CAT O B-GENE
reporter O I-GENE
gene O E-GENE
activity O O
. O O
Local O O
control O O
rates O O
were O O
91% O O
for O O
metastatic O O
lung O O
cancer O O
, O O
89% O O
for O O
primary O O
lung O O
cancer O O
and O O
85% O O
for O O
T1 O O
, O O
2N0M0 O O
cases O O
. O O

Utility O O
of O O
OAE O O
screener O O
( O O
GSI O O
70 O O
) O O
for O O
the O O
evaluation O O
of O O
distortion O O
product O O
otoacoustic O O
emissions O O
] O O
The O O
purpose O O
of O O
this O O
study O O
was O O
to O O
investigate O O
the O O
ability O O
of O O
the O O
OAE O O
screener O O
GSI O O
70 O O
to O O
evaluate O O
of O O
cochlea O O
function O O
in O O
neonates O O
, O O
infants O O
and O O
adults O O
. O O

For O O
the O O
sample O O
of O O
systematic O O
reviews O O
drawn O O
from O O
ACP O O
Journal O O
Club O O
( O O
n O O
= O O
103 O O
) O O
, O O
the O O
PubMed O O
strategy O O
achieved O O
a O O
sensitivity O O
of O O
97% O O
( O O
CI O O
, O O
91% O O
to O O
99% O O
) O O
. O O

Additionally O O
, O O
a O O
CaCO3-CO2/N2 O O
buffered O O
solution O O
was O O
necessary O O
to O O
maintain O O
a O O
pH O O
of O O
8 O O
. O O

Inhibition O O
of O O
JNK1 S-GENE S-GENE
and O O
ERK S-GENE B-GENE
kinase O E-GENE
activities O O
either O O
by O O
expression O O
of O O
the O O
dominant O O
negative O O
mutant O B-GENE
JNK1 O E-GENE
or O O
by O O
treatment O O
with O O
a O O
selective O O
chemical O O
inhibitor O O
of O O
ERK O S-GENE
( O O
PD098059 O S-GENE
) O O
substantially O O
abrogates O O
the O O
UV O O
induction O O
of O O
the O O
GADD45 B-GENE B-GENE
promoter E-GENE E-GENE
. O O
With O O
a O O
GC O O
content O O
of O O
45% O O
the O O
one O O
segment O O
would O O
correspond O O
to O O
" B-GENE O
isochore I-GENE O
H1 I-GENE O
" E-GENE O
and O O
the O O
other O O
segment O O
( O O
39% O O
GC O O
in O O
human O O
, O O
40% O O
GC O O
in O O
mouse O O
) O O
to O O
" O O
isochore O O
L1/L2 O O
" O O
. O O
Copyright O O
2001 O O
S. O O

No O O
mutation O O
of O O
the O O
NRL B-GENE B-GENE
gene E-GENE E-GENE
was O O
found O O
in O O
any O O
of O O
the O O
two O O
families O O
. O O
NF B-GENE B-GENE
- I-GENE I-GENE
kappaB E-GENE E-GENE
is O O
involved O O
in O O
the O O
regulation O O
of O O
CD154 S-GENE S-GENE
( O O
CD40 B-GENE B-GENE
ligand E-GENE E-GENE
) O O
expression O O
in O O
primary O O
human O O
T O O
cells O O
. O O
After O O
nerve O O
injury O O
, O O
the O O
nociceptive O O
responses O O
through O O
type O O
I O O
neurons O O
, O O
which O O
are O O
polymodal O O
C O O
- O O
fibers O O
and O O
drive O O
NK1-receptor S-GENE O
mechanisms O O
in O O
spinal O O
pain O O
transmission O O
, O O
were O O
completely O O
lost O O
, O O
but O O
without O O
changes O O
in O O
type O O
II O O
ones O O
, O O
which O O
are O O
polymodal O O
C O O
- O O
fibers O O
and O O
drive O O
NMDA B-GENE B-GENE
receptor E-GENE E-GENE
- O O
mechanisms O O
, O O
while O O
type O O
III O O
ones O O
, O O
which O O
are O O
capsaicin O O
- O O
insensitive O O
( O O
possibly O O
A O O
- O O
fibers O O
) O O
and O O
drive O O
NMDA B-GENE B-GENE
- I-GENE I-GENE
receptor E-GENE E-GENE
mechanisms O O
, O O
were O O
markedly O O
enhanced O O
. O O
This O O
article O O
reports O O
the O O
design O O
and O O
development O O
of O O
an O O
ECG O O
simulator O O
intended O O
for O O
use O O
in O O
the O O
testing O O
, O O
calibration O O
and O O
maintenance O O
of O O
electrocardiographic O O
equipment O O
. O O

Subacute O O
diencephalic O O
angioencephalopathy O O
( O O
SDAE O O
) O O
is O O
a O O
rare O O
and O O
fatal O O
disease O O
of O O
unknown O O
etiology O O
that O O
involves O O
the O O
thalami O O
bilaterally O O
. O O

Third O O
, O O
consistent O O
with O O
these O O
data O O
, O O
N O O
- O O
acetylcysteine O O
reduced O O
the O O
stimulatory O O
effect O O
of O O
HGF S-GENE S-GENE
on O O
stress B-GENE B-GENE
kinase E-GENE E-GENE
activities O O
, O O
while O O
p42/44 S-GENE B-GENE
mitogen O I-GENE
activated O I-GENE
kinase O E-GENE
( O O
MAPK O S-GENE
) O O
was O O
unmodified O O
, O O
suggesting O O
an O O
involvement O O
of O O
c B-GENE B-GENE
- I-GENE I-GENE
Jun I-GENE I-GENE
- I-GENE I-GENE
N I-GENE I-GENE
- I-GENE I-GENE
terminal I-GENE I-GENE
kinase E-GENE E-GENE
( O O
JNK S-GENE S-GENE
) O O
and O O
p38 S-GENE B-GENE
MAPK O E-GENE
in O O
HIF-1 S-GENE S-GENE
activation O O
. O O
Mutation O O
of O O
the O O
octamer O O
element O O
also O O
significantly O O
reduced O O
the O O
ability O O
of O O
HDAC1 S-GENE S-GENE
to O O
confer O O
repression O O
of O O
inducible O O
HLA B-GENE B-GENE
- I-GENE I-GENE
DRA I-GENE I-GENE
promoter E-GENE E-GENE
activation O O
. O O
There O O
was O O
no O O
significant O O
difference O O
in O O
developmental O O
scores O O
at O O
9 O O
or O O
18 O O
months O O
, O O
although O O
PDF O O
infants O O
had O O
a O O
2.8 O O
( O O
-1.3 O O
- O O
6.8 O O
) O O
point O O
advantage O O
in O O
Bayley O O
motor O O
score O O
scales O O
. O O

In O O
the O O
single O O
case O O
the O O
restoration O O
of O O
a O O
structured O O
daily O O
routine O O
represents O O
the O O
presupposition O O
for O O
a O O
cognitive O O
therapy O O
. O O

However O O
these O O
search O O
engines O O
respond O O
with O O
such O O
cumbersome O O
results O O
that O O
domain O O
specific O O
experts O O
can O O
not O O
tolerate O O
. O O

The O O
binary O O
and O O
tertiary O O
combinations O O
of O O
plant O O
- O O
derived O O
molluscicides O O
Azadirachta O O
indica O O
and O O
Cedrus O O
deodara O O
oil O O
with O O
synergists O O
MGK-264 O O
, O O
piperonyl O O
butoxide O O
( O O
PB O O
) O O
and O O
fruit O O
powder O O
of O O
Embelia O O
ribes O O
were O O
used O O
against O O
the O O
Lymnaea O O
acuminata O O
. O O

From O O
the O O
above O O
results O O
, O O
we O O
might O O
infer O O
that O O
the O O
seizure O O
type O O
of O O
TLE O O
and O O
a O O
high O O
frequency O O
of O O
seizure O O
are O O
two O O
major O O
independent O O
precipitate O O
factors O O
for O O
abnormal O O
latencies O O
of O O
P300 O O
in O O
the O O
epileptic O O
patients O O
. O O

Audiological O O
findings O O
in O O
pregnancy O O
. O O

The O O
deubiquitinating O B-GENE
enzyme O I-GENE
DUB-2 S-GENE E-GENE
is O O
induced O O
in O O
response O O
to O O
IL-2 S-GENE O
but O O
as O O
yet O O
its O O
function O O
has O O
not O O
been O O
determined O O
. O O
The O O
isoform O O
, O O
designated O O
HDAC9a S-GENE S-GENE
, O O
is O O
132 O O
aa O O
shorter O O
at O O
the O O
C O O
terminus O O
than O O
HDAC9 O O
. O O
Pulmonary O O
embolectomy O O
and O O
lung O O
transplantation O O
are O O
the O O
main O O
indications O O
for O O
the O O
use O O
of O O
heart O O
- O O
lung O O
- O O
machine O O
. O O

In O O
such O O
conditions O O
, O O
the O O
following O O
kinetic O O
reactions O O
have O O
been O O
studied O O
: O O
SP O O
N2(A O O
) O O
+ O O
N2(A O O
) O O
-- O O
> O O
N2(C O O
, O O
B O O
, O O
V O O
' O O
) O O
+ O O
N2(X O O
) O O
, O O
N2(A O O
) O O
+ O O
N2(X O O
, O O
V>5 O O
) O O
-- O O
> O O
N2(X O O
) O O
+ O O
N2(B O O
, O O
V O O
' O O
) O O
in O O
pure O O
N2 O O
post O O
- O O
discharges O O
and O O
N2(A O O
) O O
+ O O
CH4 O O
-- O O
> O O
products O O
, O O
C O O
+ O O
N O O
+ O O
M2 O O
-- O O
> O O
CN(B O O
, O O
V O O
' O O
) O O
+ O O
M2 O O
, O O
N2(X O O
, O O
V>4 O O
) O O
+ O O
CN O O
-- O O
> O O
N2(X O O
) O O
+ O O
CN(B O O
, O O
A O O
, O O
V O O
' O O
) O O
, O O
in O O
N2 O O
- O O
1% O O
CH4 O O
post O O
- O O
discharges O O
. O O

The O O
NAUSICAA O O
system O O
gives O O
a O O
good O O
knowledge O O
of O O
LET O O
spectra O O
for O O
the O O
first O O
time O O
in O O
space O O
dosimetry O O
. O O

In O O
order O O
to O O
quantify O O
these O O
effects O O
, O O
tests O O
were O O
conducted O O
in O O
the O O
NASA O O
MSFC O O
Neutral O O
Buoyancy O O
Simulator O O
, O O
in O O
the O O
NASA O O
KC-135 O O
in O O
parabolic O O
flight O O
, O O
and O O
in O O
space O O
with O O
the O O
EASE O O
program O O
during O O
the O O
Shuttle O O
Atlantis O O
mission O O
61-B O O
. O O

This O O
article O O
comparatively O O
evaluates O O
five O O
Generic O O
Systems O O
that O O
describe O O
the O O
basic O O
alternatives O O
to O O
composting O O
facility O O
design O O
and O O
control O O
. O O

Different O O
thermoluminescent O O
detectors O O
( O O
TLD O O
) O O
have O O
been O O
used O O
to O O
measure O O
the O O
contribution O O
of O O
the O O
low O O
linear O O
energy O O
transfer O O
component O O
( O O
LET O O
< O O
10 O O
keV O O
/ O O
micrometer O O
) O O
and O O
plastic O O
nuclear O O
track O O
detectors O O
( O O
PNTD O O
) O O
for O O
the O O
high O O
linear O O
energy O O
tranfer O O
( O O
LET O O
) O O
component O O
. O O

Responses O O
of O O
TLD O O
Mg2SiO4:Tb O O
and O O
radiophotoluminescent O O
glass O O
to O O
heavy O O
charged O O
particles O O
and O O
space O O
radiation O O
. O O

The O O
absorbed O O
dose O O
was O O
measured O O
by O O
combination O O
of O O
two O O
integrating O O
detectors O O
: O O
thermo- O O
luminescent O O
dosemeter O O
of O O
Mg2SiO4 O O
: O O
Tb O O
( O O
TDMS O O
) O O
and O O
plastic O O
nuclear O O
track O O
detector O O
( O O
PNTD O O
) O O
. O O

Six O O
of O O
the O O
gstC B-GENE B-GENE
' I-GENE I-GENE
mutants E-GENE E-GENE
, O O
primarily O O
in O O
the O O
C O O
- O O
terminal O O
half O O
of O O
C O O
' O O
, O O
exhibited O O
a O O
defect O O
in O O
the O O
ability O O
to O O
bind O O
L B-GENE B-GENE
protein E-GENE E-GENE
. O O
Thus O O
, O O
while O O
the O O
folds O O
of O O
all O O
Myb B-GENE S-GENE
domains E-GENE O
resemble O O
each O O
other O O
closely O O
, O O
the O O
function O O
of O O
each O O
Myb O B-GENE
domain O E-GENE
depends O O
on O O
the O O
amino O O
acid O O
residues O O
that O O
are O O
located O O
on O O
the O O
surface O O
of O O
each O O
protein O O
. O O
METHODS O O
: O O
Experiments O O
testing O O
the O O
new O O
catheter O O
and O O
comparing O O
it O O
to O O
the O O
existing O O
catheter O O
included O O
: O O
( O O
1 O O
) O O
measurement O O
of O O
the O O
laser O O
output O O
beam O O
sizes O O
and O O
divergences O O
; O O
( O O
2 O O
) O O
evaluation O O
of O O
particulate O O
matter O O
generation O O
during O O
ablation O O
of O O
atherosclerotic O O
tissue O O
; O O
( O O
3 O O
) O O
measurement O O
of O O
ablation O O
hole O O
sizes O O
and O O
tissue O O
penetration O O
rates O O
; O O
( O O
4 O O
) O O
histopathologic O O
examination O O
of O O
laser O O
- O O
induced O O
in O O
vivo O O
vessel O O
wall O O
injury O O
. O O

A O O
proposal O O
of O O
50 O O
performance O O
indicators O O
divided O O
into O O
five O O
different O O
groups O O
is O O
presented O O
here O O
, O O
namely O O
structural O O
indicators O O
, O O
operational O O
indicators O O
, O O
water O O
and O O
service O O
quality O O
indicators O O
, O O
personnel O O
indicators O O
and O O
economic O O
indicators O O
. O O

Overexpression O O
of O O
RORgamma S-GENE S-GENE
has O O
been O O
shown O O
to O O
inhibit O O
T B-GENE B-GENE
cell I-GENE I-GENE
receptor E-GENE E-GENE
- O O
mediated O O
apoptosis O O
in O O
T O O
cell O O
hybridomas O O
and O O
to O O
repress O O
the O O
induction O O
of O O
Fas B-GENE B-GENE
- I-GENE I-GENE
ligand E-GENE E-GENE
and O O
interleukin B-GENE O
2 E-GENE O
. O O
Once O O
ICP O O
reaches O O
critical O O
values O O
( O O
> O O
30 O O
mm O O
Hg O O
) O O
herniation O O
occurs O O
, O O
usually O O
within O O
2 O O
to O O
5 O O
days O O
. O O

Other O O
therapies O O
are O O
also O O
available O O
, O O
including O O
hypertonic O O
saline O O
solution O O
, O O
THAM O O
( O O
Tris O O
- O O
hydroxy O O
- O O
methyl O O
- O O
aminomethane O O
) O O
buffer O O
, O O
and O O
high O O
- O O
dose O O
barbiturates O O
. O O

CONCLUSIONS O O
: O O
ChromaFlo O O
- O O
enhanced O O
IVUS O O
demonstrates O O
colorized O O
blood O O
flow O O
inside O O
the O O
vessel O O
lumen O O
, O O
which O O
is O O
helpful O O
in O O
distinguishing O O
echolucent O O
disease O O
from O O
luminal O O
blood O O
flow O O
and O O
can O O
also O O
be O O
used O O
to O O
perform O O
peripheral O O
interventions O O
in O O
patients O O
with O O
renal O O
failure O O
or O O
allergy O O
, O O
avoiding O O
the O O
use O O
of O O
contrast O O
media O O
. O O

CYP2C19 B-GENE O
genotype E-GENE O
was O O
determined O O
by O O
the O O
polymerase O B-GENE
chain O I-GENE
reaction O I-GENE
- O I-GENE
restriction O I-GENE
fragment O E-GENE
length O O
polymorphism O O
method O O
. O O
The O O
results O O
indicate O O
that O O
a O O
more O O
differentiated O O
diagnosis O O
of O O
the O O
molar O O
relationship O O
will O O
allow O O
for O O
a O O
more O O
causally O O
directed O O
correction O O
of O O
Class O O
II O O
molar O O
relationship O O
. O O

Similar O O
data O O
were O O
also O O
obtained O O
when O O
either O O
dominant O O
negative O O
EGFR S-GENE B-GENE
- O I-GENE
CD533 S-GENE E-GENE
or O O
dominant B-GENE O
negative I-GENE O
Ras I-GENE B-GENE
N17 E-GENE E-GENE
were O O
used O O
to O O
block O O
MAPK S-GENE S-GENE
activation O O
. O O
These O O
analyses O O
re O O
- O O
open O O
the O O
question O O
whether O O
all O O
the O O
CesA B-GENE B-GENE
genes E-GENE I-GENE
encode O I-GENE
cellulose B-GENE I-GENE
synthases E-GENE E-GENE
or O O
whether O O
some O O
of O O
the O O
sub O O
- O O
class O O
members O O
may O O
encode O O
other O O
non B-GENE O
- I-GENE O
cellulosic I-GENE O
( I-GENE O
1 I-GENE B-GENE
- I-GENE I-GENE
->4)beta I-GENE I-GENE
- I-GENE I-GENE
glycan I-GENE I-GENE
synthases E-GENE E-GENE
in O O
plants O O
. O O
The O O
hatcher O O
incubators O O
of O O
both O O
companies O O
were O O
also O O
persistently O O
contaminated O O
with O O
Salmonella O O
livingstone O O
and O O
Salmonella O O
thomasville O O
in O O
company O O
A O O
and O O
with O O
Salmonella O O
senftenberg O O
in O O
company O O
B. O O

At O O
both O O
companies O O
sites O O
Salmonella O O
enteritidis O O
and O O
Salmonella O O
typhimurium O O
Tr104 O O
were O O
also O O
isolated O O
occasionally O O
from O O
various O O
locations O O
. O O

The O O
mutation O O
experiments O O
showed O O
that O O
the O O
most O O
critical O O
sequence O O
for O O
the O O
repression O O
of O O
PTH S-GENE O
was O O
5'-GGGGGAGGGGAG-3 O O
' O O
( O O
+ O O
1 O O
to O O
+ O O
12 O O
) O O
of O O
PTHSR S-GENE O
. O O
Cardiac O O
output O O
at O O
anaerobic O O
threshold O O
( O O
COAT O O
) O O
< O O
or O O
= O O
7.3 O O
L O O
/ O O
min O O
was O O
the O O
best O O
cutoff O O
value O O
for O O
identifying O O
multivessel O O
coronary O O
artery O O
disease O O
( O O
relative O O
risk O O
, O O
3.1 O O
) O O
. O O

Experience O O
with O O
xylene O O
- O O
free O O
sections O O
since O O
1995 O O
at O O
the O O
Vrinnevi O O
Hospital O O
is O O
favorable O O
. O O

A O O
randomized O O
mix O O
of O O
180 O O
sections O O
( O O
10 O O
samples O O
x O O
3 O O
tissues O O
x O O
3 O O
stains O O
x O O
2 O O
) O O
gave O O
90 O O
matched O O
pairs O O
. O O

Interestingly O O
, O O
the O O
CYP71D20-encoded B-GENE B-GENE
enzyme E-GENE E-GENE
activity O O
was O O
capable O O
of O O
converting O O
both O O
5-epi O B-GENE
- O I-GENE
aristolochene O E-GENE
and O O
1-deoxycapsidiol O O
to O O
capsidiol O O
in O O
vitro O O
, O O
consistent O O
with O O
the O O
notion O O
that O O
this O O
P450 B-GENE B-GENE
enzyme E-GENE I-GENE
catalyzes O E-GENE
both O O
hydroxylations O O
of O O
its O O
hydrocarbon O O
substrate O O
. O O
In O O
conclusion O O
, O O
NF B-GENE B-GENE
- I-GENE I-GENE
Y E-GENE E-GENE
and O O
Sp1 S-GENE B-GENE
binding O I-GENE
sites O E-GENE
play O O
a O O
decisive O O
role O O
in O O
the O O
basal O O
expression O O
of O O
the O O
rat B-GENE B-GENE
mrp2 I-GENE I-GENE
gene E-GENE E-GENE
, O O
while O O
the O O
human B-GENE B-GENE
MRP2 I-GENE I-GENE
gene E-GENE E-GENE
is O O
regulated O O
differently O O
. O O
E2F1-mediated O S-GENE
transcriptional O O
inhibition O O
of O O
the O O
plasminogen B-GENE B-GENE
activator I-GENE I-GENE
inhibitor I-GENE I-GENE
type I-GENE I-GENE
1 I-GENE I-GENE
gene E-GENE E-GENE
. O O
Transcriptional O O
regulation O O
of O O
the O O
estrogen O B-GENE
- O I-GENE
inducible O I-GENE
pS2 S-GENE I-GENE
breast B-GENE I-GENE
cancer I-GENE I-GENE
marker I-GENE I-GENE
gene E-GENE E-GENE
by O O
the O O
ERR B-GENE B-GENE
family E-GENE E-GENE
of O O
orphan B-GENE B-GENE
nuclear I-GENE I-GENE
receptors E-GENE E-GENE
. O O
NB-506 O S-GENE
completely O O
inhibits O O
the O O
capacity O O
of O O
topoisomerase B-GENE B-GENE
I E-GENE E-GENE
to O O
phosphorylate O O
, O O
in O O
vitro O O
, O O
the O O
human O B-GENE
splicing O I-GENE
factor O I-GENE
2/alternative O I-GENE
splicing O I-GENE
factor O E-GENE
( O O
SF2/ASF O S-GENE
) O O
. O O
However O O
, O O
during O O
our O O
work O O
with O O
a O O
replication O O
- O O
deficient O O
virus O O
expressing O O
the O O
ASF S-GENE S-GENE
/ O O
SF2 S-GENE B-GENE
splicing O I-GENE
factor O E-GENE
from O O
a O O
progesterone O B-GENE
antagonist O I-GENE
- O I-GENE
inducible O I-GENE
gene O I-GENE
cassette O E-GENE
, O O
we O O
discovered O O
that O O
ASF O S-GENE
/ O O
SF2 O S-GENE
was O O
expressed O O
at O O
a O O
significant O O
level O O
in O O
the O O
293 O O
producer O O
cell O O
line O O
, O O
even O O
in O O
the O O
absence O O
of O O
inducer O O
. O O
DNA O O
binding O O
assays O O
confirmed O O
the O O
interference O O
of O O
p30(II B-GENE S-GENE
) E-GENE O
with O O
the O O
assembly O O
of O O
CREB S-GENE B-GENE
- O I-GENE
Tax S-GENE I-GENE
- O I-GENE
p300/CBP O I-GENE
multiprotein O I-GENE
complexes O E-GENE
on O O
21-bp O O
repeat O O
oligonucleotides O O
in O O
vitro O O
. O O
Using O O
the O O
presented O O
categorical O O
structure O O
as O O
domain O O
model O O
a O O
prototype O O
DSS O O
for O O
dipslide O O
urine O O
cultures O O
has O O
been O O
developed O O
. O O

DNA O O
recognition O O
by O O
F B-GENE B-GENE
factor E-GENE I-GENE
TraI36 S-GENE E-GENE
: O O
highly O O
sequence O O
- O O
specific O O
binding O O
of O O
single O O
- O O
stranded O O
DNA O O
. O O
E47 B-GENE B-GENE
protein E-GENE E-GENE
levels O O
remain O O
high O O
until O O
the O O
double O O
positive O O
developmental O O
stage O O
, O O
at O O
which O O
point O O
they O O
drop O O
to O O
relatively O O
moderate O O
levels O O
, O O
and O O
are O O
further O O
downregulated O O
upon O O
transition O O
to O O
the O O
single O O
positive O O
stage O O
. O O
The O O
dual O O
specificity O O
kinases O B-GENE
mitogen B-GENE I-GENE
- I-GENE I-GENE
activated I-GENE I-GENE
protein I-GENE I-GENE
kinase I-GENE E-GENE
( I-GENE O
MAPK I-GENE S-GENE
) I-GENE O
kinase I-GENE S-GENE
( I-GENE O
MKK)7 E-GENE S-GENE
and O O
MKK4 S-GENE S-GENE
are O O
the O O
only O O
molecules O O
known O O
to O O
directly O O
activate O O
the O O
stress O B-GENE
kinases O I-GENE
stress B-GENE I-GENE
- I-GENE I-GENE
activated I-GENE I-GENE
protein I-GENE I-GENE
kinases E-GENE E-GENE
( O O
SAPKs)/c O B-GENE
- O I-GENE
Jun O I-GENE
N O I-GENE
- O I-GENE
terminal O I-GENE
kinases O E-GENE
( O O
JNKs S-GENE S-GENE
) O O
in O O
response O O
to O O
environmental O O
or O O
mitogenic O O
stimuli O O
. O O
SAPK S-GENE S-GENE
/ O O
JNK S-GENE S-GENE
activation O O
was O O
completely O O
abolished O O
in O O
the O O
absence O O
of O O
MKK7 S-GENE S-GENE
, O O
even O O
though O O
expression O O
of O O
MKK4 S-GENE S-GENE
was O O
strongly O O
upregulated O O
in O O
mkk7(-/- B-GENE S-GENE
) E-GENE O
mast O O
cell O O
lines O O
, O O
and O O
phosphorylation O O
of O O
MKK4 O S-GENE
occurred O O
normally O O
in O O
response O O
to O O
multiple O O
stress O O
stimuli O O
. O O
Thus O O
, O O
MKK7 S-GENE S-GENE
is O O
an O O
essential O O
and O O
specific O O
regulator O O
of O O
stress O O
- O O
induced O O
SAPK S-GENE S-GENE
/ O O
JNK S-GENE S-GENE
activation O O
in O O
mast O O
cells O O
and O O
MKK7 O B-GENE
negatively O I-GENE
regulates O I-GENE
growth O I-GENE
factor O E-GENE
and O O
antigen O B-GENE
receptor O E-GENE
- O O
driven O O
proliferation O O
in O O
hematopoietic O O
cells O O
. O O
The O O
small O O
copepod O O
Pseudonychocamptus O O
proximus O O
progressively O O
replaced O O
the O O
large O O
Tisbe O O
furcata O O
in O O
sand O O
filters O O
during O O
the O O
fall O O
of O O
1995 O O
and O O
was O O
responsible O O
for O O
the O O
large O O
increase O O
in O O
meiofaunal O O
biomass O O
observed O O
after O O
spring O O
1996 O O
. O O

When O O
mixed O O
with O O
aqueous O O
solutions O O
of O O
TMT-55 O O
, O O
aqueous O O
solutions O O
of O O
either O O
reagent O O
- O O
grade O O
zinc O O
, O O
cadmium O O
, O O
or O O
lead O O
salts O O
precipitate O O
crystalline O O
" O O
Zn O O
- O O
TMT O O
" O O
, O O
amorphous O O
or O O
crystalline O O
" O O
Cd O O
- O O
TMT O O
" O O
or O O
amorphous O O
" O O
Pb O O
- O O
TMT O O
" O O
( O O
M3[S3C3N3]2.nH2O O O
, O O
where O O
M O O
= O O
Cd2 O O
+ O O
, O O
Pb2 O O
+ O O
, O O
and O O
Zn2 O O
+ O O
and O O
n O O
> O O
or O O
= O O
0 O O
) O O
that O O
may O O
eventually O O
crystallize O O
if O O
stored O O
in O O
air O O
. O O

Many O O
of O O
the O O
important O O
genes O O
associated O O
with O O
G1 O O
regulation O O
have O O
been O O
shown O O
to O O
play O O
a O O
key O O
role O O
in O O
proliferation O O
, O O
differentiation O O
and O O
oncogenic O O
transformation O O
and O O
programmed O O
cell O O
death O O
( O O
apoptosis O O
) O O
. O O

The O O
probability O O
of O O
treatment O O
with O O
lamotrigine O O
being O O
maintained O O
for O O
six O O
months O O
was O O
86% O O
, O O
for O O
twelve O O
months O O
61% O O
and O O
for O O
three O O
years O O
31% O O
. O O

These O O
results O O
indicate O O
the O O
presence O O
of O O
TATA O O
- O O
unified O O
transcription O O
systems O O
in O O
contemporary O O
eukaryotes O O
and O O
provide O O
insight O O
into O O
the O O
residual O O
need O O
for O O
TBP S-GENE O
by O O
all O O
three O O
Pols S-GENE O
in O O
other O O
eukaryotes O O
despite O O
a O O
lack O O
of O O
TATA O O
elements O O
in O O
their O O
promoters O O
. O O
Thus O O
, O O
through O O
a O O
change O O
in O O
conformation O O
upon O O
repair O O
of O O
the O O
6RG O O
lesion O O
, O O
MGMT S-GENE S-GENE
switches O O
from O O
a O O
DNA O O
repair O O
factor O O
to O O
a O O
transcription O O
regulator O O
( O O
R B-GENE O
- I-GENE O
MGMT E-GENE S-GENE
) O O
, O O
enabling O O
the O O
cell O O
to O O
sense O O
as O O
well O O
as O O
respond O O
to O O
mutagens O O
. O O
Data O O
from O O
in O O
vitro O O
splicing O O
assays O O
, O O
UV O O
crosslinking O O
and O O
RNA O O
- O O
binding O O
competition O O
experiments O O
indicates O O
a O O
strong O O
correlation O O
between O O
the O O
binding O O
affinities O O
of O O
PSI S-GENE S-GENE
for O O
the O O
SELEX O S-GENE
sequences O O
and O O
their O O
ability O O
to O O
modulate O O
splicing O O
of O O
P B-GENE B-GENE
element E-GENE I-GENE
IVS3 S-GENE E-GENE
in O O
vitro O O
. O O
A O O
split O O
motor O O
domain O O
in O O
a O O
cytoplasmic B-GENE O
dynein E-GENE O
. O O
In O O
hypertensive O O
nephrosclerosis O O
, O O
therapy O O
containing O O
an O O
ACEI O O
alone O O
or O O
in O O
combination O O
significantly O O
reduces O O
the O O
incidence O O
of O O
renal O O
events O O
. O O

Body O O
weight O O
reduction O O
increases O O
insulin S-GENE S-GENE
sensitivity O O
and O O
improves O O
both O O
blood O O
glucose O O
and O O
blood O O
pressure O O
control O O
. O O
Here O O
we O O
suggest O O
that O O
uvrA S-GENE S-GENE
and O O
the O O
nucleotide O O
excision O O
repair O O
pathway O O
are O O
involved O O
in O O
the O O
repair O O
of O O
acid O O
- O O
induced O O
DNA O O
damage O O
and O O
are O O
associated O O
with O O
successful O O
adaptation O O
of O O
S. O O
mutans O O
to O O
low O O
pH. O O
The O O
best O O
regression O O
model O O
for O O
predicting O O
changes O O
in O O
the O O
WCXR O O
included O O
time O O
to O O
first O O
positive O O
culture O O
and O O
antibody O O
titer O O
for O O
Pa B-GENE B-GENE
elastase E-GENE E-GENE
. O O
Temperature O O
measurement O O
in O O
microfluidic O O
systems O O
using O O
a O O
temperature O O
- O O
dependent O O
fluorescent O O
dye O O
. O O

APC S-GENE S-GENE
- O O
resistance O O
was O O
determined O O
with O O
a O O
functional O O
method O O
with O O
high O O
sensitivity O O
and O O
specificity O O
for O O
the O O
factor B-GENE B-GENE
V I-GENE I-GENE
Leiden I-GENE I-GENE
mutation E-GENE E-GENE
. O O
Zarix O O
expected O O
patient O O
enrollment O O
in O O
Canadian O O
clinical O O
sites O O
to O O
begin O O
in O O
Spring O O
2001 O O
[ O O
397955 O O
] O O
, O O
[ O O
405928 O O
] O O
. O O

RESULTS O O
: O O
The O O
subjects O O
in O O
the O O
augmented O O
feedback O O
group O O
significantly O O
reduced O O
their O O
peak O O
vertical O O
ground O O
reaction O O
force O O
in O O
both O O
post O O
- O O
test O O
conditions O O
( O O
2-minute O O
post O O
- O O
test O O
reduction O O
, O O
0.85+/-0.62 O O
; O O
1-week O O
post O O
- O O
test O O
reduction O O
, O O
0.74+/-0.58 O O
) O O
as O O
compared O O
to O O
the O O
sensory O O
, O O
control O O
I O O
, O O
and O O
control O O
II O O
feedback O O
groups O O
. O O

Four O O
casein B-GENE B-GENE
kinase I-GENE I-GENE
I I-GENE I-GENE
isoforms E-GENE E-GENE
are O O
differentially O O
partitioned O O
between O O
nucleus O O
and O O
cytoplasm O O
. O O
Use O O
of O O
a O O
dual O O
- O O
pulse O O
lithotripter O O
to O O
generate O O
a O O
localized O O
and O O
intensified O O
cavitation O O
field O O
. O O

This O O
paper O O
describes O O
the O O
results O O
of O O
an O O
initial O O
study O O
on O O
the O O
application O O
of O O
linear O O
solvation O O
energy O O
relationships O O
( O O
LSERs O O
) O O
to O O
the O O
prediction O O
of O O
internal O O
standard O O
compounds O O
in O O
reversed O O
- O O
phase O O
liquid O O
chromatographic O O
( O O
RPLC O O
) O O
method O O
development O O
. O O

When O O
the O O
blood O O
clot O O
is O O
formed O O
in O O
the O O
vitreous O O
cavity O O
, O O
intravitreal O O
injection O O
of O O
t B-GENE B-GENE
- I-GENE I-GENE
PA E-GENE E-GENE
can O O
convert O O
plasminogen S-GENE S-GENE
to O O
plasmin O S-GENE
and O O
remove O O
the O O
clot O O
. O O
Management O O
of O O
postvitrectomy O O
diabetic O O
vitreous O O
hemorrhage O O
with O O
tissue B-GENE B-GENE
plasminogen I-GENE I-GENE
activator E-GENE E-GENE
( O O
t B-GENE O
- I-GENE O
PA E-GENE O
) O O
and O O
volume O O
homeostatic O O
fluid O O
- O O
fluid O O
exchanger O O
. O O
Effect O O
of O O
heat O O
treatments O O
on O O
the O O
meltability O O
of O O
cheeses O O
. O O

RESULTS O O
: O O
Sixty O O
per O O
cent O O
of O O
African O O
Americans O O
exposed O O
in O O
26 O O
community O O
outbreaks O O
were O O
TST O O
positive O O
compared O O
to O O
only O O
40% O O
of O O
whites O O
following O O
comparable O O
exposures O O
. O O

The O O
mean O O
waiting O O
time O O
to O O
receive O O
the O O
pancreas O O
transplant O O
was O O
244 O O
days O O
for O O
SPK O O
and O O
167 O O
days O O
for O O
PAK O O
recipients O O
( O O
P O O
= O O
0.001 O O
) O O
. O O

Patients O O
with O O
antibody O O
peaks O O
, O O
defined O O
as O O
fivefold O O
or O O
higher O O
increase O O
in O O
antibody O O
titer O O
compared O O
to O O
the O O
lowest O O
antibody O O
titer O O
over O O
the O O
course O O
of O O
GBS O S-GENE
, O O
had O O
higher O O
disability O O
scores O O
during O O
the O O
first O O
two O O
weeks O O
of O O
GBS O O
and O O
a O O
worse O O
clinical O O
outcome O O
( O O
anti B-GENE B-GENE
- I-GENE I-GENE
GM1 I-GENE I-GENE
IgG E-GENE E-GENE
and O O
anti B-GENE B-GENE
- I-GENE I-GENE
GD1a I-GENE I-GENE
IgM I-GENE E-GENE
antibody E-GENE O
peaks O O
) O O
and O O
axonal O O
damage O O
( O O
anti O B-GENE
- O I-GENE
GD1a O I-GENE
IgM O E-GENE
antibody O O
peaks O O
) O O
, O O
compared O O
to O O
patients O O
without O O
peak O O
antibody O O
titers O O
. O O
Following O O
baseline O O
clinical O O
examination O O
and O O
initial O O
periodontal O O
therapy O O
, O O
32 O O
patients O O
received O O
mucogingival O O
surgery O O
with O O
free O O
gingival O O
grafts O O
for O O
treatment O O
of O O
insufficient O O
attached O O
gingiva O O
. O O

However O O
, O O
patients O O
with O O
isolated O O
office O O
hypertension O O
had O O
fewer O O
previous O O
cardiovascular O O
complications O O
. O O

In O O
the O O
TVD O O
- O O
patients O O
decreases O O
in O O
skin O O
blood O O
flow O O
were O O
similar O O
compared O O
with O O
the O O
healthy O O
controls O O
. O O

2 O O
: O O
The O O
dynamic O O
moduli O O
of O O
microcrystalline O O
cellulose O O
. O O

These O O
findings O O
suggest O O
that O O
an O O
intracellular O O
WT-1/HSAL2 O S-GENE
pathway O O
may O O
play O O
a O O
role O O
in O O
development O O
and O O
hematopoiesis O O
. O O
ICAM-1 S-GENE S-GENE
has O O
been O O
suggested O O
a O O
predictor O O
of O O
the O O
onset O O
of O O
GO O O
. O O
Phosphotyrosyl O O
peptides O O
block O O
Stat3-mediated O O
DNA O O
binding O O
activity O O
, O O
gene O O
regulation O O
, O O
and O O
cell O O
transformation O O
. O O
Plane O O
wave O O
geometry O O
is O O
impractical O O
for O O
clinical O O
use O O
but O O
the O O
results O O
of O O
this O O
work O O
encouraged O O
us O O
to O O
further O O
develop O O
the O O
P3 O O
approximation O O
for O O
a O O
spherical O O
geometry O O
, O O
described O O
in O O
this O O
paper O O
. O O

The O O
diagnosis O O
of O O
HCV O O
arthritis O O
in O O
patients O O
with O O
positive O O
rheumatoid B-GENE B-GENE
factor E-GENE E-GENE
and O O
chronic O O
inflammatory O O
polyarthritis O O
may O O
be O O
difficult O O
. O O
METHODS O O
: O O
We O O
retrospectively O O
selected O O
13 O O
TFCD O O
patients O O
who O O
underwent O O
surgery O O
for O O
intractable O O
epilepsy O O
with O O
the O O
aim O O
of O O
removing O O
the O O
magnetic O O
resonance O O
( O O
MR)-detectable O O
lesion O O
and/or O O
the O O
epileptogenic O O
zone O O
defined O O
by O O
stereoelectroencephalographic O O
recordings O O
. O O

RESULTS O O
: O O
At O O
latest O O
examination O O
, O O
mean O O
UPDRS O O
II O O
and O O
III O O
scores O O
had O O
improved O O
by O O
30% O O
( O O
on O O
stimulation O O
, O O
off O O
therapy O O
) O O
with O O
mean O O
50% O O
reduction O O
in O O
daily O O
off O O
time O O
. O O

In O O
Exp O O
. O O

Several O O
distinct O O
apoptotic O O
stimuli O O
induce O O
the O O
expression O O
and O O
caspase S-GENE O
- O O
dependent O O
cleavage O O
of O O
hTAF(II)80 B-GENE B-GENE
delta E-GENE E-GENE
. O O
hTAF(II)80 O B-GENE
delta O E-GENE
, O O
unlike O O
hTAF(II)80 O S-GENE
, O O
forms O O
a O O
TFIID B-GENE B-GENE
- I-GENE I-GENE
like I-GENE I-GENE
complex E-GENE E-GENE
lacking O O
hTAF(II)31 S-GENE S-GENE
. O O
Endovascular O O
aneurysm O O
repair O O
with O O
the O O
AneuRx O O
stent O O
- O O
graft O O
is O O
safe O O
, O O
but O O
is O O
it O O
effective O O
? O O

Chronic O O
nutritional O O
diseases O O
of O O
infectious O O
origin O O
: O O
an O O
assessment O O
of O O
a O O
nascent O O
field O O
. O O

Drug O O
interactions O O
have O O
been O O
found O O
with O O
drugs O O
that O O
compete O O
for O O
the O O
same O O
CYP450 B-GENE B-GENE
isoenzymes E-GENE E-GENE
as O O
statins O O
. O O
METHODS O O
: O O
We O O
studied O O
the O O
clinical O O
benefit O O
of O O
depth O O
- O O
dependent O O
RR O O
, O O
nonuniform O O
AC O O
using O O
a O O
scanning O O
line O O
source O O
, O O
and O O
scatter O O
correction O O
( O O
photon O O
energy O O
recovery O O
[ O O
PER O O
] O O
) O O
compared O O
with O O
filtered O O
backprojection O O
alone O O
. O O

Because O O
of O O
differences O O
in O O
patient O O
characteristics O O
, O O
control O O
measurements O O
were O O
obtained O O
from O O
normal O O
muscle O O
in O O
all O O
patients O O
. O O

However O O
, O O
the O O
abi1 B-GENE B-GENE
- I-GENE I-GENE
1 I-GENE I-GENE
gene I-GENE I-GENE
product E-GENE E-GENE
has O O
no O O
effect O O
on O O
the O O
ABA O O
suppression O O
of O O
a O O
GA O B-GENE
- O I-GENE
responsive O I-GENE
alpha B-GENE I-GENE
- I-GENE I-GENE
amylase I-GENE I-GENE
gene E-GENE E-GENE
. O O
In O O
children O O
unable O O
to O O
perform O O
forced O O
expiratory O O
maneuvers O O
( O O
n O O
= O O
25 O O
) O O
, O O
FOT O O
, O O
contrary O O
to O O
the O O
interrupter O O
technique O O
, O O
clearly O O
identified O O
a O O
subgroup O O
of O O
young O O
children O O
with O O
high O O
resistance O O
values O O
at O O
baseline O O
, O O
which O O
returned O O
to O O
normal O O
after O O
bronchodilation O O
. O O

In O O
budding O O
yeast O O
, O O
this O O
latter O O
checkpoint O O
response O O
involves O O
the O O
proteins O O
Mad1 B-GENE O
, I-GENE O
2 I-GENE O
, I-GENE O
3 E-GENE O
, O O
Bub1 S-GENE O
and O O
Bub3 S-GENE O
, O O
whose O O
vertebrate O O
counterparts O O
localize O O
to O O
unattached O O
kinetochores O O
. O O
HTLV-1 O O
decreases O O
Th2 O O
type O O
of O O
immune O O
response O O
in O O
patients O O
with O O
strongyloidiasis O O
. O O

However O O
, O O
the O O
beta5L O O
splice O O
variant O O
was O O
found O O
only O O
in O O
the O O
retina O O
. O O

PROCEDURE O O
: O O
Cannulas O O
were O O
surgically O O
positioned O O
in O O
the O O
abomasal O O
body O O
and O O
pyloric O O
antrum O O
of O O
each O O
calf O O
. O O

METHODS O O
: O O
Humphrey O O
Field O O
Analyzer O O
model O O
630 O O
( O O
HFA O O
I O O
, O O
program O O
30 O O
- O O
2 O O
with O O
a O O
rectangular O O
6 O O
degrees O O
x O O
6 O O
degrees O O
grid O O
) O O
was O O
used O O
as O O
the O O
conventional O O
perimetric O O
method O O
. O O

Transforming B-GENE B-GENE
growth I-GENE I-GENE
factor I-GENE I-GENE
- I-GENE I-GENE
beta E-GENE E-GENE
( O O
TGF B-GENE B-GENE
- I-GENE I-GENE
beta E-GENE E-GENE
) O O
induced O O
growth O O
arrest O O
of O O
cells O O
involves O O
regulation O O
of O O
the O O
activities O O
of O O
both O O
D- B-GENE S-GENE
and I-GENE O
E I-GENE B-GENE
- I-GENE I-GENE
type I-GENE I-GENE
cyclin I-GENE I-GENE
kinase I-GENE E-GENE
complexes E-GENE O
thought O O
to O O
be O O
mediated O O
primarily O O
by O O
the O O
regulation O O
of O O
p15(Ink4b O S-GENE
) O O
and O O
p27(Kip1 O S-GENE
) O O
cyclin O B-GENE
kinase O E-GENE
inhibitors O O
. O O
Alignment O O
of O O
different O O
cDNAs O O
of O O
the O O
NR5A2 S-GENE S-GENE
( O O
hB1F S-GENE S-GENE
) O O
gene O O
with O O
the O O
genomic O O
sequence O O
facilitated O O
the O O
delineation O O
of O O
its O O
structural O O
organization O O
, O O
which O O
spans O O
over O O
150 O O
kb O O
and O O
consists O O
of O O
eight O O
exons O O
interrupted O O
by O O
seven O O
introns O O
. O O
The O O
genomic O O
structure O O
of O O
the O O
human B-GENE B-GENE
SPEC1 I-GENE I-GENE
gene E-GENE E-GENE
reveals O O
complex O O
splicing O O
and O O
close O O
promoter O O
proximity O O
to O O
the O O
AF1q B-GENE B-GENE
translocation I-GENE I-GENE
gene E-GENE E-GENE
. O O
Hp O S-GENE
positive O O
relatives O O
of O O
gastric O O
cancer O O
had O O
a O O
markedly O O
higher O O
prevalence O O
of O O
atrophy O O
than O O
those O O
with O O
Hp O O
negativity O O
without O O
cancer O O
relatives O O
( O O
29 O O
vs. O O

Peripheral O O
metabolism O O
of O O
androgens O O
takes O O
place O O
in O O
various O O
areas O O
within O O
the O O
pilosebaceous O O
unit O O
, O O
as O O
indicated O O
by O O
local O O
differences O O
in O O
the O O
activities O O
of O O
aromatase S-GENE O
, O O
5alpha B-GENE B-GENE
- I-GENE I-GENE
reductase E-GENE E-GENE
as O O
well O O
as O O
of O O
the O O
presence O O
of O O
the O O
androgen B-GENE B-GENE
receptors E-GENE E-GENE
. O O
The O O
uptake O O
of O O
fluorine-18 O O
fluorodeoxyglucose O O
( O O
F-18 O O
FDG O O
) O O
by O O
a O O
malignant O O
tumor O O
depends O O
on O O
the O O
blood O O
glucose O O
level O O
. O O

Northern O O
blot O O
analysis O O
with O O
one O O
of O O
the O O
PARNAs S-GENE S-GENE
revealed O O
a O O
highly O O
abundant O O
signal O O
of O O
approximately O O
2.0 O O
kilobases O O
( O O
kb O O
) O O
present O O
in O O
all O O
cell O O
lines O O
tested O O
. O O
This O O
analysis O O
supports O O
the O O
use O O
of O O
fluticasone O O
propionate O O
88 O O
microg O O
twice O O
daily O O
as O O
first O O
- O O
line O O
treatment O O
in O O
patients O O
with O O
persistent O O
asthma O O
previously O O
treated O O
with O O
short O O
- O O
acting O O
beta2-agonist O O
alone O O
. O O
By O O
using O O
space O O
- O O
discrete O O
/ O O
continuous O O
metapopulation O O
dynamic O O
models O O
and O O
computer O O
simulations O O
, O O
we O O
show O O
that O O
there O O
can O O
be O O
two O O
principally O O
different O O
regimes O O
of O O
metapopulation O O
dynamics O O
. O O

Eight O O
CAD O S-GENE
patients O O
who O O
were O O
matched O O
to O O
the O O
treated O O
patients O O
for O O
age O O
( O O
+ O O
/-3 O O
years O O
) O O
, O O
baseline O O
low B-GENE O
density I-GENE O
lipoprotein E-GENE O
( O O
+ O O
/-5 O O
mg O O
/ O O
dL O O
) O O
, O O
and O O
triglycerides O O
( O O
+ O O
/-50 O O
mg O O
/ O O
dL O O
) O O
but O O
who O O
had O O
never O O
been O O
treated O O
with O O
lipid O O
- O O
lowering O O
drugs O O
were O O
selected O O
as O O
controls O O
. O O
The O O
corresponding O O
orifice O O
voltages O O
for O O
the O O
three O O
instruments O O
were O O
20/50/80 O O
V O O
( O O
API O O
365 O O
) O O
, O O
30/90/130 O O
V O O
( O O
API O O
2000 O O
) O O
and O O
40/80/120 O O
V O O
( O O
API O O
3000 O O
) O O
. O O

RESULTS O O
: O O
A O O
novel O O
gene O O
was O O
cloned O O
. O O

The O O
moduli O O
of O O
elasticity O O
of O O
the O O
gray O O
and O O
white O O
matter O O
were O O
3.4+/-1.4 O O
kPa O O
( O O
mean O O
+ O O
/- O O
standard O O
deviation O O
) O O
and O O
3.4+/-0.9 O O
kPa O O
in O O
the O O
axial O O
section O O
, O O
3+/-0.3 O O
kPa O O
and O O
3.5+/-0.5 O O
kPa O O
in O O
the O O
frontal O O
section O O
, O O
and O O
3.5+/-0.9 O O
kPa O O
and O O
2.8+/-0.4 O O
kPa O O
in O O
the O O
sagittal O O
section O O
, O O
respectively O O
. O O

The O O
LA O O
50s O O
derived O O
from O O
this O O
combined O O
data O O
when O O
compared O O
with O O
our O O
earlier O O
series O O
from O O
1965 O O
to O O
1970 O O
also O O
did O O
not O O
show O O
a O O
significant O O
change O O
in O O
mortality O O
. O O

Direct O O
current O O
polarography O O
and O O
differential O O
pulse O O
polarographic O O
methods O O
have O O
been O O
developed O O
for O O
the O O
qualitative O O
as O O
well O O
as O O
quantitative O O
analysis O O
of O O
vitamin O O
B1 O O
, O O
B2 O O
and O O
B6 O O
. O O

Against O O
gram O O
- O O
positive O O
organisms O O
, O O
E-4767 O O
and O O
E-5065 O O
were O O
, O O
in O O
general O O
, O O
eight- O O
and O O
fourfold O O
more O O
active O O
than O O
tosufloxacin O O
, O O
which O O
is O O
the O O
most O O
potent O O
of O O
the O O
reference O O
compounds O O
. O O

However O O
, O O
most O O
produced O O
significant O O
alteration O O
of O O
small O O
intestinal O O
permeability O O
. O O

These O O
included O O
HNF-3 B-GENE B-GENE
beta E-GENE E-GENE
, O O
HFH-1 S-GENE S-GENE
, O O
HFH-2 S-GENE S-GENE
, O O
HFH-3 S-GENE S-GENE
, O O
C B-GENE O
/ I-GENE O
EBP E-GENE S-GENE
, O O
and O O
C B-GENE O
/ I-GENE O
EBP I-GENE B-GENE
beta E-GENE E-GENE
, O O
all O O
of O O
which O O
are O O
consistent O O
with O O
the O O
tissue O O
- O O
specific O O
expression O O
profiles O O
of O O
the O O
gene O O
. O O
Managing O O
vertigo O O
and O O
vertigo O O
syndromes O O
in O O
the O O
elderly O O

The O O
MABP O S-GENE
and O O
MCBFV O O
signals O O
were O O
bandpass O O
filtered O O
in O O
the O O
very O O
low O O
- O O
frequency O O
range O O
( O O
VLF O O
, O O
0.015 O O
- O O
0.07 O O
Hz O O
) O O
, O O
low O O
- O O
frequency O O
range O O
( O O
LF O O
, O O
0.07 O O
- O O
0.15 O O
Hz O O
) O O
and O O
high O O
- O O
frequency O O
range O O
( O O
HF O O
, O O
0.15 O O
- O O
0.40 O O
Hz O O
) O O
before O O
applying O O
CCF O O
for O O
the O O
purpose O O
of O O
studying O O
the O O
effect O O
of O O
different O O
bandwidths O O
on O O
the O O
resulting O O
mean O O
CCFs O O
. O O

Treatment O O
of O O
ischemic O O
heart O O
disease O O
in O O
the O O
elderly O O

Hepatitis O O
B O O
and O O
C O O
seroprevalence O O
rates O O
among O O
high O O
- O O
risk O O
adolescents O O
are O O
lower O O
in O O
El O O
Paso O O
than O O
in O O
other O O
similar O O
US O O
populations O O
, O O
presenting O O
an O O
ideal O O
climate O O
for O O
prevention O O
programs O O
. O O

A O O
twelfth O O
insertion O O
disrupts O O
two O O
genes O O
, O O
Nrk S-GENE S-GENE
, O O
a O O
" B-GENE O
neurospecific I-GENE B-GENE
" I-GENE I-GENE
receptor I-GENE I-GENE
tyrosine I-GENE I-GENE
kinase E-GENE E-GENE
, O O
and O O
Tpp S-GENE S-GENE
, O O
which O O
encodes O O
a O O
neuropeptidase S-GENE O
. O O
A O O
peculiar O O
people O O
: O O
" O O
the O O
physiological O O
aspects O O
of O O
Mormonism O O
1850 O O
- O O
1975 O O
. O O
" O O

Not O O
Available O O

This O O
unique O O
work O O
needs O O
to O O
be O O
edited O O
critically O O
and O O
afterwards O O
translated O O
into O O
Urdu O O
and O O
other O O
languages O O
for O O
the O O
benefit O O
of O O
the O O
present O O
day O O
students O O
and O O
scholars O O
. O O

Comparison O O
of O O
German O O
language O O
versions O O
of O O
the O O
QWB O O
- O O
SA O O
and O O
SF-36 O O
evaluating O O
outcomes O O
for O O
patients O O
with O O
prostate O O
disease O O
. O O

Disciplinary O O
action O O
for O O
DNA O O
violation O O
. O O

Epithelial O O
cytotoxicity O O
of O O
combined O O
antibiotics O O
was O O
additive O O
, O O
with O O
no O O
evidence O O
of O O
competition O O
or O O
synergism O O
. O O

Pro O B-GENE
- O I-GENE
inflammatory O I-GENE
cytokine O E-GENE
, O O
tumor B-GENE B-GENE
necrosis I-GENE I-GENE
factor I-GENE I-GENE
- I-GENE I-GENE
alpha E-GENE E-GENE
( O O
TNF B-GENE B-GENE
- I-GENE I-GENE
alpha E-GENE E-GENE
) O O
, O O
produced O O
from O O
adipose O O
tissues O O
in O O
obese O O
subjects O O
, O O
is O O
known O O
to O O
play O O
a O O
predominant O O
role O O
in O O
inducing O O
insulin S-GENE S-GENE
resistance O O
. O O
She O O
drank O O
alcohol O O
once O O
or O O
twice O O
a O O
week O O
and O O
regularly O O
took O O
an O O
analgesic O O
preparation O O
, O O
containing O O
aspirin O O
and O O
acetaminophen O O
, O O
for O O
alleviation O O
of O O
headaches O O
. O O

The O O
most O O
important O O
risk O O
factors O O
are O O
: O O
1 O O
) O O
genetic O O
; O O
2 O O
) O O
Epstein O O
- O O
Barr O O
virus O O
( O O
infectious O O
mononucleosis O O
) O O
; O O
3 O O
) O O
congenital O O
and O O
acquired O O
immunodeficiency O O
; O O
4 O O
) O O
occupational O O
exposure O O
( O O
the O O
wood O O
industry O O
) O O
. O O

The O O
most O O
important O O
finding O O
, O O
however O O
, O O
was O O
that O O
IMT O O
values O O
were O O
related O O
with O O
24 O O
h O O
SBP O O
or O O
PP O O
standard O O
deviation O O
( O O
P O O
< O O
0.001 O O
) O O
, O O
a O O
measure O O
of O O
overall O O
SBP O O
or O O
PP O O
variability O O
. O O

The O O
difference O O
between O O
the O O
patients O O
and O O
the O O
controls O O
was O O
statistically O O
significant O O
( O O
p O O
= O O
0.03 O O
) O O
. O O

The O O
effect O O
of O O
crude O O
oil O O
spillage O O
on O O
growth O O
, O O
productivity O O
and O O
nutrient O O
uptake O O
of O O
maize O O
( O O
Zea O O
mays O O
L. O O
) O O
was O O
assessed O O
in O O
a O O
pot O O
experiment O O
using O O
an O O
Evwreni O O
manifold O O
sample O O
of O O
a O O
petroleum O O
development O O
company O O
, O O
which O O
had O O
a O O
specific O O
gravity O O
of O O
0.8778 O O
. O O

NO O O
metabolites O O
were O O
determined O O
by O O
the O O
measurement O O
of O O
nitrate O O
/ O O
nitrite O O
( O O
NOx O O
, O O
micromol O O
/ O O
mmol O O
creatinine O O
) O O
and O O
cyclic O O
guanosine O O
monophosphate O O
( O O
cGMP O O
, O O
nmol O O
/ O O
mmol O O
creatinine O O
) O O
in O O
plasma O O
and O O
urine O O
. O O

In O O
the O O
base O O
- O O
case O O
analysis O O
, O O
total O O
direct O O
costs O O
per O O
patient O O
were O O
$ O O
728 O O
for O O
zoledronic O O
acid O O
and O O
$ O O
776 O O
for O O
pamidronate O O
. O O

The O O
diet O O
of O O
migrants O O
showed O O
both O O
positive O O
( O O
macronutrients O O
) O O
and O O
negative O O
( O O
micronutrients O O
) O O
differences O O
with O O
the O O
general O O
Dutch O O
diet O O
. O O

C. O O
elegans O O
embryogenesis O O
begins O O
with O O
a O O
stereotyped O O
sequence O O
of O O
asymmetric O O
cell O O
divisions O O
that O O
are O O
largely O O
responsible O O
for O O
establishing O O
the O O
nematode O O
body O O
plan O O
. O O

Finally O O
, O O
a O O
chromogenic O O
method O O
was O O
used O O
, O O
based O O
on O O
thrombin S-GENE O
inhibition O O
and O O
the O O
substrate O O
S-2238 O O
. O O
[ O O
Diabetologia O O
( O O
2001 O O
) O O
44 O O
[ O O
Suppl O O
3 O O
] O O
: O O
B37-B44 O O
] O O

The O O
5 O O
' O O
flanking O O
sequence O O
of O O
the O O
3B B-GENE B-GENE
gene E-GENE E-GENE
is O O
extremely O O
A O O
+ O O
T O O
rich O O
but O O
contains O O
five O O
G O O
/ O O
C O O
rich O O
stretches O O
, O O
each O O
approximately O O
7bp O O
long O O
, O O
which O O
have O O
strong O O
sequence O O
similarity O O
to O O
the O O
G O B-GENE
boxes O E-GENE
found O O
upstream O O
of O O
other O O
developmentally O O
regulated O O
Dictyostelium O B-GENE
genes O E-GENE
. O O
Considering O O
that O O
the O O
reactor O O
is O O
thoroughly O O
mixed O O
during O O
each O O
discharge O O
and O O
that O O
LD50 O O
= O O
0.9 O O
values O O
are O O
nearly O O
independent O O
of O O
E. O O
coli O O
concentrations O O
in O O
the O O
range O O
of O O
2 O O
x O O
10(3 O O
) O O
< O O
or O O
= O O
E O O
coli O O
/ O O
cfu O O
mL(-1 O O
) O O
< O O
or O O
= O O
3 O O
x O O
10(6 O O
) O O
, O O
we O O
ascribe O O
the O O
nonexponential O O
Pn O O
decay O O
of O O
single O O
- O O
strain O O
E. O O
coli O O
colonies O O
to O O
a O O
shielding O O
phenomenon O O
where O O
inactive O O
cells O O
protect O O
the O O
successively O O
smaller O O
numbers O O
of O O
viable O O
cells O O
in O O
the O O
EHD O O
. O O

OBJECTIVES O O
: O O
The O O
objective O O
of O O
this O O
review O O
was O O
to O O
assess O O
the O O
effects O O
of O O
prophylactic O O
prostaglandin O O
use O O
in O O
the O O
third O O
stage O O
of O O
labour O O
. O O

In O O
the O O
long O O
term O O
, O O
questions O O
still O O
remain O O
about O O
whether O O
pre O O
- O O
dialysis O O
rHu B-GENE O
EPO E-GENE S-GENE
either O O
speeds O O
up O O
or O O
delays O O
the O O
onset O O
of O O
dialysis O O
. O O
METHODS O O
: O O
This O O
retrospective O O
review O O
comprised O O
2711 O O
eyes O O
that O O
had O O
LASIK O O
between O O
September O O
1996 O O
and O O
September O O
1999 O O
. O O

No O O
ISREs S-GENE O
could O O
be O O
identified O O
in O O
the O O
mouse O B-GENE
promoter O E-GENE
. O O
BACKGROUND O O
: O O
Ischemic O O
heart O O
disease O O
is O O
the O O
primary O O
cause O O
of O O
morbidity O O
and O O
mortality O O
among O O
diabetics O O
, O O
especially O O
those O O
who O O
became O O
ill O O
at O O
a O O
young O O
age O O
. O O

A O O
38-year O O
- O O
old O O
woman O O
with O O
ulcerative O O
colitis O O
subsequently O O
developed O O
sarcoidosis O O
. O O

Cholesteryl B-GENE B-GENE
ester I-GENE I-GENE
transfer I-GENE I-GENE
protein E-GENE E-GENE
and O O
atherosclerosis O O
in O O
Japanese O O
subjects O O
: O O
a O O
study O O
based O O
on O O
coronary O O
angiography O O
. O O
Electrophoretic O O
mobility O O
shift O O
assays O O
and O O
coimmunoprecipitation O O
studies O O
suggest O O
that O O
homo- O O
and O O
heterodimerization O O
occurs O O
between O O
cKrox B-GENE B-GENE
family I-GENE E-GENE
members E-GENE O
. O O
The O O
hcKrox S-GENE B-GENE
gene O I-GENE
family O I-GENE
regulates O I-GENE
multiple O I-GENE
extracellular O I-GENE
matrix O I-GENE
genes O E-GENE
. O O
A O O
review O O
of O O
the O O
literature O O
identified O O
8 O O
comprehensive O O
clinical O O
studies O O
, O O
all O O
of O O
which O O
failed O O
to O O
document O O
any O O
relationship O O
between O O
NF1 S-GENE O
and O O
intracranial O O
aneurysms O O
. O O
These O O
utilisation O O
data O O
imply O O
annual O O
drug O O
costs O O
in O O
the O O
range O O
of O O
$ O O
US O O
480,000 O O
to O O
$ O O
US O O
3,600,000 O O
for O O
TNF S-GENE O
antagonists O O
for O O
RA O O
per O O
1 O O
million O O
population O O
. O O
Under O O
our O O
conditions O O
, O O
the O O
combination O O
O3/UV O O
did O O
not O O
improve O O
the O O
degradation O O
rate O O
obtained O O
by O O
ozonation O O
. O O

This O O
study O O
investigated O O
whether O O
boron O O
would O O
enhance O O
the O O
ability O O
of O O
17beta O B-GENE
- O I-GENE
estradiol O E-GENE
( O O
E2 O O
) O O
or O O
parathyroid B-GENE B-GENE
hormone E-GENE E-GENE
( O O
PTH S-GENE S-GENE
) O O
to O O
improve O O
bone O O
quality O O
in O O
ovariectomized O O
OVX O O
rats O O
. O O
We O O
found O O
in O O
the O O
control O O
subjects O O
rCBF O O
increases O O
in O O
regions O O
associated O O
with O O
the O O
meso O O
- O O
striatal O O
and O O
meso O O
- O O
corticolimbic O O
circuits O O
in O O
response O O
to O O
both O O
monetary O O
reward O O
and O O
nonmonetary O O
reinforcement O O
. O O

Doxorubicin O O
( O O
DOX O O
) O O
is O O
commonly O O
used O O
for O O
the O O
treatment O O
of O O
hematological O O
and O O
solid O O
tumors O O
. O O

The O O
event O O
rate O O
in O O
patients O O
with O O
chronic O O
Irr O O
- O O
rMFP O O
or O O
Un O O
- O O
nrMFP O O
was O O
markedly O O
higher O O
than O O
it O O
was O O
in O O
those O O
with O O
Rev O O
- O O
rMFP O O
or O O
Sta O O
- O O
nrMFP O O
. O O

Subtraction O O
hybridization O O
identified O O
melanoma B-GENE O
differentiation I-GENE O
associated I-GENE O
gene-7 E-GENE O
( O O
mda-7 S-GENE O
) O O
, O O
as O O
a O O
gene O O
induced O O
during O O
these O O
physiological O O
changes O O
in O O
human O O
melanoma O O
cells O O
. O O
Therefore O O
, O O
vitamin O O
D3 O O
analogues O O
have O O
a O O
substantial O O
antipsoriatic O O
effect O O
. O O

Hydrocoele O O
is O O
common O O
in O O
men O O
in O O
Wuchereria O O
bancrofti O O
- O O
endemic O O
areas O O
, O O
the O O
treatment O O
for O O
which O O
is O O
currently O O
surgical O O
intervention O O
. O O

Growth B-GENE O
hormone E-GENE S-GENE
and O O
insulin B-GENE B-GENE
- I-GENE I-GENE
like I-GENE I-GENE
growth I-GENE I-GENE
factor I-GENE I-GENE
I I-GENE I-GENE
receptors E-GENE E-GENE
in O O
the O O
temporomandibular O O
joint O O
of O O
the O O
rat O O
. O O
On O O
the O O
other O O
hand O O
, O O
hepatic O O
arterial O O
infusion O O
therapy O O
prolongs O O
the O O
survival O O
of O O
H3 O O
patients O O
only O O
. O O

In O O
addition O O
to O O
that O O
, O O
she O O
received O O
hepatic O O
intra O O
- O O
arterial O O
infusion O O
of O O
levoforinate O O
( O O
l O O
- O O
LV O O
) O O
250 O O
mg O O
and O O
5-fluorouracil O O
( O O
5-FU O O
) O O
500 O O
mg O O
for O O
combined O O
multiple O O
hepatic O O
metastases O O
starting O O
on O O
postoperative O O
day O O
14 O O
, O O
and O O
these O O
medications O O
were O O
administered O O
over O O
48 O O
hours O O
once O O
weekly O O
by O O
infuser O O
pump O O
. O O

The O O
astronaut O O
crew O O
operates O O
the O O
payload O O
and O O
documents O O
its O O
operation O O
. O O

For O O
these O O
patients O O
the O O
introduction O O
of O O
a O O
separate O O
category O O
" O O
extended O O
oligoarthritis O O
at O O
onset O O
" O O
should O O
be O O
considered O O
to O O
establish O O
comparable O O
patient O O
groups O O
. O O

Finally O O
, O O
there O O
are O O
a O O
growing O O
number O O
of O O
arguments O O
favouring O O
the O O
use O O
of O O
ACE S-GENE S-GENE
inhibitors O O
very O O
early O O
in O O
patients O O
with O O
diabetes O O
mellitus O O
. O O
Phase O O
II O O
trial O O
of O O
the O O
anti B-GENE B-GENE
- I-GENE I-GENE
G(D2 I-GENE I-GENE
) I-GENE I-GENE
monoclonal I-GENE I-GENE
antibody I-GENE I-GENE
3F8 E-GENE E-GENE
and O O
granulocyte B-GENE B-GENE
- I-GENE I-GENE
macrophage I-GENE I-GENE
colony I-GENE I-GENE
- I-GENE I-GENE
stimulating I-GENE I-GENE
factor E-GENE E-GENE
for O O
neuroblastoma O O
. O O
Hepatitis O O
A O O
infected O O
food O O
handler O O
at O O
an O O
Edmonton O O
, O O
Alberta O O
retail O O
food O O
facility O O
: O O
public O O
health O O
protection O O
strategies O O
. O O

Hydrogels O O
for O O
tissue O O
engineering O O
. O O

Eliminating O O
any O O
subset O O
of O O
ASCUS O O
reduces O O
the O O
ASCUS O O
/ O O
SIL O O
ratio O O
but O O
also O O
significantly O O
diminishes O O
the O O
sensitivity O O
of O O
the O O
Papanicolaou O O
test O O
. O O

Eliminating O O
any O O
subset O O
of O O
ASCUS O O
reduces O O
the O O
ASCUS O O
/ O O
SIL O O
ratio O O
but O O
also O O
significantly O O
diminishes O O
the O O
sensitivity O O
of O O
the O O
Papanicolaou O O
test O O
. O O

Two O O
nuclear O O
medicine O O
physicians O O
blinded O O
to O O
the O O
surgical O O
findings O O
interpreted O O
all O O
available O O
images O O
and O O
various O O
Tc-99 O O
m O O
MIBI O O
image O O
combinations O O
at O O
15 O O
minutes O O
alone O O
; O O
15 O O
minutes O O
and O O
2 O O
hours O O
, O O
15 O O
minutes O O
and O O
4 O O
hours O O
; O O
and O O
15 O O
minutes O O
and O O
2 O O
and O O
4 O O
hours O O
each O O
with O O
and O O
without O O
correlative O O
pertechnetate O O
thyroid O O
imaging O O
. O O

Is O O
clopidogrel O O
superior O O
to O O
aspirin O O
in O O
secondary O O
prevention O O
of O O
vascular O O
disease O O
? O O
The O O
cornerstone O O
in O O
clinical O O
evidence O O
of O O
the O O
relative O O
efficacy O O
of O O
thienopyridines O O
( O O
clopidogrel O O
, O O
ticlopidine O O
) O O
versus O O
aspirin O O
in O O
the O O
secondary O O
prevention O O
of O O
vascular O O
disease O O
is O O
the O O
Clopidogrel O O
versus O O
Aspirin O O
in O O
Patients O O
at O O
Risk O O
of O O
Ischaemic O O
Events O O
trial O O
. O O

We O O
hypothesize O O
that O O
proprioception O O
may O O
be O O
used O O
to O O
calibrate O O
the O O
efference O O
copy O O
during O O
development O O
and O O
in O O
response O O
to O O
perturbations O O
by O O
signaling O O
potential O O
mismatches O O
between O O
eye O O
movement O O
information O O
derived O O
from O O
the O O
efferent O O
command O O
and O O
the O O
actual O O
motion O O
of O O
the O O
eye O O
transduced O O
by O O
the O O
proprioceptive O O
organs O O
. O O

Between O O
1967 O O
and O O
1994 O O
, O O
495 O O
patients O O
underwent O O
surgery O O
for O O
primary O O
PTC O O
at O O
the O O
Department O O
of O O
Surgery O O
, O O
Helsinki O O
University O O
Central O O
Hospital O O
. O O

ISS O O
and O O
the O O
acute O O
physiology O O
and O O
chronic O O
health O O
evaluation O O
( O O
APACHE O O
II O O
) O O
calculated O O
on O O
admission O O
. O O

The O O
procedure O O
is O O
less O O
aggressive O O
and O O
painful O O
than O O
sternotomy O O
. O O

Paul O O
Monagle O O
addresses O O
the O O
epidemiology O O
of O O
neonatal O O
thrombosis O O
outside O O
of O O
the O O
central O O
nervous O O
system O O
in O O
both O O
arterial O O
and O O
venous O O
locations O O
, O O
and O O
those O O
that O O
occur O O
in O O
utero O O
. O O

[ O O
Clinical O O
and O O
epidemiological O O
characteristics O O
of O O
squamous O O
cell O O
carcinoma O O
of O O
the O O
oral O O
cavity O O
in O O
women O O
] O O
BACKGROUND O O
: O O
Squamous O O
cell O O
carcinoma O O
( O O
SCC O O
) O O
of O O
the O O
oral O O
cavity O O
occurs O O
mainly O O
in O O
the O O
male O O
population O O
. O O

Regarding O O
gestational O O
risk O O
, O O
3,243 O O
drugs O O
used O O
( O O
34% O O
) O O
belonged O O
to O O
category O O
A O O
risk O O
, O O
1,923 O O
( O O
22.6% O O
) O O
to O O
category O O
B O O
, O O
3,798 O O
( O O
39.7% O O
) O O
to O O
category O O
C O O
, O O
289 O O
( O O
3.0% O O
) O O
to O O
category O O
D O O
, O O
and O O
55 O O
( O O
0.6% O O
) O O
to O O
category O O
X. O O

The O O
severity O O
of O O
clinical O O
course O O
was O O
expressed O O
by O O
means O O
of O O
SOFA O O
score O O
( O O
group O O
A O O
0.3 O O
- O O
1 O O
- O O
1.3 O O
point O O
, O O
group O O
B O O
2.2 O O
- O O
2.9 O O
- O O
2.6 O O
point O O
, O O
group O O
C O O
7.4 O O
- O O
8.3 O O
- O O
7.7 O O
point O O
) O O
and O O
APACHE O O
II O O
score O O
( O O
group O O
A O O
3.7 O O
- O O
7.6 O O
- O O
8.1 O O
point O O
, O O
group O O
B O O
8.6 O O
- O O
11.1 O O
- O O
10.5 O O
point O O
, O O
group O O
C O O
16.3 O O
- O O
15.2 O O
- O O
14.3 O O
point O O
) O O
. O O

The O O
process O O
has O O
been O O
applied O O
to O O
the O O
river O O
reclamation O O
in O O
Yangpu O O
District O O
of O O
Shanghai O O
City O O
, O O
China O O
. O O

Physical O O
principles O O
in O O
therapeutic O O
apheresis O O
. O O

These O O
results O O
were O O
compared O O
with O O
the O O
estimates O O
of O O
penetration O O
from O O
steady O O
- O O
state O O
calculations O O
, O O
square O O
root O O
of O O
time O O
calculations O O
, O O
and O O
a O O
biologically O O
based O O
mathematical O O
model O O
. O O

Rind O O
et O O
al O O
. O O
's O O
study O O
's O O
main O O
conclusions O O
were O O
not O O
supported O O
by O O
the O O
original O O
data O O
. O O

Of O O
major O O
concern O O
to O O
food O O
processors O O
is O O
the O O
inadvertent O O
cross O O
- O O
contact O O
of O O
food O O
products O O
with O O
allergenic O O
residues O O
, O O
which O O
could O O
result O O
in O O
potentially O O
life O O
- O O
threatening O O
reactions O O
in O O
those O O
with O O
a O O
food O O
allergy O O
. O O

Lactate O O
accumulation O O
peak O O
was O O
unaffected O O
by O O
supplementation O O
( O O
HMB O O
, O O
8.1 O O
+ O O
/- O O
1.1 O O
mM O O
; O O
LEU O O
, O O
6.2 O O
+ O O
/- O O
0.8 O O
mM O O
; O O
CON O O
, O O
7.5 O O
+ O O
/- O O
1.3 O O
mM O O
) O O
. O O

The O O
increased O O
clearance O O
observed O O
in O O
young O O
infants O O
is O O
in O O
contrast O O
to O O
other O O
opioids O O
. O O

These O O
results O O
were O O
robust O O
to O O
changes O O
in O O
the O O
baseline O O
assumptions O O
of O O
the O O
model O O
. O O

CONCLUSION O O
: O O
The O O
training O O
of O O
novices O O
using O O
MIST O O
- O O
VR O O
yields O O
quantifiable O O
changes O O
in O O
skill O O
that O O
are O O
transferable O O
to O O
a O O
simple O O
real O O
task O O
and O O
are O O
similar O O
to O O
the O O
results O O
achieved O O
with O O
conventional O O
training O O
. O O

The O O
patients O O
and O O
their O O
families O O
were O O
closely O O
questioned O O
, O O
and O O
full O O
clinical O O
examination O O
included O O
a O O
test O O
for O O
orthostasia O O
. O O

They O O
have O O
not O O
been O O
previously O O
reported O O
as O O
a O O
reaction O O
to O O
i.v O O
. O O
contrast O O
material O O
. O O

There O O
was O O
a O O
statistically O O
significant O O
correlation O O
between O O
simultaneous O O
weekly O O
average O O
pollen O O
levels O O
in O O
Philadelphia O O
and O O
in O O
Cherry O O
Hill O O
( O O
Acer O O
, O O
r(p O O
) O O
= O O
0.987 O O
, O O
Quercus O O
, O O
r(p O O
) O O
= O O
0.645 O O
, O O
Betula O O
, O O
r(p O O
) O O
= O O
0.896 O O
, O O
Pinus O O
, O O
r(p O O
) O O
= O O
0.732 O O
, O O
Cupressaceae O O
, O O
r(p O O
) O O
= O O
0.695 O O
, O O
Poaceae O O
, O O
r(p O O
) O O
= O O
0.950 O O
, O O
Ambrosia O O
, O O
r(p O O
) O O
= O O
0.903 O O
, O O
and O O
Rumex O O
, O O
r(p O O
) O O
= O O
0.572 O O
, O O
P O O
< O O
0.001 O O
) O O
. O O

Encouraged O O
by O O
a O O
Dutch O O
study O O
using O O
etidronate O O
/ O O
fluoride O O
in O O
corticoid O O
- O O
induced O O
osteoporosis O O
, O O
we O O
performed O O
a O O
pilot O O
study O O
in O O
33 O O
men O O
with O O
severe O O
established O O
primary O O
osteoporosis O O
giving O O
cyclically O O
etidronate O O
for O O
14 O O
days O O
followed O O
by O O
fluoride O O
plus O O
calcium O O
/ O O
vitamin O O
D O O
for O O
76 O O
days O O
. O O

Treadmill O O
training O O
at O O
least O O
for O O
2 O O
weeks O O
can O O
reduce O O
the O O
infarction O O
size O O
and O O
edema O O
caused O O
by O O
MCA O O
occlusion O O
( O O
P<0.01 O O
) O O
. O O

In O O
order O O
to O O
overcome O O
the O O
false O O
positive O O
readings O O
that O O
are O O
possible O O
in O O
sphincter O O
manometry O O
, O O
we O O
proposed O O
to O O
use O O
secretin S-GENE O
stimulated O O
endoscopic O O
ultrasound O O
( O O
SSEUS O O
) O O
to O O
measure O O
pancreatic O O
ductal O O
response O O
as O O
an O O
adjunctive O O
method O O
to O O
aid O O
and O O
supplement O O
the O O
diagnosis O O
. O O
The O O
cut O O
- O O
off O O
percentage O O
positivity O O
value O O
was O O
established O O
using O O
500 O O
brucellosis O O
- O O
positive O O
and O O
500 O O
brucellosis O O
- O O
negative O O
serum O O
samples O O
, O O
confirmed O O
with O O
reference O O
to O O
the O O
sample O O
data O O
using O O
the O O
indirect O O
ELISA O O
kit O O
. O O

An O O
analysis O O
of O O
the O O
dynamics O O
is O O
performed O O
of O O
exactly O O
solvable O O
models O O
for O O
fragile O O
and O O
strong O O
glasses O O
, O O
exploiting O O
the O O
partitioning O O
of O O
the O O
free O O
- O O
energy O O
landscape O O
in O O
inherent O O
structures O O
. O O

Fifty O O
- O O
six O O
semen O O
samples O O
were O O
included O O
in O O
this O O
study O O
; O O
18 O O
were O O
subnormal O O
( O O
G1 O O
) O O
and O O
38 O O
were O O
normal O O
( O O
G2 O O
) O O
based O O
on O O
World O O
Health O O
Organization O O
criteria O O
, O O
except O O
for O O
morphology O O
, O O
which O O
was O O
evaluated O O
according O O
to O O
strict O O
criteria O O
. O O

At O O
this O O
timepoint O O
, O O
many O O
leucocytes O O
in O O
the O O
ME O O
and O O
ET O O
mucosa O O
had O O
incorporated O O
BrdU O O
( O O
between O O
15 O O
and O O
25% O O
within O O
the O O
subsets O O
) O O
. O O

Modality O O
- O O
specific O O
areas O O
( O O
e.g. O O
, O O
right O O
Wernicke O O
, O O
left O O
fusiform O O
gyrus O O
, O O
Broca O O
BA44 O O
, O O
supramarginal O O
gyrus O O
) O O
, O O
appear O O
to O O
cope O O
with O O
the O O
computations O O
relevant O O
to O O
making O O
contact O O
with O O
these O O
more O O
abstract O O
dimensions O O
. O O

We O O
found O O
no O O
correlation O O
between O O
plasma O B-GENE
COP O E-GENE
and O O
body O O
weight O O
at O O
the O O
same O O
age O O
( O O
r2 O O
= O O
0.05 O O
, O O
P O O
= O O
0.155 O O
) O O
. O O

Their O O
chemical O O
structures O O
were O O
elucidated O O
as O O
1 O O
alpha,2 O O
alpha O B-GENE
- O I-GENE
diacetoxy-8 O I-GENE
beta O I-GENE
- O I-GENE
isobutanoyloxy- O I-GENE
9 O I-GENE
alpha O I-GENE
- O I-GENE
benzoyloxy-13-(alpha O I-GENE
- O I-GENE
methyl)butanoyloxy-4 O I-GENE
beta O E-GENE
, O O
6 O O
beta O B-GENE
- O I-GENE
dihydroxy O I-GENE
- O I-GENE
beta O E-GENE
- O O
dihydroagarofuran O O
( O O
1 O O
) O O
, O O
1 O O
alpha,2 O O
alpha O B-GENE
- O I-GENE
diacetoxy-8 O I-GENE
beta-(beta- O I-GENE
furancarbonyloxy)-9 O I-GENE
alpha O I-GENE
- O I-GENE
benzoyloxy-13-isobutanoyloxy-4 O I-GENE
beta O E-GENE
, O O
6 O O
beta O O
- O O
dihydroxy O O
- O O
beta O O
- O O
dihydroagarofuran O O
( O O
2 O O
) O O
and O O
1 O O
alpha O O
, O O
6 O O
beta O O
, O O
8 O O
alpha,13-tetraacetoxy-9 O O
alpha O O
- O O
benzoyloxy-2 O O
alpha O O
- O O
hydroxy O O
- O O
beta O O
- O O
dihydroagarofuran O O
( O O
3 O O
) O O
mainly O O
by O O
analyses O O
NMR O O
and O O
MS O O
spectral O O
data O O
. O O

Both O O
toxins O O
in O O
a O O
dose O O
10-fold O O
surpassing O O
the O O
maximum O O
permissible O O
concentration O O
increased O O
activity O O
of O O
glutathione B-GENE B-GENE
peroxidase E-GENE E-GENE
in O O
brain O O
tissue O O
; O O
moreover O O
, O O
toluene O O
increased O O
chemiluminescence O O
intensity O O
, O O
which O O
attested O O
to O O
activation O O
of O O
free O O
radical O O
processes O O
. O O
Saunders O O
Company O O
. O O

The O O
performance O O
of O O
pH O O
- O O
sensitive O O
particles O O
is O O
attributed O O
to O O
their O O
ability O O
to O O
release O O
the O O
drug O O
selectively O O
in O O
the O O
upper O O
part O O
of O O
the O O
intestine O O
in O O
a O O
molecular O O
or O O
amorphous O O
form O O
. O O

Comparison O O
of O O
remnant O O
- O O
like O O
lipoprotein O O
particles O O
in O O
postmenopausal O O
women O O
with O O
and O O
without O O
coronary O O
artery O O
disease O O
and O O
in O O
men O O
with O O
coronary O O
artery O O
disease O O
. O O

Because O O
results O O
of O O
recent O O
randomized O O
trials O O
indicate O O
minimal O O
efficacy O O
of O O
continuing O O
MAC O O
prophylaxis O O
in O O
patients O O
who O O
respond O O
to O O
potent O O
combination O O
antiretroviral O O
therapy O O
, O O
the O O
observed O O
high O O
incidence O O
of O O
macrolide O O
- O O
resistant O O
bacterial O O
colonization O O
of O O
the O O
respiratory O O
tract O O
in O O
this O O
trial O O
supports O O
the O O
discontinuation O O
of O O
macrolide O O
prophylaxis O O
in O O
all O O
AIDS O O
patients O O
whose O O
CD4 S-GENE O
counts O O
have O O
risen O O
above O O
100 O O
cells O O
/ O O
microL. O O
Acute O O
stress O O
in O O
7 O O
rats O O
also O O
increased O O
the O O
mean O O
amount O O
of O O
IL-6 S-GENE O
released O O
in O O
the O O
urine O O
by O O
31.5% O O
from O O
775.9 O O
+ O O
/- O O
69.2 O O
to O O
1,021.1 O O
+ O O
/- O O
93.3 O O
pg./ml O O
. O O
Patients O O
with O O
CF O O
and O O
meconium O O
ileus O O
presented O O
a O O
poor O O
nutritional O O
status O O
at O O
diagnosis O O
and O O
a O O
lower O O
survival O O
rate O O
compared O O
to O O
the O O
general O O
CF O O
population O O
. O O

( O O
Cactaceae O O
) O O
waste O O
matter O O
. O O

Skin O O
cancers O O
, O O
followed O O
by O O
gastrointestinal O O
tract O O
and O O
male O O
genital O O
system O O
affected O O
mostly O O
older O O
age O O
patients O O
. O O

CONCLUSION O O
: O O
MMF O O
( O O
2 O O
- O O
3 O O
g O O
/ O O
day O O
) O O
is O O
unable O O
to O O
control O O
the O O
signs O O
of O O
mucocutaneous O O
Adamantiades O O
- O O
Behcet O O
's O O
disease O O
. O O

In O O
the O O
treatment O O
of O O
opioid O O
naive O O
patients O O
who O O
underwent O O
surgery O O
and O O
received O O
opioids O O
for O O
acute O O
pain O O
, O O
oral O O
ADL O O
8 O O
- O O
2698 O O
( O O
6.0 O O
mg O O
) O O
improved O O
the O O
management O O
of O O
postoperative O O
ileus O O
( O O
POI O O
) O O
by O O
shortening O O
the O O
time O O
to O O
achieve O O
normal O O
bowel O O
function O O
and O O
, O O
ultimately O O
, O O
hospital O O
stay O O
. O O

METHODS O O
: O O
302 O O
consecutive O O
patients O O
with O O
BS O O
and O O
438 O O
patients O O
with O O
other O O
rheumatological O O
conditions O O
were O O
surveyed O O
for O O
the O O
presence O O
or O O
absence O O
of O O
the O O
features O O
of O O
BS O O
by O O
means O O
of O O
a O O
standard O O
form O O
which O O
had O O
been O O
prepared O O
according O O
to O O
ISG O O
criteria O O
. O O

Evidence O O
suggests O O
that O O
PHACES O S-GENE
syndrome O O
is O O
not O O
a O O
random O O
association O O
but O O
a O O
true O O
phakomatosis O O
; O O
further O O
studies O O
are O O
awaited O O
to O O
shed O O
light O O
on O O
a O O
possible O O
genetic O O
background O O
. O O

A O O
computer O O
program O O
, O O
ACCESS O O
- O O
IAQ O O
, O O
is O O
developed O O
to O O
simulate O O
the O O
airflow O O
pattern O O
, O O
the O O
time O O
history O O
of O O
the O O
contaminant O O
concentrations O O
in O O
the O O
occupied O O
zone O O
, O O
and O O
the O O
inhalation O O
exposures O O
. O O

Moreover O O
, O O
a O O
severe O O
decrease O O
of O O
antithrombin S-GENE S-GENE
activity O O
became O O
evident O O
during O O
both O O
experiments O O
( O O
eg O O
, O O
in O O
experiment O O
2 O O
from O O
95.6 O O
+ O O
/- O O
4.8 O O
to O O
59.2 O O
+ O O
/- O O
6.6% O O
) O O
. O O
The O O
Penn O O
State O O
Worry O O
Questionnaire O O
for O O
Children O O
( O O
PSWQ O O
- O O
C O O
) O O
is O O
a O O
14-item O O
self O O
- O O
report O O
questionnaire O O
that O O
intends O O
to O O
measure O O
the O O
tendency O O
of O O
children O O
to O O
engage O O
in O O
excessive O O
, O O
generalized O O
, O O
and O O
uncontrollable O O
worry O O
( O O
Chorpita O O
et O O
al O O
. O O
, O O
Behav O O
. O O

Classification O O
according O O
to O O
the O O
ILAR O O
criteria O O
was O O
possible O O
in O O
321 O O
patients O O
; O O
290 O O
patients O O
had O O
a O O
disease O O
duration O O
> O O
or O O
= O O
3 O O
months O O
and O O
were O O
classified O O
according O O
to O O
the O O
EULAR O O
criteria O O
. O O

Described O O
X O O
- O O
ray O O
projection O O
were O O
performed O O
in O O
70 O O
patients O O
. O O

We O O
conducted O O
a O O
clinical O O
and O O
pathologic O O
review O O
of O O
nine O O
patients O O
with O O
immature O O
ovarian O O
teratoma O O
. O O

Pyrethroid O O
insecticides O O
are O O
widely O O
used O O
in O O
agriculture O O
and O O
private O O
households O O
. O O

The O O
sorption O O
mechanisms O O
changed O O
from O O
adsorption O O
to O O
partition O O
in O O
the O O
process O O
of O O
repetitious O O
sorption O O
. O O

Although O O
the O O
spatial O O
and O O
temporal O O
variability O O
of O O
LDF O O
signals O O
evoked O O
by O O
cerebrocortical O O
microflow O O
is O O
in O O
the O O
same O O
range O O
as O O
with O O
other O O
methods O O
and O O
in O O
other O O
organs O O
, O O
LDF O O
cerebrocortical O O
mapping O O
is O O
restricted O O
by O O
the O O
large O O
temporal O O
and O O
spatial O O
heterogeneity O O
of O O
the O O
cerebrocortical O O
vasculature O O
. O O

The O O
5-year O O
overall O O
survival O O
( O O
OS O O
) O O
and O O
progression O O
- O O
free O O
survival O O
( O O
PFS O O
) O O
rates O O
were O O
58.9% O O
and O O
55.4% O O
for O O
arm O O
A O O
and O O
44.5% O O
and O O
41.3% O O
for O O
arm O O
B O O
( O O
P O O
= O O
.007 O O
and O O
P O O
= O O
.02 O O
) O O
, O O
respectively O O
. O O

METHODS O O
: O O
P B-GENE O
- I-GENE O
selectin E-GENE O
expression O O
of O O
nonstimulated O O
and O O
ADP O O
- O O
stimulated O O
platelets O O
was O O
flow O O
cytometrically O O
measured O O
before O O
the O O
clopidogrel O O
loading O O
dose O O
and O O
on O O
3 O O
consecutive O O
days O O
in O O
52 O O
patients O O
with O O
coronary O O
artery O O
disease O O
: O O
21 O O
patients O O
in O O
group O O
1 O O
received O O
300 O O
mg O O
of O O
clopidogrel O O
after O O
stent O O
implantation O O
and O O
11 O O
patients O O
in O O
group O O
2 O O
received O O
the O O
higher O O
450-mg O O
clopidogrel O O
loading O O
dose O O
followed O O
by O O
a O O
daily O O
dose O O
of O O
75 O O
mg O O
of O O
clopidogrel O O
for O O
both O O
groups O O
. O O
Traditional O O
surgical O O
exploration O O
was O O
followed O O
by O O
survey O O
with O O
a O O
gamma O O
- O O
detecting O O
probe O O
. O O

No O O
effect O O
of O O
the O O
intervention O O
on O O
depression O O
scores O O
was O O
found O O
. O O

IV O O
. O O
combined O O
sclerosis O O
and O O
resorption O O
of O O
the O O
skull O O
base O O
( O O
6 O O
cases O O
, O O
2 O O
group O O
I O O
lesions O O
and O O
4 O O
group O O
II O O
lesions O O
) O O
. O O

The O O
quantity O O
of O O
each O O
population O O
( O O
L. O O
bulgaricus O O
, O O
S. O O
thermophilus O O
) O O
was O O
then O O
estimated O O
in O O
the O O
pellet O O
by O O
PyMS O O
, O O
and O O
the O O
data O O
were O O
analysed O O
by O O
artificial O O
neural O O
networks O O
( O O
ANNs O O
) O O
. O O

AF S-GENE O
showed O O
a O O
mixed O O
nuclear O O
/ O O
cytoplasmic O O
pattern O O
of O O
expression O O
in O O
the O O
epithelial O O
, O O
endothelial O O
, O O
and O O
stromal O O
component O O
of O O
the O O
normal O O
breast O O
and O O
benign O O
lesions O O
, O O
whereas O O
an O O
impressive O O
loss O O
of O O
AF O O
expression O O
was O O
noted O O
in O O
in O O
situ O O
and O O
invasive O O
breast O O
cancer O O
and O O
tumoral O O
stroma O O
. O O
We O O
derive O O
joint O O
probability O O
density O O
distributions O O
for O O
three O O
key O O
uncertain O O
properties O O
of O O
the O O
climate O O
system O O
, O O
using O O
an O O
optimal O O
fingerprinting O O
approach O O
to O O
compare O O
simulations O O
of O O
an O O
intermediate O O
complexity O O
climate O O
model O O
with O O
three O O
distinct O O
diagnostics O O
of O O
recent O O
climate O O
observations O O
. O O

Frequency O O
of O O
seeing O O
curves O O
were O O
examined O O
for O O
the O O
method O O
most O O
similar O O
to O O
FDT O O
. O O

Chronic O O
graft O O
- O O
versus O O
- O O
host O O
disease O O
( O O
cGVHD O O
) O O
is O O
a O O
major O O
complication O O
of O O
allogeneic O O
hematopoietic O O
cell O O
transplantation O O
. O O

Compared O O
to O O
white O O
- O O
on O O
- O O
white O O
( O O
W O O
- O O
W O O
) O O
perimetry O O
, O O
SWAP O O
is O O
limited O O
clinically O O
by O O
: O O
greater O O
variability O O
associated O O
with O O
the O O
estimation O O
of O O
threshold O O
, O O
ocular O O
media O O
absorption O O
, O O
increased O O
examination O O
duration O O
and O O
an O O
additional O O
learning O O
effect O O
. O O

Preservatives O O
are O O
an O O
important O O
component O O
of O O
ophthalmic O O
preparations O O
, O O
providing O O
antimicrobial O O
activity O O
in O O
the O O
bottle O O
and O O
preventing O O
decomposition O O
of O O
active O O
drug O O
. O O

Comparative O O
analysis O O
of O O
various O O
techniques O O
of O O
prostatic O O
drainage O O
in O O
patients O O
with O O
chronic O O
obstructive O O
prostatitis O O
] O O
The O O
efficacy O O
of O O
prostatic O O
drainage O O
using O O
transurethral O O
vacuum O O
aspiration O O
( O O
Introl-4 O O
unit O O
) O O
and O O
transrectal O O
pneumovibromassage O O
( O O
PVM O O
- O O
R-01 O O
) O O
was O O
compared O O
in O O
1511 O O
patients O O
with O O
chronic O O
obstructive O O
prostatitis O O
. O O

The O O
results O O
are O O
discussed O O
in O O
relation O O
to O O
acoustical O O
models O O
of O O
sound O O
propagation O O
and O O
physiology O O
, O O
and O O
it O O
is O O
suggested O O
that O O
height O O
- O O
dependent O O
degradation O O
within O O
a O O
forest O O
is O O
an O O
important O O
selection O O
pressure O O
for O O
transmissibility O O
in O O
avian O O
communication O O
. O O

Consumption O O
of O O
4% O O
sucrose O O
was O O
not O O
affected O O
by O O
excitotoxic O O
lesions O O
of O O
the O O
PPTg O O
, O O
but O O
PPTg O O
lesioned O O
rats O O
consumed O O
significantly O O
more O O
12% O O
and O O
20% O O
sucrose O O
than O O
sham O O
controls O O
. O O

Actuarial O O
freedom O O
from O O
ventricular O O
arrhythmias O O
at O O
4-year O O
follow O O
- O O
up O O
was O O
74.1 O O
+ O O
/- O O
6.0% O O
in O O
group O O
A O O
vs. O O

Mental O O
development O O
is O O
generally O O
normal O O
. O O

Influence O O
of O O
different O O
methods O O
of O O
chemical O O
disinfection O O
on O O
the O O
physical O O
properties O O
of O O
type O O
IV O O
and O O
V O O
gypsum O O
dies O O
] O O
Several O O
instruments O O
and O O
materials O O
frequently O O
used O O
in O O
prosthodontics O O
-- O O
such O O
as O O
stone O O
casts O O
, O O
dental O O
impressions O O
, O O
interocclusal O O
records O O
-- O O
are O O
classified O O
, O O
by O O
the O O
dental O O
literature O O
, O O
as O O
vehicles O O
of O O
transmission O O
of O O
infectious O O
diseases O O
to O O
those O O
who O O
handle O O
them O O
. O O

In O O
sterilized O O
milk O O
there O O
was O O
a O O
slight O O
decrease O O
of O O
linoleic O O
acid O O
( O O
C18:2n6 O O
; O O
-0.7% O O
vs. O O
fresh O O
; O O
P O O
= O O
0.006 O O
) O O
and O O
arachidonic O O
acid O O
( O O
C20:4n6 O O
; O O
-2.5% O O
; O O
P O O
= O O
0.045 O O
) O O
. O O

Vitrectomy O O
and O O
removal O O
of O O
retained O O
lens O O
fragments O O
restores O O
good O O
visual O O
acuity O O
and O O
reduces O O
secondary O O
glaucoma O O
in O O
the O O
majority O O
of O O
patients O O
. O O

CONCLUSIONS O O
: O O
The O O
mechanism O O
of O O
MIRI O O
is O O
Qi O O
deficiency O O
and O O
blood O O
stasis O O
in O O
TCM O O
, O O
its O O
treating O O
principles O O
should O O
be O O
promoting O O
Qi O O
and O O
removing O O
the O O
blood O O
stasis O O
. O O

Effects O O
of O O
activating O O
blood O O
circulation O O
to O O
remove O O
blood O O
stasis O O
on O O
barrier O O
action O O
of O O
gastric O O
wall O O
in O O
chronic O O
atrophic O O
gastritis O O

Proteomic O O
patterns O O
of O O
nipple O O
aspirate O O
fluids O O
obtained O O
by O O
SELDI O O
- O O
TOF O O
: O O
potential O O
for O O
new O O
biomarkers O O
to O O
aid O O
in O O
the O O
diagnosis O O
of O O
breast O O
cancer O O
. O O

According O O
to O O
the O O
laboratory O O
results O O
, O O
the O O
application O O
of O O
neural O O
network O O
can O O
solve O O
the O O
problem O O
successfully O O
. O O

A O O
high O O
- O O
efficiency O O
cross O O
- O O
flow O O
micronebulizer O O
interface O O
for O O
capillary O O
electrophoresis O O
and O O
inductively O O
coupled O O
plasma O O
mass O O
spectrometry O O
. O O

The O O
electrodes O O
themselves O O
do O O
not O O
need O O
to O O
be O O
polished O O
prior O O
to O O
their O O
use O O
but O O
are O O
observed O O
to O O
be O O
slightly O O
recessed O O
from O O
the O O
surrounding O O
insulating O O
surface O O
. O O

The O O
experimental O O
results O O
showed O O
that O O
the O O
coagulation O O
- O O
electrooxidation O O
process O O
could O O
efficiently O O
remove O O
the O O
color O O
and O O
the O O
COD O O
from O O
the O O
simulated O O
dye O O
wastewater O O
. O O

Cyclic O O
loading O O
of O O
bone O O
during O O
normal O O
daily O O
activity O O
leads O O
to O O
the O O
formation O O
of O O
microcracks O O
within O O
the O O
tissue O O
matrix O O
of O O
compact O O
bone O O
. O O

The O O
weight O O
- O O
bearing O O
surface O O
of O O
the O O
PE O O
head O O
became O O
smoother O O
with O O
time O O
after O O
THA O O
, O O
and O O
the O O
friction O O
coefficient O O
did O O
not O O
differ O O
significantly O O
from O O
that O O
of O O
an O O
unused O O
PE O O
head O O
. O O

OBJECTIVE O O
: O O
To O O
demonstrate O O
a O O
lack O O
of O O
effect O O
of O O
steady O O
- O O
state O O
concentrations O O
of O O
cilomilast O O
, O O
a O O
new O O
oral O O
phosphodiesterase B-GENE O
4 E-GENE O
inhibitor O O
for O O
the O O
treatment O O
of O O
chronic O O
obstructive O O
pulmonary O O
disease O O
, O O
on O O
warfarin O O
- O O
induced O O
anticoagulation O O
. O O
Postdocs O O
face O O
hardship O O
across O O
mainland O O
Europe O O
. O O

The O O
design O O
principle O O
based O O
on O O
a O O
uniform O O
vibration O O
mode O O
is O O
presented O O
. O O

Because O O
the O O
DPPD B-GENE B-GENE
gene E-GENE E-GENE
is O O
not O O
present O O
in O O
non O O
- O O
tuberculous O O
bacilli O O
, O O
these O O
results O O
suggest O O
that O O
this O O
molecule O O
can O O
be O O
an O O
additional O O
tool O O
for O O
a O O
more O O
specific O O
diagnosis O O
of O O
tuberculosis O O
. O O
Dynamic O O
imaging O O
of O O
nuclear O O
wave O O
functions O O
with O O
ultrashort O O
UV O O
laser O O
pulses O O
. O O

Efficacy O O
and O O
safety O O
of O O
aspirin O O
in O O
the O O
long O O
- O O
term O O
management O O
of O O
atherothrombosis O O
. O O

The O O
General O O
Practice O O
Research O O
Database O O
( O O
GPRD O O
) O O
is O O
the O O
world O O
's O O
largest O O
computerized O O
database O O
of O O
anonymized O O
longitudinal O O
patient O O
records O O
from O O
general O O
practice O O
and O O
is O O
a O O
unique O O
public O O
health O O
research O O
tool O O
. O O

This O O
paper O O
reports O O
the O O
results O O
of O O
a O O
laboratory O O
study O O
on O O
aldicarb O O
and O O
its O O
main O O
metabolites O O
, O O
aldicarb O O
sulfone O O
and O O
aldicarb O O
sulfoxide O O
. O O

Only O O
one O O
DC O O
cardioversion O O
was O O
required O O
in O O
the O O
HBS O O
group O O
, O O
whereas O O
2 O O
DC O O
in O O
the O O
CBC O O
group O O
and O O
total O O
7 O O
DC O O
in O O
the O O
GIK O O
group O O
. O O

Since O O
August O O
1994 O O
, O O
the O O
ENRP O O
has O O
retained O O
70.3 O O
metric O O
tons O O
of O O
TP O O
that O O
otherwise O O
would O O
have O O
entered O O
the O O
Everglades O O
. O O

It O O
was O O
found O O
that O O
the O O
disappearance O O
of O O
BOD5 O O
and O O
NH3-N O O
could O O
be O O
approximated O O
using O O
first O O
- O O
order O O
kinetics O O
, O O
but O O
the O O
kinetics O O
of O O
TP O O
removal O O
were O O
unclear O O
. O O

It O O
was O O
found O O
that O O
the O O
disappearance O O
of O O
BOD5 O O
and O O
NH3-N O O
could O O
be O O
approximated O O
using O O
first O O
- O O
order O O
kinetics O O
, O O
but O O
the O O
kinetics O O
of O O
TP O O
removal O O
were O O
unclear O O
. O O

Losses O O
of O O
dichlofluanid O O
( O O
54% O O
) O O
, O O
chlozolinate O O
( O O
22% O O
) O O
, O O
and O O
etridiazole O O
( O O
40% O O
) O O
, O O
previously O O
reported O O
to O O
occur O O
during O O
ambient O O
processing O O
of O O
apples O O
, O O
were O O
reduced O O
to O O
barely O O
significant O O
levels O O
( O O
10 O O
, O O
17 O O
, O O
and O O
14% O O
, O O
respectively O O
) O O
by O O
cryogenic O O
processing O O
. O O

The O O
TB O O
incidence O O
in O O
the O O
" O O
AIRIN O O
" O O
area O O
, O O
where O O
about O O
20% O O
TB O O
patients O O
are O O
homeless O O
, O O
shows O O
highest O O
rate O O
of O O
above O O
1,000/100,000 O O
. O O

It O O
is O O
shown O O
that O O
the O O
displacement O O
distribution O O
measured O O
by O O
q O O
- O O
space O O
MRI O O
in O O
both O O
the O O
large O O
displacement O O
( O O
i.e. O O
, O O
large O O
r O O
) O O
and O O
the O O
long O O
- O O
wavelength O O
( O O
i.e. O O
, O O
small O O
q O O
) O O
limits O O
is O O
the O O
same O O
3D O O
Gaussian O O
displacement O O
distribution O O
assumed O O
in O O
DT O O
- O O
MRI O O
. O O

The O O
procedure O O
facilitated O O
the O O
retention O O
of O O
a O O
mandibular O O
molar O O
with O O
a O O
Class O O
III O O
FI O O
in O O
a O O
manner O O
acceptable O O
to O O
both O O
the O O
patient O O
and O O
the O O
clinician O O
. O O

The O O
results O O
of O O
our O O
ten O O
- O O
fold O O
cross O O
- O O
validation O O
experiments O O
show O O
that O O
, O O
on O O
the O O
average O O
, O O
the O O
system O O
increases O O
the O O
specificity O O
from O O
0.19 O O
( O O
0.35 O O
) O O
to O O
0.69 O O
( O O
0.74 O O
) O O
at O O
a O O
sensitivity O O
level O O
of O O
1.0 O O
( O O
0.95 O O
) O O
. O O

The O O
physical O O
characteristics O O
of O O
these O O
calls O O
vary O O
among O O
species O O
of O O
bat O O
, O O
and O O
variations O O
also O O
exist O O
in O O
the O O
timing O O
and O O
patterns O O
of O O
respiratory O O
muscle O O
recruitment O O
during O O
echolocation O O
. O O

Clicking O O
on O O
" O O
Examples O O
and O O
Explanations O O
of O O
APA O O
Form O O
" O O
provides O O
a O O
help O O
system O O
with O O
examples O O
of O O
the O O
various O O
sections O O
of O O
a O O
review O O
article O O
, O O
journal O O
article O O
that O O
has O O
one O O
experiment O O
, O O
or O O
journal O O
article O O
that O O
has O O
two O O
or O O
more O O
experiments O O
. O O

The O O
drug O O
packets O O
contained O O
acetyl O O
aspirin O O
, O O
acetaminophen O O
and O O
chloramphenicol O O
. O O

Karger O O
AG O O
, O O
Basel O O

AIM O O
: O O
To O O
understand O O
the O O
role O O
of O O
nutritional O O
status O O
in O O
cirrhotic O O
patients O O
without O O
clinical O O
porto O O
- O O
systemic O O
encephalopathy O O
( O O
PSE).METHODS O O
: O O
Fifty O O
- O O
one O O
non O O
- O O
alcoholic O O
patients O O
with O O
cirrhosis O O
without O O
PSE O O
were O O
studied O O
prospectively O O
and O O
compared O O
with O O
20 O O
healthy O O
volunteers O O
. O O

MAIN O O
OUTCOME O O
MEASURE(S O S-GENE
) O O
: O O
Serum O O
levels O O
of O O
FSH S-GENE S-GENE
, O O
LH S-GENE S-GENE
, O O
and O O
inhibin O S-GENE
A O O
and O O
B. O O
For O O
instance O O
, O O
a O O
total O O
SIP O O
score O O
of O O
an O O
individual O O
patient O O
of O O
28.3% O O
( O O
which O O
is O O
taken O O
as O O
an O O
example O O
, O O
being O O
the O O
mean O O
score O O
in O O
the O O
study O O
population O O
) O O
should O O
decrease O O
by O O
at O O
least O O
9.26% O O
or O O
approximately O O
13 O O
items O O
, O O
before O O
any O O
improvement O O
beyond O O
reproducibility O O
noise O O
can O O
be O O
detected O O
. O O

Group O O
I O O
comprised O O
5 O O
adult O O
Collies O O
that O O
received O O
at O O
least O O
400 O O
microg O O
/ O O
kg O O
ivermectin O O
p.o O O
. O O
and O O
were O O
presented O O
to O O
the O O
VMTH O O
3 O O
hours O O
after O O
intoxication O O
. O O

Patients O O
with O O
a O O
secondary O O
cardiac O O
event O O
had O O
more O O
common O O
Type O O
A O O
behavior O O
patterns O O
and O O
higher O O
Bortner O O
scores O O
than O O
patients O O
without O O
a O O
secondary O O
cardiac O O
event O O
. O O

Interestingly O O
, O O
continuation O O
of O O
the O O
interferon S-GENE S-GENE
therapy O O
in O O
the O O
presence O O
of O O
a O O
mild O O
- O O
to O O
- O O
moderate O O
exacerbation O O
of O O
sarcoidosis O O
may O O
be O O
safe O O
in O O
a O O
minority O O
of O O
patients O O
with O O
noncritical O O
organ O O
involvement O O
. O O
No O O
increased O O
tumor O O
- O O
related O O
mortality O O
was O O
observed O O
after O O
a O O
mean O O
follow O O
- O O
up O O
of O O
44 O O
months O O
. O O

Dissociable O O
effects O O
of O O
lidocaine O O
inactivation O O
of O O
the O O
rostral O O
and O O
caudal O O
basolateral O O
amygdala O O
on O O
the O O
maintenance O O
and O O
reinstatement O O
of O O
cocaine O O
- O O
seeking O O
behavior O O
in O O
rats O O
. O O

The O O
population O O
studied O O
comprised O O
4472 O O
men O O
and O O
5212 O O
women O O
aged O O
30 O O
- O O
74 O O
years O O
, O O
without O O
coronary O O
heart O O
disease O O
, O O
who O O
had O O
CRP S-GENE O
measurements O O
in O O
the O O
Third O O
National O O
Health O O
and O O
Nutrition O O
Examination O O
Survey O O
( O O
NHANES O B-GENE
III O E-GENE
) O O
. O O
Herceptin O O
, O O
which O O
recognizes O O
the O O
HER-2/neu O B-GENE
antigen O E-GENE
and O O
has O O
similar O O
size O O
( O O
10 O O
nm O O
) O O
to O O
G6-(1B4M O O
- O O
Gd)(256 O O
) O O
, O O
accumulated O O
and O O
internalized O O
in O O
the O O
WIBC-9 O O
tumors O O
more O O
quickly O O
than O O
in O O
the O O
control O O
MC-5 O O
tumors O O
that O O
progress O O
with O O
normal O O
angiogenesis O O
. O O
Forty O O
- O O
eight O O
pigs O O
were O O
removed O O
from O O
sows O O
at O O
1 O O
d O O
of O O
age O O
and O O
randomly O O
assigned O O
to O O
one O O
of O O
three O O
treatments O O
: O O
1 O O
) O O
control O O
with O O
lactose O O
as O O
the O O
carbohydrate O O
source O O
, O O
2 O O
) O O
lactose O O
replaced O O
( O O
gram O O
for O O
gram O O
) O O
with O O
CSS O O
( O O
dextrose O O
equivalent O O
[ O O
DE]-20 O O
) O O
, O O
and O O
3 O O
) O O
lactose O O
replaced O O
with O O
DE-42 O O
. O O

CONCLUSIONS O O
: O O
AMVT O O
is O O
rare O O
but O O
a O O
potentially O O
lethal O O
emergency O O
disease O O
. O O

There O O
was O O
no O O
difference O O
in O O
apnea O O
duration O O
between O O
the O O
supine O O
and O O
prone O O
positions O O
. O O

Therefore O O
, O O
in O O
a O O
large O O
animal O O
model O O
of O O
permanent O O
focal O O
ischemia O O
in O O
which O O
transfusion O O
starts O O
30 O O
min O O
after O O
ischemia O O
, O O
tetrameric O O
cross O O
- O O
linked O O
hemoglobin S-GENE S-GENE
transfusion O O
can O O
augment O O
oxygen O O
transport O O
to O O
the O O
ischemic O O
cortex O O
, O O
but O O
the O O
increase O O
can O O
be O O
delayed O O
and O O
not O O
necessarily O O
provide O O
protection O O
. O O
Since O O
the O O
early O O
1980s O O
there O O
has O O
been O O
increasing O O
awareness O O
of O O
the O O
importance O O
of O O
quantifying O O
health O O
- O O
related O O
quality O O
of O O
life O O
( O O
HRQL O O
) O O
in O O
patients O O
with O O
chronic O O
respiratory O O
disorders O O
included O O
in O O
clinical O O
trials O O
. O O

They O O
were O O
randomly O O
allocated O O
to O O
receive O O
either O O
625 O O
mg O O
of O O
calcium O O
carbonate O O
( O O
250 O O
mg O O
of O O
elemental O O
calcium O O
) O O
at O O
the O O
end O O
of O O
a O O
meal O O
three O O
times O O
a O O
day O O
( O O
group O O
A O O
, O O
n=26 O O
) O O
or O O
calcium O O
carbonate O O
in O O
the O O
same O O
manner O O
plus O O
0.625 O O
mg O O
/ O O
day O O
of O O
conjugated O O
equine O O
estrogen O O
and O O
5 O O
mg O O
medrogestone O O
acetate O O
from O O
day O O
1 O O
- O O
12 O O
each O O
month O O
( O O
group O O
B O O
, O O
n=30 O O
) O O
. O O

TNFalpha S-GENE O
and O O
IL-6 S-GENE S-GENE
levels O O
were O O
determined O O
in O O
the O O
culture O O
supernatants O O
. O O
Therefore O O
, O O
this O O
study O O
has O O
demonstrated O O
that O O
prenatal O O
disturbance O O
can O O
induce O O
a O O
lasting O O
change O O
in O O
cytokine O O
biology O O
, O O
which O O
persists O O
well O O
beyond O O
the O O
fetal O O
and O O
infant O O
stage O O
. O O

The O O
two O O
- O O
wave O O
, O O
1995 O O
- O O
1996 O O
National O O
Longitudinal O O
Study O O
of O O
Adolescent O O
Health O O
uses O O
a O O
measure O O
of O O
depressive O O
symptomatology O O
across O O
a O O
12-month O O
interval O O
. O O

METHODS O O
: O O
9 O O
cases O O
of O O
conventional O O
intermittent O O
tissue O O
expansion O O
( O O
CITE O O
) O O
and O O
9 O O
cases O O
of O O
continuous O O
pressure O O
- O O
controlled O O
tissue O O
expansion O O
( O O
CPTE O O
) O O
were O O
chosen O O
for O O
the O O
study O O
. O O

Wegener O O
's O O
granulomatosis O O

There O O
was O O
a O O
significant O O
effect O O
of O O
hematocrit O O
on O O
the O O
General O O
Health O O
scale O O
on O O
the O O
SF-36 O O
( O O
P O O
= O O
0.03 O O
) O O
. O O

Based O O
on O O
analytic O O
precisions O O
, O O
a O O
+ O O
/- O O
2% O O
urine O O
- O O
plasma O O
difference O O
was O O
set O O
as O O
the O O
cut O O
- O O
off O O
value O O
. O O

Schistosoma O O
mansoni O O
schistosomiasis O O
] O O
Schistosomosis O O
are O O
parasitic O O
diseases O O
caused O O
by O O
blood O O
flukes O O
of O O
the O O
Schistosoma O O
genus O O
. O O

A O O
global O O
response O O
rate O O
was O O
17% O O
( O O
95% O O
confidence O O
interval O O
( O O
95% O O
CI O O
) O O
: O O
2%-32% O O
) O O
and O O
the O O
median O O
overall O O
survival O O
was O O
12 O O
months O O
. O O

We O O
also O O
studied O O
a O O
new O O
parameter O O
: O O
the O O
angle O O
to O O
maximal O O
peak O O
torque O O
( O O
APT O O
) O O
. O O

For O O
the O O
2.5 O O
to O O
4 O O
ng O O
/ O O
mL O O
model O O
, O O
the O O
AUC O O
of O O
the O O
ANN O O
ROC O O
curve O O
was O O
significantly O O
higher O O
than O O
the O O
AUCs O O
for O O
percentage O O
of O O
free O O
PSA S-GENE O
( O O
P O O
= O O
.0239 O O
) O O
, O O
PSA O O
- O O
TZ O O
( O O
P O O
= O O
.0204 O O
) O O
, O O
and O O
PSA O O
density O O
and O O
total O O
prostate O O
volume O O
( O O
P O O
< O O
.01 O O
for O O
both O O
) O O
. O O
Potential O O
treatments O O
include O O
dobutamine O O
, O O
KATP O O
channel O O
activators O O
, O O
and O O
21-aminosteroids O O
. O O

Selenium O O
is O O
an O O
essential O O
element O O
for O O
humans O O
, O O
animals O O
and O O
some O O
species O O
of O O
microorganisms O O
. O O

The O O
GT O O
- O O
foreign O O
- O O
pictures O O
showed O O
that O O
the O O
judgment O O
of O O
other O O
subjects O O
changed O O
toward O O
hedonic O O
and O O
permeability O O
directions O O
. O O

Emphysematous O O
cholecystitis O O
: O O
sonographic O O
findings O O
. O O

Age O O
was O O
categorized O O
into O O
four O O
groups O O
: O O
20 O O
- O O
44 O O
, O O
45 O O
- O O
64 O O
, O O
65 O O
- O O
74 O O
, O O
and O O
75+.RESULTS O O
: O O
At O O
the O O
initiation O O
of O O
dialysis O O
PD O O
patients O O
were O O
approximately O O
6 O O
years O O
younger O O
( O O
P O O
< O O
0.0001 O O
) O O
than O O
HD O O
patients O O
. O O

RESULTS O O
: O O
The O O
target O O
dose O O
was O O
comparable O O
in O O
the O O
3D O O
- O O
CRT O O
and O O
IMRT O O
plans O O
, O O
although O O
improvements O O
were O O
seen O O
when O O
seven O O
and O O
nine O O
IMRT O O
fields O O
were O O
used O O
. O O

We O O
therefore O O
applied O O
a O O
radiolabelled O O
serumalbumin S-GENE O
method O O
to O O
determine O O
blood O O
volume O O
after O O
haemodilution O O
with O O
crosslinked O O
or O O
conjugated O O
haemoglobin S-GENE O
, O O
in O O
comparison O O
with O O
a O O
reference O O
solution O O
of O O
hydroxyethyl O O
starch O O
( O O
HES O O
) O O
. O O
The O O
equilibrium O O
phosphorus O O
content O O
( O O
EPC0 O O
) O O
of O O
surface O O
soil O O
was O O
generally O O
higher O O
than O O
the O O
SRP O O
content O O
of O O
drainage O O
water O O
, O O
at O O
one O O
farm O O
by O O
1 O O
order O O
of O O
magnitude O O
. O O

The O O
long O O
- O O
term O O
prediction O O
is O O
based O O
on O O
an O O
algorithm O O
for O O
R O O
- O O
R O O
interval O O
estimation O O
. O O

Despite O O
considerable O O
research O O
, O O
an O O
explanation O O
of O O
this O O
effect O O
has O O
been O O
elusive O O
. O O

The O O
structure O O
has O O
been O O
established O O
by O O
a O O
study O O
of O O
its O O
mono- O O
and O O
bidimensional O O
NMR O O
spectra O O
and O O
mass O O
spectrometry O O
. O O

We O O
argue O O
that O O
this O O
is O O
the O O
general O O
property O O
of O O
QSAR O O
models O O
developed O O
using O O
LOO O O
cross O O
- O O
validation O O
. O O

We O O
compared O O
the O O
efficacy O O
and O O
costs O O
of O O
valacyclovir O O
in O O
preventing O O
HSV O O
reactivation O O
among O O
HSV O O
seropositive O O
autologous O O
progenitor O O
cell O O
transplantation O O
( O O
APCT O O
) O O
patients O O
with O O
historical O O
controls O O
in O O
whom O O
intravenous O O
acyclovir O O
or O O
no O O
HSV O O
prophylaxis O O
were O O
used O O
. O O

All O O
adults O O
attending O O
the O O
outpatient O O
clinics O O
of O O
a O O
dermatological O O
hospital O O
on O O
predetermined O O
days O O
were O O
given O O
the O O
12-item O O
General O O
Health O O
Questionnaire O O
. O O

Data O O
on O O
prosthesis O O
use O O
are O O
encouraging O O
, O O
although O O
a O O
follow O O
- O O
up O O
study O O
is O O
required O O
to O O
determine O O
the O O
functional O O
outcome O O
for O O
prosthesis O O
users O O
and O O
non O O
- O O
users O O
. O O

A O O
mail O O
survey O O
of O O
Georgia O O
members O O
of O O
the O O
American O O
College O O
of O O
Obstetricians O O
and O O
Gynecologists O O
was O O
conducted O O
. O O

HIV-1 O O
C O O
subtype O O
in O O
IDUs O O
accounted O O
for O O
61.3% O O
. O O

When O O
a O O
plateau O O
of O O
enhancement O O
was O O
reached O O
, O O
a O O
single O O
lesion O O
in O O
each O O
patient O O
was O O
imaged O O
using O O
five O O
different O O
continuous O O
scanning O O
modes O O
, O O
fundamental O O
grey O O
scale O O
( O O
FGS O O
) O O
; O O
fundamental O O
colour O O
Doppler O O
( O O
FCD O O
) O O
; O O
fundamental O O
power O O
Doppler O O
( O O
FPD O O
) O O
; O O
second O O
harmonic O O
grey O O
scale O O
( O O
HGS O O
) O O
; O O
and O O
pulse O O
inversion O O
mode O O
( O O
Pim O O
) O O
using O O
an O O
HDI5000 O O
scanner O O
and O O
C5 O O
- O O
2 O O
probe O O
( O O
ATL O O
, O O
Bothell O O
, O O
WA O O
) O O
. O O

A O O
comparative O O
study O O
of O O
the O O
effects O O
of O O
carbamazepine O O
and O O
the O O
NMDA B-GENE B-GENE
receptor E-GENE E-GENE
antagonist O O
remacemide O O
on O O
road O O
tracking O O
and O O
car O O
- O O
following O O
performance O O
in O O
actual O O
traffic O O
. O O
We O O
find O O
that O O
the O O
measured O O
Nusselt O O
number O O
decreased O O
about O O
20% O O
over O O
the O O
range O O
of O O
Pr O O
spanned O O
in O O
the O O
experiment O O
. O O

Viral O O
and O O
atypical O O
pathogens O O
as O O
causes O O
of O O
type O O
1 O O
acute O O
exacerbations O O
of O O
chronic O O
bronchitis O O
. O O

Treatment O O
for O O
this O O
condition O O
often O O
involves O O
use O O
of O O
a O O
wax O O
softening O O
or O O
dispersing O O
agent O O
( O O
cerumenolytic O O
) O O
before O O
syringing O O
. O O

In O O
addition O O
, O O
benzocaine O O
and O O
2-phenoxyethanol O O
depressed O O
complement O O
activity O O
and O O
phagocytosis O O
, O O
while O O
MS222 O O
and O O
quinaldine O O
sulphate O O
did O O
not O O
. O O

The O O
EC(50 O O
) O O
for O O
suppression O O
of O O
long O O
- O O
term O O
memory O O
( O O
the O O
concentration O O
decreasing O O
memory O O
by O O
50% O O
) O O
of O O
fear O O
conditioning O O
to O O
context O O
was O O
2.00% O O
plus O O
/ O O
minus O O
0.01% O O
( O O
mean O O
plus O O
/ O O
minus O O
SEM O O
) O O
, O O
and O O
for O O
fear O O
conditioning O O
to O O
tone O O
was O O
3.45% O O
plus O O
/ O O
minus O O
0.26% O O
, O O
( O O
P O O
< O O
0.05 O O
) O O
. O O

The O O
utility O O
of O O
such O O
analyses O O
in O O
the O O
design O O
of O O
ceramic O O
/ O O
substrate O O
bilayer O O
systems O O
for O O
optimal O O
resistance O O
to O O
lifetime O O
- O O
threatening O O
damage O O
is O O
discussed O O
. O O

It O O
has O O
been O O
proposed O O
that O O
insulin S-GENE S-GENE
resistance O O
( O O
IR O S-GENE
) O O
underlies O O
a O O
cluster O O
of O O
cardiovascular O O
disease O O
( O O
CVD O O
) O O
risk O O
factors O O
constituting O O
a O O
" O O
metabolic O O
syndrome O O
. O O
" O O
CVD O O
is O O
a O O
leading O O
cause O O
of O O
premature O O
mortality O O
among O O
indigenous O O
Australians O O
. O O
Dementia O O
is O O
being O O
avoided O O
in O O
NHS O O
and O O
social O O
care O O
. O O

HIV-1 O O
infection O O
in O O
rural O O
Africa O O
: O O
is O O
there O O
a O O
difference O O
in O O
median O O
time O O
to O O
AIDS O O
and O O
survival O O
compared O O
with O O
that O O
in O O
industrialized O O
countries O O
? O O
OBJECTIVES O O
: O O
To O O
describe O O
the O O
progression O O
times O O
of O O
HIV-1 O O
infection O O
from O O
seroconversion O O
to O O
AIDS O O
and O O
to O O
death O O
, O O
and O O
time O O
from O O
first O O
developing O O
AIDS O O
to O O
death O O
in O O
rural O O
Uganda O O
. O O

The O O
use O O
of O O
highly O O
active O O
antiretroviral O O
therapy O O
( O O
HAART O O
) O O
has O O
resulted O O
in O O
significant O O
improvements O O
in O O
the O O
treatment O O
of O O
HIV O O
infection O O
, O O
including O O
a O O
decrease O O
in O O
the O O
incidence O O
and O O
severity O O
of O O
several O O
acquired O O
immune O O
deficiency O O
syndrome O O
( O O
AIDS)-related O O
malignancies O O
. O O

Time O O
to O O
progression O O
was O O
6 O O
months O O
( O O
5 O O
- O O
7 O O
months O O
) O O
with O O
a O O
median O O
survival O O
from O O
registration O O
of O O
9.6 O O
months O O
( O O
95% O O
CI O O
8 O O
- O O
12 O O
months O O
) O O
. O O

Heparin O O
( O O
100 O O
U O O
. O O
kg(-1 O O
) O O
. O O
day(-1 O O
) O O
) O O
was O O
injected O O
subcutaneously O O
to O O
the O O
rats O O
in O O
H O O
group O O
while O O
normal O O
saline O O
to O O
those O O
in O O
N O O
group O O
once O O
a O O
day O O
. O O

MAIN O O
OUTCOME O O
MEASURE O O
: O O
A O O
positive O O
test O O
result O O
for O O
gonococcal O O
or O O
chlamydial O O
infection O O
by O O
the O O
ligase S-GENE O
chain O O
reaction O O
assay O O
; O O
secondary O O
outcome O O
measure O O
was O O
a O O
positive O O
test O O
result O O
for O O
human O O
immunodeficiency O O
virus O O
( O O
HIV O O
) O O
. O O
The O O
purpose O O
of O O
this O O
study O O
was O O
to O O
develop O O
a O O
reliable O O
and O O
culturally O O
meaningful O O
exercise O O
self O O
- O O
efficacy O O
questionnaire O O
for O O
older O O
Mexican O O
American O O
women O O
. O O

Neutrophil O O
: O O
lymphocyte O O
ratio O O
, O O
plasma O B-GENE
haptoglobin S-GENE E-GENE
, O O
and O O
CBG S-GENE S-GENE
levels O O
were O O
greater O O
( O O
P O O
< O O
0.01 O O
) O O
during O O
the O O
INITIAL O O
period O O
than O O
during O O
the O O
PRE O O
or O O
POST O O
periods O O
but O O
did O O
not O O
differ O O
between O O
treatments O O
. O O
Adjacent O O
to O O
those O O
lesions O O
, O O
and O O
in O O
homologous O O
contralateral O O
structures O O
, O O
FMZ O O
binding O O
was O O
analysed O O
in O O
four O O
pairs O O
of O O
cortical O O
9 O O
x O O
9-mm O O
regions O O
of O O
interest O O
( O O
ROIs O O
) O O
placed O O
on O O
transaxial O O
and O O
coronal O O
slices O O
, O O
respectively O O
, O O
as O O
well O O
as O O
in O O
the O O
lesion O O
volume O O
and O O
its O O
mirror O O
region O O
. O O

Because O O
a O O
close O O
correlation O O
between O O
regional O O
decreases O O
in O O
FMZ O O
binding O O
and O O
spiking O O
activity O O
was O O
recently O O
demonstrated O O
in O O
neocortical O O
epilepsies O O
, O O
abnormal O O
peri O O
- O O
lesional O O
FMZ O O
binding O O
may O O
bear O O
some O O
relation O O
to O O
the O O
mechanisms O O
of O O
epileptogenesis O O
in O O
symptomatic O O
epilepsies O O
. O O

CD O O
was O O
determined O O
using O O
the O O
Farnsworth O O
D-15 O O
method O O
. O O

Here O O
is O O
presented O O
the O O
monitoring O O
of O O
the O O
accidental O O
spill O O
on O O
vertical O O
distribution O O
of O O
heavy O O
metals O O
in O O
the O O
estuarine O O
sediments O O
. O O

The O O
large O O
fluxes O O
of O O
239 O O
+ O O
240Pu O O
might O O
be O O
attributed O O
to O O
episodic O O
lateral O O
transport O O
of O O
particles O O
that O O
flow O O
down O O
the O O
continental O O
slope O O
with O O
the O O
nepheloid O O
layer O O
which O O
was O O
considered O O
to O O
be O O
significant O O
for O O
239 O O
+ O O
240Pu O O
transport O O
on O O
the O O
continental O O
slope O O
in O O
the O O
East O O
China O O
Sea O O
. O O

Rigorous O O
treatment O O
protocols O O
for O O
diet O O
delivery O O
and O O
EEN O O
- O O
related O O
GI O O
adverse O O
effects O O
were O O
applied O O
. O O

We O O
found O O
three O O
out O O
of O O
four O O
original O O
( O O
Volkan O O
's O O
) O O
groups O O
of O O
linking O O
objects O O
, O O
but O O
also O O
an O O
additional O O
one O O
, O O
hitherto O O
undescribed O O
, O O
comprising O O
objects O O
used O O
for O O
designing O O
a O O
memorial O O
shrine O O
to O O
the O O
deceased O O
. O O

The O O
range O O
of O O
200 O O
000 O O
- O O
300 O O
000 O O
spermatozoa O O
/ O O
microl O O
appeared O O
to O O
be O O
a O O
reasonable O O
compromise O O
for O O
both O O
criteria O O
. O O

Gastritis O O
score O O
was O O
significantly O O
lower O O
in O O
nod-/CagA- O O
children O O
than O O
in O O
nod+/CagA- O O
( O O
p O O
= O O
.004 O O
) O O
, O O
nod-/CagA+ O O
( O O
p O O
= O O
.002 O O
) O O
and O O
nod+/CagA+ O O
( O O
p O O
< O O
.001 O O
) O O
, O O
both O O
in O O
the O O
antrum O O
and O O
corpus O O
. O O
The O O
mean O O
thickness O O
of O O
the O O
visceral O O
peritoneum O O
was O O
comparable O O
in O O
both O O
groups O O
of O O
animals O O
, O O
but O O
, O O
macroscopically O O
, O O
more O O
severe O O
fibrosis O O
was O O
found O O
in O O
the O O
peritoneum O O
of O O
rats O O
exposed O O
to O O
CAPD O O
3 O O
as O O
compared O O
with O O
animals O O
treated O O
with O O
CAPD O O
3 O O
Balance O O
( O O
p O O
< O O
0.05 O O
) O O
. O O

A O O
further O O
analysis O O
has O O
been O O
performed O O
using O O
the O O
series O O
of O O
maximum O O
intensity O O
for O O
fixed O O
duration O O
( O O
1 O O
, O O
3 O O
, O O
6 O O
, O O
12 O O
, O O
24 O O
hrs O O
) O O
and O O
annual O O
daily O O
maxima O O
. O O

BACKGROUND O O
: O O
We O O
hypothesized O O
that O O
the O O
postoperative O O
serum O O
level O O
of O O
TA90-IC S-GENE S-GENE
, O O
an O O
immune O O
complex O O
of O O
a O O
90-kDa O B-GENE
tumor O I-GENE
- O I-GENE
associated O I-GENE
antigen O E-GENE
and O O
its O O
antibody O O
, O O
might O O
have O O
a O O
significant O O
correlation O O
with O O
recurrence O O
and O O
survival O O
in O O
patients O O
with O O
thick O O
primary O O
melanomas O O
. O O
Genetics O O
Institute O O
has O O
developed O O
and O O
launched O O
oprelvekin S-GENE O
( O O
rhIL-11 S-GENE O
; O O
Neumega O O
) O O
, O O
a O O
recombinant O O
form O O
of O O
human B-GENE B-GENE
IL-11 E-GENE E-GENE
. O O
Patients O O
subsequently O O
returned O O
to O O
the O O
clinic O O
every O O
3 O O
days O O
to O O
have O O
the O O
wounds O O
checked O O
and O O
dressings O O
changed O O
. O O

Elements O O
that O O
are O O
fundamental O O
to O O
the O O
safety O O
evaluation O O
of O O
flavor O O
ingredients O O
include O O
exposure O O
, O O
structural O O
analogy O O
, O O
metabolism O O
, O O
pharmacokinetics O O
and O O
toxicology O O
. O O

The O O
mass O O
- O O
specific O O
resting O O
minute O O
ventilation O O
( O O
E O O
) O O
and O O
the O O
ventilatory O O
equivalent O O
( O O
VE/(O(2 O O
) O O
) O O
) O O
were O O
approximately O O
the O O
same O O
at O O
the O O
two O O
ages O O
, O O
with O O
a O O
breathing O O
pattern O O
significantly O O
deeper O O
and O O
slower O O
at O O
day O O
1 O O
. O O

INTERPRETATION O O
: O O
It O O
is O O
probable O O
that O O
the O O
cognitive O O
dissonance O O
created O O
by O O
more O O
health O O
information O O
on O O
smoking O O
after O O
1964 O O
, O O
i.e. O O
the O O
necessary O O
motivation O O
to O O
quit O O
, O O
was O O
reduced O O
as O O
a O O
result O O
of O O
strategic O O
changes O O
in O O
the O O
amount O O
and O O
content O O
of O O
advertising O O
. O O

Nine O O
cases O O
of O O
GBS O O
and O O
five O O
of O O
TM O O
reported O O
to O O
the O O
active O O
AFP O O
surveillance O O
were O O
not O O
found O O
in O O
the O O
hospital O O
searches O O
. O O

The O O
ability O O
of O O
rats O O
with O O
control O O
or O O
hippocampal O O
lesions O O
to O O
learn O O
an O O
object O O
- O O
place O O
, O O
odor O O
- O O
place O O
, O O
or O O
object O O
- O O
odor O O
paired O O
- O O
associate O O
task O O
was O O
assessed O O
in O O
a O O
cheeseboard O O
maze O O
apparatus O O
. O O

The O O
shift O O
in O O
the O O
earliest O O
activation O O
site O O
after O O
administration O O
of O O
esmolol O O
was O O
compared O O
with O O
the O O
shift O O
after O O
RFA O O
. O O
RESULTS O O
: O O
The O O
heart O O
rate O O
at O O
rest O O
and O O
in O O
drug O O
- O O
free O O
state O O
ranged O O
between O O
95 O O
and O O
125 O O
beats O O
/ O O
min O O
( O O
mean O O
99 O O
+ O O
/- O O
14 O O
beats O O
/ O O
min O O
) O O
. O O

Urine O O
samples O O
collected O O
after O O
the O O
administration O O
of O O
these O O
supplements O O
can O O
test O O
positive O O
. O O

CONCLUSIONS O O
: O O
Lymphoscintigraphy O O
of O O
the O O
cynomolgus O O
monkey O O
eyelids O O
reveals O O
discrete O O
lymphatic O O
drainage O O
pathways O O
for O O
the O O
upper O O
and O O
lower O O
eyelids O O
and O O
a O O
dual O O
pathway O O
for O O
the O O
central O O
upper O O
eyelid O O
. O O

Data O O
management O O
in O O
practice O O
- O O
based O O
research O O
. O O

We O O
have O O
previously O O
reported O O
reduced O O
levels O O
of O O
choline B-GENE B-GENE
acetyltransferase E-GENE E-GENE
activity O O
in O O
the O O
cerebral O O
cortex O O
of O O
patients O O
who O O
died O O
after O O
a O O
head O O
injury O O
, O O
demonstrating O O
that O O
there O O
is O O
a O O
loss O O
of O O
cortical O O
cholinergic O O
innervation O O
. O O
After O O
taking O O
smears O O
from O O
lesions O O
of O O
the O O
oral O O
mucosa O O
( O O
tongue O O
, O O
cheeks O O
, O O
palate O O
) O O
and O O
the O O
contiguous O O
denture O O
surface O O
by O O
cotton O O
wool O O
swabs O O
and O O
inoculating O O
them O O
onto O O
Sabouraud O O
glucose O O
agar O O
and O O
CHROMagar O O
Candida O O
, O O
individual O O
yeast O O
species O O
were O O
identified O O
by O O
a O O
germ O O
tube O O
, O O
filamentous O O
, O O
and O O
assimilation O O
tests O O
employing O O
the O O
commercial O O
kit O O
AuxaColor O O
. O O

The O O
effects O O
of O O
pharmacological O O
treatment O O
and O O
professional O O
care O O
and O O
support O O
may O O
improve O O
when O O
dementia O O
is O O
detected O O
in O O
an O O
early O O
stage O O
. O O

Sexually O O
conditioned O O
incentives O O
: O O
attenuation O O
of O O
motivational O O
impact O O
during O O
dopamine B-GENE O
receptor E-GENE O
antagonism O O
. O O
One O O
CKD O O
patient O O
's O O
journey O O
. O O

PATIENTS O O
AND O O
METHODS O O
: O O
This O O
study O O
is O O
a O O
retrospective O O
cohort O O
study O O
of O O
all O O
children O O
with O O
cancer O O
admitted O O
to O O
a O O
single O O
institution O O
with O O
fever O O
and O O
neutropenia O O
( O O
defined O O
as O O
an O O
absolute O O
neutrophil O O
count O O
< O O
500 O O
cells O O
/ O O
mm3 O O
) O O
in O O
a O O
1-year O O
period O O
. O O

Concentrations O O
of O O
N(O3-)-N O O
and O O
N(H3-)-N O O
at O O
Deoprayag O O
varied O O
from O O
0.30 O O
to O O
0.50 O O
and O O
0.02 O O
to O O
0.12 O O
mg O O
/ O O
L O O
, O O
respectively O O
, O O
depending O O
on O O
season O O
. O O

Steal O O
is O O
a O O
pathophysiological O O
process O O
in O O
which O O
increased O O
blood O O
flow O O
through O O
a O O
low O O
- O O
resistance O O
vascular O O
bed O O
is O O
sufficient O O
to O O
divert O O
flow O O
away O O
from O O
a O O
region O O
of O O
the O O
central O O
nervous O O
system O O
. O O

The O O
orientations O O
of O O
the O O
contact O O
surfaces O O
and O O
their O O
locations O O
relative O O
to O O
the O O
object O O
's O O
center O O
of O O
mass O O
were O O
varied O O
. O O

The O O
results O O
are O O
given O O
as O O
: O O
flux O O
, O O
number O O
of O O
stars O O
per O O
cm3 O O
, O O
charge O O
of O O
the O O
ions O O
, O O
comparison O O
with O O
other O O
detectors O O
( O O
plastics O O
, O O
AgCl O O
crystals O O
, O O
LiF O O
) O O
, O O
energy O O
loss O O
, O O
hit O O
region O O
in O O
the O O
biological O O
objects O O
. O O

Nodal O O
domains O O
are O O
regions O O
where O O
a O O
function O O
has O O
definite O O
sign O O
. O O

DESIGN O O
: O O
Prospective O O
, O O
randomized O O
, O O
double O O
- O O
blind O O
, O O
controlled O O
trial O O
. O O

CONCLUSIONS O O
: O O
This O O
retrospective O O
uncontrolled O O
study O O
shows O O
that O O
in O O
patients O O
with O O
type O O
1 O O
HRS O O
, O O
terlipressin O O
- O O
induced O O
improved O O
renal O O
function O O
is O O
associated O O
with O O
an O O
increase O O
in O O
survival O O
. O O

In O O
patients O O
who O O
respond O O
to O O
quetiapine O O
, O O
therapy O O
should O O
be O O
continued O O
at O O
the O O
optimal O O
dose O O
that O O
maintains O O
remission O O
, O O
within O O
the O O
range O O
of O O
150 O O
to O O
750 O O
mg O O
/ O O
d O O
. O O

Calcimimetic O O
agents O O
directly O O
inhibit O O
PTH S-GENE S-GENE
secretion O O
by O O
activating O O
the O O
calcium O B-GENE
- O I-GENE
sensing O I-GENE
receptor O E-GENE
in O O
the O O
parathyroid O O
glands O O
, O O
but O O
clinical O O
experience O O
with O O
them O O
is O O
limited O O
. O O
With O O
such O O
analysis O O
, O O
one O O
can O O
test O O
hypotheses O O
about O O
the O O
structure O O
of O O
latent O O
variability O O
within O O
a O O
given O O
data O O
set O O
. O O

The O O
subjects O O
were O O
shown O O
to O O
be O O
capable O O
of O O
assessing O O
integrally O O
the O O
value O O
of O O
accelerations O O
and O O
estimating O O
it O O
with O O
an O O
error O O
of O O
0.1 O O
- O O
0.12 O O
g. O O

The O O
observed O O
incidence O O
rates O O
were O O
compared O O
to O O
expected O O
rates O O
in O O
the O O
general O O
population O O
. O O

The O O
only O O
predictor O O
of O O
response O O
to O O
tacrolimus O O
was O O
a O O
previous O O
response O O
to O O
cyclosporin O O
and O O
prednisone O O
, O O
either O O
as O O
a O O
complete O O
or O O
partial O O
remission O O
( O O
remission O O
rate O O
75% O O
vs O O
15.3 O O
; O O
P=0.036 O O
) O O
. O O

Based O O
on O O
a O O
morphological O O
study O O
of O O
the O O
resin O O
- O O
dentine O O
interface O O
, O O
a O O
broad O O
selection O O
of O O
dentine O O
adhesive O O
systems O O
was O O
classified O O
following O O
their O O
adhesion O O
- O O
strategy O O
. O O

Copyright O O
2002 O O
American O O
Cancer O O
Society O O
. O O
DOI O O
10.1002/cncr.10318 O O

In O O
this O O
study O O
we O O
wanted O O
to O O
assess O O
the O O
DR O O
using O O
the O O
' O O
combined O O
test O O
' O O
in O O
an O O
unselected O O
population O O
of O O
self O O
- O O
referred O O
pregnant O O
women O O
at O O
a O O
false O O
- O O
positive O O
rate O O
( O O
FPR O O
) O O
of O O
about O O
5% O O
. O O

As O O
measured O O
by O O
the O O
PDQ-39 O O
, O O
STN O O
- O O
DBS O O
significantly O O
improves O O
important O O
aspects O O
of O O
QoL O O
in O O
patients O O
with O O
advanced O O
PD O O
. O O
